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Abstract 
Enamel is the body’s hardest, most mineralised tissue and protects the 
underlying tissues of the tooth from the forces exerted during mastication and 
from bacterial attack. Amelogenesis imperfecta (AI) is a heterogeneous group of 
genetic conditions that result in defective dental enamel formation. AI can 
present as either isolated disease or as part of a syndrome. This thesis 
documents the identification of the genes involved in Heimler syndrome (HS) 
and in hypomineralised AI. 
  
HS is an autosomal recessively inherited combination of sensorineural hearing 
loss, AI and variable nail abnormalities, with or without visual defects. Biallelic 
mutations in the peroxisomal biogenesis factor genes, PEX1 and PEX6 were 
identified through whole exome sequencing (WES) of ten HS patients from 
seven families. Both proteins were found to be present throughout the retina. 
Mutations in PEX1 and PEX6 were already known to cause the Zellweger 
syndrome spectrum disorders (ZSSD), a group of conditions of varying severity. 
HS represents a mild ZSSD and results from combinations of mutations that 
include at least one hypomorphic variant, leaving patients with some residual 
peroxisomal function. For two additional families, mutations in the Usher 
syndrome (USH) gene, USH2A, were identified, highlighting the phenotypic 
overlap of HS with the more common USH. 
  
One family with autosomal dominantly inherited hypomineralised AI was 
recruited and DNA from three affected individuals was subjected to WES. DNA 
copy number variant analysis identified a heterozygous in-frame deletion of 
exons 3-6 of amelotin. Exfoliated primary teeth from an affected family member 
had enamel that was of a lower mineral density compared to control enamel 
and exhibited structural defects. Some of this appeared to be associated with 
organic material as evidenced by elemental analysis. 
  
Both cases in this study highlight the heterogeneity of AI and the importance of 
a genetic diagnosis for the clinical management of patients. 
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1 Introduction 
1.1 Structure, function and origins of teeth 
Human teeth are formed from a collection of mineralised tissues, namely 
enamel, dentine and cementum, and the non-mineralised pulp tissue (Figure 
1.1). 
 
Figure 1.1: Structure of a human molar tooth. 
Image reproduced with permission from Blausen.com staff. “Blausen gallery 2014”. Wikiversity 
Journal of Medicine. DOI:10.15347/wjm/2014.010. ISSN 200187762  
 
The basic tooth structure consists of the crown and the root, which are 
composed of four layers of material. The hard enamel covering the crown 
overlays the softer and more elastic dentine of both crown and root. The 
enamel provides a surface for mastication and defence against acid attack and 
pathogens. The dentine is supported by soft pulp tissue that provides nutrients 
and contains cells that allow dentine to maintain and repair itself. The 
cementum links to the dentine layer of the root and covers the root of the tooth, 
linking it to the periodontal ligament and ultimately, to the bone. 
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Teeth provide a scaffold for the shape of the lower face and are important for 
proper speech. They are also essential for mastication of food and are involved 
in emotional and social cues and perceptions (Beall, 2007). 
 
Teeth are found in jawed vertebrates (gnathostomes) and originated 
approximately 450 million years ago (Davit-Beal et al., 2009), although for 
several vertebrate taxa, either teeth or their enamel has been lost (Davit-Beal et 
al., 2009). Whilst tooth morphology has diversified during evolution, the 
underlying structure remains similar (Huysseune and Sire, 1998). Humans are 
heterodont (have teeth of more than one type of morphology) and diphyodont 
(have a deciduous and permanent dentition). 
 
1.2 Biomineralisation 
Biomineralisation is the formation of mineralised tissues by living organisms. It 
involves the production of organic signalling molecules and in some cases the 
establishment of a scaffold on which mineral is to form, followed by the process 
of mineral deposition. Many different tissues undergo biomineralisation, but the 
process of biomineralisation in enamel is unique since it involves a specific 
proteinaceous extracellular matrix instead of the collagenous scaffold used in 
bone and dentine and it cannot be repaired. 
 
Biomineralised tissues are mainly formed from calcium phosphate in the form of 
hydroxy(l)apatite (HA), with varying amounts of proteins. The molecular formula 
of HA, Ca10(PO4)6(OH)2, is conventionally written as two molecules to represent 
the repeating unit of the crystal. However, HA has a crystal lattice structure in 
which particular ions are often substituted. For example, the mineral can be 
deficient in calcium or hydroxyl, and either carbonate, fluoride, sodium or 
magnesium may substitute for them, which in turn can affect the lattice’s 
solubility (Robinson et al., 2000).  
 
Biomineralisation results from the controlled deposition of calcium and 
phosphate from supersaturated compartments. Control is elicited by energy 
barriers to mineral seeding and by specific proteins that, depending upon the 
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context, can either stabilise the ions or promote their organised deposition on to 
extracellular matrices. These proteins include the secretory calcium-binding 
phosphoproteins (SCPPs) that include milk/salivary proteins, enamel proteins 
and dentine/bone proteins. The SCPPs are encoded by genes believed to have 
evolved via gene duplication events (Kawasaki and Weiss, 2003). In humans, 
they mainly reside within a conserved gene cluster on chromosome 4 (Figure 
1.2) (Kawasaki and Weiss, 2003, Kawasaki and Weiss, 2006), although AMELX 
is also thought to have evolved via a gene duplication event but has been 
translocated to the X chromosome (with another copy present on the Y 
chromosome, AMELY) (Iwase et al., 2007). Other genes that are important for 
biomineralisation are distributed throughout the genome. 
 
 
Figure 1.2: Chromosomal locations of the conserved SCPP genes in humans. 
The main cluster of enamel genes are located on chromosome 4 distal to the milk / saliva gene 
cluster and proximal to the dentine / bone gene cluster. AMELX is located separately on 
chromosome X. Image based on information presented by Yoshizaki and Yamada (2013). 
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1.3 Tooth formation 
Odontogenesis, the process of tooth formation, involves a number of processes 
that can be broadly defined as initiation, morphogenesis, cell differentiation and 
matrix secretion. These processes occur over a number of contiguous stages 
that are defined by their morphological features. 
 
Human teeth begin to form from the seventh week of gestation (Nanci, 2012). 
They are derived from the ectodermal cranial neural crest-derived mesenchyme 
and epithelium of the first pharyngeal arch and a part of the frontonasal process 
(Figure 1.3) (Mitsiadis and Luder, 2011). Tooth formation is initiated by the oral 
epithelium, but subsequently the process is maintained by the 
ectomesenchyme, although transient epithelial signalling centres are 
established later in tooth morphogenesis to specify the shape of each tooth’s 
crown (Kollar and Baird, 1970, Mina and Kollar, 1987, Thesleff and Mikkola, 
2002). A “homeobox code” is established to provide instructions as to the 
position and type of teeth to be formed (Sharpe, 1995). 
 
The majority of studies on tooth morphogenesis have been undertaken in 
rodents because of the difficulty in obtaining appropriate embryological human 
tissues and the ethical questions that such experimental studies would raise. 
Therefore the majority of current literature is based on findings in rodent model 
systems, more specifically on the odontogenesis of the mandibular arch. 
 
Tooth development consists of five major stages: initiation / placode stage, bud 
stage, cap stage, bell stage and root formation followed later by eruption 
(Figure 1.4).  
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Figure 1.3: Early embryonic development of the head, face and jaws. 
Left: Schematic diagram depicting the side view of a human embryo at around 4 weeks gestation. The arrows represent the patterns of migration of 
mesencephalic, and rhombencephalic neural crest cells (NCCs) into the frontonasal process and the first pharyngeal arch. The green arrows represent the 
first stream of migration of NCCs from the mesencephalon and rhobomeres 1 and 2, which contributes to the skull, forehead and nasal process. The red 
arrows represent the second stream of migration of NCCs from the mesencephalon and rhobomeres 1 and 2, which go on to contribute to the formation of the 
jaws. The stomatodeum, the depression between the frontonasal process and the first pharyngeal arch, is the precursor of the oral cavity. Right: Schematic 
diagram to depict the front view of a human embryo at around 6 weeks gestation. The maxillary and mandibular facial process and the medial nasal process 
contribute to a region of epithelium with the potential to form teeth (red shading). 
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Figure 1.4: Diagram of the stages of tooth development. 
The process of tooth development is described in Section 1.3. Red dots represent the positions 
of signalling centres that direct development of the tooth at that particular stage. Figure 
reproduced and adapted with permission from Thesleff (2003)  
 
1.3.1 Initiation / placode stage (Mouse E11.5) 
During initiation, patterns of expression of homeobox-containing genes are 
established in the ectomesenchyme by the oral epithelium (Tucker et al., 1999). 
These induce localised proliferation of the dental lamina to form dental placodes 
that act as transient epithelial signalling centres (Biggs and Mikkola, 2014). The 
exact tooth position and type is determined by a complex interplay and 
cascades of signalling molecules and transcription factors (Neubuser et al., 
1997, Bei and Maas, 1998, Tucker et al., 1998, Trumpp et al., 1999, Ferguson 
et al., 2000). In particular, molecules of the bone morphogenetic protein (BMP), 
wingless, notch, sonic hedgehog (SHH) and fibroblast growth factor (FGF) 
families are involved in tooth positioning, formation and type patterning (Li et al., 
2013). SHH, BMP4, FGF8, Msh homeobox1 (MSX1) and paired box 9 (PAX9) 
are the signalling molecules involved in the initial stages of tooth development, 
although some also have roles at later stages (Caton and Tucker, 2009).  
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1.3.2 Bud stage (Mouse E13.5) 
The bud stage involves the invagination of the dental epithelium into the 
underlying condensed ectomesenchyme and corresponds to a shift in the 
odontogenic potential from the oral epithelium to the mesenchyme (Chen et al., 
1996, Peters et al., 1998). 
 
1.3.3 Cap stage (Mouse E14.5) 
The cap stage is so-called since it results in the formation of an epithelially-
derived “cap”, now termed the enamel organ, on top of a condensed 
ectomesenchyme “ball”, now called the dental papilla, for each tooth germ. 
Within the enamel organ, the stellate reticulum, a collection of star shaped 
epithelial cells, forms. Surrounding the entire structure is the dental follicle, 
which marks the limit of the condensed ectomesenchyme. A cluster of non-
dividing epithelial cells, termed an enamel knot, establishes itself as a transient 
epithelial signalling centre as a result of signalling from the mesenchyme (Caton 
and Tucker, 2009) and contributes to the formation of each tooth’s distinctive 
architecture (Pispa et al., 1999). The cell cluster that will form the enamel knot 
is in fact present earlier than bud stage but is not technically referred to as an 
enamel knot until it undergoes morphological changes at the cap stage. In 
molar teeth secondary and tertiary enamel knots are also established (Jernvall 
et al., 1994). 
 
1.3.4 Bell stage (Mouse E16.5-20) 
During the bell stage, the epithelial “cap” proliferates more deeply into the 
dental papilla and the dental organ is separated from the oral epithelium as the 
dental lamina breaks down (Figure 1.5). The section of the epithelial layer that 
lies over the dental papilla, and that is bounded by the cervical loops, is termed 
the inner enamel epithelium (IEE). Some of the cells of the IEE differentiate to 
form the stratum intermedium (SI) (Harada et al., 2006). Waves of differentiation 
of the IEE and the dental papilla produce both preodontoblasts and 
preameloblasts that will go on to form the hard tissues of the crown; dentine 
and enamel (Tompkins, 2006). 
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Figure 1.5: Haemotoxylin and eosin stained bell stage human tooth germs. 
Left: early bell stage, right: late bell stage. 
Images reproduced with permission from Dozenist, Wikipedia, accessed 24th June 2016. 
 
Both dentinogenesis, the process of dentine formation (Section 1.5) and 
amelogenesis, the process of enamel formation (Section 1.4), take place in the 
bell stage. Signalling from the preameloblasts across the basement membrane 
to the preodontoblasts initiates the reciprocal signalling to initiate the final 
stages of each cell type’s differentiation into ameloblasts and odonotoblasts 
(Ruch et al., 1995, Tompkins, 2006). The preodontoblasts polarise and undergo 
internal reorganisation to become odonotoblasts. The odontoblasts secrete a 
pre-dentine matrix, which when it begins to mineralise, prompts the 
preameloblasts to elongate and change their polarity so that their apical face is 
adjacent to the papilla (Nanci, 2012). 
 
The odontoblasts move towards the centre of the dental papilla as they secrete 
an extracellular matrix, mainly composed of collagen I, that mineralises to form 
dentine (Nanci, 2012). At the same time the ameloblasts move away from the 
mineralising dentine while secreting an extracellular matrix of enamel proteins, 
that will mineralise to form enamel. The boundary between the layers of dentine 
and enamel is termed the dentine-enamel junction. 
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1.3.5 Root formation and eruption 
Root formation initiates after coronal dentine formation and the root is itself 
formed from dentine covered by cementum (Nanci, 2012). Tooth eruption is 
prompted by the formation of the root. The remnants of the ameloblasts and 
other cells, form the reduced enamel epithelium that fuses with the oral 
epithelium and degenerates to form an epithelial canal through which the tooth 
erupts (Nanci, 2012). The reduced enamel epithelium and the oral epithelium 
then form the junctional epithelium (Bosshardt and Lang, 2005). 
 
Once teeth erupt, they are subject to physical and chemical insult from 
mastication, physical injury and bacterial attack that can result in post eruptive 
change. The high mineral content of saliva, its pH buffering activity, antibody 
content, and action as a lubricant, all help to protect teeth (Lagerlof, 1983, 
Dawes et al., 2015). 
 
1.3.6 Diphyodont dentitions 
Humans, unlike mice, have a diphyodont dentition with deciduous teeth 
preceding a permanent dentition (Section 1.1). The formation of teeth in both 
dentitions is similar. In humans, the permanent successional teeth (teeth that 
have deciduous equivalents) such as incisors, canines and premolars, form 
from dormant tooth buds formed by proliferation of the dental lamina (Jarvinen 
et al., 2009). Non-successional teeth form from new tooth buds formed by 
posterior outgrowths of the dental lamina (Nanci, 2012). 
 
1.4 Amelogenesis 
Amelogenesis is the process of enamel formation. Mature enamel is the body’s 
hardest, most mineralised tissue (at greater than 95% mineral by weight (Smith, 
1998)) and forms from a secreted extracellular matrix that is progressively 
mineralised in a series of repetitive steps. It results in the formation of a highly 
organised and distinctive architecture, consisting of enamel prisms made up of 
hydroxyapatite crystals (Smith, 1998). 
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Since the cells that form enamel, the ameloblasts, are lost when teeth erupt 
(Abiko et al., 1996), enamel is formed only once for each dentition and cannot 
undergo cellular repair. Therefore enamel is required to maintain function over a 
lifetime. Its ability to achieve this is due to its high mineral content and complex 
structure (Section 1.6), both of which are acquired during its highly orchestrated 
formation. 
 
Amelogenesis itself has three basic contiguous stages, namely secretory, 
transition and maturation, but the morphogenesis, cytodifferentiation, pre-
secretory stage and eventual fate of the ameloblasts are also important to the 
formation and properties of enamel. The events of transition and maturation 
stages are difficult to separate as most maturation stage processes initiate in 
the transition stage. Histological sections of the murine incisor of various stages 
of amelogenesis are shown in Figure 1.6. 
 
1.4.1 Pre-secretory stage 
The ameloblasts are derived from cells of the IEE and differentiate in response 
to reciprocal signalling between the IEE and the dental papilla (Morotomi et al., 
2005, Mitsiadis et al., 2008). The basal lamina then breaks down between the 
dental papilla and the IEE so that the cells are in contact with the pre-dentine 
(Figure 1.7A) (Reith, 1967, Kjoelby et al., 1994). Preameloblasts are known to 
secrete proteins even at the very early stages of their differentiation, including 
prior to the breakdown of the basal lamina (Nanci, 2012). Transient secretion of 
dentin sialoprotein (DSP) (a protein more associated with odontoblast secretion 
(Section 1.5)) has been noted during ameloblast differentiation (Ritchie et al., 
1997).  
 
Next the ameloblasts elongate and their nuclei shift proximally to the side of the 
cell nearest the SI, resulting in a reverse in their polarity (Matsuo et al., 1992). 
The Golgi apparatus and rough endoplasmic reticulum (ER) increase in size to 
increase ameloblast capacity for protein production, post-translational 
modification and secretion (Smith and Nanci, 1995). These develop at the distal 
end of the cell that faces the odontoblasts. The non-dividing cell becomes 
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polarised further as, just after a junctional complex, it forms a distal extension 
that will become the Tomes’ process. Each ameloblast develops and maintains 
anchoring junctions that hold the cells in alignment and control what passes 
between them (Bartlett and Smith, 2013). 
 
Figure 1.6: Histology of the ameloblasts in the murine mandibular incisor. 
A: Representation of the basic structure of the murine mandible. B-E: Haemotoxylin and eosin 
stained sections of decalcified developing murine incisor. B: Secretory stage ameloblasts (a) 
with apical Tomes’ processes and the developing enamel matrix (m). C: Transition stage 
ameloblasts: note the reduction in ameloblast length. D: Maturation stage ameloblasts with the 
stratum intermedium and papillary cell layer below. E: Post-maturation stage, reduced 
ameloblasts. The white space in panels D and E represents an artefactual space resulting from 
removal of the mineralised enamel. The mineralised enamel is removed by the demineralising 
treatment necessary for the histological analysis of hard tissues. Scale bars represent 50m. 
Image reproduced with permission from Barron et al. (2010). 
 
1.4.2 Secretory stage 
During the secretory stage, protein secretion by ameloblasts is at its maximum 
and the future enamel is created to its full thickness. A proteinaceous 
extracellular matrix is secreted from the ameloblast Tomes’ process, as the 
ameloblasts retreat from the dentine layer (Skobe, 1976). To achieve this, 
ameloblasts produce large amounts of membrane bound secretory granules 
si 
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containing enamel matrix proteins (EMPs). EMPs are constitutively secreted by 
exocytosis (Kallenbach, 1977, Sasaki, 1984), into the extracellular space at the 
distal end of the cell, against the newly formed dentine. HA mineral immediately 
forms in this initial enamel matrix and forms a close association with the dentine 
mineral (Diekwisch et al., 1995, Fang et al., 2011). This will form aprismatic 
enamel (Figure 1.7B). The ameloblasts then begin to move away from the 
dentine and further develop their Tomes’ processes at their distal end (Reith, 
1967). To form prismatic enamel (Figure 1.7C, D), EMPs are secreted from two 
aspects of the ameloblasts. Enamel matrix that will form the interprismatic 
enamel is secreted from the proximal part of the Tomes’ process and the 
enamel matrix that will form the prismatic enamel is secreted from the distal part 
(Nanci, 2012).  
 
As secretion progresses, the Tomes’ process of the ameloblasts lengthens and 
thins. The distal portion secreting the prism-forming enamel matrix is reduced 
before secretion ceases, meaning that the final enamel formed is aprismatic like 
the initial enamel.  
 
EMPs that are secreted include amelogenin (AMEL, from both chromosome X 
and chromosome Y copies, Section 1.9.1), enamelin (ENAM, Section 1.9.3) and 
ameloblastin (AMBN, Section 1.9.2). AMEL, ENAM and AMBN proteins are 
cleaved at specific positions by the secretory stage proteinase, matrix 
metalloproteinase 20 (MMP20, Section 1.9.4) (Ryu et al., 1999, Moradian-Oldak 
et al., 2001, Yamakoshi et al., 2006, Iwata et al., 2007). Cleavage products from 
all three EMPs are believed to occupy particular compartments in the 
developing enamel architecture and to have specific roles in the formation and 
organisation of the developing matrix (Uchida et al., 1991, Murakami et al., 
1997, Yamakoshi, 2011). 
 
1.4.3 Transition stage 
The transition stage is characterised by reduced enamel matrix protein 
secretion and internal reorganisation of the ameloblasts (Reith, 1970). The 
ameloblasts shorten to around half their original height and reduce in volume 
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(Figure 1.7E), the nuclei become more central and the ER is reduced in size. 
The Tomes’ process is completely lost (Reith, 1970) and an atypical basal 
lamina is formed against the enamel matrix. Ameloblasts adhere to this via 
hemidesmosomal structures (Section 1.9.6).  
 
During the transition stage, the cells of the SI, stellate reticulum and the outer 
enamel epithelium form the papillary cell layer (PL) (Josephsen et al., 2010). 
Capillaries invaginate into the PL and overlay the ameloblasts (Robinson et al., 
1979). The PL and the ameloblasts have been proposed to constitute a 
functional unit since the cells of the PL may assist ameloblasts in the maturation 
stage by participating in ion transport and removal of enamel protein products 
and water from the developing enamel (Ohshima et al., 1998, Josephsen et al., 
2010). 
 
The ameloblast population reduces at this stage, and continues to reduce in the 
maturation stage, due to apoptosis. Overall, approximately 50% of the 
ameloblast cell population is lost (Smith and Warshawsky, 1977). 
 
1.4.4 Maturation stage 
During the maturation stage, the partially mineralised enamel matrix becomes 
fully mineralised by the breakdown and removal of residual enamel proteins, the 
removal of water and the expansion of existing HA crystals (Robinson et al., 
1995). The maturation stage proteinase, kallikrein-related peptidase 4 (KLK4, 
Section 1.9.5), is responsible for the complete degradation of the EMP peptides 
that have been produced in the secretory stage by MMP20. This liberates a 
fluid filled space in which the HA crystals can grow in width and thickness.  
 
Ameloblasts can take a long period of time to mature the enamel. Human 
enamel can take 4-5 years to complete, although the enamel of primary human 
teeth and that of rodents forms much faster than this (Smith, 1998). This 
process is the result of very small-scale changes achieved through repeated 
cyclical processes. The ameloblasts act as a gated, cell-lined thoroughfare for 
the movement of ions and degraded protein between the SI and the developing 
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enamel and vice versa. To this end, the ameloblast membrane facing the 
developing enamel repeatedly alternates in its structure between a ruffle-ended 
and a smooth-ended form (Figure 1.7F, G) (Warshawsky and Smith, 1974). 
This is achieved in coordinated groups of ameloblasts across the developing 
enamel (Takano et al., 1982). The ruffle-ended ameloblasts (RA) form 
membrane invaginations and tight junctions at the apical end, near the enamel 
surface, whereas the smooth-ended ameloblasts (SA) are more leaky 
(Josephsen and Fejerskov, 1977).  
 
Growth of enamel crystals generates large amounts of protons (Simmer and 
Fincham, 1995), but it has also been shown that protons are pumped into the 
enamel by RA (Josephsen et al., 2010). Both RA and SA release bicarbonate 
ions in to the enamel that act as a buffer to increase pH (Josephsen et al., 
2010). A mildly acidic pH is found in enamel at RA regions and a more neutral 
pH in SA regions (Sasaki et al., 1991, Smith et al., 1996).  
 
1.4.5 Post-maturation stage 
The ameloblasts, and other cells of the enamel organ, form the reduced enamel 
epithelium, which eventually contributes to the junctional epithelium of mature 
teeth (Bosshardt and Lang, 2005) (Figure 1.7H, Section 1.3.5). However, many 
of the ameloblasts apoptose before the formation of the junctional epithelium is 
completed (Abiko et al., 1996). 
 
 
Figure 1.7: Schematic of amelogenesis. 
See next page. Only the key features of each stage are shown and are described in Sections 
1.4.1 to 1.4.5. Ameloblasts are represented in blue. Tight junctions are represented by black 
circles. 
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1.5 Dentinogenesis 
Dentinogenesis is the process of dentine formation. Dentine is less mineralised 
than enamel, but more mineralised than bone, with 70% mineral content by 
weight (Nanci, 2012). It consists of type I collagen, which forms a lattice for 
mineral deposition (Prescott et al., 2008), and various non-collagenous 
proteins, including Small Integrin Binding Ligand N-Linked Glycoproteins 
(SIBLINGs). The SIBLINGs are a group of SCPPs that include dentin matrix 
phosphoprotein 1 (DMP1; MIM *600980) and dentin sialophosphoprotein 
(DSPP; MIM *125485). DSPP is cleaved by proteases to form dentin 
sialoprotein (DSP), dentin glycoprotein (DGP) and dentin phosphoprotein (DPP) 
(MacDougall et al., 1997). These proteins are thought to regulate 
dentinogenesis (Boskey et al., 1990)  
 
The initiation of dentinogenesis is a pre-requisite for amelogenesis and the 
processes have many similarities. Pre-secretory odontoblasts form during the 
bell stage of tooth development (Nanci, 2012). They form from differentiation of 
the mesenchyme as a result of epithelial-mesenchymal interactions and 
signalling. Much like amelogenesis, dentinogenesis involves the secretion of an 
extracellular matrix followed by its mineralisation. Differentiated odontoblasts 
polarise to form cell bodies and a membrane process (Ruch et al., 1995). At the 
same time, odontoblasts move towards the centre of the dental papilla whilst 
secreting an initial collagenous predentine layer. Mineral crystals are seeded in 
the predentine and various non-collageneous proteins control mineral formation 
to form primary dentine. Other types of dentine, such as secondary dentine 
(Dean, 1998) and tertiary dentine (Smith et al., 1995) are formed throughout life 
to maintain the dentine layer. Therefore, unlike enamel, dentine can undergo 
cellular repair. 
 
1.6 Enamel structure 
Mature dental enamel consists of approximately 96% HA mineral by weight, 3% 
water and 1% protein (Avery et al., 2002). Enamel has a hierarchical structure 
that consists of crystallites as the most basic unit. These make up enamel 
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ribbons that form both the prismatic and interprismatic enamel created by 
secretion from two faces of each Tomes’ process. 
 
Rodent incisor enamel has a decussating (intersecting) pattern (Figure 1.8). 
Human enamel has less distinction between the prismatic and interprismatic 
enamel (Figure 1.9). 
 
 
Figure 1.8: Electron microscopy (EM) images of rodent enamel. 
A, B: Scanning EM images. C: Transmission EM image. Scale bars represent 40m (A), 5m 
(B) and 100nm (C). Note prism decussation shown in A. D: Crystal lattice structure of calcium 
hydroxy(l)apatite. Each colour represents the following: phosphorus (red), oxygen (green), 
calcium (screw-axis: yellow; columnar: blue). Adapted from images kindly provided by Dr. 
Steven Brookes, (University of Leeds). Inset image D reproduced with permission from Brunton 
et al. (2013). 
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Figure 1.9: Scanning EM images of human enamel. 
Scale bars represent 150m (A) and 50m (B). 
  
1.7 Rodents as models for amelogenesis 
Rodents have been used as experimental models for amelogenesis due to the 
utility of their constantly erupting incisor teeth. This characteristic means that 
dissected incisors can be used to study the histology of amelogenesis at all 
developmental stages. Since rodents and humans share evolutionarily 
conserved EMPs, proteinases and other proteins associated with 
amelogenesis, models to determine the effects of perturbations of gene 
expression have been engineered. These models either have genes “knocked 
out” by transgene insertion, specific mutations of the coding sequence inserted 
or have genes overexpressed or expressed in inappropriate compartments or at 
different developmental points via insertion of alternative promoters. 
 
The use of rodent models to study the effects of changes in gene expression on 
amelogenesis is enabled by the extensive and detailed previous study of 
amelogenesis in rodent species. Importantly, the position of the secretory-
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transition-maturation stage border has been histologically well defined in the 
mandibular incisor (Smith and Nanci, 1989). 
 
Rodents also have molar teeth that, like human teeth, are formed once and for 
which the ameloblasts are lost upon tooth eruption. Amelogenesis has also 
been studied in these teeth, but unless animals at different developmental 
stages are studied, the teeth only provide a snapshot of amelogenesis. 
 
 
Figure 1.10: Micro computerised tomography scan of a murine lower mandible. 
Section is shown through the mesial-distal axis. False colour has been used to highlight both 
the radiodense enamel of the molar teeth and of the incisor incisal edge. The dashed line shows 
the position of the molar line, used to define the position of the secretory-transition-maturation 
stage ameloblast border by some researchers. Adapted from an image kindly provided by Dr. 
Steven Brookes (University of Leeds). 
 
1.8 Defects of enamel 
1.8.1 Amelogenesis imperfecta 
Amelogenesis imperfecta (AI; MIM PS104500) is a heterogeneous group of 
conditions characterised by defects in the formation of enamel of all teeth in 
both dentitions. The reported prevalence of AI differs depending upon the 
population studied. For example, in an isolated Swedish population, the 
incidence of AI was reported to be 1 in 700 (Backman and Holm, 1986), 
whereas it was reported to be 1 in 14,000 for a US population (Witkop and 
Sauk, 1976).  
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Figure 1.11: Clinical images and dental radiographs of dentitions affected by AI. 
A-D: Clinical images that illustrate the phenotypic variability of AI. A: Hypoplastic AI is 
characterised by teeth without the curves associated with a normal enamel volume. B: AI 
enamel can be apparently normal, as illustrated by the posterior teeth, but structural 
weaknesses result in rapid post-eruptive enamel loss with exposure of the underlying dentine (B 
has features of hypomaturation AI). C: The quality of the enamel is abnormal, with variable 
colouration and enamel volume. Focal pitting is evident on the inset image. C depicts a mixed 
AI phenotype. D: Brown discolouration and early post-eruptive enamel loss is typical of poorly 
mineralised forms of AI. E-G: Dental radiographs from three unrelated cases of AI give insight 
into the phenotype with respect to enamel volume formed and differences in radiodensity 
compared to adjacent mineralised tissues. Comparison between unerupted and erupted teeth 
can highlight post-eruptive changes. E: The unerupted molar tooth (arrow) has a near normal 
enamel volume but without the difference in radiodensity between enamel and dentine that is 
observed in health (inset image). By contrast, the adjacent lower molar tooth that is in occlusion 
is characterised by minimal remaining enamel, reflecting post-eruptive hard tissue loss. F: The 
molar teeth have some mild changes to the enamel volume, but this is near-normal. There is a 
clear difference in radiodensity between enamel and dentine. Despite the radiographic 
appearances on clinical examination, there is obvious AI. G: The developing teeth are unable to 
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form normal enamel prior to eruption. Images kindly provided by Dr. Alan Mighell (University of 
Leeds). 
 
AI can occur in both syndromic and non-syndromic forms. Although mixed 
phenotypes occur, AI can broadly be divided into hypoplastic and 
hypomineralised AI. Hypoplastic AI results from failure during the secretory 
stage and produces thin and variably mineralised enamel. Hypomineralised AI 
is caused by failure during the maturation stage, giving rise to enamel that is of 
full thickness but is weak and fails prematurely. The hypomineralised phenotype 
can be further subdivided into hypomaturation and hypocalicified AI. The former 
produces brittle enamel, while the latter produces soft enamel. The distinction 
between these two subdivisions is poor. 
 
A combination of visual assessment of the physical appearance of the enamel 
and dental radiography is still used to classify AI. The enamel may be 
discoloured to yellow or brown, have a chalky or cheesy appearance and may 
have pits or grooves. In many cases, post-eruptive changes will alter the pre-
eruption phenotype. This can make classification of AI via clinical features 
difficult, making the literature hard to interpret. Examples of the varied clinical 
presentation of AI are shown in Figure 1.11. 
 
AI was first described in 1890 but it was not described as a separate clinical 
entity from dentinogenesis imperfecta (MIM #125490, #125500) until 1938 
(Finn, 1938, Weinmann et al., 1945). Attempts have been made to classify AI 
based upon phenotype since 1945, with more recent systems focusing on the 
mode of inheritance or even the molecular defect as the first dichotomy in 
classification (Weinmann et al., 1945, Rao and Witkop, 1971, Winter and Brook, 
1975, Witkop and Sauk, 1976, Sundell and Koch, 1985, Sundell and Valentin, 
1986, Witkop, 1988, Aldred and Crawford, 1995, Aldred et al., 2003), for review 
see Aldred et al. (2003) and Crawford et al. (2007). Since the last review of 
classification in 2007, the number of genes in which mutations are known to 
cause AI has substantially increased (Section 1.9). Therefore it seems likely 
that this and the more frequent use of genetic diagnostics in medicine will lead 
to new classification based solely on the genetic cause.  
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AI can be inherited in an autosomal recessive (AR), dominant (AD) or X-linked 
manner, can occur in isolation or as a component of various syndromes, and is 
highly genetically heterogeneous. Despite mutations in a particular gene often 
resulting in one particular typical phenotype, studies have shown that the 
phenotype is sometimes substantially affected by the type and position of the 
mutation within each gene (Hart et al., 2002). The phenotype has also been 
reported to show variation between affected individuals within the same family 
(Aldred et al., 2002), suggesting that genetic background, the environment and 
life history factors may also contribute to the phenotype. 
 
AI is also associated with other oral anomalies such as anterior open bite 
(Rowley et al., 1982, Pavlic et al., 2011, Alachioti et al., 2014), defined as a lack 
of vertical overlap between the maxillary and the mandibular dentition during 
occlusion, and taurodontism (Price et al., 1999), defined as molar teeth with 
enlarged pulp chambers. It can also occur as part of a syndromic condition 
which includes extra-oral phenotypes, such as Jalili syndrome (MIM #217080), 
junctional epidermolysis bullosa (JEB; MIM #226700, #226650), Kohlschütter-
Tönz syndrome (MIM #226750) and trichodentoosseous syndrome (MIM 
#190320). Older classifications did not include syndromic AI with extra-oral 
symptoms but it has been proposed to include such syndromes within the AI 
classification due to the similarity of treatment options (Aldred et al., 2003). 
Therefore the definition of AI proposed by Aldred et al. is, “A group of 
conditions, genomic in origin, which affect the structure and clinical appearance 
of all or nearly all teeth, and which may be associated with morphologic or 
biochemical changes elsewhere in the body”. 
 
Patients with AI experience dental pain and sensitivity, poor aesthetics and are 
reported to experience a lower quality of life due to social anxiety (Coffield et al., 
2005, Hashem et al., 2013). Treatment of AI is expensive since it requires 
continuous lifetime assessment and management to maintain function and 
aesthetics. 
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1.8.2 Other developmental abnormalities of enamel 
The long developmental period for enamel means that life history and 
environmental factors acting at this time, as well as genetics, may affect the 
eventual phenotype. Specific non-genetic causes include factors that lead to 
ameloblast stress or altered differentiation or function such as premature birth 
(Cruvinel et al., 2012), viral infection (Chaves et al., 2007), factors that lead to 
the incorporation within or diffusion into the enamel of extraneous substances 
such fluorosis (Robinson et al., 2004) and tetracycline exposure (Sanchez et al., 
2004), or that affect calcium availability such as vitamin D deficiency (Foster et 
al., 2014). 
 
Molar Incisor Hypomineralisation (MIH) is a common developmental enamel 
defect that has been found to affect between 2.8% (Cho et al., 2011) and 44% 
(Soviero et al., 2009) of people depending upon the definition of MIH used and 
the population and age of the cohort studied. MIH describes asymmetric enamel 
opacities of systemic origin that affect at least one of the permanent first molars 
and may also affect the incisors (Weerheijm et al., 2001). The enamel of these 
teeth is mineralising from around the 8th month in utero to around age 5 (Logan 
and Kronfeld, 1933). This suggests that ameloblasts are either only sensitive to 
the causative agent during this specific window of time or they are subject to an 
acute exposure at this time. 
 
The aetiology of MIH is much debated and is thought to be multi-factorial. Both 
genetic and environmental factors have been suggested to be involved but all 
remain unproven (Whatling and Fearne, 2008, Crombie et al., 2009). 
Associated factors reported in the literature include mid to high socio-economic 
status (Balmer et al., 2012), use of certain drugs (chemotherapy (Bagattoni et 
al., 2014), antibiotics (Hong et al., 2011), anti-epileptic drugs (Jacobsen et al., 
2013)), asthma (Guergolette et al., 2009), those whose mothers had 
experienced problems during pregnancy (Whatling and Fearne, 2008), early 
childhood infections (Lygidakis et al., 2008) environmental pollutants (Alaluusua 
et al., 2004, Jedeon et al., 2013) and a positive family history of MIH (Whatling 
and Fearne, 2008). However, the associations reported are often weak, 
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perhaps due to the involvement of multiple factors in aetiology. Also, the 
majority of epidemiological MIH studies were small and failed to control for 
potentially confounding factors such as water fluoridation. 
 
One recent study assessed the degree of association of 63 single nucleotide 
polymorphisms (SNPs) in 21 candidate genes with MIH status in 101 Brazilian 
families (Jeremias et al., 2016). This study identified significant associations 
with SNPs positioned in many genes associated with tooth and enamel 
development, however the most significant was for a SNP within AMELX, 
suggesting that variants in AMELX may not only be associated with AI, but also 
with MIH. Additional studies involving different ethnicities and larger patient 
cohorts will be required to confirm these findings. 
 
1.9 Genetics of non-syndromic amelogenesis imperfecta 
Mutations in many genes are known to cause non-syndromic (NS) AI. Some of 
the encoded proteins have well documented roles in amelogenesis, acting as 
EMPs or the proteases that degrade them, HA nucleating factors, cell adhesion 
molecules or regulators of calcium homeostasis. However for others, their 
function is less clear, and further research is needed to understand the 
pathways and processes essential for the development of healthy enamel. 
 
The first AI-causing mutations were identified in the genes encoding the EMPs. 
The EMPs are known to make up the bulk of the secreted enamel matrix. The 
proteins have a distinctive architecture since they all have a signal peptide and 
a conserved casein kinase 2 phosphorylation domain likely to be targeted by 
family with sequence similarity 20, member C (FAM20C) (Yang et al., 2016). 
Although the EMPs originate from a common ancestral gene, over the hundreds 
of millions of years since, their sequences have diverged and they have 
acquired distinct functions (Sire et al., 2007). Another group are the enamel 
matrix proteinases, which process the EMPs by cleavage and eventually 
degrade the protein matrix of the forming enamel so that it may be removed to 
accommodate subsequent mineral growth. 
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Several other genes, for which mutations are known to cause AI, have also 
been identified, however, for reasons of brevity only the AMELX, AMBN and 
ENAM (the EMPs) and MMP20 and KLK4 (the enamel matrix proteases) will be 
detailed here. A summary of the other genes known to be mutated in NS AI will 
be given in Section 1.9.6. Further details as to the human phenotypes and 
mutations associated with these genes can be found in Appendix 1 and the 
Leeds amelogenesis LOVD resource (Section 1.9.7). Mouse models used to 
study the effect of altered expression of genes known to cause NS AI are 
detailed in Appendix 2. 
 
1.9.1 Amelogenin, X linked (AMELX)  
Amelogenin, X linked (AMELX, MIM *300391) comprises around 90% of the 
enamel matrix proteins secreted by ameloblasts (Hart et al., 2000). In males, a 
highly homologous copy of AMELX exists as AMELY (MIM *410000) on the Y 
chromosome, but AMELY transcription is present at around 10% of that of 
AMELX in males (Aldred et al., 1992, Salido et al., 1992) and hence cannot 
compensate for loss of AMELX expression. 
 
AMELX is regarded as a tooth specific protein since it has not been detected 
elsewhere in human tissues (Chan et al., 2011), however, in murine tissues, it 
has been detected in dentine-forming, cementum-forming and bone-forming 
cells, as well as in developing eye and brain (Fong and Hammarstrom, 2000, 
Janones et al., 2005, Haze et al., 2007). AMELX is thought to act as an enamel 
matrix buffer and as a scaffold for the spacing and growth of enamel crystallites 
(Chen et al., 2011). AMELX transcripts are subject to extensive alternative 
splicing (Brookes et al., 1995) that generates molecules with specific roles in 
enamel mineralisation and signalling (Veis et al., 2000, Veis, 2003). The most 
abundant human transcript lacks exon 4, which when spliced out has been 
proposed to act as a microRNA that may control ameloblast and odontoblast 
differentiation (Le et al., 2016). AMELX proteins are also subject to proteolysis 
to produce a variety of peptides (Ryu et al., 1999, Moradian-Oldak et al., 2001, 
Moradian-Oldak, 2012), and amelogenin peptides have been used 
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commercially to stimulate periodontal tissue regrowth in dental patients 
(Sculean et al., 2007, Olivares-Navarette, 2013). 
 
Evolutionary analysis shows that AMELX (/AMELY) is most closely related to 
AMBN (Sire et al., 2007), although analysis of the amelogenin protein sequence 
shows that it consists of a signal peptide and an amelogenin domain, meaning 
that it is unlike other proteins. Amelogenin is rich in proline, glutamine, leucine 
and histidine and is therefore hydrophobic. This hydrophobic nature induces the 
assembly of AMELX protein into nanospheres in vitro (Du et al., 2005). 
However, the C-terminal end is hydrophilic and has been shown to enhance the 
binding of the peptide to HA in vitro (Aoba et al., 1987) and may be a 
mechanism by which AMELX orientates itself along the forming enamel prisms 
(Kirkham et al., 2000). 
 
AMELX mutations cause X-linked AI (Lagerstrom et al., 1991). To date, twenty-
six variants, including gene deletions have been reported. Heterozygous 
mutations tend to present in female AI patients as stripes of normal and AI 
affected enamel due to lyonisation (Berkman and Singer, 1971). The AI 
phenotype in males is determined by the type and position of the mutation. 
Large deletions and N-terminal variants cause a hypomaturation AI defect with 
variable hypoplasia while mutations in the signal peptide and C-terminus cause 
smooth hypoplastic AI (Hart et al., 2002). 
 
1.9.2 Ameloblastin (AMBN) 
Ameloblastin (AMBN; MIM *610259) is the second most abundant enamel 
matrix protein secreted by ameloblasts (Smith, 1998). AMBN is rich in glycine, 
leucine and proline and localises to the Tomes’ processes and the dentino-
enamel junction (DEJ) (Krebsbach et al., 1996, MacDougall et al., 2000), but 
has also been found in pre-odontoblasts, developing tooth roots and 
craniofacial bone (Fong et al., 1996, Fong et al., 1998, Spahr et al., 2006). 
AMBN is expressed throughout amelogenesis (Lee et al., 1996) but peaks 
during the secretory stage (Fukumoto et al., 2004). AMBN undergoes 
alternative splicing to form two isoforms (Krebsbach et al., 1996, Hu et al., 
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1997). Porcine ameloblastin is extensively modified and is cleaved upon 
secretion by MMP20 to form a number of protein products that accumulate 
within different compartments (Bartlett and Simmer, 1999). Although it is known 
that AMBN can influence the differentiation and proliferation of ameloblasts 
(Fukumoto et al., 2004), it is also important in extracellular signalling to induce 
osteoblast differentiation (Iizuka et al., 2011) and cell adhesion via heparin and 
fibronectin (Beyeler et al., 2010), as well as in mineralisation (Yamakoshi et al., 
2001, Zhang et al., 2011). A 16 amino acid synthetic N-terminal AMBN peptide 
has been shown to stimulate differentiation of human periodontal ligament cells 
(Kitagawa et al., 2011) and to promote bone formation in vitro (Kitagawa et al., 
2016). Evolutionary analysis shows that AMBN is most closely related to 
AMELX (/AMELY) (Sire et al., 2007), although analysis of the AMBN sequence 
shows that it consists of a signal peptide and an amelin domain, meaning that it 
is unlike other proteins. 
 
Two AMBN mutations have been reported in AI patients. A large in-frame 
deletion encompassing exon 6 segregated with recessive hypoplastic AI in a 
consanguineous family (Poulter et al., 2014c). Scanning electron microscopy 
(SEM) showed both reduced mineral density and enamel thickness, mirroring 
the murine Ambn-5,6/-5,6 model (Poulter et al., 2014c). A second homozygous 
mutation, thought to alter splicing, was identified in a large cohort of patients 
with oro-dental disease, using a targeted next-generation sequencing assay 
(Prasad et al., 2016). 
 
1.9.3 Enamelin (ENAM) 
Enamelin (ENAM; MIM *606585) is a tooth specific glycoprotein expressed 
primarily by secretory stage ameloblasts (Hu and Yamakoshi, 2003, Hu et al., 
2008). It is successively cleaved from its C-terminus, resulting in numerous 
products (Fukae et al., 1993, Hu and Yamakoshi, 2003, Lu et al., 2008). The 
uncleaved protein is found only at the mineralisation front and is known to be 
involved in enamel crystal extension (Hu et al., 2008). Some ENAM cleavage 
products, such as the 32kDa fragment identified in pigs, have the ability to bind 
HA crystals and accumulate within and between the enamel prisms (Hu and 
 28 
Yamakoshi, 2003). More N-terminal products cannot bind HA. Its exact roles in 
enamel formation are not yet well defined. Like AMELX and AMBN, ENAM is 
believed to have diverged from a common ancestral SCPP gene, however 
ENAM is less closely related to AMELX and AMBN (Sire et al., 2007). Analysis 
of the RNA sequence shows that the untranslated regions of ENAM are much 
larger than for AMELX or AMBN and that exon 3 encodes the signal peptide (in 
AMELX and AMBN, the signal peptide is encoded by exon 2). The protein 
sequence does not show similarity to other proteins and the protein itself is 
much larger than AMELX or AMBN. 
 
The first human mutation identified in ENAM caused autosomal dominant AI 
with a severe smooth hypoplastic phenotype as a result of a dominant-negative 
effect of aberrant splicing (Rajpar et al., 2001, Mardh et al., 2002). 
Subsequently, a milder local hypoplastic phenotype was identified in a family 
with a dominantly inherited nonsense mutation (Mardh et al., 2002). Autosomal 
recessive inheritance has also been documented for ENAM mutations (Hart et 
al., 2003, Ozdemir et al., 2005a, Chan et al., 2010); homozygous and 
heterozygous patients present with a severe and a milder, local form 
respectively (Ozdemir et al., 2005a). To date, twenty-six ENAM variants have 
been reported to cause AI. In addition to these variants, a non-synonymous 
SNP within ENAM has been associated with thinner enamel in the African 
American population (Daubert et al., 2016). 
 
1.9.4 Matrix metalloproteinase 20 (MMP20) 
Matrix metalloproteinases (MMPs) influence cell motility by regulating cell 
interactions and matrix degradation, crucial processes in many aspects of 
development (VanSaun and Matrisian, 2006). Like other MMPs, MMP20 (MIM 
*604629) is a zinc-dependent endopeptidase that is secreted in a form that 
must be cleaved to activate it (Llano et al., 1997). MMP20 is secreted by 
ameloblasts throughout the secretory stage, concurrent with the enamel matrix 
proteins, and is responsible for their cleavage, at specific residues, shortly after 
secretion (Simmer and Hu, 2002). This generates EMP cleavage products with 
specific and diverse roles in amelogenesis. Therefore, MMP20 has been shown 
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to be necessary for controlling HA crystal morphology (Prajapati et al., 2016). 
MMP20 is also capable of cleaving the extracellular domains of cadherins that 
mediate cell-cell interactions as part of adherens junctions to allow ameloblast 
cell movement (Guan and Bartlett, 2013, Guan et al., 2016). This may affect 
amelogenesis since ameloblasts must move in synchronous groups in order to 
form the typical enamel architecture. Since cadherins are linked to the actin 
cytoskeleton via catenins, cadherin cleavage releases -catenin, which can act 
as a transcription factor and may be important for ameloblast differentiation 
(Bartlett et al., 2011, Guan et al., 2016). 
 
Many MMPs have been identified throughout the genome, although MMP20 
resides within a cluster of nine MMP genes on chromosome 11 (Kawasaki and 
Suzuki, 2011). Whilst other genes within this cluster encode MMPs that are 
grouped as collagenases or stromelysins, MMP20 is not part of either group 
and its expression has only been detected outside of the tooth at very low levels 
(Turk et al., 2006). MMP20 consists of a signal peptide, a propeptide, a catalytic 
domain, a linker and a hemopexin domain, consisting of hemopexin repeats 
(Ryu et al., 1999). The hemopexin domain is of unknown function, but through 
homology, it may influence substrate specificity, bind to inhibitors or activation 
of the pro-enzyme, although it is not essential for enzymatic activity per se (Kim 
et al., 2005). Whilst the protein has low sequence similarity to other MMPs 
overall (45%), the catalytic domain is known to have a higher level of similarity 
with other MMPs (59%). This domain is known to bind both calcium and zinc 
ions at particular residues. Cleavage of MMP20 by KLK4 has been shown to 
inactivate MMP20 in vitro and may remove some or all of the metal ion 
coordinating residues (Yamakoshi et al., 2013). 
 
Mutations in MMP20 lead to autosomal recessive hypomaturation AI (Kim et al., 
2005). To date, eight variants have been reported that include a variety of 
missense, nonsense, frameshift and splice site mutations, all resulting in a 
similar phenotype (Ozdemir et al., 2005b, Papagerakis et al., 2008, Lee et al., 
2010, Gasse et al., 2013, Wang et al., 2013b). 
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1.9.5 Kallikrein-related peptidase 4 (KLK4) 
Kallikrein-related peptidase 4 (KLK4; MIM *603767) encodes a serine protease 
that is expressed and secreted by ameloblasts in both transition and maturation 
stages (Hu et al., 2000, Hu et al., 2002, Simmer et al., 2009). Like MMP20, 
newly secreted KLK4 must be cleaved for activity. In vitro experiments have 
shown that MMP20 can activate newly secreted KLK4 and that KLK4 can 
inactivate MMP20, potentially explaining the shift in proteinase activity during 
the transition stage (Yamakoshi et al., 2013). 
 
KLK4 acts to further degrade the enamel proteins cleaved by MMP20 during 
secretion (Bartlett, 2013). Such activity aids removal of protein from the 
developing enamel by ameloblasts, allowing the enamel prisms to grow in width 
(Simmer et al., 2009, Bartlett, 2013). KLK4 is also capable of functioning over 
the wide pH range that occurs during the maturation stage (Smith, 1998). 
 
In humans, KLK4 lies within a cluster of fifteen KLK genes on chromosome 19 
and is believed to have arisen via duplication of KLK5 (Lundwall, 2013). Hence 
the KLK4 protein shows the greatest sequence homology with KLK5 (45%). 
Unlike MMP20, KLK4 is expressed in tissues other than the tooth including the 
prostate (Nelson et al., 1999), testis, ovary, mammary and salivary gland 
(Yousef et al., 1999) and skin (Komatsu et al., 2003). The protein consists of a 
signal peptide, a propeptide and a trypsin-like serine protease domain. Like all 
KLKs, it contains a catalytic triad of residues critical to its function and a series 
of disulphide bonds are required to maintain its structure in an active 
conformation (Debela et al., 2006, Debela et al., 2008). 
 
Human KLK4 mutations were first identified in autosomal recessive 
hypomaturation AI (Hart et al., 2004). KLK4 variants appear to be a rare cause 
of AI since only three mutations have been reported in a total of four families 
(Hart et al., 2004, Wright et al., 2011, Wang et al., 2013b, Seymen et al., 2015). 
The mutations include a frameshift and a stop mutation, both assumed to be 
null mutations (Hart et al., 2004, Wright et al., 2011, Wang et al., 2013b). The 
most recently reported variant is a frameshift mutation affecting a codon in the 
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final exon, which, whilst not subject to nonsense mediated decay (NMD), has 
been shown to result in greatly reduced protein expression and proteolytic 
function (Seymen et al., 2015). Despite the expression of KLK4 outside of the 
tooth, no additional phenotypes have been associated with mutations in KLK4. 
 
1.9.6 Other non-syndromic amelogenesis imperfecta genes and 
pathways 
The great variety of other genes known to be mutated in NS AI give snapshots 
of various important processes and structural features that are essential for 
normal enamel development. In some cases, the delineation between NS and 
syndromic AI is unclear, since several genes at first reported as causing NS AI 
have later been reported to be associated with additional phenotypes. 
 
Mutations in genes encoding proteins that stabilise or are components of 
hemidesmosomes, such as laminin, alpha 3 (LAMA3; MIM *600805), laminin, 
beta 3 (LAMB3; MIM *150310) and collagen type XVII, alpha-1 (COL17A1; MIM 
*113811) are known to cause hypoplastic AI (Murrell et al., 2007, Pasmooij et 
al., 2007, Yuen et al., 2012, Kim et al., 2013, Poulter et al., 2014b). 
Hemidesmosomes link epithelial cells, such as ameloblasts, to the basement 
membrane of extracellular matrices such as the enamel matrix (Nievers et al., 
1999). While homozygous mutations in these genes lead to JEB (Aberdam et 
al., 1994, Pulkkinen et al., 1994a, Pulkkinen et al., 1994b, Kivirikko et al., 1995, 
McGrath et al., 1995), a syndrome that includes AI, heterozygous carriers of 
particular mutations are known to have NS hypoplastic AI (Murrell et al., 2007, 
Pasmooij et al., 2007, Yuen et al., 2012, Kim et al., 2013, Poulter et al., 2014b). 
More recently, AI-causing mutations in another gene, family with sequence 
similarity 83, member H (FAM83H; MIM *611927), have been shown to affect 
the keratin cytoskeleton and to impair the formation of desmosomes via altered 
binding to casein kinase 1 alpha 1 (CSNK1A1; MIM *600505) (Kuga et al., 
2016, Wang et al., 2016). Interestingly, all twenty-five of the hypocalcified AI 
causing truncating mutations identified so far in FAM83H are predicted to 
escape NMD and to and to maintain interaction with CSK1A1 but may instead 
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affect the normal cellular trafficking of CSK1A1 and phosphorylation of its target 
proteins within the cell (Wang et al., 2016). 
 
Mutations in an integrin component, integrin, beta 6 (ITGB6; MIM *147558), 
have also been identified as causes of hypomineralised / hypoplastic AI (Poulter 
et al., 2014a, Wang et al., 2014b). Integrins mediate cell-cell and cell-
extracellular matrix interactions by facilitating interaction with the cytoskeleton 
(Alberts, 2002). Ameloblast adhesion to the developing enamel matrix may 
therefore be perturbed in these patients. 
 
Hypocalcified AI-causing mutations have been identified in the gene encoding 
the WD repeat domain 72 (WDR72; MIM *613214) protein. WDR72 is predicted 
to be an intracellular vesicle coat protein involved in endocytosis (El-Sayed et 
al., 2009, Katsura et al., 2014). A Wdr72-/- mouse exhibited mislocalisation of 
solute carrier family 24 (sodium/potassium/calcium exchanger), member 4 
(SLC24A4; MIM *609840) protein away from the basement membrane (the 
ameloblast-enamel matrix interface) (Wang et al., 2015). Mutations in SLC24A4 
are also known to cause AI (Parry et al., 2013) and it is has been suggested 
that the encoded protein is responsible for calcium transport from the 
ameloblast in to the enamel matrix during the maturation stage, mainly in RA 
(Wang et al., 2014a, Bronckers et al., 2015). The switching of ameloblast 
cellular morphology between the SA and RA forms may be due to pH sensing 
mechanisms. Mutations in G-protein coupled receptor 68 (GPR68; MIM 
*601404), a pH sensing protein, have recently been shown to cause 
hypomineralised AI in three families (Parry et al., 2016). 
 
Mutations in chromosome 4 open reading frame 26 (C4orf26; MIM *614829), 
encoding a member of the acidic phosphoprotein family, are also known to 
cause hypomineralised AI (Parry et al., 2012). Such proteins are known to 
promote HA crystallisation, and a C4orf26 peptide with a phosphorylated C-
terminus was shown to promote nucleation and crystallisation in vitro (Parry et 
al., 2012). However, both the gene and the protein are relatively poorly studied. 
 
Finally, family with sequence similarity 20, member A (FAM20A; MIM *611062) 
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is one of a family of three human homologues of the Drosophila four jointed 
protein kinase (Ishikawa et al., 2012). Additional family member, FAM20C (MIM 
*611061), is a Golgi casein kinase responsible for phosphorylating many 
secreted proteins involved in biomineralisation (Tagliabracci et al., 2012). 
Mutations in FAM20C lead to a severe, syndromic form of AI, Raine syndrome 
(MIM #259775). In vitro expression of FAM20A has shown that it is also located 
in the Golgi (Ishikawa et al., 2012, Wang et al., 2013a). FAM20A has been 
shown to potentiate the action of FAM20C in vitro and it has been shown that 
FAM20A promotes the secretion of FAM20C (Ohyama et al., 2016). It is 
currently debated whether FAM20A is itself a pseudokinase (Cui et al., 2015). 
 
Mutations in FAM20A have been shown to cause autosomal recessive AI and 
gingival fibromatosis syndrome (O'Sullivan et al., 2011) and Enamel Renal 
Syndrome (ERS) (Jaureguiberry et al., 2012, Wang et al., 2013a). Both 
syndromes have since been recognised as phenotypic variants of the same 
condition and are now collectively termed ERS (MIM #204690) (de la Dure-
Molla et al., 2014). Patients with FAM20A mutations have hypoplastic AI which, 
in extreme cases, may present as a complete absence of enamel (de la Dure-
Molla et al., 2014). The symptoms associated with ERS (de la Dure-Molla et al., 
2014, Poulter et al., 2015) suggest that FAM20A, perhaps in combination with 
FAM20C, phosphorylates proteins involved in enamel formation and other 
aspects of tooth development, as well as those critical to Ca2+ regulation within 
the kidney. 
 
It is evident that some of the genes implicated in NS AI encode either proteins 
secreted into the enamel matrix or proteins that aid post translational 
modification or trafficking of secreted proteins. Successful amelogenesis hinges 
on the secretion of large amounts of protein, appropriate processing of the 
proteins by proteases and the endocytosis of the protein products, concurrent 
with mineralisation of the enamel matrix. Therefore the secretory pathway is of 
critical importance in amelogenesis. Perturbations of the secretion of mutated 
proteins, for example, by aberrant intracellular aggregation, as proposed in the 
Amelx Y64H mouse model (Barron et al., 2010), has been shown to result in ER 
stress and ameloblast cell death (Brookes et al., 2014). Such a mechanism of 
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disease for AI may be more important than previously realised and may partially 
explain the cause of disease of AI-causing mutations with dominant inheritance 
patterns. 
 
1.9.7 Leiden Open Variant Database of NS AI mutations 
In order to consolidate the large number of NS AI-causing mutations reported in 
the literature into one easily accessed, fully referenced resource for benefit of 
the scientific community, a Leiden Open Variant Database (LOVD) has been 
established. This resource is accessible at http://dna2.leeds.ac.uk/LOVD/ and 
includes over 160 variants in a total of 14 genes (Date accessed 1st July 2016). 
The webpage and LOVD hosting was created and is managed by Miss Agne 
Antanaviciute (University of Leeds) and has been curated by the author, for 
variants in all of the genes included therein, except for FAM20A, which is 
curated by Dr. James Poulter (University of Leeds). 
 
1.10 Heimler syndrome 
Heimler syndrome (HS; MIM #234580 and #616617) was first described as a 
combination of sensory neural hearing loss (SNHL), enamel hypoplasia and nail 
abnormalities (Heimler et al., 1991). Two siblings were originally documented 
and at the start of this study, three further reports of three families (five cases) 
had been described (Tischkowitz et al., 1999, Pollak et al., 2003, Ong et al., 
2006). These reports are summarised in Table 1.1. Due to reports of HS in 
siblings and in both sexes, born from unaffected parents, HS was thought to be 
an AR genetic condition. 
 
Descriptions of the phenotype suggest that the enamel defects affect the 
permanent dentition but not the deciduous. Some reports also detailed that only 
particular teeth were affected (Figure 1.12) (Heimler et al., 1991, Ong et al., 
2006). The SNHL described was moderate to profound in severity, was 
generally bilateral and appeared to develop early in childhood rather than to be 
present from birth. Reports of nail abnormalities, such as leukonychia and 
Beau’s lines, were not a consistent finding. Both leukonychia, the presence of 
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white spots on the nail and Beau’s lines, nail ridging, are common abnormalities 
often related to trauma and infection, respectively (Fawcett et al., 2004). 
Therefore the presence of these symptoms may be coincidental. 
 
Of the HS patients described in the literature, case 1-2 (Table 1.1) was later 
reported to have developed macular dystrophy (MD) at the age of 29 (Lima et 
al., 2011). This description of an eye phenotype was the only one reported in 
the seven HS patients, and the brother of case 1-2 (case 1-1), who also has 
HS, was not reported to have MD. However, all of the other individuals reported 
at that time were under 16 years old and therefore the eye phenotype reported 
only in case 1-2 may suggest that HS is a progressive disease that includes MD 
as a later onset symptom. 
 
At the start of this study, no genetic cause for HS had been reported. 
Speculation by case report authors as to the cause of the HS led to the 
suggestion of a ciliary defect, since the tissues affected have a common 
ectodermal origin (Lima et al., 2011).  
 
Despite the paucity of HS case reports, a literature search revealed a number of 
reports of patients diagnosed with Usher syndrome (USH; Section 1.11) who 
also have enamel defects (summarised in Table 1.1). These reports highlight 
the phenotypic overlap of the two syndromes and the possibility that HS cases 
with an eye phenotype may be misdiagnosed as USH. Alternatively, as only 
one report on HS detailed an enamel phenotype in the primary dentition, while 
other HS reports stated that only particular teeth were affected, the possibility 
that the enamel phenotype was not AI could not be ruled out. If this was the 
case, HS cases may have been USH cases with a coincidental enamel defect 
due to MIH or an environmental / life history cause (Section 1.8.2). 
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Figure 1.12: Clinical details of an HS patient. 
Patient is labelled 4-1 in Table 1.1. A and B: Photographs of maxillary (A) and mandibular (B) 
dentitions of an HS patient at 11 years old showing hypoplastic enamel confined to the first 
molars and the lower second pre-molar teeth. C: Dental radiographs showing the developing 
dentition and the radiographic appearance of the hypoplastic first molar teeth. D: Leukonychia 
of the fingernails. Images reproduced with permission from Ong et al. (2006).
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Table 1.1: Summary of case reports published as Heimler syndrome or as Usher syndrome and enamel defects. 
Cases 1-1 to 4-2 were reported as Heimler syndrome. Cases 5 to 11 were reported as Usher syndrome and enamel defects. Familial cases are indicated by 
numbering, i.e. cases 1-1 and 1-2 are siblings, cases 2 and 3-1 are unrelated. Cases 4-1 and 4-2 are monozygotic twins. Abbreviations used: B bilateral, esp 
especially, F female, Fi fingernails, L left, M male, Mi mild, Mo moderate, mo months, N/R not reported, RPE retinal pigment epithelium, S severe, P 
Profound, T toenails, U unilateral, yrs years. References: cases 1-1 and 1-2: Heimler et al. (1991), Lima et al. (2011); case 2: Tischkowitz et al. (1999); cases 
3-1 and 3-2: Pollak et al. (2003); cases 4-1 and 4-2: Ong et al. (2006); cases 5 and 6: Bateman et al. (1980); cases 7-1, 7-2, 7-3 Innis et al. (1998); cases 8 
and 9: Pieke-Dahl et al. (2000); case 10: Balmer and Fayle (2007); case 11: de la Pena and Valea (2011). 
Age
Type; 
severityPrimaryPermanent
Beau's 
linesLeukonychia
1-1M18 moB; S to PNormalHypoplasticNormalYes - TYes - FMixed European
1-2F30 moB; PNormalHypoplasticAdult on-set macular dystophy diagnosed at 29Yes - TYes - FMixed European
2F7 yrsU-L; PNormalHypomineralisedNormalYes - F+TNoN/R; Caucasian
3-1F30 moB; Mo to SNormalHypoplasticNormalYes - F+TNoMixed European
3-2F14 moB; S to PNormalHypoplasticNormalNoNoMixed European
4-1F3 yrsB; Mo to SNormalHypoplastic / hypomineralisedNormalYes - TYes - FN/R; Caucasian
4-2F3 yrsB; Mo to SNormalHypoplastic / hypomineralisedNormalYes - TYes - FN/R; Caucasian
5M<2 yrsB; SN/RHypoplasticRP, bone spicule formationN/RN/RN/R
6F<5 yrsB; Mo to SN/RHypoplasticMaculopathy, pigmentary clumpingN/RN/RN/R
7-1M4 yrsB; Mi to SN/RUneruptedRPE granularity, esp in macula; white lesions on RPEN/RN/RN/R
7-2F3 yrsB; Mi to SN/RUneruptedRPE granularity, esp in macula; white lesions on RPEN/RN/RN/R
7-3M26 moB; SN/RUneruptedAbnormal heavy RPE granularityN/RN/RN/R
8N/RN/RB; S to PNystagmus since early infancy; RP diagnosed at 3N/RN/RMixed European
9N/RN/RB; S to PNystagmus since early infancy; RP diagnosed at 5N/RN/RMixed European
10FN/RB; PNormalHypoplasticDiagnosis: Usher syndrome type 1N/RN/REuropean
11MN/R"Deaf"HypoplasticHypoplasticDiagnosis: Usher syndrome type 2N/RN/RN/R
Parental origin
Case 
no.Sex
Hearing loss 
diagnosisDentitionNail abnormalities
Vision
Enamel hypoplasia of unknown dentition
Enamel hypoplasia of unknown dentition
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1.11 Usher syndrome 
Usher syndrome (USH; MIM PS276900) is a combination of SNHL and retinitis 
pigmentosa (RP) with a reported prevalence ranging from 1 in 6,000 to 1 in 
50,000 (Keats and Corey, 1999, Kimberling et al., 2010). USH is thought to 
account for more than 50% of cases of deaf blindness in adults (Boughman et 
al., 1983) and is inherited in an AR manner. There are three distinct types of the 
syndrome. USH type I (USH1) is characterised by congenital, bilateral, profound 
SNHL and vestibular dysfunction. Progressive RP typically develops in 
childhood. USH type II (USH2) is the most common form and is characterised 
by prelingual moderate to severe SNHL and normal vestibular function. 
Progressive RP usually develops within the second decade. USH type III 
(USH3) is rare except in particular populations such as the Finnish and 
Ashkenazi Jewish. USH3 is characterised by variable onset and progression of 
the SNHL phenotype, variable vestibular dysfunction and variable RP onset. 
Atypical USH is also used to describe atypical phenotypes resulting from 
mutations in genes that are more often associated with USH1 or USH2. 
Mutations in eleven genes have been identified (Appendix 3) and other 
modifiers and genetic loci are known to exist (Mathur and Yang, 2015). 
 
USH genes encode a wide variety of proteins essential for the correct 
development of the hair bundle in the cells of the cochlea and in the vestibular 
organ of the ear (Ahmed et al., 2013). The proteins are also important for the 
maintenance of the transport links within the retina (Millan et al., 2011). Since 
both the kinocilium, the structure that directs the development of the hair cell 
bundles, and the photoreceptors of the retina are modified cilia, USH is 
regarded as a ciliopathy (Goetz and Anderson, 2010, Wheway et al., 2014). 
The proteins implicated in USH1 and those implicated in USH2, are each known 
to form USH1 and USH2 protein complexes in vivo (Michalski et al., 2007, 
Grillet et al., 2009). These complexes are thought to bind to each other to form 
one large complex and to interact in the inner ear and retina to form a large 
network (Reviewed by Mathur and Yang (2015)). 
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The gene most commonly found to be mutated in USH is usherin (USH2A; MIM 
*608400) which leads to an USH2 phenotype (Aller et al., 2006, Baux et al., 
2007, Dreyer et al., 2008). The most commonly mutated USH1 gene is myosin 
VIIA (MYO7A; MIM *276903) (Jaijo et al., 2006, Roux et al., 2011). 
 
1.12 DNA sequencing 
The development of the chain termination method of DNA sequencing (Sanger 
et al., 1977) and further improvement through the use of fluorescent dyes 
(Smith et al., 1986), capillary electrophoresis and laser detection of sequencing 
reads (Ruiz-Martinez et al., 1993) has meant that automated identification of 
500-1000bp of DNA sequence in a few hours is now routine. This and the 
development of PCR (Saiki et al., 1988) have combined to allow the specific 
amplification of a DNA region of choice which can then undergo incorporation of 
four different, fluorescently labelled dideoxyribonucleotide tri-phosphates 
(ddNTPs) to provide chain terminated products for sequence analysis. Modern 
sequencers separate fragments using a capillary column filled with a 
replaceable polymer matrix, and detect the light emitted by the fluorescent 
ddNTPs upon laser excitation as they exit the capillary column. These four 
different emissions are then plotted graphically and the DNA sequence can be 
determined. 
 
1.13 Next generation sequencing technologies 
Chain termination capillary sequencing was used to complete sequencing of the 
human genome over thirteen years and at a cost of $2.7 billion, in 2001 (Lander 
et al., 2001, McPherson et al., 2001, Sachidanandam et al., 2001). Today a 
genome can be sequenced in a few days and costs around $1500. This is due 
to the development of massively parallel sequencing, also called next 
generation sequencing (NGS). NGS technologies include both whole genome 
sequencing (WGS, Section 1.13.1) and whole exome sequencing (WES, 
Section 1.13.2).  
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Although many sequencing platforms have been developed, all simultaneously 
sequence multiple DNA molecules within a single slide or flow cell. Leeds Next 
Generation Sequencing Facility uses both the Illumina HiSeq 2500 and 3000, 
which use a clonal bridge amplification and “sequencing by synthesis” 
reversible dye termination method (Figure 1.13) (Bentley et al., 2008). 
 
Illumina sequencing is achieved by shearing target DNA into fragments, ligating 
adapters to each end, then adding these to a flow cell precoated with 
oligonucleotides complementary to the adaptors. Each DNA fragment, attached 
to the flow cell at both ends, forms a “bridge” which is then PCR amplified. Next 
the resulting strands are denatured and allowed to attach to adjacent 
oligonucleotides to form two attached copy strands in close proximity. Further 
rounds of the same process form millions of clusters of identical molecules, 
attached as spots to the flow cell. Sequencing proceeds by the use of four 
different fluorescently labelled reversible terminators. At each round of 
synthesis, one new nucleotide is incorporated, and molecules within each 
cluster, being identical copies, all fluoresce with the same colour. Thus each 
spot fluoresces with a colour corresponding to the next base of its sequence at 
each round of extension. An image of the flow cell surface logs which base has 
been incorporated in each spot. Afterwards, each incorporated nucleotide’s 
terminating 3 end and fluorescence is chemically inactivated, so that a further 
round of sequencing can take place. The resulting sequence for each molecule 
is termed a read. These reads can be aligned to a reference sequence. 
 
For studies investigating the genetic causes of Mendelian diseases, variations 
from the reference sequence are identified. These variants are then filtered 
against databases of known variation with reference to the frequency of the 
disease and the mode of inheritance. Refinement of the remaining variants can 
be achieved by the sequencing of multiple family members, use of mutation 
prediction software and by the individual Sanger sequencing and segregation 
analysis of candidates. The first Mendelian disease mutations identified by this 
method were reported in 2009 (Ng et al., 2010). NGS has shifted the rate 
limited step and challenge from sequence acquisition to the processing, 
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interpretation and storage of the vast amounts of data generated. It has also 
raised ethical considerations around secondary and incidental findings. 
 
 
Figure 1.13: The Illumina clonal bridge amplification and sequencing by synthesis 
method. 
A: Cluster generation on the surface of the flow cell. (1) Denatured libraries are annealed to the 
short oligonucleotides on the surface of the flow cell. (2) Bridging amplification generates 
clusters. (3) One strand from the double-strand DNA library is cleaved and washed out for 
unidirectional sequencing. B: Primers for inserts are annealed for the sequencing of the insert 
DNA. In each sequencing cycle, protected and fluorescently labelled A, T, G and C bases are 
applied. After the addition of each nucleotide, the sequencing reaction is stopped, and the 
image is taken. Because the newly added nucleotides within each cluster are identical, the 
signal is high enough to be detected by a light sensor. After the image is taken, the protection 
group and the fluorescent molecules are removed. C: When the first-strand sequencing reaction 
is finished, the synthesised strand is removed and the process is repeated for the opposite 
strand. Image reproduced with permission from Shin et al. (2014). 
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1.13.1 Whole Genome Sequencing (WGS) 
WGS is the sequencing of the entire DNA sequence of an organism, the 
genome. Recently, use of WGS has increased due to falling costs. In addition, 
the absence of any capture step means that this approach may provide better 
coverage of the entire exome than WES (Belkadi et al., 2015). Regions of low 
or high GC content and complex regions, such as repeats, centromeres and 
telomeres, may not be well covered (Aird et al., 2011). At present, the scant 
annotation of the majority of non-protein coding regions limits the interpretation 
and prioritisation of non-coding changes (Kircher et al., 2014, Ritchie et al., 
2014, Ionita-Laza et al., 2016). However, even low coverage WGS is useful for 
the assessment of copy number variants (CNVs) and other structural variants 
(Hayes et al., 2013). 
 
1.13.2 Whole Exome Sequencing (WES) 
WES traditionally sequences only the protein coding regions of the genome, the 
exome. However some more recently developed reagents also target functional 
non-protein coding sequences such as microRNAs. WES focuses sequence 
acquisition and therefore increases coverage of the approximately 1.5% of the 
genome that represents the exome. This is achieved by specifically capturing 
only these regions using biotinylated cRNA baits, which hybridise to target 
sequences by complementary base pairing (Gnirke et al., 2009). WES has 
become the preferred method for rare disease gene discovery since it is less 
costly to undertake, produces a greater read depth for targeted regions and 
produces a smaller volume of, and less complex, data than WGS. 
 
Since pathogenic variants are found most commonly in the most conserved 
regions of the genome, it seems likely that the exome will contain the majority of 
the variants with functional consequences for proteins. As of 2008, over 99% of 
the mutations identified as causing a Mendelian disease were identified within 
the exome (Ng et al., 2008), although this must reflect, in part, the sole focus on 
the exome in the majority in studies. WES has been successfully used to 
identify genes in which mutations cause AI, with or without prior use of linkage 
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analysis, in a number of studies (Poulter et al., 2014a, Poulter et al., 2014b, 
Poulter et al., 2014c, Huckert et al., 2015). 
 
1.14 The aims of this study 
The first aim of this study was to identify the gene(s) mutated in HS and to 
determine the localisation of the encoded protein in the tissues affected. 
 
WES of ten families segregating HS or HS-like phenotypes in an AR manner, 
identified biallelic mutations in PEX1 and PEX6 as the cause of disease in a 
total of seven families. Both PEX1 and PEX6 are well-characterised proteins 
with roles in peroxisomal function. Two of the other families had biallelic 
mutations in USH2A and were assumed to have USH, not HS. For the one 
remaining family, a heterozygous deletion within MYO7A was identified but 
remains unconfirmed. The localisation of PEX1 and PEX6 proteins within the 
murine retina was determined and attempts were made to determine the 
proteins’ localisation within the murine incisor, however technical difficulties 
meant that this was not possible. 
 
The second aim of this study was to identify gene(s) mutated in NS AI and to 
characterise the enamel defect in the patient(s). 
 
WES of one family segregating NS AD hypomineralised AI revealed a 
heterozygous deletion of AMTN exons 3-6. Characterisation of the enamel 
phenotype revealed differences between the human phenotype and that of the 
Amtn mouse models. A dominant gain of function was predicted to be the mode 
of disease. 
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2 Materials and Methods 
All reagents in this section were obtained from Sigma (St. Louis, MO, USA) 
unless otherwise stated. 
2.1 Solutions 
2.1.1 Red cell lysis solution 
155mM Ammonium chloride 
10mM  Potassium bicarbonate 
1mM  Ethylenediaminetetraacetic acid (EDTA; pH 8.0) 
 
2.1.2 White cell lysis solution 
25mM  EDTA (pH 8.0) 
2% (w/v) Sodium dodecyl sulphate (SDS) 
 
2.1.3 1x Tris-EDTA (TE) buffer (pH 8.0) 
10mM  Tris HCl (pH 8.0) 
1mM  EDTA (pH 8.0) 
 
2.1.4 Cell lysis buffer for DNA extraction 
10mM  Tris HCl (pH 8.0) 
100mM  EDTA (pH 8.0) 
20g/ml  RNAase A 
0.25% (w/v)  Sodium dodecyl sulphate (SDS) 
 
2.1.5 50x Tris-Acetate-EDTA (TAE) electrophoresis buffer 
2M  Tris HCl 
50mM  EDTA (pH 8.0) 
0.97M  Glacial acetic acid 
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2.1.6 10x Gel loading dye 
6x  TAE 
20% (w/v) Ficoll 400 
0.1% (w/v) Bromophenol blue 
0.2% (w/v) Xylene cyanol 
 
2.1.7 Radio Immunoprecipitation Assay (RIPA) buffer 
50mM  Tris HCl (pH 8.0) 
150mM  Sodium chloride 
1% (v/v)  IGEPAL® CA-630 
0.5% (w/v) Sodium deoxycholate 
0.1% (w/v) SDS 
 
2.1.8 1x Tris Buffered Saline (TBS) 
150mM Sodium chloride 
20mM  Tris HCl (pH 7.4) 
 
2.1.9 1x TBS Tween (TBST) 
1x  TBS 
0.05%  Tween 20 
 
2.1.10 Scott’s tap water substitute 
0.2% (w/v) Sodium hydrogen carbonate 
2% (w/v) Magnesium sulphate 
 
2.2 Patients 
All samples were obtained with informed consent for research use under ethical 
approval from the Yorkshire & The Humber - South Yorkshire Research Ethics 
Committee Leeds (reference 13/YH/0028). The diagnostic criteria for Heimler 
syndrome and amelogenesis imperfecta are detailed in Sections 2.2.1 and 2.2.2 
respectively.  
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2.2.1 Heimler syndrome patients 
DNA samples from patients diagnosed with Heimler syndrome (HS; MIM 
#234580, #616617), along with samples from other family members, were 
obtained from a group of local, national and international collaborators. HS was 
suspected in patients who were reported to have both SNHL and AI. Since 
published reports of HS at the commencement of this study included only one 
individual who had developed retinal dystrophy in adulthood (Lima et al., 2011), 
this was not regarded as a diagnostic criterion. 
 
Due possibly to the rarity of HS, and perhaps also in part because tooth 
abnormalities were diagnosed by a different set of healthcare professionals, in 
most cases patients had been diagnosed initially with Usher syndrome (USH; 
MIM PS276900) and amelogenesis imperfecta (AI; MIM PS104500). 
 
2.2.2 Amelogenesis imperfecta patients 
DNA samples from patients diagnosed with AI, along with samples from other 
family members, were obtained from a group of local, national and international 
collaborators. AI was diagnosed by dental practitioners based on the physical 
appearance of the dentition. Dental X-ray assisted in the diagnosis of the 
specific subtype of AI. 
 
2.3 DNA samples 
DNA from any blood sample received was extracted by Yorkshire Regional 
Genetics (St James’s University Hospital, Leeds, UK) using a salt precipitation 
protocol (Section 2.3.1) or if blood had been previously frozen, a phenol-
chloroform extraction was performed (Section 2.3.2). DNA from saliva samples 
obtained using Oragene DNA collection kits (DNA Genotek Inc., Ottawa, 
Canada) was extracted according to the manufacturer’s instructions but with an 
increased input volume of 750l and 1.5 times the volumes of other reagents 
used. Pellets were dissolved in 1x TE buffer (Section 2.1.3). 
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2.3.1 Salt precipitation 
A salt precipitation technique was performed to extract DNA from fresh blood 
samples. Briefly, 3ml of whole blood was aliquoted into a polypropylene tube 
and 9ml of red cell lysis solution (Section 2.1.1) added. The samples were 
shaken for 10 minutes and then centrifuged at 2,000 x g for 10 minutes. The 
supernatant was removed to leave the white cell pellet containing DNA. The 
pellet was resuspended in 3ml white cell lysis solution (Section 2.1.2) and the 
cells lysed by vigorous pipetting. To remove any contaminating protein, 1ml of 
protein precipitation solution (10M ammonium acetate) was added, the samples 
mixed for 20 seconds and then centrifuged for 10 minutes at 2000 x g. The 
supernatant was transferred to a new tube and the DNA was precipitated using 
0.7x volume of isopropanol. Following centrifugation for 10 minutes at 2000 x g, 
the pellet was washed twice in 70% ethanol. The pellet was air dried and 
dissolved in 1x TE buffer (Section 2.1.3). 
 
2.3.2 Phenol-chloroform extraction 
A phenol-chloroform extraction was performed to extract DNA from blood that 
had been frozen. Briefly, 3ml of whole blood was aliquoted into polypropylene 
tubes and 9ml red cell lysis solultion (Section 2.1.1) was added. After shaking 
for 10 minutes, samples were centrifuged at 2000 x g for 10 minutes. The 
supernatant was removed to leave the white cell pellet to which 500l of cell 
lysis buffer for DNA extraction (Section 2.1.4) was added. After an hour of 
incubation at 37oC, proteinase K was added to a final concentration of 100g/ml 
followed by incubation at 55oC for an hour. 500l of 1:1 phenol (pH 
8):chloroform was then added and the tube inverted several times prior to 
centrifugation at 3100 x g for 10 minutes. The aqueous phase was removed to 
a fresh tube and an equal volume of chloroform added to it. The tube was again 
inverted several times and centrifuged at 3100 x g for 5 minutes. After 
transferring the aqueous phase to a fresh tube, sodium chloride was added to a 
final concentration of 0.2M and 2 volumes of ethanol were added. The sample 
was mixed and centrifuged at 3100 x g for 5 minutes. The supernatant was 
removed and 1ml 75% ethanol was added, followed by centrifugation at 3100 x 
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g for 5 minutes. After removal of the supernatant, the pellet was dried and 
dissolved in 1x TE buffer (Section 2.1.3)  
 
2.3.3 DNA size fractionation using agarose gel electrophoresis 
DNA size fractionation using agarose gel electrophoresis was carried out 
according to the protocol outlined in Sambrook and Russell (2000). Molecular 
biology grade agarose powder (Bioline, London, UK) was dissolved in 1x TAE 
(Section 2.1.5) to a concentration of 1.5% (w/v). Ethidium bromide was added to 
a final concentration of 500ng/ml. DNA samples were mixed with 10x gel 
loading dye to a final concentration of 1x. The samples were loaded into the 
wells at the cathode alongside an EasyLadder I (Bioline) or another appropriate 
molecular size standard. An electric field was applied for 40 minutes with a 
potential difference of 120V The resulting ethidium bromide labelled bands 
within the gel were visualised on a Bio-Rad molecular imager gel 
documentation system with a UV transilluminator and displayed using Image 
Lab (v.4.0) analysis software (Bio-Rad, Hemel Hempstead, UK). 
 
2.4 Next generation (massively parallel) sequencing 
2.4.1 Whole Exome Sequencing library preparation 
DNA samples considered for WES were quantified using the Qubit dsDNA BR 
assay kit (Life Technologies, Carlsbad, CA, USA). Two library preparation 
protocols were followed, one with a 3g input and one with a 200ng input. Both 
protocols follow the original SureSelectXT method (Agilent, Santa Clara, CA, 
USA) based on the use of solution hybrid selection technology developed by 
Gnirke et al. (2009). Figure 2.1 shows the main steps in the SureSelectXT 
protocol.  
 
Samples were then sequenced using the sequencing by synthesis method, 
using fluorescent reversible terminator deoxyribonucleotides, developed by 
Bentley et al. (2008) (Figure 1.13). 
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Figure 2.1: The Agilent SureSelectXT method. 
 
2.4.1.1 3g protocol 
The manufacturer’s guidelines were followed with a few modifications, although 
the protocol is also briefly described here. 3g of DNA was diluted to 250l in 
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1x TE buffer (Section 2.1.3) and sheared using the Covaris S2 Adaptive 
Focused Acoustics sonicator (Covaris, Woburn, MA, USA) at a standard shear 
setting of 19.9% duty cycle, intensity 8, 1000 cycles/burst, 25 repetitions at 
20oC to form fragments with a peak size of between 150-200bp. Sheared 
samples were purified and size selected with 1.8x volume of AMPure beads 
(Beckman Coulter, Brea, California, USA) as described in Agilent’s 
SureSelectXT kit instructions. The following steps use reagents from the 
SureSelectXT kit (Agilent) unless otherwise stated. End repair was performed 
using T4 DNA polymerase, Klenow polymerase and T4 polynucleotide kinase. 
3 dA tailing was then performed using dATP and Exo(-) Klenow polymerase. 
Adaptor ligation was performed using T4 DNA ligase. After each step, samples 
were treated with AMPure beads as described in Agilent’s SureSelectXT kit 
instructions. A pre-capture PCR amplification step was performed using 
Herculase II Fusion polymerase (Agilent) using the cycling conditions specified 
by the protocol to a total of 6 cycles. Samples were then treated with AMPure 
beads as described previously. 750ng of the prepared DNA was dissolved in 
3.4l distilled nuclease free water by pipetting. If necessary, prepared libraries 
were concentrated by dehydration using a Savant SpeedVac 110 vacuum 
concentrator (ThermoFisher Scientific, Waltham, MA, USA). Hybridisation was 
carried out with SureSelect Human All Exon v4 or v5 capture reagent (SSV4 or 
SSV5; Agilent) at 65ºC for 24 hours. Hybridised DNA was captured by use of 
Dynabeads MyOneTM Streptavidin T1 (Life Technologies) streptavidin coated 
beads. Each sample was uniquely indexed using 6bp indexes in a post capture 
PCR amplification step carried out using the cycling conditions specified by the 
protocol to a total of 12 cycles. Samples were then treated with AMPure beads 
as described previously. Equal molar quantities of each captured library were 
pooled and diluted to 10nM in nuclease free water. Pooled libraries were stored 
at -20oC until they were prepared for sequencing and sequenced by the Leeds 
St James’ University Hospital Next Generation Sequencing Facility (Leeds, UK, 
http://dna.leeds.ac.uk/genomics/) using the Illumina HiSeq2500 platform 
(Illumina, San Diego, CA, USA) in 100bp paired end read mode. 
 
 52 
For quality control and for information necessary to continue the protocol, sizing 
and quantification of DNA was carried out throughout the library preparation 
using the DNA1000 or DNAHiSensitivity assay kit (Agilent) using the 2100 
Bioanalyzer (Agilent). Quantification was carried out using the 2100 Bioanalyzer 
Expert software (Agilent) and was achieved by integrating the area under the 
peak.  
 
2.4.1.2 200ng protocol 
Subsequent to the release of the SureSelectXT kit B4 protocol (Agilent), the 
200ng protocol was used and the manufacturer’s guidelines were followed with 
one modification; post capture PCR was carried out using the cycling conditions 
specified by the protocol to a total of 10 cycles. Pooled libraries were prepared 
for sequencing and sequenced by the Leeds St James’ University Hospital Next 
Generation Sequencing Facility using the Illumina HiSeq3000 platform 
(Illumina) in 150bp paired end read mode. 
 
2.4.2 Whole exome sequencing alignment and variant calling 
Examples of simplified alignment and variant calling commands can be found in 
Appendix 4. 
 
Fastq files were aligned to the human reference genome (Genome Reference 
Consortium human 37 (GRCh37)) using Novoalign software (Novocraft 
Technologies, Selangor, Malaysia) or BWA (Li and Durbin, 2009). The resulting 
alignment was processed in the SAM/BAM format using the SAMtools, Picard 
(http://picard.sourceforge.net) and GATK programs to correct alignments 
around indel sites and to mark potential PCR duplicates (Li et al., 2009, 
McKenna et al., 2010, DePristo et al., 2011). 
 
Indel and single-nucleotide variants (SNVs) were called in the variant call format 
(VCF) using the Haplotype Caller function of the GATK program. Recalibration 
of indel and SNVs was performed separately with hard filtering using the 
following parameters to filter variants:  
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Quality by depth (QD) <2.0, Fisher Strand (FS) >60.0, Mapping quality (MQ) < 
40.0, Mapping Quality Rank Sum <-12.5 (For SNVs) 
Quality by depth (QD) <2.0, Fisher Strand (FS) >200.0 (For indels) 
The outputs were then combined to produce one VCF file (Danecek et al., 
2011). 
 
2.4.3 Whole exome sequencing variant filtering 
Examples of simplified variant filtering commands can be found in Appendix 4. 
 
VCF files resulting from alignment and variant calling were filtered as standard 
using the following databases of known variation: 
 
The National Center for Biotechnology Information’s (NCBI’s) database of single 
nucleotide polymorphisms and multiple small-scale variations (dbSNP) version 
142 (Available at http://www.ncbi.nlm.nih.gov/SNP/) (Sherry et al., 2001). 
 
The NHLBI Exome Sequencing Project’s Exome Variant Server (EVS; available 
at http://evs.gs.washington.edu/EVS/). 
 
The Broad Institute’s Exome Aggregation Consortium (ExAc; available at 
http://exac.broadinstitute.org/) version 0.3 (Exome Aggregation Consortium et 
al., 2016). 
 
The VCF hacks package (available at http://sourceforge.net/projects/vcfhacks) 
was used to carry out filtering and annotation of variant files. The cut off values 
for variant filtering were set according to the mode of disease inheritance. For 
rare recessive disease, variants with a minor allele frequency (MAF) of ≥1% 
were filtered. For rare dominant disease, variants with a MAF of ≥0.1% were 
filtered. 
 
Synonymous, non-coding, intronic and intergenic variants, other than those 
potentially affecting splice donor or acceptor sites were filtered. Variants 
potentially affecting splice donor or acceptor sites were classed as those 
 54 
residing within the intron up to 8bp from the splice junction or within the exon up 
to 3bp from the splice junction. Variants affecting known transcription factor 
binding sites or regulatory regions were also retained. The variants retained by 
using this filtering strategy are referred to in Chapters 3 and 4 as “functional 
variants”. 
 
Variant filtration was also based on mode of inheritance, i.e. for recessive 
disease, only biallelic variants were retained, whereas for dominant disease, 
homozygous variants were removed. In cases where sequence data was 
available from multiple family members, variants were filtered based on their 
presence in affected family members and for dominant disease, their absence 
in unaffected family members. Figure 2.2 details possible strategies for variant 
filtering. 
 
2.4.4 Whole exome sequencing variant annotation 
Examples of simplified variant annotation commands can be found in Appendix 
4. 
 
VCF files were annotated using Ensembl’s Variant Effect Predictor version 79 
(VEP; available at http://www.ensembl.org/info/docs/tools/vep/index.html). 
Files were ranked according to their Combined Annotation Dependent 
Depletion (CADD) version 1.3 scaled C-score (Section 2.8.4.4) (Kircher et al., 
2014). 
 
2.4.5 Whole exome sequencing depth of coverage 
An example of a command to obtain depth of coverage statistics can be found 
in Appendix 4. 
 
Indel realigned and base recalibrated bam files were used to assess the depth 
of coverage using GATK’s Depth Of Coverage tool. Assessment of coverage 
was based on the use of the appropriate SureSelect Human All Exon captured 
regions bed file as the interval file (made available from Agilent). 
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Figure 2.2: WES variant filtration and prioritisation strategies. 
The pipeline on the left details the basic strategy for variant filtration, however other possible 
filters are detailed in the panel to the right. Variant prioritisation strategies are shown at the 
bottom of the figure. Prioritisation is based initially on the predicted pathogenicity of the variants 
identified, but can be modified by both literature searches and the existence of candidate genes. 
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Mean coverage, as well as the percentage of bases covered at minimum depths 
of 5, 10, 15, 20, 25 and 30x, were assessed. 
 
2.4.6 Whole exome sequencing based detection of copy number 
variation 
In order to identify copy number variation too large to be detected by the variant 
calling protocol described above (Section 2.4.2), both ExomeDepth (Plagnol et 
al., 2012) and FishingCNV (Shi and Majewski, 2013) were utilised, depending 
upon the availability of appropriate control data. 
 
For sequencing batches consisting of six or more unrelated samples, aligned 
sequences, processed to produce an indel realigned, indexed bam file, were 
analysed using the R package, ExomeDepth (available at https://cran.r-
project.org/web/packages/ExomeDepth/index.html) (Plagnol et al., 2012). 
ExomeDepth compares the read depths of all captured exons of the test exome 
with the read depths of a reference set of 5-10 exomes. The reference exomes 
were from unrelated individuals whose DNA had been processed in the same 
WES batches for each exome analysed, using identical conditions as for the 
test exome. The resulting CNV call .csv file output was annotated to identify 
common CNVs (Conrad et al., 2010). CNV calls were ranked, with calls not 
annotated as a common CNV prioritised and the highest rank assigned to the 
calls with the highest Bayes factor; the log10 of the likelihood ratio of data for the 
CNV call divided by that of the normal copy number call (Plagnol et al., 2012).  
 
Graphical representations of ExomeDepth CNV calls were obtained by plotting 
the observed: expected read ratio against the chromosomal position of each 
captured exon. A region denoting the 99% confidence interval for the ratio in the 
absence of any CNV call was included in each plot. Read ratios of around 1.5 
suggested a heterozygous duplication of the region, while those of around 2.0, 
0.5 and 0 suggested a homozygous duplication, a heterozygous deletion and a 
homozygous deletion respectively. 
 
For sequencing batches consisting of five or fewer unrelated families, 
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FishingCNV was used (Shi and Majewski, 2013). Fishing CNV compares 
coverage depth in the test sample against the distribution of coverage in a 
batch of control samples that need not have been sequenced in the same 
sequencing run. Aligned, indel realigned recalibrated bam files, without 
duplicates marked, were used as input for GATK’s Depth Of Coverage 
command (Section 2.4.5), with a minimum mapping quality of 15 and minimum 
base quality of 10 specified. Reads per kilobase per million mapped reads 
(RPKM) files were generated using the sample_interval_summary output file for 
test and control samples. A minimum of sixty control files were pooled and used 
to analyse the test file for CNVs using the R package FishingCNV (available at 
http://sourceforge.net/projects/fishingcnv/) with principal component analysis 
normalisation specified to remove batch effects. Comma separated values file 
output was sorted on increasing Holm-Bonferroni adjusted p values, with 
smaller values indicative of more confident calls. Graphical representations of 
CNVs were obtained from the segmented data (.seg) file using the Broad 
Institute’s Integrative Genomics Viewer (IGV) (Robinson et al., 2011). 
 
2.4.7 Low-coverage whole genome sequencing library preparation 
DNA samples considered for WGS were quantified using the Qubit dsDNA BR 
assay kit. Libraries were prepared by the Leeds St James’ University Hospital 
Next Generation Sequencing Facility using the NEBNext UltraTM DNA Library 
Prep Kit for Illumina (New England Biolabs, Ipswich, MA, USA) as described in 
the manufacturer’s instructions with a few modifications. 100ng of DNA was 
diluted to 50l in 1x TE buffer (Section 2.1.3) and sheared using the Covaris S2 
Adaptive Focused Acoustics sonicator at a standard shear setting of 20% duty 
cycle, with an intensity setting of 5, and 200 cycles/burst for 140 seconds at 4oC 
to form fragments with a peak size of around 185bp. No size selection was 
performed due to the low input and the PCR amplification step was carried out 
using the cycling conditions specified by the protocol to a total of 12 cycles. Ten 
libraries were pooled in equal molar quantities and diluted to 10nM in nuclease 
free water and sequenced by the Leeds St James’ University Hospital Next 
Generation Sequencing Facility using the Illumina HiSeq2500 platform 
(Illumina) in 50bp single end read rapid mode.  
 58 
2.4.8 Low-coverage whole genome sequencing analysis 
Analysis of low-coverage whole genome sequencing data was carried out by 
the Leeds St James’s University Hospital Next Generation Sequencing Facility. 
The protocol for analysis of copy number variation was based on the methods 
detailed by Watson et al. (2014). Briefly, fastq files were aligned to the human 
reference genome (GRCh37) using the Burrows-Wheeler aligner (BWA; 
available at http://bio-bwa.sourceforge.net/) (Li and Durbin, 2009). Duplicate 
reads were removed using Picard (Section 2.4.2) and uniquely mapped reads 
from these and three control samples were counted into genomic windows 
containing equal numbers of reference reads with adjustment for GC% 
variation. The R module, DNAcopy (available from 
https://bioconductor.org/packages/release/bioc/html/DNAcopy.html) was then 
used to segment the data into regions of equal copy number (Venkatraman and 
Olshen, 2007). CNVs identified with copy numbers less than 0.683 or more than 
1.18 were reported in an html file format with UCSC genome browser (Section 
2.8.1) links embedded for both window midpoint and window boundaries, as 
well as the log2 ratio of reads in the test sample versus the control and the 
equivalent relative copy number. Cut off values were determined empirically by 
the Leeds Genetics Laboratory (http://www.leedsth.nhs.uk/a-z-of-services/the-
leeds-genetics-laboratory/) in order to remove false positives from the dataset. 
 
2.5 Polymerase Chain Reaction 
2.5.1 Primer design 
Primer design software tools (Section 2.8.2) were used to design primers. 
Optimum design parameters were set to produce primers with annealing 
temperatures of around 60°C, with products ideally ranging between 250bp - 
600bp. For genomic templates, the appropriate mispriming library was used in 
order to reduce the design of primer sequences that included rare (MAF <1%) 
SNPs and to eliminate those that included common (MAF ≥1%) SNPs. 
 
For screening genes, primers were designed at least 50bp from the intron-exon 
boundary. Large exons (>750bp) were split into overlapping PCR products of 
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approximately 500bp, with an overlap of at least 50bp. Primers were designed 
to be a minimum of 17bp to ensure specificity and a maximum of 27bp, to 
maintain a melting temperature of around 60°C. Runs of four or more 
mononucleotides and complimentary 5’ and 3’ ends were avoided to ensure 
secondary structures did not form. A GC% of 50, calculated by dividing the sum 
of Gs and Cs by the total primer length and multiplying by 100, was considered 
optimal, although 20-80% was accepted if necessary. Primer sequences were 
checked using UCSC’s BLAST-like alignment tool (BLAT), through the UCSC 
Genome Browser (Section 2.8.1) to ensure primers only bound where expected 
and that no known SNPs were present at the binding sites. 
 
2.5.2 Standard PCR 
All reagents in this section were obtained from Invitrogen, Carlsbad, CA, USA, 
unless otherwise stated. 
 
Reactions were carried out in a 12.5l volume with 25ng of genomic DNA with 
the following reagents at the following concentrations: 400nM for each primer, 
200M for each of dATP, dCTP, dGTP, dTTP, 1x PCR buffer (20mM Tris-HCl 
(pH 8.4) and 50mM potassium chloride (KCl)), 1.5mM magnesium chloride 
(MgCl2) and 1 unit Taq DNA polymerase. After the initial denaturation step at 
95ºC for 2 minutes, the samples were processed through 35 cycles of 95ºC for 
30 seconds, the appropriate annealing temperature for 30 seconds and 72ºC for 
30 seconds per 500bp of expected product. A final extension step was 
performed at 72ºC for 5 minutes. PCR products were visualised by agarose gel 
electrophoresis (Section 2.3.3) 
 
2.5.3 HotShot Master Mix (HSMM) PCR 
Reactions were carried out in a 10l volume with 25ng genomic DNA, with the 
following reagents and concentrations: 250nM of each primer and 1x PCR 
buffer / HotShot Diamond PCR Master Mix (Clent Life Science, Stourbridge, 
UK) with optional 1M betaine and / or 10% dimethyl sulphoxide (DMSO). DNA 
was amplified according to the manufacturer’s instructions using a hot start 
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PCR cycle. Initial denaturation was at 95ºC for 10 minutes, followed by 35 
cycles of 95ºC for 30 seconds, annealing temperature for 30 seconds and 72ºC 
for 30 seconds per 500bp of expected product. A final extension step was 
performed at 72ºC for 5 minutes. PCR products were visualised by agarose gel 
electrophoresis (Section 2.3.3). 
 
2.6 Microsatellite Marker Genotyping 
Genotyping of poly-CA microsatellites and other short terminal repeat (STR) 
variants in genomic DNA was carried out by PCR using fluorescently labelled 
(HEX or FAM) primers. Markers were selected and their genetic locations 
determined using the UCSC Genome Browser (Section 2.8.1). PCR was carried 
out as previously described (Section 2.5). Amplified DNA was subsequently 
diluted between 5-20x with Hi-Di Formamide (Applied Biosystems, Foster City, 
CA, USA) and 1l of the dilution added to 8l Hi-Di Formamide and 1l 500 
ROX size standard (Applied Biosystems). Fragments were resolved on an 
ABI3130xl sequencer using a 36cm array, POP7 polymer and 3730 buffer with 
the FragmentAnalysis36_pop7_1 module (Applied Biosystems). Resulting data 
were analysed on GeneMapper v4.0 (Applied Biosystems). 
 
2.7 Sanger Sequencing 
PCR template DNA to be sequenced underwent USB® ExoSAP-IT® 
(Affymetrix, Santa Clara, CA, USA) treatment in a 5:2 ratio followed by 
incubations of 15 minutes at 37°C and 15 minutes at 85°C. This was performed 
on PCR amplified DNA to remove unincorporated primers and dNTPs, which 
could interfere with subsequent sequencing reactions. 1μl of USB® ExoSAP-
IT® treated DNA was added to 5.5μl of de-ionised H2O, 1μl of BigDye® 
Terminator v3.1 (Applied Biosystems), 1.5μl of BigDye® Terminator v3.1 
Sequencing Buffer (Applied Biosystems) and 1μl of primer of 1.6M 
concentration. After an initial denaturation step at 96ºC for 1 minute, the 
samples underwent 25 cycles of 96ºC for 10 seconds, 50ºC for 5 seconds and 
60ºC for 4 minutes. All temperatures were ramped at 1ºC/second. After cycling, 
reactions were precipitated initially using 8mM EDTA and 80% ethanol and 
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spun at 3061 x g for 30 minutes at 22ºC. After removal of supernatant, 70% 
ethanol was added and samples spun at 805 x g for 15 minutes at 4ºC. 
Precipitates were dissolved in 10l Hi-Di Formamide (Applied Biosystems) and 
resolved at 60°C using a 36cm array on an ABI3130xl Genetic Analyzer 
(Applied Biosystems). POP7 polymer, 3730 sequencing buffer and 
FragmentAnalysis36_pop7_1 module (Applied Biosystems) were used for all 
runs. Resulting data were analysed on either Sequencing Analysis v5.2 or 
Seqscape v2.5 (Applied Biosystems). 
 
2.8 Bioinformatics 
Electronic resources, available online, that have been used in the design, 
analysis and interpretation of various assays in this project, are listed below. 
 
2.8.1 UCSC Genome Browser 
The UCSC genome browser for the human genome (available at 
http://genome.ucsc.edu/) brings together the vast wealth of genomic data into a 
single database (Kent et al., 2002). It comprises various builds of the genome 
sequence alongside an increasing number of custom tracks that can be added 
as required by the user. Custom tracks include databases of variation such as 
dbSNP, EVS and ExAc (Section 2.4.3) as well as the compendium of human 
genes and phenotypes, Online Mendelian Inheritance in Man (available at 
http://www.omim.org/). The intron-exon structures, genomic sequence, protein 
sequence and the locations and frequencies of polymorphisms were all 
determined using this tool. UCSC genome browser also hosts tools such as 
BLAT and in silico PCR that were used to assess the specificity of primer 
sequences. 
 
2.8.2 Primer Design Software Tools 
Primer design software is used to produce primer sequences that meet all of the 
criteria for successful, specific amplification more rapidly than selecting 
sequences manually. The program AutoPrimer3 (available at 
https://github.com/gantzgraf/autoprimer3) utilises the primer3 software tool 
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v4.0.0 (http://primer3.ut.ee/) to design and name primers for all coding exons of 
a specified gene automatically. The following settings were used: 
 
Primer-target buffer      50bp 
Maximal target (exon) size     500bp 
Overlap (for large exons)     50bp 
Annealing Temperature     60°C 
Primer size (minimum/optimum/maximum)  18/20/27bp 
 
AutoPrimer3 was utilised in preference to primer3 alone since it is able to 
automatically download the latest reference sequence file, can design primers 
for all exons simultaneously and can automatically avoid design of primers that 
lie over common SNPs. All primers were checked using BLAT, via the UCSC 
genome browser (Section 2.8.1) to avoid sequences that anneal over a known 
SNP. 
 
If redesign of a primer was required, primer3 was used manually with sites of 
known SNPs marked to exclude them from the design template. The 
parameters were set as follows: a primer length of 20bp (range 18-27bp), a 
primer melting temperature of 60°C (range 57-63°C) and a GC% between 20% 
and 80%. Primer pairs were designed to have a melting temperature within 2°C 
of each other. If these conditions could not be met for a primer, then the melting 
temperature was raised to 65°C. 
 
2.8.3 Literature Searches 
2.8.3.1 PubMed 
PubMed (http://www.ncbi.nlm.nih.gov/pubmed/), an online database of journal 
articles, was used to find relevant previously published information. Online 
Mendelian Inheritance in Man was used to obtain further information about 
disease phenotypes, loci and known genes. 
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2.8.3.2 PubMatrix 
PubMatrix is an automated literature search tool. The user may enter up to 100 
search terms and 10 modifier terms. The tool then creates up to 1000 different 
PubMed (Section 2.8.3.1) searches and reports articles matching the search 
terms as html links. 
 
2.8.4 Mutation Prediction Software 
The advent of Next Generation Sequencing and the wealth of variants of 
unknown significance identified in data from it has meant that there is a need for 
software to grade variants based on their disease-causing potential. This 
grading allows the most promising sequence variants to be prioritised for further 
analysis. Several online tools have been developed to assess the effects of 
variants and those used in this study are described below. 
 
2.8.4.1 PROVEAN and Sorting Intolerant From Tolerant (SIFT)  
PROVEAN (available at http://provean.jcvi.org/genome_submit.php) 
produces a score based upon the amino acid variation within the context of the 
surrounding sequence. Therefore, PROVEAN is not limited to solely non-
synonymous SNPs, but can predict the effect of other types of sequence 
variation, such as indels and multiple amino acid substitutions (Choi et al., 
2012). Scores are defined as follows: 
>-2.5   neutral 
≤-2.5   deleterious 
 
SIFT (available at http://provean.jcvi.org/genome_submit.php) classifies amino 
acid substitutions based upon the evolutionary conservation of the residue 
within the relevant protein family (Kumar et al., 2009). Scores are defined as 
follows: 
<0.05   damaging 
≥0.05    tolerated 
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2.8.4.2 Polymorphism Phenotyping (PolyPhen)-2 
PolyPhen-2 (available at http://genetics.bwh.harvard.edu/pph2/) gives a score 
based upon its prediction of the possible impact of an amino acid substitution 
(Adzhubei et al., 2010). This is based upon the sequence and 3D structural 
features of the protein and its homologues and function of a protein and the 
likelihood of the substitution at that site. The HumVar trained PolyPhen-2 model 
is used to appraise variants in the case of Mendelian disease. Scores are 
defined as follows: 
<0.2    benign 
0.2-0.85   possibly damaging 
>0.85    probably damaging 
No score  unknown 
 
2.8.4.3 MutationTaster 
MutationTaster (MT) (available at http://www.mutationtaster.org/) utilises and 
presents information about evolutionary conservation, splice-site changes, 
protein features and potential alteration to the level of transcription (Schwarz et 
al., 2010). The tool can assess the impact of synonymous, selected intronic and 
complex changes as well as single amino acid changes using three different 
prediction models. Classes are as follows: 
 Disease causing automatic  
 Disease causing 
 Polymorphism automatic 
 Polymorphism 
Automatic classification is assigned when the variant has been assigned 
disease causing / polymorphic variant status in a database of variation, 
including dbSNP (Section 2.4.3), 1000 Genomes Project (Abecasis et al., 
2010), ClinVar (available at http://www.ncbi.nlm.nih.gov/clinvar/) (Landrum et 
al., 2016) and Human Gene Mutation Database (available at 
http://www.hgmd.cf.ac.uk/ac/index.php) (Stenson et al., 2014). Classifications 
are qualified by a certainty of prediction score, ranging from 0 to 1, with 1 being 
most certain. 
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2.8.4.4 Combined Annotation Dependent Depletion 
Combined Annotation Dependent Depletion (CADD; available at 
http://cadd.gs.washington.edu/) annotation uses a model developed by scoring 
naturally occurring human variation and simulated variation for a range of 
measures including conservation, exon-intron geography, expression studies 
and protein level scores such as SIFT and PolyPhen-2 (Kircher et al., 2014). 
This information was used to develop a model capable of scoring all possible 
small indel and SNV variants to produce a scaled C score measure of 
deleteriousness that is scaled relative to all other possible alterations. Scaled C 
scores range from 1 to 99 with the top 10% of the most deleterious variants 
assigned scores of 10 or higher, and the top 1% and 0.1% assigned scores of 
20 or higher and 30 or higher respectively. 
 
2.8.4.5 Splicing RegulatiOn Online Graphical Engine (SROOGLE) 
In order to assess whether intronic variants were likely to alter splicing, 
sequences were queried using SROOGLE. SROOGLE (available at 
http://sroogle.tau.ac.il/) is a platform that scores different types of splicing 
signals using different splicing prediction tools and incorporates a ranked 
percentile score of these scores based on a dataset of scores of a large number 
of exons (Schwartz et al., 2009). 
 
For scoring of splice sites, SROOGLE utilises two models of splicing prediction: 
the Position Specific Scoring Matrix (PSSM) (Shapiro and Senapathy, 1987) 
and the Maximum Entropy Model (MEM) (Yeo and Burge, 2004). PSSM uses a 
position weight matrix, where each nucleotide at each position in a splice region 
is given an independent score based on its likelihood to occur at that position 
(Shapiro and Senapathy, 1987). Individual scores are then used to produce an 
overall score, with higher scores more likely to represent true splice sites. MEM 
compares the query sequence as a whole with a dataset of known splice sites, 
therefore taking into account the interdependence between each position in the 
splice site (Yeo and Burge, 2004). Higher MEM scores are more likely to 
represent true splice sites. 
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SROOGLE ranks the output of both PSSM and MEM scores to produce 
percentile ranks (0-1) (Schwartz et al., 2009). Scores indicate the percentage of 
exons SROOGLE’s dataset with lower scores, for example, a score of 0.7 would 
indicate that 70% of exons in the dataset have lower scores than the query 
sequence and therefore 30% have higher scores. 
 
2.8.5 Clustal Omega 
Clustal Omega (available at http://www.ebi.ac.uk/Tools/msa/clustalo/) is a 
multiple sequence alignment program for DNA, RNA or proteins. Alignment 
output can be ordered by sequence similarity to highlight highly conserved 
sequences. Clustal Omega was used to analyse conservation at the positions 
of missense variants and the surrounding amino acid residues. Sequences for 
proteins of interest were obtained from the UCSC genome browser (Section 
2.8.1). Paralogous sequences were retrieved using the Basic Local Alignment 
Search Tool (BLAST; available at http://blast.ncbi.nlm.nih.gov/Blast.cgi) and 
were used as input for Clustal Omega. 
 
2.9 Protein extraction from murine tissues 
Kidney and brain tissue was collected from adult mice immediately after 
euthanasia by cervical dislocation. The tissues were washed in sterile 
phosphate buffered saline and placed in RIPA buffer (Section 2.1.7) containing 
EDTA free complete protease inhibitor cocktail (Roche, Basel, Switzerland). 
Tissues were disrupted using an Ultra-Turrax™ T25 basic homogeniser (IKA, 
Staufen im Breisgau, Germany). Disrupted tissue was then pelleted by 
centrifugation at 4oC for 20 minutes at 16000 x g. Supernatants were aliquotted 
and frozen at -80oC until use. Protein was quantified using the Pierce 
bicinchoninic acid (BCA) protein assay kit (ThermoFisher Scientific). 
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2.10 Sodium dodecyl sulphate polyacrylamide gel 
electrophoresis (SDS-PAGE) 
Protein was extracted from tissues as detailed in Section 2.9. 50 g of protein 
was incubated at 95oC for 10 minutes with 1x Laemmli sample buffer (Bio-Rad). 
For reducing conditions, 10% 2-mercaptoethanol was added to the 4x Laemmli 
buffer stock prior to addition to the protein sample and its subsequent dilution to 
1x. Samples and a Precision Plus™ Protein All Blue Prestained Protein 
Standards (Bio-Rad) were then loaded onto a 10% (for effective separation of 
70-150kDa proteins) or 12% (for effective separation of 10-70kDa proteins) 
SDS PAGE gel (Section 2.10.1.1). The gel was run in a Mini-PROTEAN Tetra 
cell gel tank using 1x Tris glycine SDS PAGE running buffer (National 
Diagnostics, Madison, NJ, USA) at 200V for 60-90 minutes, depending upon 
the expected size of the product of interest. 
 
If required, protein gels were stained by incubating with InstantBlue™ stain 
(Expedeon, Swavensey, UK) for one hour with gentle agitation. 
 
2.10.1 SDS-PAGE gel compositions 
2.10.1.1 Resolving gel 
10% / 12%  Acrylamide Bis-acrylamide stock solution (Severn Biotech Ltd, 
Kidderminster, UK) 
375mM Tris-HCl pH 8.8 
0.1%  SDS 
21.25%  Glycerol 
0.05%  Ammonium persulphate (APS) 
0.1%  Tetramethylethylenediamine (TEMED) 
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2.10.1.2 Stacking gel 
4%  Acrylamide Bis-acrylamide stock solution 
125mM Tris-HCl pH 6.8 
0.1% SDS 
0.05%  APS 
0.1%  TEMED 
 
2.11 Western blotting 
Proteins separated by SDS-PAGE (Section 2.10) were transferred from the gel 
to the polyvinylidene fluoride (PVDF) membrane in a Mini PROTEAN Tetra 
blotting module (Bio-Rad) at 30V for 60-90 minutes (depending upon the 
expected size of the product of interest). Immediately prior to transfer, the PVDF 
membrane (Life Technologies) was pre-wet in 100% methanol for 30 seconds 
and transferred to 1x Tris-glycine electroblotting buffer (National Diagnostics), 
containing 20% methanol, for 5 minutes. After transfer, the membrane was 
blocked in 5% Marvel original dried skimmed milk powder (Premier International 
Foods, Spalding, UK) in TBS (Section 2.1.8) overnight at 4oC. The membrane 
was incubated with the primary antibody in 5% Marvel original dried skimmed 
milk powder in TBS for one hour at room temperature. After two washes of ten 
minutes each with TBST (Section 2.1.9) followed by one wash of ten minutes 
with TBS, the membrane was incubated with the appropriate secondary 
antibody for one hour at room temperature and then washed again as before. 
 
Blots were visualised on a Bio-Rad molecular imager gel documentation system 
with chemiluminescence displayed using Image Lab (v.4.0) analysis software 
(Bio-Rad, Hemel Hempstead, UK). SuperSignal West Pico Chemiluminescent 
Substrate (ThermoFisher Scientific) or SuperSignal West Femto Maximum 
Sensitivity Substrate (ThermoFisher Scientific) was used to visualise any bands 
present on the membrane by chemiluminescence. 
 
If required, blots were stripped of bound antibodies using Restore™ Western 
Blot Stripping Buffer (ThermoFisher Scientific) by incubating the blot in the 
buffer for 15 minutes and following the manufacturer’s instructions. Blots were 
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probed with chemiluminescent substrate as before, to confirm that the stripping 
treatment had been successful prior to washing with TBS and reblocking with 
milk powder as before. 
 
2.12 Histology 
2.12.1 Tissues 
 
2.12.1.1 Mouse incisor 
Incisor tissue was obtained from seven C57Bl/6 mice, aged eight to fifteen 
weeks, kindly made available by Dr. Zakia Abdelhamed (University of Leeds). 
The mice were euthanised by cervical dislocation and the jaws removed by 
careful dissection. Each mandible and maxilla was separated in the mid-sagittal 
line. After fixation in 10% neutral buffered formalin for 72 hours, the incisors 
were demineralised at 4oC by immersion in 0.5M EDTA pH 7.5 with gentle 
agitation. The buffer was refreshed twice each week and after 3 months, X-ray 
images showed that the incisors were completely demineralised (Appendix 18). 
 
Incisors were embedded in paraffin wax using an automatic processor 
(Hypercentre XP, Thermo Shandon Ltd, Runcorn, UK) and sectioned at a 
thickness of 5m using a microtome (Leica Biosystems, Nussloch, Germany) 
with a disposable stainless steel blade (Leica Biosystems). Sections were 
mounted on SuperFrost Plus slides (Menzel-Glaser, Braunschweig, Germany) 
and dried overnight, in an oven at 37oC. Haematoxylin and eosin staining 
(Section 2.12.3) aided identification of the sections that included all stages of 
amelogenesis. 
 
2.12.1.2 Mouse eye 
Formalin fixed, paraffin embedded mouse eyes were kindly made available by 
Mr. Mike Shires (University of Leeds). The eyes had been obtained from three 
adult C57Bl/6 mice and had been embedded and mounted as previously 
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described for incisors (Section 2.12.1.1) except that no demineralisation was 
carried out.  
 
2.12.2 Dewaxing and rehydration 
Slides were dewaxed by submersion in three staining baths of xylene (Acros 
Organics, Loughborough, UK) for 5 minutes each. Slides were drained on 
absorbent paper and then submerged in three baths of absolute ethanol for 1 
minute each to remove any remaining xylene and to rehydrate the slides. Slides 
were rinsed in running cold tap water for a further 5 minutes before proceeding 
to haematoxylin and eosin staining (Section 2.12.3) or antigen retrieval (Section 
2.12.5). 
 
2.12.3 Haematoxylin and eosin staining 
Dewaxed and rehydrated slides were stained for 30 seconds in Harris’s 
haematoxylin (Solmedia, Shrewsbury, UK) and then rinsed for 1 minute under 
cold running tap water. Next the slides were blued in Scott’s tap water substitute 
(Section 2.1.10) for 1 minute and then rinsed again in cold running tap water for 
1 minute. Slides were then stained with eosin (Solmedia) for 2 minutes and 30 
seconds and rinsed under cold running tap water for 1 minute. Finally the slides 
were dehydrated and mounted (Section 2.12.4). 
 
2.12.4 Dehydration and mounting 
Slides were dehydrated after staining by submersion in a bath of absolute 
ethanol for 2 minutes, followed by submersion in a further two baths of absolute 
ethanol for 1 minute each. The slides were thoroughly drained on absorbent 
paper and submerged in three baths of xylene for 1 minute each. Slides 
remained in the third bath until mounting. Slides were mounted using DPX 
(distyrene plasticiser and xylene) mountant and coverslips (ThermoFisher 
Scientific). The mountant was left to cure overnight. 
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2.12.5 Immunohistochemistry 
Following dewaxing and dehydration (Section 2.12.2), antigen retrieval was 
carried out by microwave treatment at full power for 10 minutes with 10mM 
citrate buffer pH 6.0. For some tissues this was unsuitable as it led to tissue 
detachment from the slide. In such cases, antigen retrieval was carried out 
instead by enzymatic treatment with 0.1% chymotrypsin in 0.1% calcium 
chloride pH 7.8 at 37oC for 25 minutes in a Coplin jar.  
 
Blocking of endogenous peroxidases was achieved by incubating slides with 
0.3% hydrogen peroxide in methanol for 10 minutes in a staining bath. The 
dilution of primary antibody to be used was determined by trial of a range of 
antibody dilutions (1:50, 1:100, 1:200, 1:500, 1:1000) with the lowest dilution 
(1:50) also trialled without antigen retrieval. All dilutions were prepared in 
antibody diluent (ThermoFisher Scientific). The primary antibody was applied for 
1 hour. The secondary antibody to be used was determined by the species in 
which the primary antibody was raised. The duration of treatment and dilution 
also varied. Slides were washed twice with TBST and once with TBS after each 
reagent for 5 minutes each. Staining was achieved with DAB+ reagent from the 
EnVision+ System-HRP (DAB) for use with rabbit primary antibodies (Dako) as 
described in the manufacturer’s instructions. 
 
Counter staining was with haematoxylin and bluing with Scott’s tap water 
substitute (Section 2.1.10) as previously described (Section 2.12.3). The 
sections were then dehydrated and mounted (Section 2.12.4). 
 
2.13 Tooth phenotyping 
Deciduous and permanent teeth were obtained by natural exfoliation or by 
extraction for clinical reasons. The teeth were photographed by the Medical and 
Dental Illustration department (University of Leeds) and were then subjected to 
ultrastructural analysis by micro computerised tomography (microCT) and 
surface electron microscopy (SEM). The chemical composition of the enamel 
was analysed by energy-dispersive X-ray spectroscopy (EDX). 
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2.13.1 Micro Computerised Tomography 
Teeth were analysed by high resolution microCT using a Skyscan 1172 (Bruker, 
Billerica, MA, USA), operated at 100 kV with a source current of 100A and an 
aluminium / copper filter to reduce beam hardening. CT slices were 
reconstructed using Skyscan Recon software (Bruker). The CT images were 
calibrated using a 3 point standard of hydroxyapatite mineral of densities 0.25, 
0.75 (Bruker) and 2.9g/cm3 (Himed, Old Bethpage, NY, USA). Regions of 
enamel in every tenth CT slice were automatically identified using ImageJ 
(available at http://imagej.nih.gov/ij/) and the Trainable Weka Segmentation 
plugin (available at http://fiji.sc/Trainable_Weka_Segmentation). This enabled 
the mean mineral density of the enamel to be calculated with reference to the 
standards for each scan. 
 
Calibrated colour contour maps of mineral density were generated using 
ImageJ 3D interactive surface plot plugin (available at 
http://rsb.info.nih.gov/ij/plugins/surface-plot-3d.html). 
 
2.13.2 Sectioning of human teeth 
Teeth were cut in half longitudinally in the labial/bucco-lingual direction using an 
Accutom-5 cutter (Struers, Ballerup, Denmark) with a peripheral diamond 
cutting disc, cooled with minimal water to minimise the loss of organic matter 
from within the enamel. 
 
One half of the tooth was polished plano-parallel with 600 grade carborundum 
paper (3M, Maplewood, MN, USA), then acid etched for 20 seconds with 30% 
phosphoric acid to remove the smear layer. The section was then washed with 
excess distilled water for 2 hours to stop the acid etching and to remove any 
debris on the surface. The tooth section was dried overnight with a vacuum 
applied. 
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2.13.3 Scanning Electron Microscopy 
Sections were mounted on aluminium stubs and sputter coated with gold using 
an AGAR auto sputter coater (Agar Scientific, Elektron Technology, Stansted, 
UK). Microstructural analysis was undertaken using a Hitachi S-3400N scanning 
electron microscope (Hitachi, Tokyo, Japan), fitted with a 123eV Bruker Nano 
XFlash Detector 5010 (Bruker) and operated at an accelerating voltage of 
20kV using secondary electron detection. 
 
2.13.4 Energy-dispersive X-ray spectroscopy 
Elemental analysis was performed on selected regions of the enamel by EDX 
using a detector fitted with an ultrathin window using Bruker Quantax Espirit 
software version 1.9.4 (Bruker). A minimum of nine measurements were 
obtained for each enamel region from each tooth. The mean composition of 
each region was then calculated. 
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3 The identification of PEX1 and PEX6 
mutations in Heimler syndrome 
3.1 Introduction 
The aim of the research presented in this chapter was to identify the genetic 
cause or causes of Heimler syndrome (HS). To achieve this, WES of affected 
individuals from a total of ten families with HS-like phenotypes was undertaken. 
The second aim was to identify the localisation of the affected encoded 
protein(s) within tissues affected by the syndrome. To achieve this, murine 
incisor and retina was used for immunohistochemical study. 
 
At the start of this study, HS had been described as a combination of SNHL and 
enamel defects, with the presence of nail abnormalities and macular dystrophy 
reported in some cases. No genetic cause for HS was known and since only 
seven cases of HS had been reported in a total of four families, it remained 
possible that the majority of diagnosing clinicians remained unaware of the 
existence of HS and consequentially defined patients’ symptoms as a 
combination of SNHL and RP (Usher syndrome; USH), and amelogenesis 
imperfecta (AI). Recruitment therefore focused on ascertaining patients with a 
combination of the constituent phenotypes. Since the nail abnormalities variably 
reported in published cases of HS are common in the general population and 
could have been caused by physical trauma or infection, their presence was not 
considered to be part of the diagnostic criteria for HS. 
 
Ten unrelated families segregating an AR syndrome, diagnosed as either HS or 
USH and AI, were recruited to this study (Figure 3.1). At the time of recruitment, 
no genetic cause for HS had been identified. Blood or saliva DNA samples were 
therefore obtained from affected individuals and their unaffected relatives, with 
the aim of identifying the gene(s) and mutations underlying HS. 
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Figure 3.1: Pedigrees of families included in the HS study. 
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3.2 Results 
Details of the primers used in the following section are listed in Appendix 5. 
 
3.2.1 Clinical phenotype 
A summary of the clinical phenotypes of the patients recruited to this study is 
detailed in Table 3.1 and Table 3.2. Families were recruited via a network of 
clinical collaborators working with the Leeds Vision and Amelogenesis 
Research groups, both before and during the course of this PhD project. The 
phenotype of 4716 (AI-186) is detailed in Figure 3.2. The phenotypes of 2975 
(AI-138), 3000 (AI-146) and 2645 (AI-71) are detailed in Appendix 6. Pedigrees 
for each family are shown in Figure 3.1. 
 
Individuals had all been diagnosed with SNHL, retinal dystrophy and AI or 
enamel defects. All patients had been diagnosed with a combination of USH 
and AI, except for individual 3000 (family AI-146), who had been diagnosed with 
HS. The phenotype of individual 2113 (family AI-16) had been reported 
previously (Balmer and Fayle, 2007). Individual 2645 (family AI-71) presented 
with additional features including schizophrenia, mild learning disability and skin 
abnormalities over his hands and lower legs. Individuals 3466 and 4922 (family 
AI-152) also presented with mild learning disability as well as facial skin lesions. 
Families were of US (families AI-10, AI-11, AI-12, AI-146 and AI-186), UK (AI-
16, AI-138 and AI-202), Chinese (AI-71) and Israeli (AI-152) heritage. There 
were no reports of consanguinity in any of the families. 
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Family AI-10 AI-11 AI-12 AI-16 AI-71 AI-138 
Sample number 1492 1499 1500 1502 
  
1503 1504 1509 
 
1514 2113 2645 2975 
Origin USA USA USA USA USA USA USA USA UK UK born  
Chinese 
UK 
Sex M F M M F F M M F M F 
Age (years) at 
last assessment 
NA NA NA NA NA NA NA NA 11 45 17 
Amelogenesis 
imperfecta 
+ + + + + + + + + + ? Permanent first 
molars and incisors 
affected only 
Intellect, known 
psychiatric 
disorder 
NA NA NA NA NA NA NA NA N Mild LD;  
paranoid  
schizophrenia 
N 
Skin NA NA NA NA NA NA NA NA NA Dry split skin on 
hands; ichthyosis  
over limbs 
N 
SNHL            
Bilateral or 
unilateral 
B B B B B B B B B B B 
Age (years) of 
diagnosis 
NA NA NA NA NA NA NA NA 0 Early  
childhood 
Early  
childhood 
Degree of 
hearing loss 
NA NA NA NA NA NA NA NA P, 
some VD 
S S to P 
Nail 
Abnormalities 
           
Beau’s lines NA NA NA NA NA NA NA NA NA + - 
Other nail 
changes 
NA NA NA NA NA NA NA NA NA - - 
Ocular Features            
Retinal dystrophy + + + + + + + + + + + 
Table 3.1: Clinical details of individuals with HS (part 1). 
Abbreviations are as follows: B bilateral; F female; LD learning disability; M male; Mi mild; Mo moderate; N normal; NA not ascertained; P profound; S severe; 
SNHL sensory neural hearing loss; VD vestibular dysfunction.
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Family AI-146 AI-152 AI-186 AI-202 
Sample number 3000 3466 4922 4716 4505 
Origin USA Israel Israel USA UK 
Sex M F F F F 
Age (years) at 
last assessment 
12 35 22 7 24 
Amelogenesis 
imperfecta 
+ + + + + 
Intellect, known 
psychiatric 
disorder 
N Mild LD Mild LD N N 
Skin Hyper-pigmentation 
on left arm and 
shoulder 
Dryness; light 
facial lesions 
Light facial 
lesions 
N N 
SNHL      
Bilateral or 
unilateral 
B B B NA B 
Age (years) of 
diagnosis 
1.5 0 0 3 1.5 
Degree of 
hearing loss 
Mo to S Mo to P Mi to Mo Mo to S P 
Nail 
Abnormalities 
     
Beau’s lines + - - - - 
Other nail 
changes 
- - Longitudinal 
stripes 
- - 
Ocular Features      
Retinal 
dystrophy 
+ + + + + 
Table 3.2: Clinical details of individuals with HS (part 2). 
Abbreviations are as follows: B bilateral; F female; LD learning disability; M male; Mi mild; Mo moderate; N normal; NA not ascertained; P profound; S severe; 
SNHL sensory neural hearing loss; VD vestibular dysfunction.
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Figure 3.2: Clinical details of the phenotype of individual 4716 (family AI-186).  
A and B: AI affecting the primary and secondary dentitions with generalised reduced enamel volume (hypoplasia) and variable hypomineralisation (particularly 
evident in the lower left permanent first molar tooth in B (arrow)). C: Fundus image showing pigmentary maculopathy and mild retina vascular attenuation in 
individual 4716. D: Fundus autofluorescence (FAF) showing hyperfluorescence at the peripheral macula (circled) in individual 4716. E: FAF image of a 
healthy retina for comparison. F: Infrared reflectance image to show position of optical coherence tomography (OCT) image in H for individual 4716. G: OCT 
of a healthy retina for comparison with H, note the defined retinal layers. H: OCT showing depletion of photoreceptors in the perifovea (arrows) and disruption 
of the outer nuclear layer (marked with *) for individual 4716. I: Fundus image of a healthy retina for comparison with C. 
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3.2.2 Whole exome sequencing of Heimler syndrome patient DNA 
In order to identify the gene or genes mutated in HS, WES was undertaken. 
Whole exome DNA libraries were prepared from fourteen affected individuals 
from ten unrelated families (Section 2.4.1.1 and Table 3.1 and Table 3.2). 
Representative Bioanalyser traces obtained for sample 4716 (family AI-186) at 
various stages in the WES library preparation protocol are shown in Figure 3.3. 
Libraries were prepared and sequenced in six batches over the course of 18 
months, during which time the SureSelect capture reagent was reformulated to 
include a greater proportion of coding exons. The version of the capture reagent 
used for each library preparation is detailed in Appendix 8. 
 
Initially, WES libraries were prepared from two affected individuals each from 
families AI-10 (Individuals 1499 and 1500), AI-11 (1503 and 1504), AI-12 (1509 
and 1514) and one affected individual from families AI-16 (2113), AI-71 (2645), 
AI-138 (2975) and AI-152 (3466) using the 3g protocol (Section 2.4.1.1). 
Subsequently WES libraries were prepared for a further four individuals from 
families AI-146 (3000), AI-152 (4922), AI-186 (4716) and AI-202 (4505). In 
some cases, there was insufficient DNA stock to use the 3g input specified by 
the manufacturer’s instructions. Details of the DNA inputs used can be found in 
Appendix 8. 
 
The resulting Fastq sequence files were aligned using Novoalign and the 
variants were called and filtered, using an analysis pathway appropriate for rare 
recessive diseases, described previously (Sections 2.4.2 and 2.4.3). The 
filtering protocol used the vcfhacks (v.0.1.11) perlscript, AnnotateSnps.pl, to 
exclude all variants present in dbSNP129 unless they had been marked as 
pathogenic in ClinVar (release 29/09/2014), indicated by the CLNSIG flag. This 
filter is later described as dbSNP129/pathogenic filter for brevity. The depth of 
coverage was also analysed (Section 2.4.5 and Appendix 8). The resulting 
filtered variant files were further filtered by excluding any identical variants 
present in two WES datasets from unrelated patients unaffected with, and 
without a family history of HS, USH or AI, processed using the same alignment 
and variant calling pipeline. This was to aid the exclusion of artefactual variants 
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Figure 3.3: Representative bioanalyser traces. 
Traces shown were obtained using the Agilent DNA1000 assay kit (A and B) and the Agilent 
DNAHiSensitivity (C) assay kit (Section 2.4.1.1) for sample 4716 (family AI-186). Abbreviations: 
bp base pairs; FU fluorescence units. 
A: After shearing and AMPure bead purification, 1μl DNA (50μl total yield) from 4716 was 
analysed to ensure the peak DNA fragment size was between 150-200bp. 
B: After end repair, A tailing, adaptor ligation and pre-hybridisation amplification with appropriate 
AMPure bead purification steps, 1μl DNA (30μl total yield) from 4716 was analysed to ensure 
the peak DNA fragment size was between 250-275bp and to quantify the DNA prior to 
hybridisation. 
C: After hybridisation, streptavidin bead capture, post-hybridisation addition of index tags and 
amplification with appropriate AMPure bead purification steps, 1μl DNA (30μl total yield) from 
4716 was analysed to ensure the peak DNA fragment size was between 300-400bp and to 
quantify the DNA, by integration of the area under the peak, prior to pooling. 
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inherent to the library preparation and sequencing platform. Variants were 
annotated as previously described (Section 2.4.4). 
 
3.2.3 Identification of USH2A variants in families AI-12 and AI-138 
Both filtered variant lists for 1509 and 1514 (family AI-12; Appendix 9) and 2975 
(family AI-138; Appendix 10) included biallelic variants in USH2A, a known 
cause of USH2 and non-syndromic recessive retinitis pigmentosa (RP) (Section 
1.11) (Eudy et al., 1998, Rivolta et al., 2000). The USH2A variants (annotation 
based on NM_206933; Table 3.3) were verified by Sanger sequencing of DNA 
from all available family members (Figure 3.4). 
 
In individuals 1509 and 1514 (family AI-12), two heterozygous deletions, 
c.2299delG and c.11875_11876delCA, as well as an SNV, c.4714C>T, were 
identified after filtering of the WES data. Analysis of the segregation of these 
alleles revealed that the c.2299delG and c.4714C>T variant were on the same 
maternal allele in cis, with the c.11875_118876delCA variant on the paternal 
allele in trans (Figure 3.4A). 
 
In individual 2975 (family AI-138), four heterozygous variants in USH2A were 
identified after filtering of WES data. Two of these variants were identical to 
those identified in 1509 and 1514 (family AI-12), c.2299delG and c.4714C>T. 
The SNVs c.11927C>T and c.11549-1G>A were also identified. Segregation of 
the four variants was performed but was limited by the availability of only one 
additional family member. As for family AI-12, analysis of the segregation of 
these alleles revealed that the c.2299delG and c.4714C>T variant were on the 
same paternal allele (this was inferred, due to its absence in 4725 and its co-
segregation, with the same c.2299delG variant that had been identified in 1509 
and 1514, family AI-12) in cis, with the c.11927C>T and c.11549-1G>A variants 
in cis on the maternal allele (Figure 3.4). 
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Family Genomic 
variant 
(GRCh37) 
Transcript 
variant 
Amino acid 
change 
Exon / 
Intron 
(i) 
dbSNP142 
reference 
CADD  
v1.3 
Provean SIFT Polyphen2 
(HumVar) 
Mutation 
Taster 
AI-12 
and 
AI-138 
1:216420437 
delC 
c.2299delG p.E767Sfs*21 13 rs80338903 33 N/A N/A N/A Disease 
causing  
(1) 
AI-12 
and 
AI-138 
1:216270469 
G>A 
c.4714C>T p.L1572F 22 rs111033333 26.8 Neutral 
(-2.39) 
Damaging 
(0.011) 
Probably 
damaging 
(0.885) 
Disease 
causing 
(0.97944) 
AI-138 1:215914880 
C>T 
c.11549-1G>A p.? 59(i) 
 
N/A 24.1 N/A N/A N/A Disease 
causing 
(1) 
AI-12 1:215901562_ 
215901563 
delTG 
c.11875_ 
11876 
delCA 
p.Q3959Nfs*53 61 N/A 35 N/A N/A N/A Disease 
causing  
(1) 
AI-138 1:215901511 
G>A 
c.11927C>T p.T3976M 61 rs142381713 25.5 Neutral 
(-2.43) 
Tolerated 
(0.056) 
Probably 
damaging 
(0.982) 
Disease 
causing 
(0.99914) 
Table 3.3: Details of the five heterozygous genomic USH2A variants identified by WES in families AI-12 and AI-138 after filtering. 
The list is restricted to variants scoring 15 or more with CADD v1.3.  
Provean, SIFT and Mutation Taster annotations were based on Ensembl transcript ENST00000307340.  
Polyphen-2 annotations were based on RefSeq protein NP_996816.  
Annotation of exon and intron numbers follows the Leiden Open Variant Database style of nomenclature.  
All scores were obtained on the 11th February 2016. 
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Figure 3.4: Segregation analysis and Sanger sequencing traces of USH2A variants 
identified in 1509 and 1514 (family AI-12) and 2975 (family AI-138). 
Annotations based on RefSeq transcript NM_206933 and protein NP_996816. 
A: Pedigrees for AI-12 and AI-138. Family members for whom DNA was available are labelled 
with a number. Affected individuals are indicated by shading. The genotype of each individual is 
labelled based on Sanger sequencing results for the USH2A variants identified by WES. 
B: Sanger sequencing traces for mutant and wild-type sequences for the USH2A variants 
identified in i) both AI-12 and AI-138; ii) AI-12 only; and iii) AI-138 only. 
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Genomic variant 
(GRCh37) 
dbSNP142 
reference 
ClinVar 
(release 
07/01/2016) 
ExAC (v0.3)  
number of variant 
alleles (total alleles at 
this position);  
allele frequency (all 
reported individuals 
heterozygous) 
EVS  
number of variant 
alleles (total alleles at 
this position);  
allele frequency (all 
reported individuals 
heterozygous) 
LOVDa; 
number 
of 
reports 
of the 
variant 
1:216420437delC rs80338903 Allele ID 17390 96 (121284); 7.92 x10-4 12 (12518); 9.59 x10-4 535 
1:216270469G>A rs111033333 N/P 95 (120984); 7.85 x10-4 14 (13006); 1.08 x10-3 115 
1:215914880C>T N/P N/P N/P N/P 1 
1:215901562_215901563delTG N/P N/P 2 (121344); 1.65 x 10-5 N/P 7 
1:215901511G>A rs142381713 N/P 63 (121330); 5.19 x10-4 13 (13006); 1.00 x10-3 2 
Table 3.4: Frequencies in public databases for the variants in USH2A identified in 1509 and 1514 (family AI-12) and 2975 (family AI-138).   
aLOVD Retinal and hearing impairment genetic mutation database Usher syndrome 2A (USH2A) curated by David Baux (Roux et al., 2011). 
Abbreviation is as follows: N/P Not present. 
All databases accessed 27th January 2016. 
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Analysis of each USH2A variant identified by scoring with pathogenicity 
prediction software and investigation of each variant’s frequency in a variety of 
publically available databases of known variation is shown in Table 3.4. The 
variant identified in 2975 (family AI-138) within an intronic splice site, c.11549-
1G>A, was analysed using SROOGLE (2.8.4.5). 
 
The single nucleotide variants identified in 2975 (family AI-138) included both 
missenses c.4714C>T and c.11927C>T and an intronic mutation affecting a 
splice site c.11549-1G>A. Since the missense variant (c.4714C>T) was found 
to be on the same allele as the paternal (inferred) frameshift variant 
(c.2299delG), the pathogenicity of the missense mutation is likely to be of no 
consequence to the overall effect on the protein since the frameshift variant will 
lead to production of a transcript that would be subject to nonsense mediated 
decay (NMD). For the missense variant on the maternal allele, c.11927C>T, 
pathogenicity prediction software, including Polyphen-2 and Mutation taster, 
predicted that the variant was pathogenic, with borderline neutral and tolerated 
scores obtained using Provean and SIFT. The splice site variant, c.11549-1G>A 
would be expected to alter the 3’ acceptor site within intron 59 due to its 
location. Analysis and comparison of scores obtained from reference and 
variant sequences using SROOGLE, indicated that there was indeed likely to 
be altered function of the 3’ acceptor site (Table 3.5). 
 
Sequence 
(GRCh37) 
Max. 
entropy 
model 
score 
(MEMS) 
MEMS 
constant 
exons 
percentile 
MEMS 
alternative 
exons 
percentile 
Position 
specific 
scoring 
matrix 
(PSSM) 
score 
PSSM 
constant 
exons 
percentile 
PSSM 
alternative 
exons 
percentile 
Reference 
sequence 
8.57 0.47 0.54 91.05 0.94 0.94 
1:215914880C>T -0.18 0.01 0.02 67.61 0 0.01 
Table 3.5: In silico analysis of the effect of USH2A variant c.11549-1G>A, identified in 
2975 (family AI-138) on splicing. 
Maximum entropy model and position specific scoring matrix scores and their associated 
percentile ranks were obtained from SROOGLE. 
 
A literature search of the variants identified in families AI-12 and AI-138 
revealed that all had been identified previously in USH patients (Eudy et al., 
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1998, Baux et al., 2007, Dreyer et al., 2008, Lenassi et al., 2015). The 
identification of biallelic variants in USH2A, a gene previously implicated in 
USH2, in two patients from the HS cohort, suggested that these cases may 
have USH2 rather than HS. Despite a large body of literature detailing the 
phenotype of patients with USH2A mutations, there have been no reports of an 
associated enamel phenotype. It therefore seems likely that the tooth defect in 
these cases is due either to a separate mutation or to environmental enamel 
defects. The filtered WES data did not highlight any biallelic variants in genes 
other than USH2A for family AI-12. For 2975 (family AI-138), biallelic variants in 
GXYLT1, WDR89, TMEM200C, TSC2, MUC6, MUC16, ZNF880, KRT25 and 
HTT remained after filtering. To determine whether USH2A or any of the other 
genes with biallelic variants are differentially expressed during amelogenesis 
and might therefore be candidate AI genes, the presence or absence of each 
gene in RNA sequencing studies of secretory stage and maturation stage 
amelogenesis in rats was checked (Yin et al., 2014b). USH2A was not identified 
as differentially expressed. From the remaining candidate genes, TSC2, MUC6 
and KRT25 were found to be differentially expressed in rodent enamel organs 
during amelogenesis, although the fold change ratios for both were all within 
±1.35 and the changes were not significant. Of these, mutations in TSC2 are 
known to cause tuberous sclerosis 2 (OMIM #613254), a condition that can 
encompass a distinctive form of AI (Schwartz et al., 2007, Harutunian et al., 
2011). However no evidence of tubular sclerosis was observed in individual 
2975. Both MUC6 and KRT25 belong to extended gene families that consist of 
multiple paralogous genes. Alignment and subsequent variant calling may 
therefore be error prone for reads falling within these genes. In addition, 
variants within these genes are commonly observed in filtered variant lists 
generated by WES, however, the variants remain unconfirmed and of are of 
unknown significance. 
 
Further investigation of the enamel defect in 2975 (family AI-138) revealed that 
it was refined to only the first permanent molars, the upper incisors, one upper 
canine tooth and one lower incisor, with no record of it having been found in the 
deciduous dentition. The dentist thought that the phenotype did not resemble 
AI, but was more suggestive of an environmental or life history associated 
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enamel defect. The clinical notes also detailed that 2975 (family 138) had 
suffered from perinatal fevers. This further suggests that the phenotype may be 
due to a combination of USH2 and an enamel defect other than AI such as MIH. 
For family AI-12, it was not possible to obtain further enamel phenotype details 
since contact had been lost with the recruiting clinician. 
 
In summary, both families AI-12 (1509 and 1514) and AI-138 (2975) carry 
multiple variants in USH2A. Of the variants carried by 1509 and 1514 (family AI-
12), the biallelic framshift variants, c.2299delG (p.E767Sfs*21) and 
c.11875_11876delCA (p.Q3959Nfs*53) are likely to cause USH2. Of the 
variants carried by 2975 (family AI-138), biallelic frameshift and splicing 
variants, c.2299delG (p.E767Sfs*21) and c.11549-1G>A (p.?) are likely to 
cause USH2. Therefore both AI-12 and AI-138 were excluded from further 
analysis in the search to identify a causative gene for HS. 
 
3.2.4  Low coverage whole genome sequencing of Heimler 
syndrome patient DNA 
DNA from individuals 1492 (AI-10), 1502 (AI-11), 2113 (AI-16), 2645 (AI-71), 
3466 (AI-152) and 4716 (AI-186) was submitted to Leeds St James’ University 
Hospital Next Generation Sequencing Facility for low coverage WGS, to screen 
for CNVs and rearrangements that might not be detected in WES data (Section 
2.4.7). Analysis was undertaken by the same facility and results were returned 
in the form of html files (Section 2.4.8). Depth of coverage was calculated 
separately as previously described for WES (Section 2.4.5) but using the 
GRCh37 reference sequence as the interval. 
 
Coverage was calculated to be 0.61x on average (Appendix 11). The resulting 
html files detailing the positions of CNVs detected were manually checked to 
identify CNVs that encompassed gene exons and that were not reported in the 
Database of Genomic Variants (MacDonald et al., 2014). DNA from all samples 
had exonic CNVs of unknown significance but no two families had CNVs over 
the same gene. With the exception of data from family AI-11, these results were 
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not analysed further but were archived as a data set to be revisited should 
further WES reveal a candidate gene for HS. 
 
3.2.4.1 Identification of a putative CNV involving MYO7A and CAPN5 in 
family AI-11 
Although the CNVs detected for the majority of samples were of unknown 
significance, results for sample 1502 (AI-11) included a heterozygous deletion 
of the first two exons of myosin VIIA (MYO7A; Section 1.11) and the 3UTR of 
calpain 5 (CAPN5; MIM *602537). A copy number plot for chromosome 11 for 
sample 1502 that includes the region of the heterozygous deletion is shown in 
Figure 3.5. Window boundaries and midpoints for the deletion were listed as 
chr11:76,835,000-76,845,306 and chr11:76,837,355-76,842,508 respectively, 
denoting a deletion of size 5,154bp minimum and 10,307bp maximum (Table 
3.6 and Figure 3.6). The relative copy number for this region was calculated as 
0.53. Overall resolution, based on 4 windows, each with an average size of 
5,831bp, was 23kb for this sample. 
 
The CNVs identified by low coverage WGS were then compared with WES 
data-based CNV analysis for the other individuals from family AI-11, 1503 and 
1504. The batch of WES analysed on the sequencer lane that included AI-11 
libraries 1503 and 1504 also included 1492 (AI-10), 1509 and 1514 (both AI-12) 
and another unrelated sample with AI. Having only three other families in the 
same batch was considered insufficient to serve as control data for detection of 
CNVs by ExomeDepth (Section 2.4.6). Instead, around sixty other sets of WES 
data, obtained from libraries prepared and sequenced using identical conditions 
but in different batches to AI-11 samples 1503 and 1504, were used as controls 
for FishingCNV (Section 2.4.6). The resulting prioritised CNV calls were then 
used to filter the low coverage WGS CNV calls obtained for 1502. After filtering, 
only two CNVs remained that were unreported by Conrad et al. (2010), exonic 
and detected in all three family members (Table 3.6). These included a 
heterozygous deletion of ATPase family, AAA+ domain containing 3B 
(ATAD3B; MIM *612317) and ATAD3C and the heterozygous partial deletion of 
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CAPN5 and MYO7A observed on low coverage genome sequencing of 
individual 1502. 
 
 
Figure 3.5: Relative copy number plot of chromosome 11 in individual 1502 (family AI-11).  
Plot details the copy number at the position of each genomic “window” assigned by DNA copy. 
The black line represents a normalised average copy number based on calls for aggregated 
control sequences. Each blue dot represents the relative copy number for each genomic 
window for 1502. The red line represents the relative copy number over chromosome 11 for 
1502, based on groups of genomic windows. The circle highlights the heterozygous deletion of 
MYO7A exons 1 and 2 (point shown in red). 
 
The heterozygous deletion of ATAD3B and ATAD3C was detected in 1503 and 
1504, although the 3 limit of the call differed for the two individuals. The 
FishingCNV call for 1503 indicated that the heterozygous deletion may be 
limited to exons 1-4 (inclusive) for ATAD3B (NM_031921), although calls for 
1502 and 1504 suggested that the entire gene may be deleted. The 
segmentation mean values were -0.890 and -0.645 with Holm adjusted p values 
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of 6.90 x10-15 and 2.81 x10-15 respectively for individuals 1503 and 1504. The 
segmentation mean values equate to a relative copy number of 0.540 and 
0.639 for samples 1503 and 1504 respectively for the region. 
 
Reanalysis of WES data for 1503 and 1504 failed to identify any heterozygous 
variants in ATAD3B and ATAD3C that would be expected for recessive disease. 
Reanalysis was necessary since the variants could have been removed during 
the original filtering strategy due to their zygosity. Analysis of coverage of the 
ATAD3B and ATAD3C region revealed that several exons, in both genes, were 
covered by fewer than ten reads for both 1503 and 1504. Therefore, since 
these regions were not Sanger sequenced, it remains possible that a second, 
unidentified variant may be present in either ATAD3B or ATAD3C. Mutations in 
ATAD3B and ATAD3C have not been reported to result in disease in humans. 
 
The heterozygous deletion over MYO7A was detected in 1503 and 1504 as 
spanning chr11:76,833,544-76,841,805 (The final two 3 exons of CAPN5 and 
the first two 5 exons of MYO7A), with segmentation mean values of -0.8076 
and -0.6836 with Holm adjusted p values of 1.41 x10-6 and 1.73 x10-9 
respectively. The segmentation mean values equate to a relative copy number 
of 0.57 and 0.62 for samples 1503 and 1504 respectively for this region. 
 
Sample Genomic position 
(GRCh37) 
Size 
(bp) 
Relative 
copy 
number 
(diploid=1; 
to 3 s.f) 
Genes Holm 
adjusted p 
value 
(FishingCNV 
only) 
1502 1:1387895-1430620 
 
42,725 
 
0.514 
 
ATAD3B, 
ATAD3C 
N/A 
 
1503 1:1387417-1416232 
 
28,815 
 
0.540 
 
ATAD3B, 
ATAD3C 
1.37 x10-11 
 
1504 1:1387417-1431087 
 
43,670 
 
0.639 
 
ATAD3B, 
ATAD3C 
2.81 x10-12 
 
1502 11:76837355-76842508 5,153 0.534 MYO7A N/A 
1503 11:76833544-76841805 8,261 0.571 CAPN5, 
MYO7A 
2.92 x10-9 
1504 11:76833544-76841805 8,261 0.623 CAPN5, 
MYO7A 
3.21 x10-6 
Table 3.6: CNV calls shared by AI-11 family members 1502, 1503 and 1504. 
Calls for 1502 were obtained from low coverage WGS data using DNAcopy. Genomic positions 
indicate DNAcopy window midpoints. Calls for 1503 and 1504 were obtained from WES data 
using FishingCNV.  
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Mutations in MYO7A are a known cause of USH type IB (USH1B) (Weil et al., 
1995) and isolated SNHL with both recessive and dominant inheritance (Liu et 
al., 1997a, Liu et al., 1997b). Since USH1B has an AR mode of inheritance, the 
WES data for 1503 and 1504 were checked for heterozygous variants within 
MYO7A that would have been filtered out by the strategy employed in the 
original analysis due to their zygosity. Upon reanalysis, no further variants 
within MYO7A were identified. Since poor coverage over an exon containing a 
causative variant could potentially prevent its detection, coverage over MYO7A 
was assessed. It was found that exons 2, 13, 16, 32, 35, 38 and 42 contained 
regions of poor coverage (fewer than ten reads). Therefore these regions were 
Sanger sequenced, but no further variants were identified. 
 
Since digenic inheritance has been suggested for USH, the possibility of a 
second USH variant in another USH gene was investigated. Upon reanalysis, 
no variants with a CADD score of greater than 2.7 were identified in both 1503 
and 1504 (AI-11) within USH1C, CDH23, PCDH15, USH1G, CIB2, USH2A, 
ADGRV1, DFNB31, CLRN1, PDZD7 and HARS. 
 
Both predicted heterozygous deletions remain unconfirmed by Sanger 
sequencing and are of unknown significance. 
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Figure 3.6: Schematic of the location of a predicted deletion of MYO7A exons 1 and 2 and 
segregation analysis of an ENAM SNV in family AI-11. 
A: Schematic to show the locations of selected CAPN5 and MYO7A exons relative to a 
predicted deletion with unconfirmed breakpoints. The deletion was predicted to span MYO7A 
exons 1 and 2 and was detected in 1502 using DNACopy analysis of WGS data (window 
boundaries and midpoints are shown). The deletion was also detected in 1503 and 1504 by 
FishingCNV analysis of WES data. 
B: Segregation analysis of a heterozygous ENAM variant, c.332A>C (p.K111T); i: pedigree of 
Family AI-11; ii: Sanger sequencing trace of mutant and wild-type sequences.  
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3.2.5 Identification of an ENAM variant in family AI-11 
After filtering WES data for AI-11 based on an AR mode of inheritance (Section 
2.4.3), eleven variants remained (Appendix 12), of which, only WDR89, 
ABCC11 and PKHD1L1 had biallelic variants with CADD scores >15. These are 
not known AI, USH, retinal dystrophy or SNHL genes, and an examination of 
the available literature did not appear to support their involvement in AI. They 
were therefore archived for later study in the event that no better candidates 
were found. 
 
In order to screen for potentially causative mutations for the AI phenotype, data 
was filtered to select variants within known AI genes without filtering for biallelic 
variants. A rare SNV in ENAM (Section 1.9.3), c.332A>C, p.K111T, was 
identified in WES data for both 1503 and 1504 with a CADD score of 16.01 
(Appendix 13). The variant was confirmed by Sanger sequencing and its 
presence checked for the remaining family members Figure 3.6B. All affected 
AI-11 family members (1502, 1503, 1504) as well as the father (1505) and 
paternal grandfather (1507) carried this mutation. It therefore seems unlikely 
that this mutation is causative unless an AI phenotype in these two individuals 
had been missed. Loss of contact with the recruiting clinician meant that the 
phenotype of this family could not be reanalysed in more detail to determine 
whether the father or the paternal grandfather had AI. However analysis with 
mutation prediction software and investigation of public databases of variation 
would suggest that this variant is benign (Appendix 13). 
 
3.2.6 Identification of PEX1 variants in family AI-202 
After filtering of WES data (Section 3.2.2) from individual 4505 (family AI-202), 
twenty variants remained (Appendix 14). Among these were biallelic variants in 
PEX1, including a single nucleotide duplication leading to a frameshift 
c.2097dupT, p.I700Yfs*42 and a missense variant, c.1742G>C, p.R581P 
(annotation based on NM_000466.2). 
 
The PEX1 variants were verified by Sanger sequencing of DNA from all 
available family members (Figure 3.7 and Appendix 7). The variants segregated 
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with the disease phenotype. Biallelic mutations in PEX1 are known to cause the 
ZSSDs (Section 3.3.1). The maternally inherited, single nucleotide duplication 
variant identified in individual 4505, c.2097dupT, had previously been reported 
in individuals with ZSSDs (Collins and Gould, 1999). The allele inherited from 
the father that carried the SNV had not previously been reported in ZSSD 
patients. To check the conservation of the mutated residue within the 
orthologues of PEX1, the human sequence (NP_000457) was used to obtain 
orthologous sequences using BLAST. Subsequent alignment using Clustal 
Omega showed that the substitution altered a highly conserved residue within 
the PEX1 protein (Figure 3.8A). 
 
The diagnosis of milder ZSSDs, such as IRD, especially for disease that 
presents as isolated sensory deficits, can be delayed until the teenage years 
(Waterham and Ebberink, 2012). ZSSDs are also known to have been 
misdiagnosed as USH or Leber congenital amaurosis (LCA) (Raas-Rothschild 
et al., 2002, Michelakakis et al., 2004, Majewski et al., 2011). Therefore, it was 
considered possible that individual 4505 had sensory defects due to PEX1 
mutations and that a separate mutation was responsible for the AI phenotype. 
 
In order to check for potential dominantly inherited variants in genes associated 
with AI to account for the dental phenotype, data was filtered to select variants 
within known AI genes without filtering for biallelic variants. A heterozygous 
mutation in LAMA3, c.6389C>T, p.S2130F was identified, confirmed and shown 
to be maternally inherited (Appendix 15). The mother was re-examined but did 
not have AI. 
 
A literature search was conducted to see whether a tooth phenotype had been 
previously reported in ZSSD patients. It identified four reports of such defects, 
including tooth formation and eruption defects as well as enamel hypoplasia, in 
ZS and IRD patients (Bader et al., 2000, Poll-The et al., 2004, Tran et al., 2011, 
Lertsirivorakul et al., 2014). In one cohort of 24 patients aged four years or over, 
dental defects were reported in one third (Poll-The et al., 2004). Therefore, it 
was concluded that the combination of sensory defects and AI in 4505 could be 
due to the biallelic mutations in PEX1.   
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3.2.7 The search for PEX1 and PEX6 variants in other Heimler 
syndrome individuals 
After identification of bialllelic PEX1 variants in AI-202, we revealed our findings 
to Prof. W. Newman (University of Manchester). He confirmed that he had also 
identified biallelic mutations in PEX1, and in the functionally-related gene PEX6, 
in HS patients. 
 
The results of the original filtering strategy (Section 3.2.2), which aimed to 
identify rare, biallelic variants in each patient from the HS cohort, had failed to 
identify biallelic mutations in PEX1 or PEX6 in any family other than AI-202. In 
order to check for the possibility that causative PEX1 variants might have been 
filtered out by the original strategy, the functional variants (Section 2.4.3) within 
the PEX1 gene were selected from the unfiltered variant lists. PEX1 is known to 
be the most common cause of PBDs but other genes, including PEX2, PEX3, 
PEX5, PEX6, PEX7, PEX10, PEX11B, PEX12, PEX13, PEX14, PEX16, PEX19 
and PEX26 are also known to cause PBDs (Shimozawa et al., 1992, Dodt et al., 
1995, Yahraus et al., 1996, Braverman et al., 1997, Chang et al., 1997, Motley 
et al., 1997, Purdue et al., 1997, Reuber et al., 1997, Honsho et al., 1998, 
Warren et al., 1998, Matsuzono et al., 1999, Shimozawa et al., 1999, 
Shimozawa et al., 2000, Matsumoto et al., 2003, Shimozawa et al., 2004, 
Ebberink et al., 2012). Therefore, functional variants within these genes were 
also selected, as well as functional variants within two other PEX genes not 
identified as a cause of PBDs, PEX11A and PEX11G. 
 
Using this method, biallelic variants in PEX1 were identified in 2645 (family AI-
71) (Figure 3.7 and Table 3.7). The two variants were a single nucleotide 
deletion, c.1792delA, p.Q598Tfs*11 and an SNV, c.2966T>C. The frameshift 
variant had not been identified previously in ZSSD patients, whereas the 
missense variant had been reported previously (Maxwell et al., 2005). Variants 
were confirmed by Sanger sequencing but no additional family members were 
available for segregation analysis (Appendix 7). 
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Biallelic variants were also identified in PEX6 for three other families; AI-10 
(1499 and 1500), AI-146 (3000) and AI-152 (3466 and 4922) (Figure 3.7 and 
Table 3.7). All variants were confirmed by Sanger sequencing and segregated 
with the disease phenotype in all available family members (Appendix 7). 
 
Affected individuals 1492, 1499 and 1500 from family AI-10 and 3000 from 
family AI-146 shared an identical heterozygous SNV, c.1802G>A, p.R601Q, 
that has been reported previously in ZSSD patients (Yik et al., 2009). From the 
maternal allele, affected individuals (1492, 1499 and 1500) in AI-10 carried a 
second heterozygous SNV, c.654C>G, p.F218L which was previously 
unreported. Individual 3000 (AI-146) also carried a previously unreported 
heterozygous variant, c.275T>G, p.V92G. No other samples were available for 
segregation analysis for AI-146. 
 
Individuals 3466 and 4922 (AI-152) were homozygous for an SNV previously 
reported in ZSSD patients, c.1715C>T, p.T572I (Raas-Rothschild et al., 2002) 
(Figure 3.7 and Table 3.7). 
 
For the individuals in the remaining families, AI-16 and AI-186, only one 
heterozygous variant in PEX6 was identified from the WES data in each. In 
2113 (AI-16), the previously unreported SNV, c.2714G>T, p.C905F was 
identified. In 4716 (AI-186), the PEX6 SNV, c.1802G>A, p.R601Q, also found in 
1499 and 1500 (AI-10) and in 3000 (AI-146), was identified as well as a 
heterozygous SNV in PEX26, c.728C>T, p.A243V. The presence of the PEX6 
variant, previously identified in two other HS families, in 4716 (AI-186), together 
with the low CADD score and other benign mutation prediction scores for the 
PEX26 variant identified, led to the suspicion that 4716 (AI-186) may have an 
undetected PEX6 variant. It was suspected that regions of low coverage might 
harbour additional heterozygous PEX6 variants for both 2113 (AI-16) and 4716 
(AI-186). 
 
Individuals from families AI-11 (1503 and 1504), AI-12 (1509 and 1514) and AI-
138 (2975) were not found to carry variants in any PEX genes. 
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3.2.8 WES depth of coverage analysis of PEX1, PEX6 and PEX26 
for 2113 (family AI-16) and 4716 (family AI-186) 
In order to identify regions of low coverage in WES data from 2113 (AI-16) and 
4716 (AI-186) that may harbour additional PEX gene variants, the depth of 
coverage over genes PEX1, PEX6 and PEX26 was assessed. These genes 
were selected because heterozygous variants had already been identified in 
PEX6 and PEX26 in 2113 (AI-16) and 4716 (AI-186), and biallelic mutations in 
both PEX1 and PEX6 had been identified in the remainder of the HS cohort and 
Prof. Newman’s cohort. 
 
Bases covered by fewer that ten reads, and positioned within an exon or a 
splice site, were identified and screened by Sanger sequencing. For 2113 (AI-
16), PEX1 exon 7 and PEX6 exons 1, 5 and 8, and for 4716 (AI-186), PEX6 
exons 1, 8 and 12, were not covered in their entirety by ten or more reads. This 
targetted sequencing revealed additional mutations in PEX6 in both families. In 
2113, an 8bp deletion was identified, c.1314_1321delGGAGGCCT, 
p.E439Gfs*3, which had been previously reported in ZSSD patients (Krause et 
al., 2009). In 4716 (AI-186), an SNV previously unreported in ZSSD patients, 
c.296G>T, p.R99L was identified. The compound heterozygous variants co-
segregated with the disease phenotype in both AI-16 and AI-186 for all 
available family members. A summary of the PEX1 and PEX6 mutations 
identified in the HS cohort can be found in Table 3.7. 
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Figure 3.7: Sanger sequencing and genomic locations of the PEX1 and PEX6 mutations 
identified in this study. 
A: A schematic diagram of PEX1 genomic structure and transcript (NM_000466) shows the 
location and sequence traces of four mutations identified in this study. 
B: A schematic diagram of PEX6 genomic structure and transcript (NM_000287) shows the 
location and sequence traces of seven mutations identified in this study. 
a The reverse sequence trace is shown for the PEX1 c.1792delA variant. 
Reproduced with permission from Smith et al. (2016b). 
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3.2.9 Bioinformatic analysis of the PEX1 and PEX6 variants in HS 
families 
The PEX1 and PEX6 variants identified in the HS families AI-10, AI-16, AI-71, 
AI-146, AI-152, AI-186 and AI-202 were investigated by use of mutation 
prediction software, and their frequency in publically available databases was 
determined. Conservation analysis was undertaken for all missense variants 
using ClustalOmega. 
 
Mutation prediction software including SIFT, Polyphen-2 (HumVar) and 
MutationTaster, generally concluded that all identified variants were pathogenic. 
Provean recorded neutral scores for three of the PEX6 variants, p.V92G, 
p.R99L and p.F218L, identified in families AI-146 (3000), AI-186 (4716) and AI-
10 (1499 and 1500) respectively. 
 
Investigation of the variants’ frequencies in publically available databases 
revealed that the majority are extremely rare or absent (Table 3.8). Although 
only one of the four PEX1 variants was completely unreported, in contrast, four 
of the seven PEX6 variants were unreported. The PEX1 c.2097dupT variant 
has multiple records in the LOVD dbPEX database (available at 
http://www.dbpex.org/home.php) indicating that the variant has been previously 
identified in 87 ZSSD patients. dbPEX contains variant information for 52 and 
115 unique variants for PEX1 and PEX6 respectively (Date accessed 19th 
February 2016) and therefore provides a unique resource of probable 
pathogenic variants that have been previously identified in ZSSD patients. In 
contrast, the PEX6 c.1802G>A variant has been reported at a relatively high 
frequency in the ExAC and EVS databases but relatively few times in dbPEX. 
 
Conservation analysis for missense variants that have not been previously 
reported (PEX1 p.R581P and PEX6 p.V92G, p.R99L, p.F218L and p.C905F) 
revealed that PEX1 p.R581 and PEX6 p.F218 and p.C905 residues are 
conserved through evolution in all mammalian species tested and zebrafish 
(Figure 3.8). Of these residues, only p.C905 was conserved in thale cress and 
none were conserved in fruit fly. 
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Gene Genomic variant 
(GRCh37) 
Exon Transcript 
variant 
Amino acid 
change 
dbSNP142 
reference 
CADD 
v1.3 
Provean SIFT Polyphen2 
(HumVar) 
Mutation 
Taster 
PEX1 7:92136369C>G 10 c.1742G>C p.R581P N/A 21.8 Deleterious 
(-3.16) 
Damaging 
(0.006) 
Probably 
damaging 
(0.923) 
Disease 
causing 
(0.926) 
PEX1 7:92136319delT 10 c.1792delA p.Q598Tfs*11 N/A 35 N/A N/A N/A Disease 
causing 
(1) 
PEX1 7:92132483dupT 13 c.2097dupT p.I700Yfs*42 rs61750415 27.6 N/A N/A N/A Disease 
causing  
(1) 
PEX1 7:92123671A>G 19 c.2966T>C p.I989T rs61750427 29.6 Deleterious 
(-4.82) 
Damaging 
(0.001) 
Probably 
damaging 
(0.995) 
Disease 
causing 
(1) 
PEX6 6:42946614A>C 1 c.275T>G p.V92G N/A 22.9 Neutral 
(-1.5) 
Damaging 
(0) 
Probably 
damaging  
(0.987) 
Disease 
causing 
(1) 
PEX6 6:42946593C>A 1 c.296G>T p.R99L N/A 29.4 Neutral 
(-1.83) 
Damaging 
(0) 
Probably 
damaging 
(0.982) 
Disease 
causing 
(0.787) 
PEX6 6:42946235G>C 1 c.654C>G p.F218L N/A 23.8 Neutral 
(-2.06) 
Damaging 
(0.005) 
Possibly 
damaging 
(0.755) 
Disease 
causing  
(0.982) 
PEX6 6: 42937452-
42937459 
delAGGCCTCC 
5 c.1314_1321 
delGGAGGCCT 
p.E439Gfs*3 rs267608216 33 N/A N/A N/A Disease 
causing 
(1) 
PEX6 6:42935275G>A 8 c.1715C>T p.T572I rs61753224 23.5 Deleterious 
(-4.54) 
Damaging 
(0.001) 
Probably 
damaging 
(0.963) 
Disease 
causing 
(1) 
PEX6 6:42935188C>T 8 c.1802G>A p.R601Q rs34324426 35 Deleterious 
(-3.25) 
Damaging 
(0.001) 
Probably 
damaging 
(0.964) 
Disease 
causing 
(1) 
PEX6 6:42932620C>A 16 c.2714G>T p.C905F N/A 34 Deleterious 
(-9.64) 
Damaging 
(0.01) 
Probably 
damaging 
(0.961) 
Disease 
causing  
(1) 
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Table 3.7: Details of the four PEX1 variants identified in families AI-71 and AI-202 and the 
seven PEX6 variants identified in families AI-10, AI-16, AI-146, AI-152 and AI-186 by WES. 
The list is restricted to variants scoring 15 or more when scored with CADD v1.3.  
Provean, SIFT and Mutation Taster annotations were based on the relevant Ensembl transcript, 
Polyphen-2 annotations were based on the relevant RefSeq protein. 
PEX1: Ensembl transcript: ENST00000248633, RefSeq protein NP_000457. 
PEX6: Ensembl transcript: ENST00000304611, RefSeq protein NP_000287. 
All scores were obtained 16th February 2016. 
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Genomic variant 
(GRCh37) 
dbSNP142 reference 
number of variant alleles 
(total alleles at this 
position);  
allele frequency (all 
reported individuals 
heterozygous) 
ClinVar 
(release 
07/01/2016) 
ExAC (v0.3) 
number of variant alleles 
(total alleles at this position);  
allele frequency (all reported 
individuals heterozygous 
unless otherwise stated) 
EVS 
number of variant alleles 
(total alleles at this 
position);  
allele frequency (all 
reported individuals 
heterozygous) 
dbPEX 
number 
of 
records 
7:92136369C>G rs370483961 ID 214068a 1 (121398) 8.24 x 10-6 N/A N/A 
7:92136319delT N/A N/A N/A N/A N/A 
7:92132483dupT rs61750415 
no allele frequency stated 
ID 7519 77 (120218) 6.41 x10-4 10 (12518); 7.99 x 10-4 87 
7:92123671A>G rs61750427; 2 (10016); 
2.00 x 10-4 
N/A 6 (120686); 4.97 x 10-5 N/A 1 
6:42946614A>C N/A N/A N/A N/A N/A 
6:42946593C>A N/A N/A N/A N/A N/A 
6:42946235G>C N/A N/A N/A N/A N/A 
6:42937452-42937459 
delAGGCCTCC 
rs267608216;  
no allele frequency stated 
N/A 4 (121224); 3.30 x 10-5 1 (12518); 7.99 x 10-5 N/A 
6:42935275G>A rs61753224;  
no allele frequency stated 
N/A N/A N/A 3 
6:42935188C>T rs34324426; 
5 (5008); 9.98 x 10-4 
ID 198709 
(uncertain 
significance) 
316 (98988); 3.19 x 10-3 
(Includes 4 
homozygotes) 
42 (13006); 3.23 x10-3 2 
6:42932620C>A N/A N/A N/A N/A N/A 
Table 3.8: Details of the known variation in public databases for the variants in PEX1 identified in families AI-71 and AI-202 and in PEX6 identified 
in families AI-10, AI-16, AI-146, AI-152 and AI-186.   
All databases accessed 17/02/2016.  
a Variant identified in AI-202 and another HS family published by Ratbi et al. (2015), variant submitted to ClinVar 1st October 2015. 
 105 
                    PEX1 p.R581P 
     
Human      571 THSLLGR------PLSRQLMSLVAGLR 591 
Chimpanzee  571 THSLLGR------PLSRQLMSLVAGLR 591 
Marmoset 571 THSLLGR------PLSRQLMSLVAGLR 591 
Guinea pig  559 TQSLLGR------PLSRQLTSLLAGLR 579 
Mouse   572 THSLLGR------PLSRQLMALVAGLR 592 
Rat  571 THSLLGR------PLSRQLMALVAGLR 591 
Elephant  572 IHSLLGR------PLSRQLMSLVAGLR 592 
Dog    555 THSLLGR------PLSRQLMSLVAGLR 575 
Cow      570 THSLLGR------PLSRQLVSLVAGLR 590 
Sheep   583 THSLLGR------PLSRQLVSLVAGLR 603 
Cat    509 THSLLGR------PLSRQLMSLVAGLR 529 
Sperm whale 559 THSLLGR------PLSRQLMALVAGLR 579 
Horse   571 THSLLGR------PLSRQLMSLVAGLR 591 
Zebrafish 535 SHALLGG------SLSRELISTGRGLR 555 
Fruit fly 455 VDQVVQEL-----RMNLCLSADNSVMR 475 
Thale cress 565 VSDVIKRMTVLLSPAAGMWFSKFKIPS 590 
 
 
PEX1 p.I989T 
                       
Human      979 VLAATSRPDLIDPALLRPGRL 999 
Chimpanzee  979 VLAATSRPDLIDPALLRPGRL 999 
Marmoset    944 VLAATSRPDLIDPALLRPGRL 964 
Guinea pig  968 VLAATSRPDLIDPALLRPGRL 988 
Mouse      980 VLAATSRPDLIDPALLRPGRL 1000 
Rat         979 VLAATSRPDLIDPALLRPGRL 999 
Elephant    980 VLAATSRPDLIDPALLRPGRL 1000 
Dog         963 VLAATSRPDLIDPALLRPGRL 983 
Cow         978 VLAATSRPDLIDPALLRPGRL 998 
Sheep       991 VLAATSRPDLIDPALLRPGRL 1011 
Cat         917 VLAATSRPDLIDPALLRPGRL 937 
Sperm whale 967 VLAATSRPDLIDPALLRPGRL 987 
Horse       979 VLAATSRPDLIDPALLRPGRL 999 
Zebrafish   935 VLAASSRPDLIDPALLRPGRL 955 
Fruit fly   859 VIAATSRPELLDPALLRSGRI 879 
Thale cress 983 VFAATRYSHPNKS-IL---HI 999 
 
 
PEX6 p.V92G          p.R99L 
                                              
Human        82 RLLALGSGAWV------------RARAVRRPPALGWALLG 109 
Chimpanzee   82 RLLALGSGAWV------------RARAVRRPPALGWALLG 109 
Marmoset     82 RLLALGSGAWV------------RARPVRRPPALGWALLG 109 
Guinea pig   82 QLLALGSGAQV------------RARPVRRPPALGWALLG 109 
Mouse        82 RVLALGPGARV------------RARLVRRPPALGWALLA 109 
Rat          82 RVLALSPGARV------------RARPVRRPPALGWALLG 109 
Elephant     82 RLLALDSGAWV------------RARPVRRPPALGWALLG 109 
Dog          82 RLLALGSGAWV------------RARPVRRPPALGWALLG 109 
Cow          82 QLLALGSGAWV------------RARPVRRPPSLGWALLG 109 
Sheep        82 QLVALGSGAWV------------RARPVRRPPSLGWALLG 109 
Cat          82 RLLAL----------------------------------- 86  
Sperm whale  37 -----------------------------------WALLG 41  
Horse        0 ---------------------------------------- 0   
Zebrafish    89 KHYGLREQSWGTLRPQSLLPLKKIVIGARTKPSFKWASSE 128 
Fruit fly  1045 KHYGLREQSWGTLRPQSLLPLKKIVIGARTKPSFKWASSE 1085 
Thale cress   0 ---------------------------------------- 0 
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PEX6 p.F218L 
                                              
Human        208 SRSCLRGLGLFQGEWVWVAQA 228 
Chimpanzee   208 SRSCLRGLGLFQGEWVWVARA 228 
Marmoset     208 SRRCLRGLGLFQGEWVWVARA 228 
Guinea pig   210 SRTCLRGLGLFQGEWVWVARA 230 
Mouse        208 SRSCLRSLGLFQGEWVWVAQV 228 
Rat          208 SRSCLRSLGLFQGEWVWVARV 228 
Elephant     207 SRRCLRGIGLFQGEWVWVARA 227 
Dog          208 SRSCLRSLGLFQGEWVWVTRA 228 
Cow          208 SRSCLRSLSLFQGEWVWVTRA 228 
Sheep        190 SRSCLRSLGLFQGEWVWVTRA 210 
Cat          172 SRSCLRSLGLFQGEWVWVTRA 192 
Sperm whale  140 SRSCLRSLSLFQGEWVWVTRA 160 
Horse         57 SRSCLRSLGLFQGEWVWVTRA 77  
Zebrafish    287 SRSLLVKLGVFNGEWVIASVP 307 
Fruit fly   1244 SRSLLVKLGVFNGEWVIASVP 1264 
Thale cress   79 STQLLKRLSINSGS LVVVKN 99 
 
 
PEX6 p.T572I 
                                              
Human        562 SCPPLMVVATTSRAQDLPADV 582 
Chimpanzee   562 SCPPLMVVATTSRAQDLPADV 582 
Marmoset     562 SCPPLLVVATTSRAQDLPAEV 582 
Guinea pig   564 SCLPLMVVATTSRAQDLPADV 584 
Mouse        563 RCPPLMVVATTSRVQDLPTDV 583 
Rat          562 RCPPLMVVATTSRVQDLPTDV 582 
Elephant     560 SCPPLMVVATTSRARDLPADV 580 
Dog          562 SCPPLMVVATTSQAQDLPADV 582 
Cow          562 SCPPLMVVATTSRAQDLPADV 582 
Sheep        544 RXHPALSGESTERLQDLPADV 564 
Cat          526 SCPPLITVATTSKAQDLPADV 546 
Sperm whale  494 SCPPLMVVATTSRARDLPVDV 514 
Horse        412 SCPPLMVVATTSRAQDLPADV 432 
Zebrafish    655 --TSVVVVGSVSSQHELPSDV 673 
Fruit fly   1521 --------------------- 1521 
Thale cress  502 RGHQVLLIASAESTEGISPTI 522 
 
 
   PEX6 p.R601Q 
                                                 
Human        591 LEVPALSEGQ--RLS--ILRALTAH 611 
Chimpanzee   591 LEVPALSEGQ--RLS--ILRALTAH 611 
Marmoset     591 LEVPALSEGQ--RLS--ILQALTAH 611 
Guinea pig   593 LEMPVLSEGQ--RLS--ILRALTAH 613 
Mouse        592 LEVPVLSEAQ--RLS--ILQALTAH 612 
Rat          591 LEVPVLSESQ--RLS--VLQALTAH 611 
Elephant     589 LEVPVLTEGQ--RLS--ILQALTAH 609 
Dog          591 LEVPVLSEGQ--RLS--VLQALTAH 611 
Cow          591 LEVPVLAEAQ--RLS--VLRALTAH 611 
Sheep        573 LEGPVLAGAQGLRLS--VLRALTAH 595 
Cat          555 LEVPVLSEGQ--RLS--VLRALTAH 575 
Sperm whale  523 LEVPVLSEGQ--RLS--ILRALTAH 543 
Horse        441 LEVPVLSEGQ--RLS--ILRALTAH 461 
Zebrafish    682 VAIESLSEDQ--RRM--VLSSLSED 702 
Fruit fly   1521 ------------------------ 1521 
Thale cress  531 IRMGSLNDEQRSEMLSQSLQGVSQF 555 
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       PEX6 p.C905F 
                                                 
Human        895 SVSLVNVLDCCPPQLTGADLY 915 
Chimpanzee   895 SVSLVNVLDCCPPQLTGADLY 915 
Marmoset     895 SVNLVNVLDCCPPQLTGADLY 915 
Guinea pig   897 SVSLVNVLDHCPPQLTGADLY 917 
Mouse        896 SVSLANVLDCCPPQLTGADLY 916 
Rat          893 SVSLMNVLDCCPPQLTGADLY 913 
Elephant     893 TVSLVRVLDHCPPQLTGADLY 913 
Dog          895 SVSLVNVLDRCPPQLTGADLY 915 
Cow          895 SVSLVDVLDHCPPQLTGADLY 915 
Sheep        879 SVSLVDVLDHCPPQLTGADLY 899 
Cat          859 SVSLVNVLDRCPPQLTGADLY 879 
Sperm whale  827 SVSLVDVLDHCPPQLTGADLY 847 
Horse        745 SVSLVNVLDRCPPQLTGADLY 765 
Zebrafish    986 SVCLSDIVESCPPRLTGADLY 1006 
Fruit fly   1521 --------------------- 1521 
Thale cress  850 DVSLYSVAKKCPSTFTGADMY 870 
 
 
Figure 3.8: Clustal Omega multiple sequence alignment of homologous protein 
sequences for the residues surrounding each PEX1 and PEX6 missense variant 
identified in HS individuals. 
Shaded residues indicate those that are identical to the human residue at the same position. 
Arrows indicate the position of the residues of interest. 
PEX1 sequences used: Human, Homo sapiens NP_000457.1; Chimpanzee, Pan troglodytes 
XP_519198.2; Marmoset, Callithrix jacchus XP_009000794.1; Guinea pig, Cavia porcellus 
XP_003475146.1, Mouse, Mus musculus NP_001280735.1; Rat, Rattus norvegicus 
NP_001102690.1; Elephant, Loxodonta africana XP_003407197.1; Dog, Canis lupus familiaris 
XP_532459.1; Cow, Bos taurus NP_001179000.1; Sheep, Ovis aries XP_004008246.1; Cat, 
Felis Catus XP_011278778.1; Sperm whale, Physeter catodon XP_007103410.1; Horse, Equus 
caballus XP_001493415.2; Zebrafish, Danio rerio NP_001164306.1; Fruit fly, Drosophila 
melanogaster NP_652016.1; Thale cress, Arabidopsis thaliana NP_001331459.1. 
PEX6 sequences used: Human, Homo sapiens NP_000278.3; Chimpanzee, Pan troglodytes 
XP_003950894.1; Marmoset, Callithrix jacchus XP_002746596.1; Guinea pig, Cavia porcellus 
XP_003473901.1, Mouse, Mus musculus NP_663463.1; Rat, Rattus norvegicus NP_476466.1; 
Elephant, Loxodonta africana XP_003403954.1; Dog, Canis lupus familiaris XP_538926.2; 
Cow, Bos taurus NP_001179876.1; Sheep, Ovis aries XP_004018878.1; Cat, Felis Catus 
XP_011280631.1; Sperm whale, Physeter catodon XP_007107679.1; Horse, Equus caballus 
XP_005614975.1; Zebrafish, Danio rerio XP_009294800.1; Fruit fly, Drosophila melanogaster 
NP_001163114.1; Thale cress, Arabidopsis thaliana NP_171799.2. 
 
However the region encompassing PEX6 p.V92 and p.R99 residues was not 
present in three of the mammalian species tested and neither residue was 
conserved in zebrafish, fruit fly or thale cress. 
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3.2.10 Haplotyping of the region surrounding the common PEX6 
c.1802G>A variant 
Three of the families in this study (AI-10, AI-146 and AI-186) and family 6, 
reported by Ratbi et al. (2015), were found to share the same PEX6 c.1802G>A 
variant (rs34324426). All four families were all of either US or UK origin. This 
variant had also been reported in seven ZSSD patients for whom the ethnicities 
were not given but the studies themselves were of US origin (Yik et al., 2009, 
Ebberink et al., 2010). In addition, ExAC reports the allele’s frequency in the 
European population as 0.416% and EVS reports the allele frequency in the 
European American population as 0.418% (Table 3.8). Therefore, evidence 
suggests that the c.1802G>A variant appears to be relatively common in 
populations of European origin. 
 
In order to investigate whether the c.1802G>A variant represents a common 
founder mutation, analysis of the haplotype surrounding the variant was carried 
out by genotyping nearby microsatellite markers and SNPs (Appendix 16). A set 
of representative microsatellite genotyping electropherograms for marker 
D6S1650 is shown in Figure 3.9. For families AI-10 and AI-186, results from 
multiple family members enabled both haplotypes to be determined (Figure 
3.10). For AI-146, only DNA from the affected individual (3000) was available 
and therefore the haplotype of the c.1802G>A variant could not be defined. 
 
Results showed that the p.R601Q mutation was associated with a haplotype of 
two SNPs and one microsatellite spanning a region of at least 779kb (Table 
3.9). However, for two of the families, AI-10 and AI-186, the shared haplotype 
extended over a region of at least 1,279kb. 
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Figure 3.9: Examples of genotyping electropherograms. 
Electropherograms showing two alleles of marker D6S1650 in AI-10 family members (A) 1492, 
(B) 1493 and (C) 1497 as visualised on GeneMapper. 
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Figure 3.10: Analysis of the haplotype of the region surrounding the PEX6 c.1802G>A variant for families AI-10, AI-146 and AI-186.  
Results are shown for eight microsatellite markers and three SNPs, including the PEX6 c.1802G>A variant. Markers used are described in Appendix 16. A 
summary of the results can be found in Table 3.9. Haplotypes are represented by coloured bars (each colour represents a different haplotype in each family). 
The numbers alongside each haplotype bar correspond to the size of each allele amplified by the microsatellite markers, in base pairs. The markers are 
displayed in order of their physical location. In families AI-10 and AI-186, the yellow haplotype carries the c.1802G>A variant and the green haplotypes carry 
the second PEX6 variant. 
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Marker Physical location 
(hg19 / GRCh37) 
Genetic 
location 
(Marshfield) / 
cM 
Result - 
family 
AI-10 
Result - 
family 
AI-146 
Result - 
family 
AI-186 
D6S1552 6:41537757-41538086 62.28 178 154 / 164 168 
D6S400 6:41955110-41955373 63.28 150 150 / 150 150 
rs7770760 6:42915403 N/A T C / T T 
rs9471978 6:42929533 N/A T C / T T 
rs34324426 6:42935188 N/A T C / T T 
D6S1582 6:43098617-43098961 65.14 143 130 / 141 143 
D6S282 6:43234575-43234945 66.37 102 102 / 108 102 
D6S271 6:43500818-43501193 66.37 190 182 / 192 166 
D6S1604 6:43679700-43680083 66.37 197 187 / 187 189 
D6S1650 6:44130031-44130426 68.65 112 110 / 112 114 
Table 3.9: Summary of genotypes comprising the haplotype segregating with the shared 
PEX6 c.1802G>A variant (rs34324426) identified in families AI-10, AI-146 and AI-186. 
Dark grey shading indicates the markers and SNPs with identical results for all three families, 
while the light grey shading indicates the markers and SNPs with identical results for families 
AI-10 and AI-186. For family AI-146, DNA was not available from additional family members, 
therefore it was not possible to determine the haplotype associated with the c.1802G>A variant. 
 
3.2.11 Immunohistochemical staining of murine tissues 
The pathological changes in the enamel and retinas of individuals with HS and 
other ZSSDs suggest that peroxisomes are crucial to the development of the 
dental enamel and the maintenance of a functional retina. However, at the start 
of the study there had been no previous reports detailing the location of PEX1 
and PEX6 in these tissues. 
 
3.2.11.1 Western blot 
In order to carry out immunohistochemistry (IHC) on murine tissues, 
commercially available antibodies against PEX1 and PEX6 were obtained. An 
antibody against PEX14 was also obtained since PEX14 has been shown to be 
an optimal marker for identification and localisation of peroxisomes in a variety 
of cell types (Grant et al., 2013). Therefore the primary antibodies obtained 
were rabbit anti-human PEX14 polyclonal antibody (10594-1-AP, Proteintech, 
Rosemount, IL, USA), rabbit anti-human PEX1 polyclonal antibody (13669-1-
AP, Proteintech, Chicago, IL, USA) and goat anti-rat PEX6 polyclonal antibody 
(ab175064, Abcam, Cambridge, UK). Although none of the antibodies obtained 
were raised against the mouse antigen, they were predicted to cross react with 
the corresponding murine antigen. In order to verify this and to attempt to 
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assess the specificity of the antibodies, western blots were carried out using 
50g total protein from murine kidney and brain tissues (Sections 0 and 2.11). 
Mouse kidney and brain were chosen since both tissues have been shown to 
express PEX1, PEX6 and PEX14 in various studies listed in the EMBL-EBI 
Expression Atlas (available at http://www.ebi.ac.uk/gxa/home). Samples were 
run under denaturing conditions, in both the presence and absence of a 
reducing agent. Both gel electrophoresis and transfer were run for 60 minutes 
(for gels and blots to be used for detection of PEX14) or 90 minutes (for gels 
and blots to be used for detection of PEX1 or PEX6). A Coomassie blue stained 
SDS PAGE gel is shown in Appendix 17. 
 
Primary antibodies were applied at the following dilutions: anti-PEX14 1:250, 
anti-PEX1 1:500 and anti-PEX6 1:250. The secondary antibodies and dilutions 
used were: polyclonal goat anti-rabbit immunoglobulins/HRP 1:1000 (P0448; 
Dako, Ely, UK) for the blots incubated with the anti-PEX1 and anti-PEX14 
antibodies and polyclonal rabbit anti-goat immunoglobulins/HRP 1:1000 
(P0449; Dako) for the blots incubated with the anti-PEX6 antibody. Blots were 
stripped and reprobed with monoclonal mouse anti-β-actin antibody (ACTB; 
A5441, Sigma) to assess both protein loading and transfer to the membrane. 
The secondary antibody used was polyclonal rabbit anti-mouse 1:1000 (P0260; 
Dako). The results of the western blots are shown in Figure 3.11.  
 
Western blot using the anti-PEX1 antibody (Figure 3.11A) showed that a band 
of approximately the expected size of 141.4kDa was present under reducing 
conditions (solid black arrows). Another band of approximately 90kDa was also 
present for both kidney and brain samples (dot filled arrows), a protein BLAST 
search, using the recombinant protein sequence used to raise the anti-PEX1 
antibody, revealed that the antigen has some homology to nuclear valosin-
containing protein-like protein isoforms, which have a predicted protein mass of 
around 94.5kDa. Upon reprobing the blot with the anti-β-actin antibody, it was 
evident that the protein loading and transfer had only been effective for the 
samples treated with reducing agent (Figure 3.11D). 
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Figure 3.11: Western blots using anti-PEX1, -PEX6 and -PEX14 antibodies on murine tissues. 
Western blots of 50μg kidney (K1, K2) and brain (B1, B2) total protein samples obtained from two mice. Blots were probed with the following primary antibodies: 
A: anti-PEX1, B: anti-PEX6, C: anti-PEX14, D-F: anti-ACTB (loading/transfer control for blots A-C respectively). Solid black arrows refer to bands corresponding 
to expected protein sizes. Other arrows refer to bands discussed in the text.
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For the blot probed with anti-PEX6 antibody (Figure 3.11B), a faint signal of 
around 100kDa was present (solid black arrows). This was most evident for the 
brain samples treated without the reducing agent. This may represent PEX6 
since the predicted protein weight is 104.5kDa. A protein BLAST search for the 
peptide sequence against which the anti-PEX6 antibody was raised revealed 
that it was also 100% identical to part of the PEX2 (MIM *170993) protein. 
PEX2 is predicted to be 34.9kDa and may represent the faint bands present 
around this size for the kidney samples (open arrows). Two other bands of 
around 45kDa (present for all samples; dotted arrows) and 60kDa (present only 
for brain; striped arrows) were evident. Amongst other proteins, the sequence 
used as the antigen also shares identity with FAM134A (61% coverage, 81% 
identity) which is predicted to be 57.5kDa and may represent the band present 
in brain samples (striped arrows). Reprobing the blot with the anti-β-actin 
antibody revealed that the protein loading and transfer had been effective for all 
samples (Figure 3.11E). 
 
For the blot probed with anti-PEX14 antibody (Figure 3.11C), a signal at around 
57kDa (based on the human protein) was expected. PEX14 protein is predicted 
to be 41.2kDa, but the antibody datasheet suggests that the protein does not 
migrate at the position that would be expected for its size, but at around 57kDa 
for the human protein. Bands around 55kDa were identified in brain samples 
(solid black arrows). A protein BLAST search of the peptide sequence used as 
the antigen to raise the antibody did not reveal any other sequences that 
matched other than the target. Reprobing the blot with the anti-β-actin antibody 
revealed that protein loading and transfer had only been effective for the 
samples treated with reducing agent and for the untreated brain samples 
(Figure 3.11F). 
 
Therefore, on each blot, there were bands that corresponded to the respective 
sizes of each antigen for each antibody, suggesting that detection of the 
respective murine antigens with the antibodies raised against the human or rat 
antigens was possible. However other bands were present and therefore the 
western blots were inconclusive. The conditions present during SDS PAGE do 
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not reflect those present during immunohistochemistry, therefore it is not 
possible to make conclusions as to the efficacy of the antibodies. 
 
3.2.11.2 Immunohistochemical staining of incisor tissues 
Murine incisor provides an excellent model for the development of enamel since 
it grows continuously throughout life and therefore incisors display all stages of 
amelogenesis along their lengths (Section 1.7). 
 
Therefore, in order to determine the localisation of PEX proteins throughout 
amelogenesis, immunohistochemical staining was undertaken. Mouse incisor 
tissue was collected, fixed, demineralised and sectioned as described (Section 
2.12.1.1). Mandibular incisors were embedded planar to the mesial-distal axis 
and sectioned planar to the buccal-lingual axis. Staining of every tenth section 
with haematoxylin and eosin (H&E) enabled sections containing secretory, 
transition and maturation stage ameloblasts to be identified (Figure 3.12). 
 
Due to the orientation during embedding and the natural shape of the murine 
incisors, the classic morphological changes in the ameloblast cells during 
amelogenesis became masked. The “molar line” has been used by other 
researchers as a morphological reference point to signify the secretion-
transition-maturation stage boundary (Smith and Nanci, 1989). Ameloblasts 
immediately below the more distal root (of the two visible on a mid-line section) 
of the first molar are designated as residing at the transition between secretory 
and maturation stage, although the bodyweight of the animal can alter this 
position (Smith and Nanci, 1989). Ameloblasts that lay more mesial to the line 
are designated as secretory stage, while those that lay more distally are 
designated as maturation stage. In the H&E sections obtained here, the 
proximal root was not visible and the staining of the proteinaceous enamel 
matrix was lost mesial to the position of the molar line (Figure 3.12A). 
Therefore, this marker was not used as an approximate marker for the 
secretion-transition-maturation stage boundary since it may not have been 
accurate. 
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Figure 3.12: H&E staining of a mandibular incisor section. 
A: Complete murine incisor section, the position of the molar line is marked with the dashed 
line. * indicates the proteinaceous enamel matrix (PEM). 
B: Secretory stage ameloblasts (Am) and overlying stratum intermedium (SI). 
C: Maturation stage ameloblasts with overlying papillary layer (PL). 
D: A PEM is most visible adjacent to the secretory ameloblasts. An enamel space (E) reflects 
the presence of mineralised tissue that has been removed during demineralising treatment with 
EDTA. A layer of dentine (De) can also be seen that has been formed by odontoblasts (Od). 
Scale bars represent 600m (A), 50m (B and C) and 100m (D). 
 
Commercially available antibodies against PEX1, PEX6 and PEX14 were 
obtained as previously described. Although none of the antibodies obtained 
were raised against the mouse antigen, they were predicted to cross react with 
the murine antigen and bands of the predicted size of the murine antigen had 
been obtained by western blot (Section 3.2.11.1). 
 
In order to optimise the conditions for IHC with each antibody, a range of 
antibody concentrations were tested with citrate-based antigen retrieval 
(Section 2.12.5). The highest antibody concentration was also tested without 
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any form of antigen retrieval. It was found that the incisor sections without any 
antigen retrieval did not stain. Those processed using citrate-based retrieval did 
stain, but the sections detached from the slides due to the microwave based 
boiling during antigen retrieval. Trials of different types of slides, including those 
treated with silane (CellPath, Newtown, Wales, UK and lab prepared silane 
slides (amino-propyl-tri-ethoxy-silane)) as well as heating using a lower intensity 
or for a shorter period of time were undertaken. Treatment of slides by baking at 
70oC in an oven for an hour prior to antigen retrieval was also tried. All 
combinations of treatments failed to provide conditions that resulted in both 
antigen retrieval and maintained the sections’ adherence to the slide for 
imaging. 
 
Therefore enzyme-based antigen retrieval using chymotrypsin, that did not 
involve a boiling treatment, was tested. A trial of antibody dilutions for the 
enzyme-based retrieval method found that optimal staining was achieved by 
using the anti-PEX1 antibody at a 1:300 dilution and anti-PEX14 at a 1:150 
dilution. The anti-PEX6 antibody was used at a dilution of 1:80. Trials of higher 
dilutions resulted in loss of signal. For the anti-PEX1 and anti-PEX14 antibodies 
raised in rabbit, the secondary antibody used was the labelled polymer-HRP 
anti-rabbit reagent from the EnVision+ System-HRP (DAB), for use with rabbit 
primary antibodies (Dako) as described in the manufacturer’s instructions. For 
the anti-PEX6 antibody, raised in goat, some modification to the standard 
method was required (Section 2.12.5). Avidin and biotin blocking (Vector 
Laboratories, Peterborough, UK) was used as described in the manufacturer’s 
instructions, prior to primary antibody application for the sections treated with 
the anti-PEX6 antibody. The secondary antibody and dilution used for these 
sections was rabbit polyclonal anti-goat immunoglobulins/biotinylated (E0466, 
Dako) at 1:200. These sections were then treated with the Vectastain Elite ABC 
Kit (Vector Laboratories, Burlingame, CA, USA) as described in the 
manufacturer’s instructions, prior to staining with DAB reagent (Dako) as 
previously described. 
 
IHC using chymotrypsin-based antigen retrieval resulted in the no primary 
control treated slides also staining, although the staining of the no primary 
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antibody slide for the anti-goat secondary antibody was stronger than that for 
the anti-rabbit secondary antibody. An alternative anti-goat secondary antibody 
was sought but was unavailable for trial. Use of the anti-goat secondary 
antibody resulted in staining in secretory stage ameloblasts. Use of both the 
anti-PEX6 antibody and the secondary antibody resulted in staining of 
maturation stage ameloblasts (Figure 3.13). 
 
 
Figure 3.13: Immunohistochemical staining of murine ameloblasts for PEX6. 
i-iv: No primary antibody control: secondary antibody (rabbit anti-goat) only. v-viii: anti-PEX6 
antibody followed by secondary antibody. Secretory stage ameloblasts are shown in panels i, ii, 
v and vi. Maturation stage ameloblasts are shown in panels iii, iv, vii and viii. Scale bars for 
panels i, iii, v, vii represent 100m, those for panels ii, iv, vi and viii represent 50m. 
 
Use of the anti-PEX1 antibody resulted in staining only in the proteinaceous 
enamel matrix, since PEX1 is a peroxisomal membrane protein and the enamel 
matrix is an acellular compartment, the staining could have been non-specific. 
The corresponding no primary control, treated only with the anti-rabbit 
secondary antibody, had staining that was restricted to late maturation stage 
ameloblasts (Figure 3.14iii), indicating that the staining with the anti-PEX1 
antibody may not have been specific. No staining was present in the 
proteinaceous enamel matrix for the no primary control. 
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Figure 3.14: Immunohistochemical staining of murine ameloblasts for PEX1 and PEX14. 
i-iii: No primary antibody control: secondary antibody (anti-rabbit reagent) only. iv-vi: anti-PEX1 
antibody followed by secondary antibody. vii-viii anti-PEX14 antibody followed by secondary 
antibody. Secretory stage ameloblasts are shown in panels i, iv and vii. Maturation stage 
ameloblasts are shown in panels ii, iii (late maturation stage), v and viii. Image vi shows the 
staining present in the proteinaceous enamel matrix (and is shown in a different orientation to 
panels i-v). All scale bars represent 50m, except in panel vi, which represents 500m. 
 
In summary, the use of the anti-PEX1 and anti-PEX6 antibodies resulted in 
staining in the no primary antibody controls for both antibodies. Therefore it was 
concluded that the staining was not specific for the PEX1 and PEX6 proteins 
using chymotrypsin based antigen retrieval and analysis was abandoned for 
both proteins in mouse incisor sections. 
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For the anti-PEX14 antibody, chymotrypsin based antigen retrieval, using a 
primary antibody dilution of 1:150 and the secondary antibody as instructed by 
the manufacturer, resulted in staining that was specific to the slides treated with 
the primary antibody (Figure 3.15). Immunoreactivity was present in the tissue 
overlying the ameloblast cell layer, the stratum intermedium, in secretory stage 
and within the papillary layer of the maturation stage regions of incisor sections. 
The staining was faint in the secretory stage region and much stronger in that of 
the maturation stage. For sections incubated with the secondary antibody only, 
immunoreactivity in this layer was absent in all stages of amelogenesis. 
Together, this suggests that peroxisomes are present in large quantities in the 
maturation stage papillary layer. 
 
Staining of maturation stage ameloblasts was evident for sections treated with 
the anti-PEX14 antibody, but faint staining was also present in the no primary 
control sections, specifically in late maturation stage ameloblasts. This meant 
that it was impossible to conclude that the staining in the anti-PEX14 antibody 
treated sections was specific. 
 
 
Figure 3.15: Immunohistochemical staining of late maturation ameloblasts for PEX14. 
A: anti-PEX14 antibody followed by labelled polymer-HRP anti-rabbit reagent. 
B: No primary antibody control: secondary antibody (labelled polymer-HRP anti-rabbit reagent) 
only. Scale bars represent 50 m. Abbreviations are as follows: Am ameloblasts, NP no primary 
control, PL papillary layer. 
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3.2.11.3 Immunohistochemical staining of retinal tissues 
Immunohistochemical staining of eye tissues was carried out using anti-PEX1, 
anti-PEX6 and anti-PEX14 antibodies. In order to optimise the conditions for 
IHC with each antibody, a range of antibody concentrations were tested with 
citrate-based antigen retrieval (Section 2.12.5). The highest antibody 
concentration was also tested without any form of antigen retrieval. It was found 
that the eye sections without any antigen retrieval did not stain. Sections 
processed using citrate buffer antigen retrieval did stain but those incubated 
without primary antibody did not, suggesting that staining was specific to each 
primary antibody. The final dilutions used were 1:450 anti-PEX1, 1:50 anti-
PEX6 and 1:750 anti-PEX14. Higher dilutions resulted in the loss of staining. 
Immunohistochemical staining was carried out as previously described 
(Sections 2.12.5 and 3.2.11.2). 
 
Use of anti-PEX1, anti-PEX6 and anti-PEX14 antibodies revealed staining 
throughout the retina with the exception of the photoreceptor outer segment in 
all cases (Figure 3.16). The ganglion cell layer (GCL) and the photoreceptor 
inner segment (IS) layer showed the most intense PEX14 immunoreactivity. For 
PEX1, the outer plexiform layer (OPL) stained the most intensely with strong 
staining also present in the GCL and the inner plexiform layer (IPL). For PEX6, 
the most intense staining was present in the GCL.
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Figure 3.16: Immunohistochemical staining of murine retina. 
A: anti-PEX14 antibody followed by labelled polymer-HRP anti-rabbit reagent. 
B: No primary antibody control: secondary antibody (labelled polymer-HRP anti-rabbit reagent) only. 
C: anti-PEX1 antibody followed by labelled polymer-HRP anti-rabbit reagent 
D: No primary antibody control: secondary antibody (rabbit anti-goat antibody) only. 
E: anti-PEX6 antibody followed by rabbit anti-goat antibody. 
Scale bars represent 100 m. 
Abbreviations are as follows: GCL ganglion cells layer; INL inner nuclear layer; IPL inner plexiform layer; IS inner segment; NP no primary antibody control; 
ONL outer nuclear layer; OPL outer plexiform layer; OS outer segment. 
Adapted and reproduced with permission from Smith et al. (2016b). 
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3.3 Discussion 
In this study, ten families (Families AI-10, -11, -12, -16, -71, -138, -146, -152, -
186 and -202) segregating a combination of SNHL, retinal dystrophy and 
enamel defects in a pattern consistent with autosomal recessive inheritance 
were analysed in order to identify the gene(s) and mutation(s) involved. DNA 
from at least one affected individual from each family underwent WES and 
analysis initially revealed that two of the families (AI-12 and -138) carried 
compound heterozygous mutations in the USH2 gene, USH2A (Section 3.2.3). 
WGS revealed that another family (AI-11) carried a heterozygous deletion that 
included the MYO7A start codon (Section 3.2.4). WES revealed that the same 
family also carried a heterozygous ENAM variant (Section 3.2.5). 
 
Analysis of WES data from the remaining families revealed that all carried 
biallelic mutations in either PEX1 or PEX6. Mutations in PEX1 and PEX6 were 
already known to cause the ZSSDs, whose phenotypes include craniofacial 
dysmorphism, neurological abnormalities, sensory defects and liver and kidney 
pathology (Section 3.3.1). Collaboration with another research group confirmed 
that PEX1 and PEX6 mutations had been identified in other HS patients. These 
results therefore showed that HS is a mild presentation of a ZSSD, with sensory 
defects as the major phenotype, resulting from hypomorphic mutations in PEX1 
or PEX6. Both PEX1 and PEX6 are well characterised, with known roles in the 
peroxisome matrix protein import and peroxisome biogenesis, although little 
was known about their distribution within the retina or during amelogenesis. 
 
Immunohistochemical analysis of murine retina revealed that both PEX1 and 
PEX6 are present throughout many layers of the retina. Investigations of the 
localisation of PEX1 and PEX6 in murine incisors were inconclusive since the 
staining did not appear to be specific. 
 
Family AI-202 (Labelled as family 4 by Ratbi et al.) was reported as one of six 
families detailed in the first paper to report the identification of PEX1 and PEX6 
as the causative genes for HS (Ratbi et al., 2015). Families AI-10, -16, -71, -
146, -152 and -186 were reported in a subsequent paper supporting the original 
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publication, as additional HS cases associated with PEX1 and PEX6 mutations 
(Smith et al., 2016b). These were labelled as families 1, 4, 6, 2, 5 and 3 
respectively. This article also included details of the localisation of PEX1 and 
PEX6 within the murine retina. 
 
3.3.1 Zellweger Syndrome Spectrum Disorders (ZSSDs) 
The Zellweger Syndrome Spectrum Disorders (ZSSDs) are peroxisome 
biogenesis disorders (PBDs; MIM PS214100) and are inherited in an AR 
manner. PBDs are characterised by a wide range of phenotypes including 
craniofacial dysmorphism, neurological abnormalities, sensory defects and liver, 
kidney and bone abnormalities (Waterham and Ebberink, 2012). The ZSSDs 
include Zellweger syndrome (ZS), neonatal adrenoleukodystrophy (NALD) and 
infantile Refsum disease (IRD), which represent overlapping clinical phenotypes 
that vary in severity, with ZS being the most severe and IRD the least. Whilst 
ZS patients often present with serious disease at birth and live only a few weeks 
or months, patients with IRD and NALD generally present later in childhood, 
primarily with SNHL and retinal dystrophy, but also with multiple organ 
dysfunction and psychomotor impairments (Yik et al., 2009, Waterham and 
Ebberink, 2012). The reported incidence of ZSSDs in the US population is 1 in 
50,000 (Gould et al., 2001). However, this may be an underestimate since the 
milder phenotypes overlap with and have been misdiagnosed as both USH 
(Raas-Rothschild et al., 2002) and Leber congenital amaurosis (LCA; MIM 
PS204000) (Ek et al., 1986, Michelakakis et al., 2004). 
 
The ZSSDs are a result of impaired peroxisomal function. Peroxisomes are 
ubiquitous cellular organelles that perform numerous diverse vital functions, 
including -oxidation of very long chain fatty acids, the synthesis of myelin 
precursors and detoxification of hydrogen peroxide (Wanders and Waterham, 
2006). Defective peroxisomal function can result in changes in neuronal 
migration, proliferation, differentiation and survival (Powers and Moser, 1998, 
Faust et al., 2005, Krysko et al., 2007). 
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The genes most commonly mutated in ZSSDs are peroxisomal biogenesis 
factor 1 (PEX1; MIM *602136) and peroxisomal biogenesis factor 6 (PEX6; MIM 
*601498) (Ebberink et al., 2011). The phenotype variation seen in ZSSDs is 
related to the severity of the underlying PEX gene mutations. Biallelic loss of 
function or null alleles, caused by frameshift and nonsense mutations, often 
lead to a total absence of peroxisomes, resulting in ZS, whilst genotypes which 
include an allele with a minor import defect, caused by a missense mutation, 
may lead to NALD or IRD (Moser, 1999, Maxwell et al., 2002, Preuss et al., 
2002). As a result of this study and data from other centres, the ZSSD 
phenotypic spectrum was expanded to include HS (Ratbi et al., 2015). 
 
3.3.2 Heimler syndrome is the mildest presentation of a ZSSD 
In this study, WES identified biallelic mutations in PEX1 and PEX6 in HS 
patients. At the beginning of this study, mutations in PEX1 and PEX6 were 
already known to cause the ZSSDs (Section 3.3.1) that encompass a complex 
phenotype that includes sensory defects. In rare cases, more mildly affected 
individuals have been reported to have enamel defects (Bader et al., 2000, Tran 
et al., 2011, Acharya et al., 2012), and it has been suggested that this may be a 
common but underreported aspect of the phenotype (Poll-The et al., 2004, Tran 
et al., 2011, Steinberg et al., 2012). 
 
Mutations in PEX1 and PEX6 are the most common causes of ZSSD and result 
in impaired peroxisomal function (Ebberink et al., 2011). Peroxisomes are 
ubiquitous cellular organelles that consist of a single lipid bilayer membrane 
surrounding a dense matrix of proteins (Smith and Aitchison, 2013). Cellular 
peroxisomal content is controlled both by their production, mainly by fission, and 
their degradation, by pexophagy (Hutchins et al., 1999, Motley and Hettema, 
2007). Before fission can occur, new matrix proteins, synthesised in the cytosol 
must be imported into the existing peroxisome. This is achieved via peroxisomal 
import machinery that specifically imports proteins containing a peroxisomal 
targeting signal. 
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Figure 3.17: Schematic diagram of peroxisomal matrix protein import. 
Proteins with either of the peroxisomal targeting sequences become bound to cytosolic cargo 
binding proteins PEX5 (5L and 5S represent the Long and Short protein isoforms respectively) 
and/or PEX7. The bound proteins then dock at the peroxisomal membrane complex consisting 
of PEX13 and PEX14. The bound matrix protein is then translocated across the membrane to 
the lumen and the receptor proteins are targetted for recycling via ubiquitination by PEX2, 
PEX10 and PEX12. PEX1, PEX6 and PEX26 then release the ubiquitinated cargo binding 
proteins PEX5 and/or PEX7 back to the cytosol where they are deubiquitinated, ready for 
additional rounds of matrix protein import. Adapted with permission from Waterham and 
Ebberink (2012). 
 
PEX1 and PEX6 are type 2 AAA+ (ATPases Associated with diverse cellular 
Activities) ATPases. ATPases use energy from ATP hydrolysis to effect 
conformational changes on targets (Hanson and Whiteheart, 2005). PEX1 and 
PEX6 form a heterohexameric protein complex in vivo (Gardner et al., 2015). 
The complex is part of the peroxisomal import machinery that recycles the 
peroxisome-targeting signal receptor protein, PEX5, back to the cytosol after 
release of its protein cargo within the peroxisomal lumen (Figure 3.17) (Dodt 
and Gould, 1996). PEX1 and PEX6 provide the energy required to remove 
PEX5 from the luminal membrane (Platta et al., 2005) and their function is 
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dependent upon interaction with the membrane protein PEX26 (Fujiki et al., 
2008). Mutations in the genes encoding these proteins therefore give rise to a 
peroxisomal protein import defect, which in turn leads to a deficiency of 
peroxisomal biogenesis. Evidence for this includes reports that PEX1 or PEX6 
deficient cells contain so-called “peroxisomal ghosts”, enlarged structures that 
fail to import peroxisomal matrix proteins that are not present in wild-type cells 
(Santos et al., 1988, Wendland and Subramani, 1993). There are also fewer of 
these structures in affected cells than there are true peroxisomes in wild type 
cells. In yeast cells deficient in Pex1 or Pex6, an increase in pexophagy was 
observed compared to wild type cells (Nuttall et al., 2014). 
 
Peroxisomes perform numerous diverse vital functions, including -oxidation of 
very long chain fatty acids, the synthesis of myelin precursors and detoxification 
of hydrogen peroxide (Wanders and Waterham, 2006). Therefore defects in 
peroxisomal biogenesis affect many processes and the severity of the defect 
can alter the phenotype. 
 
The phenotypic variation seen in ZSSD is related to the severity of the 
underlying PEX gene mutations. Biallelic loss of function or null alleles, caused 
by frameshift and nonsense mutations often lead to a total absence of 
peroxisomes, resulting in ZS, whilst genotypes which include an allele with a 
minor import defect, caused by a missense mutation, may lead to NALD or IRD 
(Moser, 1999, Maxwell et al., 2002, Preuss et al., 2002). During this study, HS 
was also shown to result from hypomorphic mutations in PEX genes (Ratbi et 
al., 2015). Functional complementation studies of PEX1 and PEX6 variants in 
peroxisome-deficient cells, carried out by the collaborating group, revealed that 
at least one of the HS alleles in each patient retained significant activity, 
including the c.1742G>C, p.R581P variant identified in AI-202 (Ratbi et al., 
2015). Ratbi et al. (2015) reported a total of six families; four with biallelic PEX1 
mutations (including family AI-202, individual 4505, reported here) and two with 
biallelic PEX6 mutations. Similarly, Zaki et al. (2016) reported one family with 
biallelic PEX6 mutations. This study reports an additional family with biallelic 
PEX1 mutations and five families with biallelic PEX6 mutations (Smith et al., 
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2016b), bringing the total number of HS families with mutations in either PEX1 
or PEX6 to thirteen. 
 
The report by Ratbi et al. (2015) included two families in which PEX1 or PEX6 
variants were not identified. These cases may carry variants that are difficult to 
detect with the variant calling pipeline used by the authors. Alternatively the 
variants may lie in a promoter or in deep intronic regions not covered by WES. 
Further investigation using CNV calling algorithms and WGS may yet identify 
mutations within and/or affecting expression of PEX1 or PEX6. Alternatively, 
these families may carry mutations in a different gene(s). 
 
The report by Zaki et al. (2016), published after the initial report by Ratbi et al. 
(2015) and after the work described here was carried out, identified two siblings, 
born of consanguineous parents, with SNHL, RP, AI, developmental delay, liver 
dysfunction, cerebral white matter disease and microcephaly, with a 
homozygous PEX6 mutation, c.1238G>T, p.G413V. The phenotype reported is 
distinct to that reported in other ZSSD and HS cases, since it includes 
microcephaly. Consequently, the authors do not assign HS as the diagnosis in 
this case, despite the clinical overlap. The microcephaly phenotype may 
represent further phenotypic variation on the ZSSD spectrum, since mutations 
in other genes have been known to cause both peroxisomal defects and 
microcephaly (Waterham et al., 2007). Alternatively, it may be due to a co-
segregating variant at another locus, given the family’s consanguineous history. 
 
Immunohistochemical staining of murine incisor and retina was undertaken to 
determine whether PEX1 and PEX6 are normally expressed in these tissues. 
Whilst staining of murine incisor failed for both PEX1 and PEX6 due to 
detection of similar patterns of immunoreactivity for the control slide incubated 
without a primary antibody, PEX14 staining showed that there was strong 
expression in the stratum intermedium of maturation stage ameloblasts. Due to 
difficulties orientating the tissue during embedding and sectioning, the normal 
morphology of ameloblasts in the secretory or maturation stage was masked. 
Therefore the secretion-transition-maturation stage boundary was identified as 
the ameloblasts immediately below the more distal root (of the two visible on a 
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mid-line section) of the first molar (Smith and Nanci, 1989). Ameloblasts that lay 
more mesially were designated as secretory stage, while those that lay more 
distally, were designated as maturation stage. However, subsequent analysis of 
wild-type murine incisors by microCT found that mineralisation begins at a more 
mesial position than this (data not shown). It was therefore concluded that the 
anti-PEX1 and anti-PEX6 antibodies used could not be interpreted rigorously as 
they were not specific to the target proteins, while the data obtained with PEX14 
could not be satisfactorily interpreted as the stages of amelogenesis could not 
be distinguished and the early secretory stage may not have been stained at all 
due to the orientation of the sections and the possibility that this region was 
excluded from the section. 
 
Immunofluorescence in post-natal day 2 dental tissues by Zaki et al. (2016) 
detected PEX6 at the apical ends of both ameloblasts and odontoblasts, 
suggesting that it may be involved in protection of these cells from reactive 
oxygen species generated in mineralising tissues. These findings agree with 
those previously reported for PEX14 in developing murine molar teeth (Stelzig 
et al., 2013). In addition to this protective role, lipid metabolism by peroxisomes 
may influence the secretion of enamel matrix proteins by affecting membrane 
fluidity and may also affect signalling molecules involved in ameloblast 
differentiation. Tooth development in general may be affected since other oral 
phenotypes, such as delayed tooth eruption and microdontia, are associated 
with ZSSD (Poll-The et al., 2004, Lertsirivorakul et al., 2014). Lipids have been 
detected in both developing and mature enamel and dentine, although their 
source remains unknown (Goldberg and Septier, 2002). In enamel, the source 
has been suggested to be remnants of Tomes’ processes (Goldberg and 
Septier, 2002). 
 
Immunohistochemical staining of murine retinal tissue in this study revealed 
staining throughout the retina with the exception of the photoreceptor outer 
segment in all cases (Figure 3.16). The GCL and the IS showed the most 
intense PEX14 immunoreactivity. For PEX1, the OPL stained the most 
intensely, with strong staining also present in the GCL and IPL. For PEX6, the 
most intense staining was present in the GCL. Zaki et al. (2016) used 
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immunofluorescence to show that PEX6 localised throughout the retina, 
including the IPL and OPL but with the most intense staining at the IS and the 
connecting cilium. Zaki et al. (2016) suggested that this might reflect a role for 
PEX6 in outer segment maintenance and function. The results reported in this 
study overlap those of Zaki et al. (2016) but are not identical. The differences in 
the staining pattern between this and the previous study could be due to the 
use of different detection methods, antibodies or to differences in the ages of 
the mice studied. Whilst the staining of PEX1, PEX6 and PEX14 overlapped, 
the relative intensities across retinal layers differed. This is surprising since 
PEX1 and PEX6 are known to form a complex (Gardner et al., 2015) and, along 
with PEX14, all three proteins form part of the peroxisomal protein import 
machinery. A previous report of the immunolocalisation of PEX13 and PEX14, 
two peroxisomal membrane proteins that interact as part of a membrane 
complex (Schell-Steven et al., 2005), showed that the proteins had distinct 
localisations within mouse testis (Grant et al., 2013). PEX1 and PEX6 are 
known to require ATP to interact (Saffian et al., 2012), therefore, the proteins 
may also be present separately and this may explain their overlapping 
localisations with different relative intensities. 
 
In this study, the staining for all three PEX proteins suggests that peroxisomes 
are particularly abundant within the OPL and GCL. Such layers contain features 
likely to provoke metabolic stress, such as synapses, and therefore may require 
higher numbers of peroxisomes in order to provide efficient means of 
detoxification for cell survival. 
 
In conclusion, biallelic PEX1 or PEX6 variants have been identified in 
individuals with HS from a total of thirteen families, seven of them in this study 
(Ratbi et al., 2015, Smith et al., 2016b, Zaki et al., 2016). At least one allele in 
each family is likely to result in protein with some residual function. Therefore 
the aetiological basis of the HS phenotype is believed to be a mild peroxisomal 
protein import defect (Ratbi et al., 2015). A reduction in the number or efficient 
function of peroxisomes may compromise the function or survival of the 
ameloblasts, ganglion cells and the cells of the OPL. 
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3.3.3 Likely functional consequences of biallelic PEX1 and PEX6 
variants in individuals with HS 
The variants identified in PEX1 and PEX6 in the HS individuals in this study 
included those predicted to lead to missense and frameshift proteins changes. 
In all cases, there were combinations of either two hypomorphic alleles in trans 
or one hypomorphic allele and one null allele. Five of the variants identified had 
been previously reported in ZSSD patients and six were unreported. In two of 
the families, AI-71 (2645) and AI-202 (4505), variants in PEX1 were identified. 
In the remaining five families, AI-10 (1499 and 1500), AI-16 (2113), AI-146 
(3000), AI-152 (3466 and 4922) and AI-186 (4716), variants in PEX6 were 
identified. All changes were shown to be biallelic except in families AI-71 (2645) 
and 146 (3000), where segregation of alleles was not possible due to lack of 
samples from additional family members. All variants discussed in the following 
section are detailed in Table 3.7. Their frequencies in databases of variation are 
reported in Table 3.8. Sanger sequencing electropherograms are shown in 
Figure 3.7 and segregation analysis is depicted in Appendix 7. Alignments of 
homologous protein sequences surrounding each previously unreported protein 
variant are depicted in Figure 3.8. The relative positions of important domains 
and structural features of PEX1 and PEX6 and of the variants identified in HS 
patients are shown in Figure 3.18. 
 
As AAA+ ATPases, PEX1 and PEX6 contain conserved domains important to 
their function. Both proteins contain tandem arrangements of AAA+ domains, 
labelled Domain 1 (D1) and Domain 2 (D2). D1 and D2 each contain 
phosphate-binding Walker A and Walker B motifs (Walker et al., 1982, Hanson 
and Whiteheart, 2005). The D2 domains are highly conserved and the Walker A 
and B motifs are important for ATP binding and hydrolysis respectively 
(Ciniawsky et al., 2015). The D1 domains are less conserved and are thought 
not to be essential to ATP hydrolysis, but may be involved in PEX1/PEX6 
complex formation (Tamura et al., 2006, Nashiro et al., 2011). It is noteworthy 
that none of the hypomorphic mutations identified so far in HS patients affect 
residues within the important D2 Walker motifs (Figure 3.18). This supports the 
hypothesis that only relatively mild mutations in PEX1 and PEX6 result in HS.  
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Figure 3.18: Schematic of PEX1 and PEX6 proteins. 
PEX1 N terminal domain is shown by purple shading. For both PEX1 and PEX6, the AAA+ 
domains, D1 and D2, are shown in grey, conserved Walker A1 and A2 motifs are shown 
sequentially in blue, conserved Walker B1 and B2 motifs are shown in red and the second 
regions of homology (SRH) are shown in green. The position of the N terminal domain of PEX1 
is as reported by Shiozawa et al. (2006). The AAA+ domains were determined using SMART 
(Schultz et al., 1998, Letunic et al., 2015). The positions of Walker motifs and SRH are as 
reported by Ciniawsky et al. (2015) and Ghenea (2001) respectively for both PEX1 and PEX6. 
Annotations show the positions of the residues predicted to be affected by the PEX1 and PEX6 
variants identified in HS patients. Variants with labels above each schematic protein are those 
identified in this study. Variants with labels below each schematic protein were identified by 
Ratbi et al. (2015) or Zaki et al. (2016). Different colours denote the combinations of mutations 
identified in patients from different families. 
d 
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a Families reported in this study  
b Families reported by Ratbi et al. (2015). 
c Families reported by Smith et al. (2016b). 
d Family reported by Zaki et al. (2016). 
The family numbers refer to those used in the relevant publications. 
 
PEX1 variants c.2097dupT (p.I700Yfs*42) and c.1742G>C (p.R581P) were 
identified in trans in individual 4505 (family AI-202). The c.2097dupT variant has 
been reported in over 80 individuals in the LOVD dbPEX database and 
represents the second most commonly reported variant in ZSSD patients 
(Ebberink et al., 2011). Analysis of ZSSD patient cohorts has shown that of the 
approximate 58% with PEX1 mutations (Ebberink et al., 2011), around 30-32% 
of these carry the c.2097dupT variant (Collins and Gould, 1999, Maxwell et al., 
1999, Walter et al., 2001). c.2097dupT (p.I700Yfs*42) is associated with the 
more serious ZS phenotype when homozygous or in combination with other null 
alleles (Walter et al., 2001). The frameshift variant would be predicted to result 
in degradation of transcripts via NMD and analysis of RNA from a fibroblast cell 
line prepared from a patient homozygous for c.2097dupT showed the presence 
of around 8% of WT levels of PEX1 mRNA (Maxwell et al., 2002). An assay to 
determine the extent to which transfection of a PEX1 c.2097dupT construct 
could allow PEX1 deficient fibroblasts without peroxisomes to produce 
peroxisome positive cells, showed that no peroxisomes formed following 
transfection (Ratbi et al., 2015). This suggests that the c.2097dupT mutation 
leads to a complete absence of peroxisomes in vivo. 
 
The c.1742G>C (p.R581P) variant had not been previously reported in ZSSD 
patients. The mutation is predicted to alter a residue just proximal to the D1 
AAA+ domain of PEX1 at residues 591-741 (determined by Simple Modular 
Architecture Research Tool (SMART), available at http://smart.embl.de/ 
(Schultz et al., 1998)). Both mutations identified in individual 4505 (family AI-
202) were reported separately in combination with other PEX1 variants in two 
other HS families: c.[2097dupT];[2114T>G] in one of the index cases from the 
original HS family and as c.[1742G>C];[1239+1G>T] in an additional family 
(Ratbi et al., 2015).  
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The PEX1 mutations identified in individual 2645 (family AI-71) included a 
previously unreported deletion, c.1792delA (p.Q598Tfs*11) and an SNV, 
c.2966T>C (p.I989T). The lack of additional family members for AI-71 has 
meant that it is not possible to determine whether these variants are in cis or in 
trans. If the mutations exist in trans, the combination of a frameshift allele, 
predicted to result in NMD of the mutant transcript, with a missense mutation 
mirrors the combination of mutations identified in 4505 (family AI-202). The 
c.2966T>C variant had been previously reported (Maxwell et al., 2005) and was 
predicted to alter a residue within the D2 Second Region of Homology (SRH; 
residues 983-1000 (Ghenea, 2001)). The SRH is reported to be a highly 
conserved motif within D1 and D2 (Lupas and Martin, 2002). The D1 SRH 
contains a conserved sensor motif (residues 384 and 385 (Ogura et al., 2004)) 
in which mutations in another AAA+ family protein have been shown to abolish 
ATPase activity and nucleotide binding (Zhao et al., 2010). The D2 SRH also 
contains two arginine residues (at positions 995 and 998) that are known to 
contribute to ATPase activity and stability of other functional AAA+ family 
oligomers (Ogura et al., 2004). Therefore the region surrounding the I989 
residue appears to be functionally important. Additionally, I989 is conserved as 
a residue designated “hydrophobic tendency” by ClustalW (Thompson et al., 
1994) in both PEX1 and PEX6 and their homologous and orthologous proteins. 
Its replacement with a hydrophilic threonine residue may alter the structure, and 
therefore also the function, of the region. 
 
For the remaining HS families, biallelic PEX6 mutations were identified. For 
each of families AI-10 (1499 and 1500), AI-146 (3000) and AI-186 (4716), a 
heterozygous c.1802G>A (p.R601Q) variant was detected. This missense 
variant has been previously reported in seven ZSSD patients although no 
phenotype details were provided (Yik et al., 2009, Ebberink et al., 2010). It was 
identified in trans with missense variants in six patients and with a seven base 
pair deletion; c.1314_1321delGGAGGCCT (a variant also identified in AI-16) in 
one patient (Yik et al., 2009, Ebberink et al., 2010). The variant is also reported 
in two entries in dbPEX (Accessed 19th February 2016) in trans with other 
missense mutations, one with c.2579G>A reported to have IRD and one with 
c.2434C>T reported to have NALD. In addition to these families and the three 
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HS families reported here, the c.1802G>A (p.R601Q) variant has also been 
identified in one other UK family with HS, suggesting that it is associated with 
milder presentations of ZSSD (Ong et al., 2006, Ratbi et al., 2015). Therefore, 
from the thirteen HS families reported to have mutations in PEX1 or PEX6, four 
have the c.1802G>A variant. An assay to determine the extent to which 
transfection of a PEX6 c.1802G>A (p.R601Q) construct could allow PEX6 
deficient fibroblasts without peroxisomes to produce peroxisome positive cells 
showed that after transfection, peroxisomes were present in around 35% of 
cells (Ratbi et al., 2015), suggesting that the c.1802G>A (p.R601Q) variant 
results in protein with a reduced, but not abrogated, function. 
 
The c.1802G>A (p.R601Q) variant has been reported at an allele frequency of 
0.4% in European (Non Finnish) populations (ExAC v0.3). In comparison to the 
most commonly identified ZSSD-causing PEX1 mutation, rs61750420, 
c.2528G>A (p.G843D), that had been identified in 25-40% of ZSSD patients 
(Reuber et al., 1997, Imamura et al., 1998a, Maxwell et al., 1999, Walter et al., 
2001, Preuss et al., 2002, Steinberg et al., 2004), the PEX6 c.1802G>A variant 
is over nine times more frequent in the European population according to ExAC. 
Despite four reports in ExAC of homozygous individuals for the c.1802G>A 
(p.R601Q) variant, it has not been reported in a homozygous state in ZSSD 
patients. This contrasts with the PEX1 c.2528G>A (p.G843D) variant, for which 
reports of homozygotes in cohorts of ZSSD patients are common (Collins and 
Gould, 1999, Walter et al., 2001, Maxwell et al., 2002, Preuss et al., 2002, 
Steinberg et al., 2004). This suggests that either the c.1802G>A allele is only 
able to cause disease when combined with other particular pathogenic 
mutations in trans or that disease due to c.1802G>A (p.R601Q) may be 
underreported. This, perhaps, is due to a failure to recognise the phenotype as 
part of the ZSSDs or a failure to identify the causative variant via targetted 
Sanger sequencing in clinic and research studies. Since the frequency of USH 
in the US population has been estimated to be 1 in 6,000 (Kimberling et al., 
2010), it seems more likely that homozygous c.1802G>A is not sufficient to 
cause disease. 
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Analysis of the haplotype surrounding the c.1802G>A variant showed that it 
was associated with a haplotype of two SNPs and one microsatellite spanning a 
region of at least 779kb for families AI-10, AI-146 and AI-186 (Table 3.9). 
However, for two of the families, AI-10 and AI-186, the shared haplotype 
extended over a region of at least 1,279kb. These findings suggest that the 
variant may represent a founder mutation, though the relatively short distance 
over which the conserved haplotype extends makes this difficult to prove 
unequivocally, and may imply that it arose many generations ago. 
 
The c.1802G>A (p.R601Q) variant in PEX6 is predicted to alter a conserved 
arginine residue, that is within the consensus sequence of the SRH of D1, to a 
glutamine residue (Ghenea, 2001). While the first AAA+ domain is less 
conserved than the second (Shiozawa et al., 2004), it has been shown to be 
critical for interaction with PEX1 (Tamura et al., 2006). Within this domain, the 
R601 residue forms an arginine finger that is known to be conserved in the 
majority of AAA+ family members and is known to interact with ATP during 
PEX6 function (Ogura et al., 2004). Therefore the replacement of the positively 
charged R601 residue with an uncharged glutamine residue is likely to affect 
the function of PEX6. 
 
The combinations of PEX6 alleles identified in AI-10, AI-146 and AI-186 are 
unique to each family and the mutations in trans to the c.1802G>A allele have 
not been reported previously in the literature. This again suggests that particular 
combinations of hypomorphic variants cause HS as opposed to the other 
ZSSDs. AI-10 (1492, 1499, 1500) carries c.654C>G, p.F218L, AI-146 (3000) 
carries c.275T>G, p.V92G and AI-186 (4716) carries c.296G>T, p.R99L. The 
variants have not been reported in databases of human variation, suggesting 
that they are rare. All three mutations affect residues encoded by the first exon, 
which one study found to harbour around one third of all ZSSD-causing PEX6 
mutations (Ebberink et al., 2010). Conservation analysis of p.F218 showed that 
the residue is conserved in all mammalian species analysed and in zebrafish 
but not in thale cress or in fruit fly. Conservation analysis for p.V92 and p.R99 
showed that whilst the residues are conserved in the majority of the mammalian 
species analysed, the region containing both residues is entirely absent for cat, 
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sperm whale and horse as well as thale cress sequences. The region is present 
in fruit fly and zebrafish sequences but the p.V92 and p.R99 residues are not 
conserved in these sequences and the mutant G residue at position 92 is 
present in both species. The fruit fly, zebrafish, cat, sperm whale, horse and 
thale cress sequence results in isolation suggest that the region may not be 
functionally important and that the mutation might be tolerated. However, the 
conservation of the residue in other species suggests that the region may have 
evolved to develop a novel function. Pathogenicity prediction algorithms 
generally predict the variants to be disease causing, however for all three of the 
variants, Provean assigns a neutral score. This may reflect the hypomorphic 
nature of the mutations. 
 
The c.275T>G (p.V92G), c.296G>T (p.R99L) and c.654C>G (p.F218L) variants 
are predicted to affect residues in the N terminal portion of PEX6 and lie outside 
of the conserved D1 AAA+ domain (residues 462-597, as determined by 
SMART (Schultz et al., 1998)). The role of the N terminal domain in PEX6 is not 
well studied. In PEX1, the domain is known to bind phospholipids and is 
predicted to direct interaction with the peroxisomal membrane (Shiozawa et al., 
2006). However, the N terminal domain of PEX6 has been reported to be very 
different from that of PEX1 when compared to the similarity displayed by the 
conserved AAA+ domains of these two related proteins (Shiozawa et al., 2004). 
In yeast, the N terminal portion of PEX6 is known to interact with PEX26 
(Birschmann et al., 2003) and the difference between the N terminal domains of 
PEX1 and PEX6 have been hypothesised to delineate their distinct functions 
from each other (Shiozawa et al., 2004). A study that deleted the N terminus of 
PEX6 (residues 1-384) showed that while binding with PEX1 was detected via a 
yeast-two-hybrid assay, the construct was unable to complement PEX6 null 
cells with impaired import of peroxisomal proteins (Tamura et al., 2006). This 
suggests that the N terminal domain is essential for the proper function of 
PEX6. 
 
In 2113 (AI-16), a combination of an eight bp deletion, 
c.1314_1321delGGAGGCCT (p.E439Gfs*3) and a missense mutation 
c.2714G>T (p.C905F) were identified. The deletion has been previously 
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reported in a number of ZSSD patients (Krause et al., 2009, Ebberink et al., 
2010) and is described as the most commonly reported ZSSD PEX6 mutation 
(Waterham and Ebberink, 2012). It is unclear from the Krause et al. (2009) 
study in what combination of alleles the deletion was detected or the severity of 
the phenotype. However, the report by Ebberink et al. (2010) that studied 75 
ZSSD patients in the PEX6 complementation group, detected the variant in a 
homozygous state in five patients and in a heterozygous state in eight patients 
in trans with both null and missense alleles. This suggests that the allele may 
be relatively common among ZSSD patients and may be a mutational hotspot 
or founder mutation. The deletion would be expected to lead to NMD (Isken and 
Maquat, 2007). 
 
The c.2714G>T (p.C905F) missense mutation has not been previously reported 
and is predicted to affect a residue distal to the 2nd AAA+ domain. Little is 
known about this C-terminal region, but when residues 883-980 of PEX6 were 
deleted, the resulting constructs were unable to complement PEX6 null cells 
with impaired import of peroxisomal proteins despite detection of the mutant 
protein binding with PEX1 by yeast-two-hybrid assay (Tamura et al., 2006). This 
suggested that the C-terminal domain is necessary for the normal function of 
PEX6. The c.2714G>T variant identified in 2113 (AI-16) was consistently 
predicted by pathogenicity prediction programs to be disease causing and 
CADD assigned a scaled C score of 34. This means that only 0.04% of all 
variants scored by CADD v1.3 are ranked as more deleterious. 
 
In 3466 and 4922 (AI-152), a homozygous c.1715C>T (p.T572I) variant was 
identified. This variant has been previously reported in three families (Raas-
Rothschild et al., 2002, Ebberink et al., 2010). In one report, a patient with the 
same homozygous genotype and same Yemenite Jewish ethnic origin as family 
AI-152 had initially been diagnosed with USH (Raas-Rothschild et al., 2002). 
His phenotype was described as “even milder than IRD” (Raas-Rothschild et al., 
2002). Biochemical analysis of the patient, undertaken only after his child 
exhibited a phenotype intermediate between NALD and ZS, revealed mild 
peroxisomal biochemical dysfunction. Analysis of the patient’s fibroblasts 
revealed biochemical features associated with milder ZSSD phenotypes such 
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as peroxisomal mosaicism (Giros et al., 1996) and temperature sensitivity 
(Imamura et al., 1998b). Culture of the cells at a lower temperature showed that 
this increased the number of peroxisome positive cells from 7% to 82%. This 
has also been shown for a selection of other PEX mutants, including PEX1 
p.G843D (Walter et al., 2001) and PEX6 p.L57P and p.I845T (Imamura et al., 
2000). A temperature sensitive variation in the number of peroxisome positive 
cells suggests that these mutations cause instability of or misfolding of the 
protein. Such mutations have been shown to be amenable to therapy by use of 
non-specific chemical chaperones such as arginine, proline, DMSO, 4-
phenylbutyrate, glycerol, betaine and trimethyline N-oxide (Wei et al., 2000, 
Zhang et al., 2010, Berendse et al., 2013), with a small molecule screen to 
identify more specific chemical chaperones already undertaken (Zhang et al., 
2010). 
 
The utility of therapy for HS patients will be determined by whether the 
syndrome is a progressive or stable phenotype. The majority of patients that 
have been identified so far have been assessed at ages ranging from early 
childhood to young adulthood, with only one individual identified so far over 31. 
It has already been reported that one of the index cases (Heimler et al., 1991) 
developed macular dystrophy at the age of 29 (Lima et al., 2011) and family 1 
reported by Ratbi et al. (2015) were assessed at 12-16 to not have retinal 
pigmentation or macular dystrophy. Early recognition of the phenotype and 
molecular diagnosis would enable treatment to begin at a time when the 
majority of the permanent dentition would be mineralising and before the retinal 
dystrophy had manifested, so that it may be able to ameliorate the retinal and 
AI phenotypes to some degree. 
 
Additionally, some HS patients have been shown to have intellectual disability 
(2645 (AI-71) and 3466 and 4922 (AI-152)) and early use of chaperone 
therapies may improve this outcome. It is possible that once parents are 
identified as carriers of missense mutations in PEX1 or PEX6, drugs could be 
given in utero to prevent or ameliorate the sensory, intellectual and enamel 
phenotypes. 
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3.3.4 WES filtering strategy for variant identification 
The original strategy used to filter WES variants led to the identification of 
biallelic PEX1 mutations in individual 4505 (family AI-202), but failed to identify 
mutations in PEX1 and PEX6 for the remaining HS cases. This was for a 
number of reasons, that when combined, meant that the remaining mutations 
were not originally identified in any of the other six HS families. 
 
Firstly, the original filtering strategy filtered all variants present in dbSNP129 
unless they were marked as pathogenic (hereafter named as 
dbSNP129/pathogenic filter). Pathogenic variants were indicated only by values 
of 5 in the SCS flag in dbSNP and the CLNSIG flag in ClinVar. This annotation 
relies on submission of the variant to ClinVar by clinicians / scientists and 
evaluation of the evidence for pathogenicity by ClinVar. Such strict criteria 
meant that variants marked only as “clinically associated” in dbSNP (for 
example due to inclusion in locus specific databases such as dbPEX) were still 
filtered. In addition, all variants present in subsequent dbSNP builds, up to and 
including dbSNP142 at a minor allele frequency of 1% or more were filtered. 
dbSNP129, containing 11 million SNPs and 3 million indels (Abecasis et al., 
2010), is widely regarded as the final dbSNP build to be free of unannotated 
pathogenic mutations. Subsequent dbSNP builds included significant deposits 
from large scale sequencing projects, for example new deposits to dbSNP130 
included over 21 million SNPs from the 1000 Genomes Project, James Watson 
Genome, J. Craig Venter Genome, the Individual Chinese Genome and the 
Individual Korean Genome (National Centre Biotechnology Information, 2009). 
The removal of all SNPs identified in dbSNP129 but not marked as pathogenic 
has previously been used successfully as a filtering strategy in sequencing 
projects to identify causative variants in genetic diseases, including AI (Parry et 
al., 2012, Parry et al., 2013, Poulter et al., 2014a). Since then, more detailed 
annotation, including the addition of minor allele frequency (MAF) data to a 
greater number of entries in subsequent dbSNP builds, has meant that the use 
of dbSNP129 to filter WES data has become obsolete. The use of this filter 
resulted in the removal of one variant in PEX1 or PEX6 for each of individuals 
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1499 and 1500 (AI-10), 2645 (AI-71), 3000 (AI-146), 3466 and 4922 (AI-152) 
and 4716 (AI-186) (Table 3.10). 
 
However, even if WES data had not been filtered using the 
dbSNP129/pathogenic filter, the majority of variants would still have been 
absent in the filtered file due to the use of the annotateSnps perl script (Section 
3.2.2). The annotateSnps perl script filtered variants based on options specified 
by the user, for example using -b to specify a dbSNP build version (e.g. 
dbSNP129) to filter variants from in their entirely, -d to provide a dbSNP 
reference file with SNP and MAF data, -p to keep variants flagged as 
pathogenic or -f to specify a minor allele frequency cut off at and above which, 
variants are filtered. In-built to version 0.1.10, but unmentioned in the user 
manual, was a filter based on a variant’s frequency, not only in dbSNP, but also 
in the data submitted from the major populations of the 1000 Genomes Project. 
dbSNP variants are considered “common” and are therefore, filtered out, if they 
are present in at least one 1000 Genomes Project major population with a 
minor allele frequency of 1% or higher and for which two or more founders 
contribute to that minor allele frequency (National Centre Biotechnology 
Information, 2016). A major population is defined as one of the twenty-six ethnic 
groups that were sequenced as part of the project. Such filtering may be 
relevant in some situations, for example, if investigating a rare disease in one of 
the particular populations studied in the 1000 Genomes Project. However, in 
this study, the variants that were filtered were present only in one or two 
populations from which the individuals recruited to this study did not originate. 
In isolation, this filter would have removed one variant from each of 1499 and 
1500 (AI-10), 2645 (AI-71), 3000 (AI-146) and 4716 (AI-186) (Table 3.10). A 
newer version of annotateSnps (v0.2.0) includes an option to disable the use of 
1000 Genomes Project data to filter SNPs from WES data, in part, due to 
feedback from users. 
 
Finally, poor coverage of particular regions of the PEX6 gene meant that a 
variant in each of 2113 (AI-16) and 4716 (AI-186) was not identified (Table 
3.10). The regions that were poorly covered included exons 1 and 8 for both 
families. These exons are the most GC rich of the gene (70.4% (protein coding 
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region only) and 65.3% respectively). GC content has been shown to affect the 
library amplification step of WES, but also the other steps that include 
denaturation, such as cluster amplification (Aird et al., 2011). Regions of higher 
GC content often have poorer coverage. Typically, the first exon of a gene is 
affected, due to the presence of CpG islands in the proximity of the promoter 
region (Majewski and Ott, 2002). The poor coverage over these exons may also 
be due to sub-optimal bait design or capture conditions. Therefore, the poor 
coverage of these two exons may be typical of many other genes and the use 
of coverage statistics that report the mean coverage and even the percentage 
of bases covered by a specified number of reads may be misleading. A score of 
the evenness of coverage, such as that calculated by Mokry et al. (2010), may 
be more informative. 
 
The use of the dbSNP129/pathogenic filter, annotateSnps 1000 Genomes 
Project filter and the low coverage of particular exons meant that only one 
variant in PEX1 or PEX6 remained in each of 1499 and 1500 (AI-10), 2113 (AI-
16), 2645 (AI-71), 3000 (AI-146) filtered WES data and none at all for 3466 and 
4922 (AI-152) and 4716 (AI-186). The use of a perl script to filter the remaining 
variants for those that were potentially biallelic resulted in the exclusion of the 
remaining PEX1 and PEX6 variants from the final list of filtered variants (Table 
3.10). 
 
Although the use of this variant filtering strategy delayed the identification of the 
causative genes for HS, a stringent filtering strategy was deemed necessary at 
the time since the number of variants reported from WES studies of multiple 
unrelated individuals is enormous and identification of the causative mutation 
from an unfiltered list would have been impossible. Individual exomes have 
been reported to contain around 40,000 SNVs and indels in sequences covered 
using the Agilent SureSelect v4 capture reagent (Chilamakuri et al., 2014) and 
this is likely to be even more with the v5 capture reagent that has a target size 
39% larger than for v4. 
 
However, with the benefit of hindsight, without the updated version of 
AnnotateSnps, a global analysis of all unfiltered HS WES data would have been
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Gene Variant dbSNP reference, 
presence in dbSNP129 and 
pathogenicity 
classification in ClinVar 
release 29/09/2014 
annotateSnps - common filter 
number of alleles identified in 
specified population(s) of the 1000 
Genomes Project
a
 (allele frequency 
in specified population(s)) 
WES coverage 
(OK: >10 reads 
Low coverage: 
≤10 reads) 
Biallelic 
filter 
Families 
affected 
Variant 
detected  
using 
filtering 
strategy? 
PEX1 7:92136369C>G N/P N/P OK Pass AI-202 Yes 
PEX1 7:92136319delT N/P N/P OK Filter AI-71 No 
PEX1 7:92132483dupT rs61750415 
Present in dbSNP129 
Marked as pathogenic 
N/P OK Pass AI-202 Yes 
PEX1 7:92123671A>G rs61750427 
Present in dbSNP129 
Not marked as pathogenic 
KHV 2/198 (0.010) OK N/P AI-71 No 
PEX6 6:42946614A>C N/P N/P OK Filter AI-146 No 
PEX6 6:42946593C>A N/P N/P Low coverage N/P AI-186 No 
PEX6 6:42946235G>C N/P N/P OK Filter AI-10 No 
PEX6 6:42937452-
42937459 
delAGGCCTCC 
rs267608216 
Present in dbSNP137 
Not marked as pathogenic 
N/P Low coverage N/P AI-16 No 
PEX6 6:42935275G>A rs61753224 
Present in dbSNP129 
Not marked as pathogenic 
N/P OK N/P AI-152 No 
PEX6 6:42935188C>T rs34324426 
Present in dbSNP126 
Not marked as pathogenic 
CEU 2/198 (0.010) 
GIH 3/203 (0.0148) 
OK N/P AI-10 
AI-146 
AI-186 
No 
PEX6 6:42932620C>A N/P N/P OK Filter AI-16 No 
Table 3.10: Details of the stages in the original filtering strategy when each PEX1 and PEX6 variant was retained or filtered. 
The table shows that all PEX1 and PEX6 variants except those present in AI-202 were filtered out by the original variant filtering strategy. In each case a bold 
entry highlights the point at which a variant was lost in the filtering pipeline. 
a1000 Genomes Project Phase 3 data, based on release 17, November 2015. Accessed 3rd March 2016. 
Abbreviations: CEU Utah residents (CEPH) with Northern and Western ancestry (A 1000 Genomes Project major population; GIH Gujarati Indian from 
Houston, Texas (A 1000 Genomes Project major population); KHV Kinh in Ho Chi Minh City, Vietnam (A 1000 Genomes Project major population); N/P not 
present.
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a more powerful strategy. Filtering variants that were present at a frequency of 
one percent or more in a large database of variation such as ExAC and 
retaining biallelic variants occurring in the same gene in two or more families, 
would have identified PEX1 and PEX6 variants in five of the seven HS families. 
 
3.3.5 Identification of USH2A mutations in families AI-12 and AI-138 
In two families, AI-12 (1509 and 1514) and AI-138 (2975), mutations in USH2A 
were identified from WES data (Table 3.3) and confirmed as biallelic by Sanger 
sequencing and segregation analysis (Figure 3.4). Biallelic mutations in USH2A 
are known to cause USH2 and non-syndromic RP (Eudy et al., 1998, Rivolta et 
al., 2000). In both families, it seems more likely that the resulting phenotype of 
these mutations is USH2, since the patients have both visual and hearing 
defects and the variants identified have already been reported in patients with 
USH2. USH2A variants associated with the non-syndromic RP phenotype 
(Lenassi et al., 2015) are not present in either family.  
 
For 1509 and 1514 (AI-12), only five variants remained after filtering, and of 
these, the only gene with potentially biallelic variants with a CADD score of over 
15 was USH2A, suggesting that the possibility that biallelic variants in another 
gene might be causing the SNHL was unlikely (Appendix 9). For 2975 (AI-138), 
ten genes with potentially biallelic variants remained after filtering, but none 
other than USH2A were known to lead to a SNHL phenotype (Appendix 10). 
Therefore it seems likely that the phenotypic overlap of the USH2 and HS had 
led to the inclusion of two families with USH2 in this study of HS. 
 
USH is a combination of SNHL and RP without an associated enamel 
phenotype (Section 1.11), whereas, at the time of the commencement of this 
study, HS was described as a combination of SNHL and AI with or without MD 
(Lima et al., 2011). The timing of onset of the eye phenotype and the lack of 
reported vestibular dysfunction in HS most closely mirrors the phenotype of 
USH2, which is characterised by congenital moderate to severe hearing loss 
and onset of RP after puberty. 
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In general, USH is not associated with an enamel phenotype, although five 
reports of eight families detail individuals diagnosed with a combination of USH 
and an enamel phenotype (Table 1.1), including a report of one of the 
individuals included in this study, individual 2113 (AI-16) (Bateman et al., 1980, 
Innis et al., 1998, Pieke-Dahl et al., 2000, Balmer and Fayle, 2007, de la Pena 
and Valea, 2011). Of these individuals, none had mutations in known USH 
genes identified, so therefore none could be molecularly confirmed as USH 
patients. Should these patients be found to carry mutations in known USH 
genes, they may represent a new combination of phenotypes that includes an 
enamel defect, and may be the result of particular combinations of mutations in 
the USH gene affected or within an associated, but as yet unknown modifier of 
the USH phenotype. Alternatively, if the reported cases do not carry mutations 
in USH genes, they may be a mis-diagnosis of HS as USH (as is the case for 
individual 2113, family AI-16) or may consist of USH combined with an enamel 
defect that is not AI but is due to an environmental factor or life history exposure 
or event (Section 1.8.2). 
 
The enamel phenotype described in individual 2975 (AI-138) consisted of 
defective enamel restricted to particular teeth (first permanent molars, the upper 
incisors, one upper canine tooth and one lower incisor). The dentist concerned 
did not diagnose AI since the phenotype was more suggestive of an 
environmental or life history associated enamel defect. Patient 2975 had 
experienced perinatal fevers and the restriction of the enamel phenotype to 
particular teeth may reflect the developmental time period over which enamel 
development was compromised. For individual 2975, the time period would be 
birth to around one year, since the development of the pre-molars was not 
affected (Nanci, 2012). This suggests that the phenotype may be due to a 
combination of USH2 and a non-genetic enamel defect. For 1509 and 1514 (AI-
12), it was not possible to obtain a detailed description of the enamel phenotype 
and therefore it is not possible to determine whether it could be due to non-
genetic causes. 
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Figure 3.19: Schematic of USH2A protein. 
The positions of the residues affected by the variants identified in AI-12 and AI-238 are shown. 
Reference transcript, protein and length for each isoform are as follows:  
Long isoform: NM_206933, NP_996816, 5202 amino acids. 
Short isoform: NM_007123, NP_009054 1546 amino acids. 
 
USH2A spans 790kb and the full length transcript (NM_206933) includes 72 
exons, encoding two alternatively spliced isoforms of the protein usherin (Figure 
3.19). While the long isoform is a transmembrane protein encoded by all 72 
exons, the short isoform is an extracellular protein encoded by exons 2 to 21 
(Eudy et al., 1998, Weston et al., 2000, van Wijk et al., 2004). The two isoforms 
are known to have different expression patterns, structures, cellular 
localisations and may have different functions (Liu et al., 2007). The C-terminal 
PDZ binding motif present only in the long isoform has been shown to be crucial 
to interactions with other USH proteins that are necessary for its function (Adato 
et al., 2005, van Wijk et al., 2006, Ebermann et al., 2010). USH2A is expressed 
both in the inner ear and in the retina (Bhattacharya et al., 2002). In the 
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developing cochlea, the long isoform of usherin is a component of the ankle 
links, temporary structures crucial to the development of the stereocilia hair 
bundles and to the synapses (Reiners et al., 2005, van Wijk et al., 2006, 
Michalski et al., 2007, Zou et al., 2011). In the retina, usherin localises, along 
with other USH proteins, to the connecting cilium (the region between the inner 
and outer segments) and the synaptic region as well as to the periciliary 
membrane region (Maerker et al., 2008). 
 
Evidence that mutations in USH2A cause USH has been strengthened by the 
generation of a homozygous knockout Ush2a (Ush2a-/-) mouse model (Liu et 
al., 2007). Ush2a-/- mice initially had vision that was indistinguishable from that 
of wild-type (WT) mice, but over time signs of photoreceptor degeneration and 
death were detected and vision deteriorated as the photoreceptor nuclear layer 
and the photoreceptors’ outer and inner segments thinned (Liu et al., 2007). 
This suggests that USH2A is required for the maintenance, but not the 
establishment of the photoreceptor layer of the retina. In the cochlea, hearing 
assessments at four months showed loss of sensitivity to higher frequency 
sounds, but the level of hearing loss remained stable upon subsequent 
reassessment. The hearing loss phenotype was therefore moderate and non-
progressive, mirroring the phenotype seen in individuals with USH2 (Liu et al., 
2007). Investigation of the cochlear hair bundles revealed that there was loss of 
the outer hair cells (Liu et al., 2007). 
 
Tooth development, like that of the cochlear hair bundles, requires ciliated cells 
to coordinate important developmental signalling pathways involved in its 
formation (Liu et al., 2014). USH2A is temporally and spatially localised to the 
developing stereocilia bundle at the time the kinocilium is lost in the developing 
cochlea, and to the connecting cilium in photoreceptor cells (Liu et al., 2007). 
Since both the kinocilium and the connecting cilium are modified primary cilia 
(Goetz and Anderson, 2010, Wheway et al., 2014), this suggests that USH2A is 
involved in signalling from, or to, modified primary cilia. Cilia have also been 
found to be present during ameloblast development in rats (Sasano, 1986). 
Therefore it is possible that mutations in USH2A may affect amelogenesis, 
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although the absence of reports of USH patients with USH2A mutations and 
enamel defects suggests that this is not the case. 
 
The mutations identified in 1509 and 1514 (AI-12) and 2975 (AI-138) had all 
been previously identified in USH patients. The single nucleotide deletion 
c.2299delG (p.E767Sfs*21), identified in both families, was amongst the first 
mutations reported in USH2A (Eudy et al., 1998) and is the most commonly 
identified mutation in USH patients, having been reported 535 times in the 
LOVD retinal and hearing impairment genetic Usher syndrome 2A (USH2A) 
mutation database (hereafter called USH2ADB) (Roux et al., 2011). It has been 
estimated that this mutation accounts for between 10 to 47.5% of all mutations 
identified in USH2A depending upon the population studied (Dreyer et al., 2008, 
Aller et al., 2010). The c.2299delG (p.E767Sfs*21) variant is believed to have 
originated from an ancestral haplotype that arose in the European population 
between 2700-7400 years ago and has been found to be commonly inherited 
with the c.4714C>T (p.L1572F) variant, also identified in both AI-12 and AI-138, 
with which it is in linkage disequilibrium (Aller et al., 2006, Baux et al., 2007, 
Aller et al., 2010, McGee et al., 2010). A study of the haplotypes surrounding 
both SNPs found that the wild-type c.2299G allele is always associated with the 
c.4714C allele and eight out of ten different mutant c.2299delG haplotypes 
identified in Southern European populations (in around 85% of individuals) were 
associated with the c.4714T allele (Aller et al., 2010). These ten haplotypes 
have been defined based on variants at nine variant SNPs within USH2A (Aller 
et al., 2010). Investigation of the WES data for AI-12 and AI-138 showed that 
haplotypes for each family are likely to be either M6 or M7 for AI-12 and M3 for 
AI-138 (Appendix 20), although additional Sanger sequencing would be 
required to confirm this. Due to the c.4714C>T variant’s constant association 
with the c.2299delG frameshift allele, it is regarded as a non-pathogenic 
polymorphism, although the majority of scores obtained from mutation 
prediction software classify it as a pathogenic change (Table 3.3) (Baux et al., 
2007, McGee et al., 2010). The c.2299delG (p.E767Sfs*21) mutation in exon 13 
would be expected to lead to NMD of the transcript and therefore result in a null 
allele, but RT PCR analysis of RNA from homozygous individuals revealed that 
exon skipping of exon 13, or both exons 12 and 13, may also occur (Lenassi et 
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al., 2014). The skipping of exon 13 would potentially generate an in-frame 
protein product, although this may not function, could aggregate, or may be 
degraded due to misfolding (Waters, 2001, Lenassi et al., 2014). 
 
For 1509 and 1514 (AI-12), a second frameshift variant, c.11875_11876delCA 
(p.E3959Nfs*53), was identified and was found to lie in trans to the c.2299delG 
(p.E767Sfs*21) variant. This mutation has been reported seven times in 
USH2ADB in European individuals (Roux et al., 2011). The combination of the 
c.2299delG and c.11875_11876delCA alleles identified in the two affected 
individuals of family AI-12 has been identified in at least two other European 
families (Le Quesne Stabej et al., 2012, Baux et al., 2014), although for one of 
these families, segregation analysis was not performed. 
 
For individual 2975 (AI-138), a splicing mutation c.11549-1G>A (p.?) was 
identified and was found to be shared by the mother (4725). Since DNA from 
additional family members was not available for segregation analysis of the 
variants, it is possible either than the c.2299delG (p.E767Sfs*21) mutation is in 
trans on the paternal allele or that it is a de novo mutation and could be present 
on either allele. However, since the c.2299delG (p.E767Sfs*21) variant is 
regarded as a common founder mutation (Dreyer et al., 2001), it seems more 
likely that the mutation is present in trans on the paternal allele. The splicing 
variant has been reported only once in the USH2ADB in a Canadian individual 
(Roux et al., 2011), not in combination with the c.2299delG mutation (Lenassi et 
al., 2015). Analysis of the c.11549-1G>A mutation using both the PSSM and 
MEM algorithms via Sroogle (Section 2.8.4.5) suggested that it is expected to 
alter splicing by reducing the efficacy of the 3’ splice acceptor site in intron 59, 
since both scores for the variant were lower in comparison to the reference 
sequence. In addition, the percentile rank of each score (0.01 and 0 
respectively for constant exons) indicated that nearly all other sites were more 
likely as 3’ acceptor splice sites (Table 3.5). Ideally, the effect of the mutation on 
splicing would be analysed by RT-PCR, using RNA obtained from nasal 
epithelial cells (Vache et al., 2010), but no RNA from individual 2975 was 
available. One possibility is that, since exon 59 is in phase zero (Kolkman and 
Stemmer, 2001), exon 60 could be omitted from the final spliced transcript with 
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a consequential loss of 76 amino acids but without the consequence of an 
amino acid sequence frameshift or premature stop signal. Investigation of 
Ensembl transcripts and a literature search did not identify a natural, 
alternatively spliced transcript that lacked exon 60, although in-frame alternative 
splicing to exclude exons 50-52 and 62 has been documented (van Wijk et al., 
2004). The deletion of 76 amino acids resulting from the loss of exon 60 would 
disrupt fibronectin type III domains 23 and 24 and therefore the protein might be 
unstable. Whilst this scenario is one possibility, it also remains possible that 
alternative 3’ splice acceptor sites could be used or that the intron could be 
retained. The effect of the mutation may even be different in different tissues 
and at different stages of development. 
 
A missense variant, c.11927C>T (p.T3976M), was also identified in the proband 
and the mother. This variant has been reported once in a French USH patient 
(USH2ADB lists two family members who both carry the variant (Table 3.4)) that 
also carried a second mutation predicted to affect splicing on the same allele 
(Baux et al., 2007). This missense variant is therefore considered as unlikely to 
be pathogenic. Consistent with that view, mutation prediction outcomes (Table 
3.3) varied between the four algorithms used, with two that were borderline 
neutral (Provean and SIFT) and another two predicting the variant to be 
damaging (Polyphen-2 and MutationTaster). 
 
The frameshift variants identified in both AI-12 (1509 and 1514) and AI-138 
(2975) would be expected to produce a transcript that would be subject to NMD. 
However the USH2A protein has both a short (encoded by exons 2-21) and a 
long isoform (encoded by exons 2-72). Therefore the short isoform protein, 
translated from the allele with the frameshift mutation in exon 61 
(c.11875_118876delCA) in 1509 and 1514 (AI-12) and the allele with the 
splicing mutation in intron 59 (c.11549-1G>A) in 2975 (AI-138), may still 
function. 
 
In conclusion, individuals from both families AI-12 and AI-138 carry biallelic 
variants in USH2A that would be expected to produce transcripts that were 
subject to NMD, or could result in the protein being misfolded and degraded. 
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The combinations of the c.2299delG (p.E767Sfs*21) and the 
c.11875_11876delCA (p.E3959Nfs*53) variants in 1509 and 1514 (AI-12) and 
the c.2299delG (p.E767Sfs*21) and the c.11549-1G>A (p.?) variants in 2975 
(AI-138) are likely to be causing the USH phenotype. It therefore seems likely 
that the affected individuals in these two families have USH2 and not HS. The 
enamel defect in these families remains unexplained, but may result from a 
non-genetic cause, and for 2975 (AI-138), was not thought to be AI. 
 
3.3.6 Identification of a MYO7A deletion and an ENAM SNV in 
family AI-11 
In family AI-11, a heterozygous deletion that included the first two exons of 
MYO7A was detected by low coverage WGS of DNA from individual 1502 
(Figure 3.6). Analysis of WES data from individuals 1503 and 1504, affected 
members of the same family, revealed that a deletion could also be detected in 
them by the use of FishingCNV, but that it was predicted to also include the final 
two 3 exons of CAPN5 (Figure 3.6 and Table 3.6). The deletion, and therefore 
also its breakpoints, remains unconfirmed by Sanger sequencing.  
 
The predicted heterozygous deletion of MYO7A exons 1 and 2 was one of 
many CNVs identified by DNAcopy and FishingCNV, but was investigated due 
to overlapping calls from both programs using sequence data from three 
individuals, together with the known association of MYO7A with deafness and 
blindness phenotypes (Weil et al., 1995, Liu et al., 1997a). Both DNAcopy and 
FishingCNV identify large numbers of CNVs that must be prioritised in order to 
identify variants likely to cause disease. For DNAcopy, a conservative cut off of 
a copy number of ≤0.68 or ≥1.18 x diploid was used to minimise the possibility 
that the use of low coverage resulted in heterozygous CNVs being filtered out. 
Calls identified by DNAcopy were then compared with calls identified by Fishing 
CNV for both 1503 and 1504 and any non-overlapping calls were discarded. 
Unlike DNAcopy, FishingCNV assigns a Holm adjusted p value (Holm, 1979) to 
each CNV call, which allows the variants to be prioritised. A cut off value of p=1 
x10-5 was assigned to limit analysis to the CNVs most likely to represent true 
calls. 
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By definition, the CNV calls produced from WES by FishingCNV are limited to 
variants that include targetted regions i.e. they are protein coding. Therefore the 
strategy of prioritisation excluded DNAcopy CNV calls that did not affect regions 
that included protein coding exons. While it is possible that intergenic and 
intronic regions can have regulatory functions, current annotation of these 
regions limits prioritisation of CNV calls that include such regions. Also, in this 
case, the lack of data for such regions for two family members would have 
meant that prioritisation of variants could not be based on segregation with the 
disease phenotype in the family. 
 
The CNV filtering strategy left only two CNV calls (Table 3.6). The calls were 
investigated by checking for known variation in the region via the Database of 
Genomic Variants (MacDonald et al., 2014) and by Pubmed search (Section 
2.8.3.1) for information as to the genes’ functions and expression profile. 
 
One CNV call was a heterozygous deletion of ATAD3B and ATAD3C, genes not 
previously associated with disease and about which little is known. ATAD3B is 
known to be a mitochondrial membrane protein that contributes to the stability 
of nucleoids, structures consisting of mitochondrial DNA and proteins (He et al., 
2007). An Atad3 genetrap insertion model was shown to die at embryonic day 
7.5 due to the impaired mitochondrial biogenesis and its impact on trophoblast 
development (Goller et al., 2013). The related protein ATAD1 (MIM *614452) is 
known to be associated with peroxisomes and has been suggested to be 
involved in peroxisomal homeostasis (Wiese et al., 2007). Therefore, it is 
possible that the heterozygous deletion of both ATAD3B and ATAD3C may, like 
variants in PEX1 and PEX6, affect peroxisomal function. However a second 
variant, which would be expected in a recessively inherited disease, was not 
identified in either gene. 
 
The other CNV call included a partial deletion of MYO7A. Mutations in MYO7A 
are a known cause of USH1 (USH1B) (Weil et al., 1995) and isolated SNHL 
with both recessive and dominant inheritance (Liu et al., 1997a, Liu et al., 
1997b). The phenotype and mode of inheritance in AI-11 led to the suspicion 
that a second MYO7A variant may be present in WES data but had been 
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filtered out through the use of the original variant filtering strategy. A second 
variant was not identified in the unfiltered WES data for 1503 and 1504, even 
after exons covered by five or fewer reads were Sanger sequenced. Low 
coverage of particular exons, particularly those in GC rich regions, is a known 
problem for WES (discussed in Section 3.3.4). 
 
Since the predicted heterozygous partial deletion of MYO7A identified in AI-11 
remains unconfirmed by Sanger sequencing, it is not known which members of 
the family carry the variant. It seems likely that the deletion is present in 
affected individuals 1502, 1503 and 1504 since overlapping regions of 0.53, 
0.57 and 0.62x diploid copy number could be detected in three affected family 
members either by analysis of WGS data using DNAcopy or by FishingCNV 
analysis of WES data. However, no data is available for unaffected family 
members. It is expected that the deletion breakpoints will be more accurately 
predicted by the WGS analysis since data from WES is limited to only the 
protein coding exons and so breakpoints that lie within non-coding regions 
cannot be accurately located. This suggests that the deletion encompasses the 
first two exons of MYO7A and some flanking intronic sequence but does not 
include exons 12 and 13 of CAPN5 as suggested by the WES data. However, 
the accuracy of the breakpoint prediction from the low coverage WGS will be 
highly dependent on the local coverage at that region, with higher coverage 
providing more accurate breakpoint detection. 
 
Mutations in CAPN5 cause AD neovascular inflammatory vitreoretinopathy 
(Mahajan et al., 2012). This autoimmune condition may present at different 
stages of disease progression with different phenotypes, including uveitis, RP, 
proliferative diabetic retinopathy and proliferative vitreoretinopathy (Bennett et 
al., 1990). Even though the breakpoints of the putative heterozygous deletion 
remain unknown, and therefore it is uncertain to what extent the 3 region of 
CAPN5 is deleted, given the autosomal recessive mode of inheritance of 
disease in AI-11, it seems unlikely that any heterozygous deletion of CAPN5 is 
causing the blindness phenotype in this family. Ideally, further investigation of 
the family’s phenotype would have been undertaken, but this was not possible 
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due to loss of contact with the referring clinician. 
 
Low-coverage WGS detection of CNVs has been shown to be comparable in 
efficacy to the use of array comparative genomic hybridisation (aCHG) profiling 
(Hayes et al., 2013). The resolution obtained for 1502 was 23kb in comparison 
to the 76kb quoted by Hayes et al. (2013) for low-coverage WGS. The 
heterozygous MYO7A deletion detected was predicted to span 5-10kb, 
suggesting that the resolution across this locus was higher than average. 
 
Although mutations in MYO7A are known to be the most common cause (47.5-
63.3%) of USH1 in European populations (Jaijo et al., 2006, Roux et al., 2011), 
with 470 unique mutations recorded in the LOVD retinal and hearing impairment 
database myosin VIIA (MYO7A) (hereafter called MYO7ADB) (Roux et al., 
2011), very few of the mutations identified in patients are deletions of one or 
more exons. This may reflect the previous methodological bias towards 
identification of SNVs over CNVs, when Sanger sequencing was the method of 
choice for mutational screening and initial identification. Heterozygous whole 
exon deletions are “invisible” when sequencing primers do not anneal at 
positions flanking the deletion breakpoints. It may also result from a continued 
bias in the use of WES to identify only SNVs and small indels, with separate 
global analysis of WES datasets required to identify potential CNVs.  
 
Investigation of MYO7ADB (Roux et al., 2011) revealed that only one deletion 
spanning the region of the predicted deletion in AI-11 has been reported 
(Accessed 29th February 2016). The heterozygous deletion extended from 
within the second intron of CAPN5 (NM_004055) to intron 37 of MYO7A 
(Spanning chr11:76,799,656-76,913,682; 114,027bp) and was reported in trans 
with a heterozygous MYO7A pathogenic missense mutation (c.999T>G, 
p.Y333*) in an USH1 patient of French origin (Roux et al., 2011). Investigation 
of the Database of Genomic Variants (MacDonald et al., 2014), a database of 
structural and indel variation in healthy individuals, revealed two deletions over 
the CAPN5 and MYO7A genes (rsv779225 and rsv779224) spanning 
chr11:76,832,011-76,891,661 (59,651bp) and chr11:76,832,011-76,873,620 
(41,610bp) respectively (Cooper et al., 2011). While these deletions include the 
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region potentially deleted in AI-11, none of the deletions reported appear to 
match the approximate breakpoints. Since no additional variant in trans has 
been identified, it remains possible that the CNV may simply be part of the 
variation that each individual carries without pathological consequence 
(McCarroll et al., 2008, Conrad et al., 2010, Handsaker et al., 2015). 
 
Mutations in MYO7A are most commonly associated with USH1, but reports of 
individuals carrying MYO7A mutations with an USH2 phenotype, as reported in 
the case here, also exist (Bonnet et al., 2011, Aparisi et al., 2014, Rong et al., 
2014). Digenic inheritance of USH has also been suggested in an USH1 patient 
that carried single heterozygous MYO7A and PCDH15 mutations, although this 
remains to be proven since only the exonic sequence was obtained in that 
study (Rong et al., 2014). Additional evidence to support the possibility that a 
combination of heterozygous mutations in different USH genes can contribute 
to a disease phenotype is provided by increased levels of hearing loss in 
Myo7a+/- double heterozygous Ush1g+/-, Cdh23+/- and Pcdh15+/- mice (Zheng et 
al., 2012), although these results may be mutation and genetic background 
dependent, since an earlier report found no additive effect for Myo7a+/- Cdh23+/- 
mice (Holme and Steel, 2002). The possibility of digenic inheritance for AI-11 
was investigated but no additional variants, predicted to be pathogenic, were 
identified. 
 
Studies reporting on the sequencing of cohorts of USH patients have identified 
many patients for which only one mutation in MYO7A can be identified (Jaijo et 
al., 2006, Aparisi et al., 2014). If these cases are not caused by mutations in 
another gene, this could suggest that a second mutation lies either in the 
promoter, the UTRs or deep in intronic sequences that are not covered by 
conventional exonic Sanger sequencing or WES. Similarly it is also possible 
that WES and low coverage WGA failed to identify the second causative 
mutation in 1502, 1503 and 1504 (AI-11) because either the position of the 
variant or the coverage achieved meant that it was not recorded or was filtered 
out in the strategies utilised. High coverage WGS of two affected family 
members would allow a more thorough analysis through more even coverage of 
the regions targetted by WES, and greater overall coverage for more sensitive 
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detection of small to medium CNVs by reducing the window size of the 
DNAcopy analysis. 
 
For AI-11, it is possible that the AI phenotype may also be caused by the 
MYO7A variants, although if mutations in MYO7A caused AI, it would be likely 
that this would have been reported, given the number of mutations already 
identified in USH patients. Additionally, expression studies did not identify 
MYO7A as being differentially expressed during amelogenesis in rodent enamel 
organs (Lacruz et al., 2011, Lacruz et al., 2012b, Simmer et al., 2014). 
 
Alternatively, since it was possible that AI-11 was segregating mutations in two 
genes that cause components of the phenotype that has been diagnosed as a 
syndrome, variants in genes known to cause AI were investigated. This 
revealed a heterozygous variant in ENAM, c.332A>C, p.(K111T) shared by both 
1503 and 1504 in WES data and by 1502 upon confirmation of the variant by 
Sanger sequencing. The variant was also carried by two family members not 
known to have AI. Loss of contact with the recruiting physician meant that it was 
not possible to verify that these two family members did not have AI. Analysis of 
the variant with mutation pathogenicity prediction programs (Appendix 13) 
suggested that the c.332A>C variant is likely to be benign. Publications of 
ENAM mutations that cause AI have detailed only two missense variants, with 
the remainder of reports detailing fourteen null mutations and one further 
mutation that leads to an in frame insertion (Appendix 19). Comparison of the 
variant’s mutation pathogenicity prediction program scores with those for the 
ENAM variants previously reported showed that the c.332A>C variant was 
amongst the least pathogenic. Therefore it seems unlikely that the ENAM 
variant identified here is responsible for the phenotype of AI-11 affected 
individuals 1502, 1503 and 1504. As for 1509 and 1514 (AI-12) and 2975 (AI-
138), it remains possible that the enamel phenotype of AI-11 is not genetic in 
origin. 
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4 Association of an AMTN deletion with AI 
4.1 Introduction 
At the time of this study, AI was known to be caused by mutations in a number 
of genes (Section 1.9). Of these, only mutations in ENAM (Rajpar et al., 2001), 
FAM83H (Kim et al., 2008), LAMA3 (Yuen et al., 2012), LAMB3 (Kim et al., 
2013, Poulter et al., 2014b) and COL17A1 (McGrath et al., 1996) were known 
to cause non-syndromic autosomal dominant (AD) AI. Mutation screening in 
cohorts of AI patients had shown that mutations in known AI genes accounted 
for between 28-49% of AI cases (Chan et al., 2011, Wright et al., 2011, Prasad 
et al., 2016), suggesting that more genes were yet to be identified. 
 
A number of strong candidate genes for involvement in AI, implicated through 
function, pattern of expression and / or animal model studies, were also 
suggested in the literature. Foremost amongst these, was the gene encoding 
amelotin (Iwasaki et al., 2005).  
 
The aim of the work presented in this chapter was to identify novel AI gene(s). 
The second aim was to characterise the enamel phenotype and to compare this 
to the phenotype of any reported mouse models.  
 
Therefore, families with AI were recruited and their DNA subjected to WES. 
Teeth were also obtained and the enamel phenotype was analysed by microCT, 
SEM and EDX. 
 
In collaboration with Dr. Gina Murillo (University of Costa Rica, San Pedro, 
Costa Rica), one family (family AI-154) with non-syndromic, AD 
hypomineralised AI was identified and recruited to the study. This family is the 
focus of this chapter. 
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4.2 Results 
Details of the primers used in the following section are listed in Appendix 21. 
 
4.2.1 Clinical phenotype 
Five individuals were recruited to the study from family AI-154; three affected 
(II:2, III:3 and IV:1) and two unaffected (II:3 and IV:2). Affected individuals 
presented with hypomineralised AI in the absence of any co-segregating health 
problems. The pedigree for family AI-154 and the clinical phenotype of 
individual IV:1 are shown in Figure 4.1. The phenotype of the unaffected 
individual IV:2 is shown in the Appendix 22. Individuals were recruited in two 
batches, with initial recruitment including only the three affected individuals. 
 
 
Figure 4.1: Pedigree and dental phenotype of AI-154.  
A: Pedigree of the Costa Rican family investigated. Affected family members are shaded.  
B: The mixed maxilliary (i) and mandibular (ii) dentition of the index case, IV:1, aged 5 years, 
was characterised as generalised hypomineralised AI with some hypoplasia involving all teeth. 
There was post-eruptive enamel loss with retention of a thin band of enamel at the cervical 
margin (examples marked with ∗ ). Reproduced with permission from Smith et al. (2016a).  
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4.2.2 Whole exome sequencing of two affected individuals from 
family AI-154 
In an attempt to identify the genetic cause of AI in family AI-154, WES libraries 
were prepared from genomic DNA from two affected individuals, III:3 and II:2, 
using the 3g protocol (Section 2.4.1.1). DNA was extracted from saliva DNA 
as previously described (Section 2.3). Ideally, DNA from IV:1 would have been 
used to prepare a WES library instead of III:3, however DNA from IV:1 was of 
insufficient quantity and quality for the 3g protocol in use at the time. 
Therefore, libraries from III:3 and II:2 were prepared using the SSV5 capture 
reagent, each library was pooled with other samples and each pool was 
sequenced in a separate run. 
 
The resulting Fastq sequence files were aligned using Novoalign and the 
variants called, filtered and annotated as previously described for rare dominant 
disease (Sections 2.4.2, 2.4.3 and 2.4.4). The depth of coverage across the 
exome was also analysed (Section 2.4.5) and the mean was found to be 66.4x 
and 60.1x for samples III:3 and II:2 respectively (Appendix 23). The resulting 
variant files were further filtered by selecting only the heterozygous variants that 
were shared by both II:2 and III:3. In addition, any identical variants that were 
present in an additional WES dataset from an unrelated patient affected with 
autosomal recessively inherited AI caused by a homozygous mutation in 
MMP20, processed using the same alignment and variant calling pipeline, were 
also filtered. This was to aid the exclusion of artefactual variants inherent to the 
library preparation and sequencing platform. 
 
The resulting variant list contained 63 variants with a CADD score of 15 or more 
(data not shown). Investigation of the genes affected by each of the variants by 
PubMed searches did not present any clear candidates based on known 
function. Since a large number of candidate variants remained, no analysis of 
their segregation was attempted. 
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4.2.3 Identification of CNVs using WES data 
As an extension of the standard pipeline of analysis of WES data, CNVs were 
identified using the ExomeDepth software (Section 2.4.6). This was used since 
adequate numbers of controls were available for each data set. Five and eleven 
unrelated samples were sequenced in the same batches as II:2 and III:3 
respectively, although ideally ten reference exomes are required for optimal 
analysis (Plagnol et al., 2012). 
 
Analysis of ExomeDepth data for individuals III:3 and II:2 revealed a total of 
twenty-five and twenty-two CNVs respectively that were not identified as a 
common CNV in the study by Conrad and co-workers (Conrad et al., 2010). Of 
these, four were identified in both individuals, none of these included a gene for 
which mutations are known to cause AI nor any known AI candidate gene. Only 
one CNV included a gene found to be expressed during amelogenesis (Yin et 
al., 2014b), tripartite motif 16 (TRIM16; MIM *609505).  
 
Since CNV detection may not have identified all variants in both individuals, 
separate analysis of the CNVs identified in each individual was undertaken. The 
CNVs identified in III:3 included a predicted heterozygous deletion 
encompassing the region chr4:71388473-71394475 and therefore predicted to 
remove exons 3 to 6 of AMTN (Table 4.2, Figure 4.2B). No other variants were 
identified in known AI candidate genes in either individual. To determine 
whether a CNV within the AMTN gene was detectable using ExomeDepth for 
individual II:2 with less stringent parameters for calling variants, the transition 
probability setting was increased to 10-2 from the standard setting of 10-4, 
however, again there were no CNVs located over AMTN. If present, the deletion 
may not have been detected due to fewer controls being available for analysis 
using ExomeDepth for individual II:2 compared with individual III:3. 
 
Therefore, to determine whether the deletion over AMTN exons 3 to 6 was 
present in III:3 and to check whether it was also present in II:2 despite not being 
identified by ExomeDepth, the breakpoints of the predicted deletion in III:3 were 
investigated (Figure 4.2). Since ExomeDepth can only determine the extent of a  
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Figure 4.2: Identification of the breakpoints of the AMTN exons 3-6 deletion identified by 
ExomeDepth. 
A: UCSC Genome Browser view of AMTN RefSeq transcripts NM_212557 and NM_001286731, 
showing their chromosomal position at chr4:71,384,289-71,398,460 (GRCh37) and the relative 
positions of each exon and intron. B: Schematic of AMTN, comparing the relative position and 
span of the deletion detected by ExomeDepth in patient III:3 and the potential location of the 
breakpoints based on the positions of the flanking regions captured for WES and the positions 
of heterozygous SNPs. Boxes of smaller and larger height indicate the position of non-coding 
and coding exons respectively. C: Schematic of AMTN labelled with the positions of the primers 
used to identify and characterise the breakpoint. 
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CNV based on the boundaries of the capture reagent’s target for each exon, the 
possible position of the 5 breakpoint spanned from the 3 end of the capture 
reagents’ AMTN exon 2 target at chr4:71,384,656 to the 5 end of the AMTN 
exon 3 captured region at chr4:71,388,407, a region encompassing 3,751bp 
(Figure 4.2B). In order to further refine the 5 breakpoint region, the position of 
the most 3 heterozygous SNV was obtained from the unfiltered variant list for 
individual III:3. This refined the region of the 5 breakpoint to between 
chr4:71,384,840 and chr4:71,388,407 (3,567bp; Figure 4.2B). For the 3 
breakpoint, the close proximity of exon 7 meant that its possible location was 
refined to between chr4:71,394,541-71,394,809 (268bp; the 3 end of the 
captured region of exon 6 to the 5 end of the captured region of exon 7; Figure 
4.2B). Therefore primers that had previously been used to sequence exons 2 
and exons 6-7 were used in an attempt to amplify DNA spanning the 
breakpoints (Figure 4.2C). A PCR using AMTN primers ex2F and ex6-7R 
produced a product of around 2,000bp from DNA templates from affected family 
members (Figure 4.3). For comparison, a product of size 10,638bp would be 
expected from wild-type DNA. The wild-type fragment was not amplified, likely 
due to the enzyme and PCR conditions used for the reaction being 
inappropriate for such a large product size. 
 
The presence of the approximately 2,000bp product and the relative spans of 
the predicted 5 and 3 breakpoints suggested that sequencing of the product 
using the reverse (exon 6-7) primer would enable the sequence across the 
deletion breakpoints to be determined. Sanger sequencing confirmed the 
presence of the deletion and revealed that the 5 and 3 breakpoints were 
positioned at chr4:71,385,895 and chr4:71,394,574 respectively. In addition to 
the deletion, a 4bp insertion of CTCA between these points had occurred. 
 
Based on the identification of the exact breakpoints, primers were designed to 
amplify a product spanning the deletion breakpoints with flanking sequence of 
only a few hundred base pairs each side (Figure 4.2C). This would produce a 
shorter product that spanned introns 2 to 6 that could be sequenced from both 
directions to confirm the breakpoints of the deletion. These primers (intron 2F- 
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Figure 4.3: Amplification of the AMTN gene region, using primers designed to amplify 
exons 2 to 7, for AI-154 family members. 
The PCR products generated by the amplification of DNA from AI-154 family members, III:3, 
IV:1 and II:2 (lanes 2-4 respectively) and unrelated DNA (lane 5). A negative control is shown in 
lane 6. A 100bp marker is shown in lane 1. 
No product was generated from IV:1 due to the poor quality and low quantity of DNA. 
 
intron 6R) were also used to analyse the segregation of the deletion in all 
available AI-154 family members. Saliva samples were obtained from additional 
family members (III:3 and IV:2) and a second sample was obtained for IV:1. 
DNA extraction (Section 2.3), PCR amplification (Section 2.5) and subsequent 
size fractionation by agarose gel electrophoresis (Section 2.3.3) revealed that 
the deletion was present in all affected family members (II:2, III:3 and IV:1) 
corresponding to a band of approximately 400bp (Figure 4.4A). The predicted 
wild-type band of 9,073bp was not observed in controls, nor in patients, likely 
due to its large size and the PCR conditions, which were designed to be optimal 
for amplification of the 400bp band. In contrast, a PCR amplification using 
primers flanking exons 6 and 7, which would amplify the wild-type allele, 
produced a band of the expected size (713bp) in all individuals of family AI-154 
(Figure 4.4A). 
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Figure 4.4: Genotyping of the AMTN deletion in family AI-154, identification of the 
deletion breakpoints and a schematic diagram of the predicted effect of the deletion on 
the AMTN protein. 
A: PCR analysis of the heterozygous deletion of exons 3 to 6 of AMTN in the members of the 
family investigated. Amplification using primers spanning exons 6 to 7 produced a band of 
713bp in all individuals. In contrast, amplification of introns 2 to 6, designed to produce a 
product of 9,073bp for the wild-type allele, produced a product of 399bp in affected individuals 
(II:2, III:3 and IV:1) confirming a deletion encompassing exons 3 to 6. No product of size 399bp 
was amplified in unaffected individuals (II:3 and IV:2) or a control sample. 
B: Sanger sequencing electropherograms of mutant and wild-type alleles to identify the 5 and 
3 breakpoints of the deletion. Comparison of the mutant sequence with a control sequence 
revealed a deletion of 8,678bp spanning exons 3 to 6 of AMTN and an insertion of 4bp. 
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C: Schematic diagrams of the wild-type and the predicted mutant AMTN protein structures.  
The predicted mutant AMTN protein lacks the amino acid sequence encoded by exons 3 to 6, 
resulting in the loss of 92 amino acids. The contribution of each exon to the protein is signified 
by the boxes labelled with the number corresponding to the exon number. Important motifs are 
labelled with symbols as follows: the line shows the position of the putative signal peptide, 
encoded by exon 2, the asterisk shows the position of the LPQ motif, encoded by exons 2 and 
3, and the diamond shows the position of the IPLT motif, encoded by exon 4, predicted to be an 
O-glycosylation site. The arrow shows the position of the SXE phosphorylation motif, encoded 
by exon 7. Reproduced with permission from Smith et al. (2016a). 
 
The combination of both the intron 2-6 and the exon 6-7 PCR assays revealed 
that the AMTN heterozygous deletion spanning exons 3-6 was present for 
affected individuals II:2, III:3 and IV:1. Sequencing of the intron 2-F to intron 6-R 
product from affected individuals II:2, III:3 and IV:1 confirmed the breakpoints of 
the heterozygous deletion within AMTN spanning a total of 8,678bp, 
accompanied by a 4bp insertion (chr4:71,385,896-71,394,573delinsCTCA; 
GRCh37). The deletion encompasses all 276bp of exons 3-6 plus 2,576bp of 5 
genomic sequence and 98bp of 3 sequence (c.54+1347_330+98delinsCTCA 
(NM_212557, Figure 4.4B). The heterozygous deletion was present in all 
available affected family members (II:2, III:3 and IV:1) and absent from all 
unaffected family members tested (II:3 and IV:2). Since both intron 2 and intron 
6 are in phase zero (Sharp, 1981), this deletion is predicted to create an in-
frame deletion of 92 amino acids (p.Q19_Q110del, NP_997722), shortening the 
protein from 209 to 117 amino acids (Figure 4.4C). 
 
4.2.4 cDNA analysis 
In an attempt to determine the consequences of loss of exons 3-6 on 
transcription of AMTN mRNA, leukocyte cDNA was prepared by Dr. Murillo after 
obtaining whole blood from affected individual III:3. While cDNA amplification 
with control primers (P53) was successful (data not shown), amplification of 
AMTN products failed in both patient and control cDNA. This is consistent with 
the reported tissue specific expression pattern of Amtn (Iwasaki et al., 2005). As 
a consequence there is no detectable expression of AMTN mRNA in blood, a 
known issue for enamel-specific transcripts (Poulter et al., 2014c). 
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4.2.5 Whole exome sequencing of additional family members 
While the deletion in AMTN remained the prime candidate mutation in AI-154, 
there were still additional variants that were present in both affected individuals 
sequenced by WES. In order to exclude some of these SNVs, indels and CNVs, 
DNA from additional family members IV:1 and II:3 was subjected to WES using 
the 200ng protocol (Section 2.4.1.2). 
 
The resulting Fastq sequence files were aligned using BWA and the variants 
called and filtered as previously described for a rare dominant disease. The 
depth of coverage was also analysed and the mean depth was found to be 
110.5x and 89.8x for IV:1 and II:3 respectively (Appendix 23). The resulting 
filtered variant files were further filtered by selecting only the heterozygous SNV 
and indel variants that were shared by II:2, III:3 and IV:1 and absent in 
unaffected individual II:3. In addition, any identical variants that were present in 
an additional WES dataset from an unrelated patient affected with autosomal 
recessively inherited AI caused by a homozygous mutation in MMP20, 
processed using the same alignment and variant calling pipeline, were also 
filtered. This was to aid the exclusion of artefactual variants inherent to the 
library preparation and the sequencing platform. 
 
The 26 genomic variants in a total of 25 genes that remained after filtering are 
listed in Appendix 24. In order to identify any genes for which an association 
with an oral phenotype in any species had been previously reported, a 
PubMatrix search was carried out (Table 4.2). Search terms used were “tooth”, 
“teeth”, “amelogenesis”, “enamel” and “ameloblast”. Using the search term 
“amelogenesis”, negative results were obtained for all 25 genes. The search 
term “enamel” returned positive results for two genes, epidermal growth factor 
receptor (EGFR; MIM *131550) and calcium channel, voltage-dependent, T 
type, alpha-1G subunit (CACNA1G; MIM *604065). EGFR expression is 
associated with tooth eruption, but the gene is also widely expressed during 
foetal development (Wise et al., 1992, Wakeling et al., 1998). Therefore, an 
EGFR mutation would be expected to result in more complex phenotypic effects 
than isolated AI as in the family presented here. In the case of CACNA1G, its 
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chromosomal position is in the vicinity of distal-less homeobox 3 (DLX3; MIM 
*600525) and COL1A1 (MIM +120150), genes for which mutations result in 
tricho-odonto-osseous syndrome (MIM #190320; Section 1.8.1) and AI (MIM 
#104510) and osteogenesis imperfecta (MIM PS166200) respectively (Pope et 
al., 1985, Price et al., 1998). The reference identified by the PubMatrix search 
detailed an individual with an enamel phenotype with a deletion of chromosomal 
segments 17q21.33-q22 and therefore also of DLX3, COL1A1 and CACNA1G 
(Harbuz et al., 2013). Therefore, it seems likely that deletion of DLX3 or 
COL1A1 is the cause of the enamel phenotype in this case and not deletion of 
CACNA1G. The search terms “teeth” and/or “tooth” returned positive results for 
the two genes already mentioned above, as well as protein-tyrosine phosphate, 
receptor-type, F polypeptide-interacting protein alpha-1 (PPFIA1; MIM 
*611054). Similarly, the reference identified by PubMatrix for PPFIA1 reflects 
the gene’s chromosomal position near to the fibroblast growth factor (FGF3; 
MIM *164950) gene, in which mutations cause AR occulo-oto-dental syndrome 
(MIM #610706) (Gregory-Evans et al., 2007, Tekin et al., 2007). For 
comparison, AMTN was also included in the PubMatrix search and resulted in 
42 and 54 hits for the search terms “enamel” and “teeth” and/or “tooth” 
respectively. 
 
 168 
Gene Predicted effect on 
the protein 
CADD 
v1.3a 
Pathogenicity 
scoresb 
Human phenotypec Mouse modeld Pubmatrix 
search scoree 
AMTN heterozygous deletion 
of exons 3-6, in-frame 
deletion of 92 amino 
acids 
N/A N/A Not reported Enamel defects 144 
NAT8 heterozygous deletion 
of exon 2, containing 
the entire coding 
region, deletion of 227 
amino acids 
N/A N/A Not reported Not reported 0 
HECTD3 p.R583G 32 3/3 Not reported Not reported 0 
ADAM15 p.R288C 32 3/3 Not reported No tooth phenotype reported 0 
C20orf141 p.L84R 28.5 3/3 Not reported Not reported 0 
CLRN3 p.P126L 27.1 3/3 Not reported Not reported 0 
UBA7 p.I849V 26.4 2/3 Not reported No tooth phenotype reported 0 
ZNF563 p.G345C 26.0 2/3 Not reported Not reported 0 
EGFR p.M908T 25.5 3/3 Neonatal inflammatory 
skin and bowel disease 2 
No tooth phenotype reported; 
delayed ossification 
70 
IGSF9 p.V735M 25.1 2/3 Not reported No tooth phenotype reported 0 
CDH20 p.V722A 24.9 3/3 Not reported Not reported 0 
MLXIPL p.Q68H 23.9 2/3 Not reported Not reported 0 
POU2F1 p.T138M 23.8 2/3 Not reported Not reported 0 
SFPQ p.R663C 23.4 2/3 Not reported Not reported 0 
MOCOS p.S361Ffs*18 23.2 N/S Not reported Not reported 0 
LZTS3 p.K612T 23.3 2/3 Not reported Not reported 0 
LZTS3 p.K612E 23.1 2/3 Not reported Not reported 0 
BRINP3 p.T176M 22.9 1/3 Not reported Not reported 0 
MDGA1 p.A952T 22.9 1/3 Not reported Not reported 0 
ERICH2 p.P59L 22.8 1/3 Not reported Not reported 0 
ZNF717 p.A195V 22.6 1/3 Not reported Not reported 0 
SAMD14 p.E59_S64del 22.1 N/S Not reported Not reported 0 
CACNA1G p.A1582T 22.0 0/3 Spinocerebellar ataxia 42 No tooth phenotype reported 3 
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Gene Predicted effect on 
the protein 
CADD 
v1.3
a
 
Pathogenicity 
scores
b
 
Human phenotype
c
 Mouse model
d
 Pubmatrix 
search score
e
 
SYTL2 p.E1305K 21.6 1/3 Not reported Not reported 0 
CST8 p.S41P 21.5 3/3 Not reported Not reported 0 
AMPD1 p.Q189H 18.62 1/3 Myopathy due to 
myoadenylate deaminase 
deficiency 
Not reported 0 
SH3BGRL2 p.V14E 17.56 1/3 Not reported Not reported 0 
PPFIA1 p.S224R 15.91 0/3 Not reported Not reported 1 
Table 4.1: Assessment of CNVs, SNVs and indels that remain after filtering AI-154 WES data. 
List of the two heterozygous CNVs and twenty-six SNVs and indels identified by WES that remained after selecting only those shared by II:2, III:3 and IV:1, 
but not present in II:3,  and excluding variants with a MAF of 0.1% or more in dbSNP142, EVS or ExAC, variants that are homozygous and those located on 
the X chromosome. Assessment included CADD v1.3 scorea, assessment of pathogenicity scoresb, known human phenotypesc, known mouse phenotypesd 
and a score based on a Pubmatrix searche. 
a The list is restricted to variants scoring 15 or more when scored with CADD v1.3. 
b Pathogenicity scores included were generated using Provean, SIFT and PolyPhen2. Scores were classified as pathogenic if they were not classified as 
neutral, tolerated or benign by the programs (Sections 2.9.4.1 and 2.9.4.2). The fraction here denotes the number of pathogenic scores obtained using the 
three different programs. 
c A human phenotype was recorded if it was specified in OMIM (Section 2.9.1). 
d A mouse phenotype was recorded if a mouse model was specified to exist in the gene’s OMIM page. A dental phenotype was recorded if the teeth were 
reported to be affected in any way in the journal articles concerning the generation and characterisation of the phenotype of the mouse model(s) referenced 
on OMIM. Any phenotype reported for other mineralised tissues was also recorded. 
e A Pubmatrix search (Section 2.9.3.2) was conducted with the search terms, “tooth”, “teeth”, “amelogenesis”, “enamel” and “ameloblast”. The number of hits 
were recorded as a combined score. 
All pathogenicity scores were obtained, and the Pubmatrix search was conducted, on 4th April 2016. 
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4.2.6 CNV analysis using ExomeDepth of additional family 
members 
 
For both IV:1 and II:3, CNVs were identified using ExomeDepth as before 
(Section 2.4.6). The sequencing batch included nine other unrelated exomes 
that were used as controls for ExomeDepth analysis. 
 
Analysis of ExomeDepth data for IV:1 revealed a total of twenty-six CNVs not 
identified as a common CNV (Conrad et al., 2010), including the same 
heterozygous deletion spanning AMTN exons 3 to 6 identified in III:3 (Table 
4.2). Analysis of ExomeDepth data for unaffected individual II:3 revealed a total 
of twenty-three CNVs not identified as a common CNV. The heterozygous 
deletion spanning AMTN exons 3 to 6 identified in individuals III:3 and IV:1 was 
not identified in II:3. 
 
Sample Type Span 
(GRCh37) 
Bayes 
Factor 
Reads 
Expected Observed Ratio 
III:3 Deletion 4:71388473
-71394475 
13.6 344 185 0.538 
IV:1 Deletion 4:71388473
-71394475 
24.4 401 208 0.519 
Table 4.2: ExomeDepth output detailing the AMTN deletion identified in individuals III:3 
and IV:1. 
The Bayes Factor is the log10 of the likelihood ratio of data for the CNV call divided by that of the 
normal copy number call, i.e. higher scores suggest that the CNV is more like to be real. 
The expected number of reads is based on the reads identified in the batch of control exomes. 
 
Selection of the CNV calls shared by individuals III:3 and IV:1 but absent from 
II:3 resulted in two calls remaining after filtering (Appendix 25). Filtering did not 
take into account the CNV calls from individual II:2 due to the low number of 
controls available. One of the CNVs that remained after filtering was the 
heterozygous deletion of AMTN exons 3-6 and the other was a heterozygous 
deletion of exon 2 of the N-acetyltransferase 8 (GCN5-related, putative) gene 
(NAT8; OMIM *606716). This deletion is predicted to remove the entire coding 
sequence. However a PubMatrix search for NAT8, using the search terms 
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“tooth”, “teeth”, “amelogenesis”, “enamel” and “ameloblast”, did not identify any 
articles (Table 4.2). By comparison, the same search returned a total of 214 
positive results for AMTN. 
 
Graphical representations of ExomeDepth CNV calls in the region spanning 
chr4:71,339,000-71,480,000, which includes AMTN and its flanking genes 
mucin 7, secreted (MUC7) and AMBN, were plotted for each family member 
(Section 2.4.6) and are represented in Figure 4.5. 
 
4.2.7 Screening of AMTN in a panel of autosomal dominant AI 
patients 
In an attempt to identify additional AMTN mutations, all coding exons and 
flanking introns of AMTN in DNA samples obtained from an additional thirty-five 
families with suspected AD AI were sequenced (Appendix 26). No SNVs or 
small indels were identified. The cohort was also screened for the deletion 
identified in family AI-154, using the primer pair designed to amplify introns 2 to 
6, but no other family was identified that carried the same deletion. 
Subsequently, WES libraries were prepared from genomic DNA, using the 
200ng protocol (Section 2.4.1.2), from twelve of these families. Analysis of 
SNVs, indels and CNVs was undertaken as previously described but no 
mutations in AMTN were identified. 
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Figure 4.5: ExomeDepth data plots of read ratios within chr4:71,330,000-71,480,000 
The red crosses indicate the ratio of the observed / expected number of reads for: A III:3, B: IV:1, C: II:2 (all 
affected) and D: II:3 (unaffected). The grey shaded region shows the estimated 99% confidence interval for 
this ratio in the absence of the CNV call. The presence of four contiguous exons with read count ratios 
falling outside the confidence intervals is indicative of a heterozygous deletion in sample III:3 (A) and IV:1 
(B). For sample II:2 (C), the heterozygous deletion spanning exons 3 to 6 of AMTN was not found by 
ExomeDepth analysis, however, the region lies marginally outside the grey shaded 99% confidence 
interval for this sample. For sample II:3 (D) the observed calls lie within the confidence limits suggesting 
the heterozygous deletion is not present in this sample. 
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4.2.8 Investigation of the enamel phenotype 
Based on the genetic analysis of AI-154, the most likely cause of the phenotype 
was a large deletion in AMTN. Localisation of murine AMTN within the basal 
lamina of maturation stage ameloblasts and at the internal basal lamina within 
the junctional epithelium of erupted rodent teeth had been previously reported 
(Iwasaki et al., 2005, Moffatt et al., 2006). Therefore, the family under 
investigation was revisited to check for any notable periodontal clinical 
phenotype that might have been overlooked previously but none was identified. 
 
In order to determine whether the phenotype in the AI-154 affected individuals 
was comparable with the Amtn-/- rodent model, two deciduous incisor teeth from 
IV:1 were obtained after natural exfoliation. Photographs of the exfoliated teeth 
can be seen in Appendix 27. In order to investigate the phenotype, CT, SEM 
and EDX (Section 2.13) were used to compare the teeth to two age and cuspid 
matched healthy deciduous human teeth obtained from the Skeletal Tissues 
Research Bank (School of Dentistry, University of Leeds) with ethical approval 
and patient consent. 
 
4.2.8.1 Micro Computerised Tomography (micro CT) 
In order to reveal the underlying structure of the teeth and to calculate the 
mineral density of the enamel in the teeth from IV:1, high resolution CT was 
carried out (Section 2.13.1). Two control teeth (A and B) were also scanned for 
comparison with the teeth from IV:1 (C and D). Representative longitudinal 
sections through each tooth are presented in Figure 4.6. One of the teeth (tooth 
D) had undergone some restoration. 
 
Mean enamel mineral density was calculated (Section 2.13.1) for each tooth by 
comparison to three HA standards of known mineral density. The three 
standards were scanned alongside each tooth and used to calibrate the mineral 
density measurement for each tooth separately, based on the readings of the 
standard obtained only during the same scan. For the tooth that had undergone 
restoration (Tooth D), a density threshold was established to identify the regions 
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of restoration. These regions were then excluded by the automated protocol run 
by the ImageJ software, which is used to identify the enamel regions using the 
Trainable Weka Segmentation plugin (Section 2.13.1). The regions in each 
section identified by the plugin as enamel were checked manually to ensure 
that the training had been successful. Selected regions were altered manually 
only if necessary, although this was rare. Mean enamel density across the 
whole tooth was then calculated and is presented in graphical form in Figure 
4.6. 
 
The enamel mineral densities of teeth C and D were calculated as 2.05 g/cm3 
+/-0.02 g/cm3 (2x standard error of the mean) and 2.16 g/cm3 +/-0.02 g/cm3 
respectively, compared to 2.66 g/cm3 +/-0.02 g/cm3 and 2.72 +/-0.06 g/cm3 for 
the two control teeth, A and B. For reference, a range of 2.69-2.92 g/cm3 has 
been previously reported for deciduous enamel (Wong et al., 2004). 
 
The values obtained equate to a 18.8-24.6% reduction in enamel mineral 
density for the teeth from Individual IV:1 compared to teeth from the controls. 
While both teeth C and D had lower enamel mineral density measurements 
than control teeth A and B, statistical analysis was not appropriate due to the 
small number of non-independent samples investigated and the nested nature 
of the data. 
 
High resolution-CT scanning (Figure 4.6) of control teeth A and B and affected 
teeth C and D from IV:I, showed that teeth C and D exhibited reduced enamel 
mineral density in comparison to control teeth A and B. Enamel thickness also 
appeared to be reduced compared to the control tooth though this was difficult 
to confirm due to the possibility of post-eruptive tissue loss and the normal 
variation of the enamel thickness from the cemento-enamel junction to the 
cuspal edge (Gillings and Buonocore, 1961). 
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Figure 4.6: High resolution X-ray CT analysis of exfoliated teeth from two control 
individuals and from individual IV:1.  
Typical CT sections through the teeth are presented using false colour calibrated with respect to 
mineral density to generate mineral density maps. Mean enamel mineral density for each tooth 
is also shown graphically, with error bars representing twice the standard error of the mean. The 
teeth from the control individuals (A and B) exhibit an enamel layer apparently normal in 
structure and density. Teeth C and D from IV:1 exhibit an obvious enamel covering though it is 
thinner, chipped, absent in places and is significantly reduced in mineral density compared with 
teeth A and B (P < 0.05). Note that tooth D has undergone restoration (arrows).  
Figure reproduced with permission from Smith et al. (2016a). 
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4.2.8.2 Scanning Electron Microscopy (SEM) 
In order to examine the enamel phenotype further, one of the teeth from 
individual IV:1 (Tooth D) was prepared for SEM (Section 2.13.2). A control tooth 
(Tooth A) was also prepared for comparison. Photographs of the sections from 
the tooth from IV:1 (Tooth D) as well as a control tooth (Tooth A) can be seen in 
Figure 4.7. 
 
SEM (Section 2.13.3) revealed that the control tooth (Figure 4.7, A and B) 
exhibited the prismatic structure characteristic of normal human enamel. The 
tooth from individual IV:1 (Tooth D), also exhibited areas of prismatic enamel 
though the fine detail of the ultrastructure was obscured by overlying material, 
giving a “smooth” appearance (Figure 4.7C and D). The enamel also displayed 
distinct regions where the enamel structure was particularly disturbed; the 
prismatic structure having a “gnarled” appearance (Figure 4.7E and F). These 
regions spanned the entire enamel and were not confined to the outermost 
enamel layers. In some areas of the tooth, enamel was missing, perhaps 
indicative of post-eruptive failure under masticatory stress. 
 177 
 
Figure 4.7: SEM of representative exfoliated teeth. 
A and B: SEM of tooth A from the control individual. C-F: SEM of tooth D from individual IV:1. 
Boxed regions on pictures A, C and E reflect the boundaries of the photographs taken at higher 
power in these regions, labelled B, D and F. Tooth A exhibits normal, typical enamel 
architecture comprising prisms (rods) of individual enamel crystallites. Tooth D exhibits both 
regions of relatively normal enamel and disturbed structure. The cross sectional surface of 
Tooth D has a “smooth” appearance that may reflect the presence of organic material.  
Figure reproduced with permission from Smith et al. (2016a). 
 
4.2.8.3 Energy-dispersive X-ray spectroscopy (EDX) 
In order to determine whether the enamel of the tooth from IV:1 (Tooth D) 
differed in its elemental composition to that of the control tooth (Tooth A), EDX 
was undertaken on the tooth sections prepared for SEM. 
 
Since the EDX software (Section 2.13.4) utilises the peak to background atomic 
number, absorbance and fluorescence (PB-ZAF) correction (Small et al., 1978, 
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Statham and Pawley, 1978, Heckel and Jugelt, 1984, Trincavelli and Van 
Grieken, 1994), accurate elemental analysis does not require that results are 
compared with those obtained for standards. However, in order to verify that the 
detector and the software could detect the elements normally present in tooth 
enamel, a standard of HA mineral (Himed) was first analysed. Oxygen, calcium, 
carbon and phosphorus were detected, suggesting that the standard may also 
contain a carbonated form of HA or that another carbon containing compound 
may be present in addition to the HA. The atomic mass percent (AM%) 
calcium:phosphorus ratio of the standard was determined to be 2.11. The ratio 
for pure HA was calculated as 2.15, based on an atomic weight for HA of 1004 
and taking into account that EDX is unable to analyse the percentage content 
due to hydrogen. Therefore the result of 2.11 appeared to be close to that 
expected for HA. 
 
The limit of detection for EDX analysis is determined by the bremsstrahlung 
background radiation that is used as a calibration point in the PB-ZAF method. 
For the equipment and software used for detection and analysis in this study, 
this is specified as around 0.1% mass concentration (Bruker Quantax User 
Manual) which would equate to approximately 0.05-0.15% for elements with 
relative atomic mass of between 12 (C) and 40 (Ca), hence results are 
presented to one decimal place. In addition, the percentage error for 
measurements has been calculated by the manufacturer as between 3-5% 
(Bruker Quantax User Manual). 
 
For the control tooth (Tooth A), twenty-three readings were taken throughout 
the enamel region and the elemental percentage contributions were recorded 
(Figure 4.9C). The control tooth A consisted primarily of elements expected to 
be found in enamel, which is predominantly comprised of a substituted calcium 
hydroxyapatite (Robinson et al., 1971, Robinson et al., 2000). Atomic mass 
percentage contributions showed that tooth A enamel consisted of 57.2% 
oxygen, 19.9% calcium, 12.3% carbon and 10.1% phosphorus, with the 
remaining 0.45% being sodium (Table 4.1). A representative EDX spectrum for 
control tooth A is presented in Figure 4.8A. 
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SEM analysis of tooth D had revealed several distinct regions of enamel with 
diverse architectures (Section 4.2.8.2). Therefore, EDX readings were taken 
from four distinct regions in order to try to identify if these regions of diverse 
architecture also had distinctive elemental percentage contributions. Separate 
analysis of each of these regions also avoided aggregating readings from 
regions with obvious structural differences, leading to the reporting of averaged 
results that may not have been representative. Again, the areas of enamel with 
restoration were not included in the analysis, but separate analysis of the 
spectra resulting from the restored region confirmed that it presented a very 
different spectral profile to the enamel which would be immediately recognisable 
as it contained elements such as Al, Si, Zr and Ba (Figure 4.8C). 
 
Analysis of these four areas of tooth D enamel (individual IV:1) showed that 
they did consist of varying elemental percentage content, although areas D1 
and D2 were similar. A representative EDX spectrum for tooth D area 2 is 
presented in Figure 4.8B. All areas of tooth D had higher carbon and lower 
oxygen percentage content than tooth A (Figure 4.9 and Table 4.3). Three of 
the four enamel areas analysed for tooth D also had a lower phosphorus 
percentage content than tooth A. Furthermore, three areas of tooth D enamel 
contained nitrogen (Area 1: 11.1%, area 2: 11.6% and area 4: 7.2%) which was 
not detected in enamel from tooth A. 
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Figure 4.8: Representative EDX spectra. 
See previous page. A: Wild-type enamel (control tooth A) contained the elements typically found 
in HA substituted with CO32- and Na. B: Enamel affected by the heterozygous deletion of AMTN 
exons 3-6 (tooth D from individual IV:1) shows N is also present in addition to the elements 
typically found in enamel (Area D - 2 in Table 4.3 and Figure 4.9). C: Analysis of the restored 
region of tooth D confirmed that it produced a distinct spectrum from that of typical enamel, 
since it contained Al, Zr, Si and Ba.  
D: Analysis of a standard of HA mineral showed a similar spectral profile to the enamel of the 
wild-type tooth (control tooth A, panel A). 
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Figure 4.9: EDX elemental analysis of tooth D from individual IV and tooth A from a 
control individual. 
A: Measurements for tooth D were taken from four separate areas of enamel, highlighted by the 
white boxes. White arrows indicate the areas of enamel that had undergone restoration and 
therefore where elemental analysis was specifically not undertaken. Panels i and ii detail the 
appearance of enamel areas 1 and 4 for tooth D. 
B: Elemental analysis results are plotted as pie charts, with the percentage atomic contribution 
of each element to the enamel displayed in separate charts for each region. The number of 
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measurements was as follows: i: Area 1: N=30, ii: Area 2: N=11, iii: Area 3: N=10, iv: Area 4: 
N=9.  
C For comparison, control tooth A was also analysed at points throughout the area of enamel 
shown in panel i. Panel ii shows elemental analysis results for control tooth A plotted as before, 
with N=23 measurements. 
In all cases, the “others” section for each elemental analysis pie chart refers to the elements Na 
and/or Mg that were found to contribute <1% collectively to the enamel. 
Detailed percentage contributions of each element to each of the tooth regions analysed can be 
seen in Table 4.3. 
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Standard 
/ tooth 
and area 
analysed 
Composition (Atomic Mass % a) 
Number of 
readings Oxygen Calcium Carbon Phosphorus Nitrogen 
Otherb 
(Specified) 
HA 
standard 
59.9 ± 0.6 23.1 ± 0.4 6.02 ± 0.3 10.95 ± 0.7 0.0 ± 0.0 N/A 3 
A 57.2 ± 0.5 19.9 ± 0.4 12.4 ± 0.9 10.1 ± 0.3 0.0 ± 0.0 
0.5± 0.1 
(Sodium) 
23 
D - 1 28.0 ± 2.3 11.3 ± 1.0 43.6 ± 2.8 6.2 ± 0.5 11.1 ± 1.9 
0.2 ± 0.1 
(Sodium) 
30 
D - 2 23.8 ± 2.4 11.3 ± 1.5 46.9 ± 4.9 6.1 ± 1.0 11.6 ± 2.6 
0.3 ± 0.2 
(Sodium) 
11 
D - 3 47.4 ± 1.1 20.3 ± 0.4 20.4 ± 1.7 11.2 ± 0.6 0.0 ± 0.0 
0.7 ± 0.2 
(Sodium) 
10 
D - 4 33.6 ± 1.6 4.5 ± 1.9 52.1 ± 3.1 2.6 ± 1.0 7.2 ± 3.6 N/A 9 
 
Table 4.3: EDX elemental analysis of an HA standard, tooth A from a control individual and tooth D from individual IV:1.  
Values shown are mean values calculated from the number of measurements specified for each area. The error was calculated as 2 x the standard error of 
the mean. This data has been displayed graphically and in relation to the areas measured in Figure 4.9.  
a Values may not always sum to 100% since values are shown to 1 decimal place.  
b For tooth D, areas 1 and 3, magnesium was also variably present, but the mean composition was less than 0.1% and so it is not included in the table above.
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4.3 Discussion 
A family from Costa Rica segregating AD hypomineralised AI was identified. 
DNA from three affected and one unaffected individuals was subjected to WES. 
Analysis of rare, heterozygous, functional variants that segregated with the 
disease phenotype in silico identified a total of twenty-six SNVs and small 
indels, none of which were in known or candidate AI genes. Analysis of rare 
CNVs using ExomeDepth identified two heterozygous deletions, one of which 
was predicted to include exons 3 to 6 of the AI candidate gene AMTN. Further 
investigation confirmed this to be an 8,678bp deletion encompassing AMTN 
exons 3-6 and flanking intronic sequence. PCR and electrophoresis showed 
that the deletion segregated with the disease phenotype in all available family 
members.  
 
Attempts to study the effect of the deletion on leukocyte RNA splicing failed due 
to the tooth specific expression of AMTN. An attempt to identify additional 
mutations in AMTN by screening 35 additional AI families revealed no further 
mutations in the coding exons, or any recurrence of the same large deletion 
identified in AI-154. 
 
Phenotypic analysis of the enamel of affected teeth using microCT revealed 
that it was less mineralised and appeared to be thinner in comparison to the 
enamel of control teeth. SEM revealed that the enamel of affected teeth 
contained regions with the prismatic architecture typical of enamel but that this 
appeared to be obscured by overlying material. There were also regions of 
more disturbed structure that spanned the entire enamel layer. 
 
Elemental analysis showed that the affected teeth contained areas of enamel 
with elemental percentage contributions that were different, both in comparison 
to different enamel areas within the same tooth and in comparison to the 
enamel of the control. In general, compared to the control enamel, there were 
higher carbon and lower oxygen percentage contributions in affected enamel 
and, in three of the four regions analysed, nitrogen was present, but this was 
below the limit of detection for the control. 
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The research presented in this chapter is published in Smith et al. (2016a). 
 
4.3.1 Whole exome sequencing analysis 
WES was used to try to identify the genetic cause of AI in this family since all 
previously published AI-causing mutations reside in regions of DNA captured by 
WES (http://dna2.leeds.ac.uk/LOVD/). Although it is likely that AI-causing 
mutations in regions not targetted by WES exist (Maurano et al., 2012, Poulter 
et al., 2015), interpretation of non-coding variants is currently difficult. 
 
This family was particularly informative for mutation discovery, since DNA from 
three affected individuals spanning three non-consanguineous generations was 
available. The pedigree, which demonstrated male-to-male transmission, also 
suggested that the disease had an AD pattern of inheritance. This knowledge 
informed the filtering strategy used, as it allowed the list of variants to be filtered 
for single shared heterozygous variants.  
 
Filtering of WES data from three affected individuals and one unaffected 
individual based on an AD mode of inheritance resulted in twenty-six variants 
remaining with CADD scores over 15. Whilst it was possible that one of these 
variants could be responsible for the AI phenotype, none were implicated for 
further analysis by a known role in amelogenesis or by the existence of a 
mouse model with a tooth phenotype. WES of individual IV:2 would be 
expected to approximately halve the number of variants segregating with the 
disease phenotype and would be less labour intensive and potentially also 
cheaper than individual segregation analysis of each variant by Sanger 
sequencing. However, Sanger sequencing would also confirm the presence of 
each variant since alignment and variant calling of WES data can result in 
spurious variant calls, although the inclusion of the unaffected individual II:3 
may have already removed such variants from the filtered list. 
 
CNV analysis was performed separately since genetic variation encompasses 
changes that exist over a broad size range, but the standard variant calling 
pipeline using GATK is only capable of detecting smaller variations such as 
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SNVs and small indels. Studies of the degree of variation of genomes from 
reference sequence have shown that whilst differences of around 0.1% are due 
to SNVs, around 1.2% are due to indels and CNVs (Pang et al., 2010). Studies 
of the span of CNV regions have found that they equate to around 12% of the 
human genome (Redon et al., 2006) and are associated with changes in gene 
expression (Stranger et al., 2007). This suggests that such variation is also 
likely to encompass a significant proportion of the variants that cause disease, 
and that analysis of CNVs should be undertaken alongside SNV and indel 
variant analysis. Analysis of eleven WES data sets generated from patients with 
AI, for which an SNV or indel mutation in an AI candidate gene had not been 
identified, revealed that two carried CNVs that deleted one or more exons of an 
AI candidate gene. This equates to 18.2% and suggests that CNVs may be the 
cause of a substantial proportion of AI cases without a SNV or indel in a known 
AI gene. 
 
Many algorithms exist that utilise meta-analysis of WES datasets to detect 
variation of a larger scale such as CNVs, for example, CoNIFER (Krumm et al., 
2012), eXome Hidden Markov Model (Krumm et al., 2012), ExomeDepth 
(Plagnol et al., 2012), FishingCNV (Shi and Majewski, 2013) and CopyWriteR 
(Kuilman et al., 2015). Such algorithms compare read depths between different 
samples for the same targetted regions and use the information to infer 
changes in copy number. Despite the number of tools to carry out such 
analysis, the accurate detection of CNVs using WES data alone remains 
problematic. In comparison to WGS data, where paired end mapping (Korbel et 
al., 2007), split read mapping (Ye et al., 2009), assembly based- (Ye et al., 
2009) or combined methodologies can also be used to identify CNVs, analysis 
of WES data is mostly limited to methodologies based on read depth analysis. 
For WES data, read depth over individual exons is affected by PCR bias and 
capture efficiency, whereas the read depth profile is more homogeneous for 
WGS data, meaning that it is easier to identify CNVs (Meynert et al., 2014). 
Successful identification of a true CNV using read depth analysis requires that 
the regions containing the CNV are normally well covered by WES and are not 
commonly variable. In addition, the nature of the exome, which represents a 
series of small, non-contiguous regions that are unevenly distributed across the 
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genome, means that analysis of WES data often fails to accurately map the 
breakpoints of CNVs, as statistically, they are more likely to reside within 
uncovered deep intronic and intergenic regions, as for the deletion identified 
here. Assessments of the accuracy of WES-based CNV discovery have shown 
that algorithms often produce erroneous calls (Samarakoon et al., 2014, Tan et 
al., 2014) and may miss true CNVs, especially those that are small, since each 
exon effectively represents a single data point (Krumm et al., 2012, de Ligt et 
al., 2013). Therefore, WGS would be a better choice of method for detection of 
CNVs and their breakpoints, but the additional cost and burdens of data volume 
and analysis associated with WGS are prohibitive to its use at present. 
 
In this study, the ExomeDepth R package (Plagnol et al., 2012) was used to 
screen for CNVs from WES data. ExomeDepth builds a reference data set of 
read count data from, ideally ten, control samples sequenced in the same batch 
as the test sample. It then compares the test sample with the reference set to 
generate a likelihood for each copy number scenario, i.e. deletion, diploid or 
duplication. ExomeDepth has been reported to perform well in identifying 
clinically relevant CNVs (de Ligt et al., 2013) but has reported rates of true CNV 
detection ranging from 16-75% (Plagnol et al., 2012, de Ligt et al., 2013, Guo et 
al., 2013) depending upon the read depth and correlation of the samples 
analysed and the method of confirmation for comparison used. It is therefore 
difficult to assess its effectiveness. 
 
The variability of CNV detection using ExomeDepth is apparent for the data 
presented here in that the heterozygous deletion of AMTN exons 3-6 was not 
detected from analysis of WES data from individual II:2. This may be due to the 
smaller number of reference sequences used for analysis of II:2 data (five) in 
comparison to III:3 (eleven) and IV:2 (nine) data. Therefore, if analysis using 
ExomeDepth is to be undertaken, a minimum of ten unrelated individuals 
should be sequenced per batch to increase the chances of the identification of 
all relevant CNVs. In the case of the heterozygous deletion identified here, its 
position within such a well known AI candidate gene as AMTN (Santos et al., 
2007, Gasse et al., 2012, Abbarin et al., 2015) meant that it was prioritised for 
investigation. However, it is still possible that the remaining variants that 
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segregate with the phenotype in this family are contributing to the phenotype. 
WES of IV:2 would reduce the number of remaining variants by 50% on 
average, and further recruitment of additional family members may also help to 
exclude those present in unaffected individuals, although this may not be 
possible. Prior knowledge of the role of Amtn in rodent models and its status as 
an AI candidate gene may therefore have biased the decision to follow up on 
this variant above others, which is an inherent weakness in this study. 
 
4.3.2 Amelotin (AMTN) is a candidate gene for non-syndromic 
amelogenesis imperfecta 
Amelotin (Amtn) was first cloned in rodents during studies to identify proteins 
secreted by the enamel organ (Iwasaki et al., 2005, Moffatt et al., 2006). Since 
then, AMTN (MIM *610912) has become a strong candidate gene for AI due to 
its chromosomal position, structure, evolution, protein localisation and in vitro 
activity, as well as due to evidence from mouse models. 
 
AMTN is found within the SCPP conserved enamel gene cluster and is thought 
to have evolved with the EMP genes from a common ancestral gene (Section 
1.2). The SCPP EMP cluster includes the genes encoding enamelin (Section 
1.9.3) and ameloblastin (Section 1.9.2), for which mutations are already known 
to cause AI (Rajpar et al., 2001, Poulter et al., 2014c). However AMTN is not 
regarded as an EMP due to its absence from the enamel matrix and lack of 
expression during the secretory stage (Sire et al., 2007). Pseudogenisation of 
AMTN in enamel-less species has meant that AMTN is regarded as an enamel-
specific protein (Gasse et al., 2012). It has also been proposed that prismatic 
enamel evolved in mammals concurrently with AMTN expression becoming 
restricted to the maturation stage and with changes to AMTN exon boundaries 
and splicing (Gasse et al., 2012, Gasse et al., 2015a, Gasse et al., 2015b). 
 
AMTN encodes a 209 amino-acid protein (NP_997722) rich in proline, leucine, 
threonine, glutamine, and glycine, with an N-terminal signal sequence that, 
once cleaved, gives rise to a mature 20.4kDa secreted protein (Moffatt et al., 
2006, Ganss and Abbarin, 2014). AMTN has been shown to be restricted to the 
 190 
basal lamina (the structure that links ameloblasts with the developing enamel) 
and to maturation, but not secretory, stage ameloblasts in rodents (Iwasaki et 
al., 2005, Moffatt et al., 2006, Dos Santos Neves et al., 2012, Somogyi-Ganss 
et al., 2012). AMTN has also been detected at the internal basal lamina within 
the junctional epithelium of erupted rodent teeth suggesting a possible function 
in dento-gingival attachment (Iwasaki et al., 2005, Moffatt et al., 2006). 
 
The exact function of AMTN is unknown, although its localisation, experiments 
using AMTN peptides and observations from mouse models have inspired 
hypotheses. A functional study by Abbarin and colleagues found that AMTN 
promotes HA precipitation in vitro, leading the authors to suggest that AMTN 
may serve a critical role in the formation of the final compact aprismatic enamel 
surface layer during the maturation stage of amelogenesis (Abbarin et al., 
2015). Consistent with these findings, both an Amtn overexpression mouse 
model in which AMTN was over-expressed under the control of an Amel 
promoter (pAmel:Amtn+/+), and a knockout (Amtn-/-) mouse model, have 
defective enamel (Lacruz et al., 2012a, Nakayama et al., 2015). The 
pAmel:Amtn+/+ mouse model has brittle enamel that is thinner than wild-type 
(WT), with a defective surface layer (Lacruz et al., 2012a). By contrast, the 
Amtn-/- mouse model has mandibular incisors with a chalky appearance and 
rough, irregular surface enamel that is easily chipped away, though maxillary 
incisors and molars were unaffected, as were Amtn+/- mice (Nakayama et al., 
2015). 
 
These observations have made AMTN a strong candidate gene for involvement 
in human AI, as noted by a number of research groups (Santos et al., 2007, 
Gasse et al., 2012, Abbarin et al., 2015, Bartlett and Simmer, 2015). Núñez et 
al. speculated that AMTN loss of function mutations would result in AR AI 
(Nunez et al., 2015) but, at the start of this study, no human mutations had 
been reported. 
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4.3.3 The potential consequences of the heterozygous deletion of 
AMTN exons 3-6 
AMTN consists of nine exons, of which eight (exons 2 to 9) are protein coding. 
The heterozygous deletion identified by ExomeDepth was confirmed by Sanger 
sequencing and found to be an 8,678bp deletion and 4bp insertion predicted to 
remove exons 3-6 of AMTN, c.54+1347_330+98delinsCTCA (NM_212557). No 
AMTN transcript could be amplified from patient blood, so it was not possible to 
determine the precise effect of the loss of exons 3-6 on the mRNA produced. 
One hypothesis is that the deletion leads to the production of a mature 
transcript containing exons 1 (5’ UTR), 2, 7, 8 and 9. This is a strong possibility 
as the relevant splice consensus sequences remain intact and the introns 
flanking the deleted region are in phase zero, meaning that the deletion would 
leave any translated protein in frame (Kolkman and Stemmer, 2001). For this 
reason the transcript is unlikely to be subject to nonsense-mediated decay 
(NMD) (Isken and Maquat, 2008). 
 
The deletion of AMTN exons 3-6 would delete an IPLT motif in exon 4 (Gasse 
et al., 2012), which is predicted to be an O-glycosylation site and is therefore 
likely to be important for AMTN function (Sire et al., 2007). Glycosylation plays 
an important role in influencing the physiochemical properties of proteins such 
as conformation, protection from proteolysis and interactions with other proteins 
and minerals (Brooks et al., 2008). Proteins encoded by known AI genes such 
as KLK4, ENAM and AMBN are all glycosylated at key stages of amelogenesis, 
suggesting correct post-translational modification of enamel proteins is required 
for enamel to form correctly (Kobayashi et al., 2007, Al-Hashimi et al., 2009, 
Yamakoshi et al., 2011).  
 
Previous studies have found that AMTN exon 2 encodes the putative signal 
peptide to target the protein to the endoplasmic reticulum (ER) and exon 7 
encodes a consensus SXE phosphorylation motif targeted by the casein kinase 
FAM20C (Moffatt et al., 2006, Gasse et al., 2012). Assuming that a mutant 
transcript and protein are produced, the deletion identified in the family 
described here would not remove either of these highly conserved regions 
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(Gasse et al., 2012). However, deletion of exons 3-6 would disrupt a conserved, 
amino terminal, IPV-like, tripeptide motif, LPQ, encoded by the last six bases of 
exon 2 and the first three bases of exon 3 respectively. This motif is thought to 
be responsible for the efficient trafficking of acidic proteins (the calculated pI of 
unmodified human AMTN is 5.29) out of the ER (Nam et al., 2014). The deletion 
identified in this family, if expressed, will replace the polar glutamine residue 
encoded by the first three bases of exon 3 with non polar glycine encoded by 
the first three bases of exon 7. 
 
IPV-like motifs are found in many of the secretory calcium-binding 
phosphoproteins (SCPPs) and in other secreted proteins such as pro-hormones 
and those found in blood plasma. They are thought to function as a signal to, as 
yet unknown, receptor proteins that are responsible for the packaging of 
proteins into vesicles for transport from the ER to the Golgi. Analysis of the IPV-
like motifs found in a selection of secreted proteins noted that they are 
positioned immediately carboxy to the signal peptide for secretion (Appendix 
28). The consensus sequence for such a motif is hydrophobic / polar residue-
proline-hydrophobic / polar residue (Nam et al., 2014). For the human secreted 
protein sequences analysed, proline was always present at position 2 of the 
motif and in only one case was a non-polar residue present at either of the 
flanking positions (glycine at position 1 of the motif for decorin (DCN; OMIM 
*125255)). More specifically, the motifs of the enamel proteins generally contain 
only hydrophobic residues at positions 1 and 3, but AMTN contains a polar 
glutamine residue at position 3. The variation of the residues used in the motifs 
for different secretory proteins may reflect targeting by multiple, as yet unknown 
receptors for ER export. Investigation of the residues present in the motif in 
AMTN in a variety of mammalian species found that while the residues at 
positions 1 and 2 are always leucine and proline respectively, the residue at 
position 3 varies (lysine, arginine, glutamine, leucine, methionine, threonine, 
alanine are present for the species analysed) and is sometimes positively 
charged (Appendix 29). This variation could suggest that substitution of the 
glutamine residue for glycine, as in the deletion identified in family AI-154, may 
be tolerated or may not, in isolation, completely abolish export of the protein 
from the ER. For both the human enamel and dentine/bone matrix proteins 
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encoded within gene clusters at 4q13.3 and 4q22.1 respectively and for 
AMELX, the motifs are interrupted by phase zero exon boundaries between the 
second and third residues, whereas for the other proteins studied, this is not the 
case (Appendix 28). It is unclear whether alternative splicing, such as is 
observed for AMELX (Brookes et al., 1995), could alter Golgi targeting for some 
functional reason in amelogenesis. 
 
Mutations affecting the IPV motif of the dentine matrix protein, dentin 
sialophosphoprotein (DSPP, OMIM *125485), are known to result in dominant 
negative dentinogenesis imperfecta I (DGI-I, formerly DGI Shields type II; OMIM 
#125490) due to a failure to traffic the protein out of the ER and the associated 
retention of wild-type protein (Shields et al., 1973, von Marschall et al., 2012). 
Mutations identified in patients with DGI-I include those directly affecting the IPV 
residues at positions 16-18 (NM_014208; NP_055023), for example c.52G>T, 
p.V18F (Xiao et al., 2001) or those likely to result in the skipping of exon 3, such 
as the intronic mutation, c.52-3C>G (Kim et al., 2004). This mutation would be 
predicted to result in the substitution of the third residue in the motif, V, for the 
first residue encoded by exon 4, D. These DSPP mutations are similar to the 
AMTN exon 3-6 deletion identified in family AI-154 since they also result in 
substitution of the third residue in the IPV-like motif. Modelling of mutation of the 
third residue of the IPV-like motif for two other SCPPs, dentin matrix protein 1 
(DMP1; OMIM *600980) and secreted phosphoprotein 1 (SPP1; OMIM 
*166490), as well as for the neuroendocrine secretory protein, chromogranin A 
(CHGA; OMIM *118910) also resulted in the retention of the mutant proteins 
within the ER (von Marschall et al., 2012). Mutation of the DMP1 IPV-like motif, 
LPV, at the second residue or at both the second and the third residues 
resulted in retention of the protein within the ER, although some secretion of the 
mutant protein into the media was detected (Liang et al., 2016). The authors 
suggested that this might reflect the existence of a transport mechanism 
independent of the IPV-like motif (Liang et al., 2016). This is possible, although 
the use of plasmid expression constructs with elevated expression profiles ex 
vivo may not accurately reflect what would occur in vivo. 
 
The consequences of mutation of IPV-like domains are thought to be influenced 
 194 
by the sequence of the rest of the protein (von Marschall et al., 2012, Nam et 
al., 2014, Liang et al., 2016). In the case of a DSPP mutation that delayed or 
prevented trafficking of the protein from the ER to the Golgi, the large number of 
acidic, negatively charged residues present within DSPP would interact with the 
high concentrations of Ca2+ found within the ER. This is thought to lead to 
aggregation (von Marschall et al., 2012) that may in turn lead to ER stress and 
autophagy. Unlike DSPP, AMTN does not contain large tracts of acidic 
residues. However it does contain an SXE motif that when phosphorylated, 
binds Ca2+ (Sorensen et al., 1995, Kawasaki et al., 2004). The deletion of 
AMTN exons 3-6 would leave this motif intact and therefore ER accumulation 
due to mutation of the IPV domain and aggregation of both wild-type and 
mutant protein due to aberrant Ca2+ binding via the SXE motif within the ER is a 
possible disease mechanism. However, it is likely that FAM20C acts to 
phosphorylate proteins only once they reach the Golgi, not in the ER. 
Therefore, it may be more likely that the protein is simply misfolded, forms 
aggregates and interacts with the wild-type protein resulting in sequestration of 
the wild-type protein and prevention of its normal function, thereby causing a 
dominant negative effect. 
 
Overall, the deletion of a significant proportion of a protein or defective covalent 
modification, is likely to result in misfolding, leading to endoplasmic reticulum 
stress driven cell pathologies (Hetz et al., 2011). Rat Amtn transcript variants 
lacking exons 3 to 7 have been identified (Moffatt et al., 2006) suggesting that 
amelotin lacking the IPV-like tripeptide motif and the O-glycosylation site may 
still have some functional role and that the protein is tolerated during secretory 
trafficking. However, the expression level of this truncated Amtn transcript is 
unknown and it may be that it is expressed at very low levels only. It is 
important to note that, in addition to the exons deleted in the human mutation 
identified here, the alternatively spliced rat transcript also lacks exon 7. When 
phosphorylated, the SXE motif within exon 7 has been shown to promote HA 
precipitation in vitro (Abbarin et al., 2015) and is known to bind Ca2+ (Sorensen 
et al., 1995, Kawasaki et al., 2004). Therefore, in contrast to the alternatively 
spliced rat transcript, it is possible that the unique combination of the absence 
of exons 3-6 in the mutant transcript, along with the presence of the SXE motif 
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in exon 7, may be playing a role in the enamel pathology reported for this 
family. 
 
4.3.4 Amtn mouse models and comparison of the enamel 
phenotype with that described for Individual IV:2 of family AI-
154 
Both an Amtn overexpression mouse model in which AMTN was over-
expressed under the control of an Amel promoter (pAmel:Amtn+/+), and a 
knockout (Amtn-/-) mouse model, have defective enamel (Lacruz et al., 2012a, 
Nakayama et al., 2015). The pAmel:Amtn+/+ mouse model has brittle enamel 
that is thinner than wild-type (WT), with a defective surface layer (Lacruz et al., 
2012a). By contrast the Amtn-/- mouse model has mandibular incisors with a 
chalky appearance and rough, irregular surface enamel that is easily chipped 
away, though maxillary incisors and molars were unaffected, as were Amtn+/- 
mice (Nakayama et al., 2015). 
 
The variation in the effect of loss of Amtn expression in different teeth in Amtn-/- 
mice may be related to the rate of formation/eruption of the different teeth. 
Comparatively, the enamel of the continually erupting mandibular incisors was 
most affected, while molars were apparently unaffected and maxillary incisors 
appeared stained (Nakayama et al., 2015). Mandibular incisor enamel has less 
time in which to fully mineralise prior to eruption and AMTN may be required to 
ensure that the finished enamel surface is fully mineralised prior to enamel 
eruption. Enamel thickness (at eruption) and the characteristic decussating 
prismatic architecture were also apparently unaffected in Amtn-/- teeth. This may 
reflect the fact that in WT animals AMTN is not expressed during the secretory 
stage (Moffatt et al., 2006, Somogyi-Ganss et al., 2012), during which enamel 
thickness and rod architecture are determined (Risnes, 1998). In the ensuing 
transition/maturation stages, where AMTN is maximally expressed and the 
enamel accrues the majority of its final mineral content (Hiller et al., 1975), 
secondary mineralisation was delayed in Amtn-/- mice, especially in the deeper 
enamel layers (Nakayama et al., 2015). The final mean enamel mineral density 
achieved across the full enamel thickness in Amtn-/- teeth was not significantly 
 196 
different to WT (Nakayama et al., 2015, Nunez et al., 2015). Microhardness 
values for the inner and middle enamel layers in null mice were also no different 
to WT but the microhardness of the surface layer in null mice was significantly 
reduced by approximately 23% (Nunez et al., 2015). It was concluded that 
AMTN plays a crucial role in the production of a normally mineralised enamel 
surface in rodent mandibular incisors. 
 
Pseudogenisation of AMTN in enamel-less species has meant that AMTN is 
regarded as an enamel-specific protein (Gasse et al., 2012). It has been 
proposed that prismatic enamel evolved in mammals concurrently with AMTN 
expression becoming restricted to the maturation stage and with changes to 
AMTN exon boundaries and splicing (Gasse et al., 2012, Gasse et al., 2015a, 
Gasse et al., 2015b). The exact function of AMTN in mammals remains 
unknown, but its expression within the basal lamina of maturation stage 
ameloblasts and at the internal basal lamina within the junctional epithelium of 
erupted rodent teeth suggests functions in both enamel mineralisation and in 
dento-gingival attachment (Iwasaki et al., 2005, Moffatt et al., 2006, Dos Santos 
Neves et al., 2012). However, dento-gingival attachment appeared unaffected 
in both amelotin null (Amtn-/-) mice (Nakayama et al., 2015) and the AI affected 
individuals carrying the heterozygous AMTN exon 3-6 deletion reported here. 
 
Analysis of the teeth from the individual with the heterozygous deletion of AMTN 
exons 3-6 found that the mean mineral density was 18.8-24.6% lower in 
comparison to matched control teeth. In contrast, the final mean enamel density 
achieved across the full enamel thickness in Amtn-/- teeth was reduced by only 
2.1% and was not significantly different to WT (Nakayama et al., 2015, Nunez et 
al., 2015). Microhardness values for the inner and middle enamel layers in null 
mice were also no different to WT but the microhardness of the surface layer in 
null mice was significantly reduced by approximately 23% (Nunez et al., 2015). 
It was concluded that AMTN plays a crucial role in the production of a normally 
mineralised enamel surface in rodent mandibular incisors. Given that the human 
teeth characterised in this study were erupted and subject to wear in the mouth, 
it was not appropriate to assess the integrity of the outer aprismatic enamel (the 
enamel that was most severely disrupted in the Amtn-/-  mouse) in the context of 
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the presence of the AMTN mutation. However, the difference in the percentage 
reduction in mean enamel density represents a clear phenotypic difference 
between the Amtn-/- mouse model and the human phenotype characterised in 
this study. 
 
The differences observed between the mouse and human enamel phenotypes 
may reflect the type of mutation present. The human patients have an in-frame 
deletion, predicted to produce a mutant transcript and possibly also a mutant 
protein, whereas the mice have been shown not to produce any protein and to 
exhibit a 300-fold reduction in transcript levels (Nakayama et al., 2015). Núñez 
et al. reported that heterozygous Amtn+/- mice had no enamel defects and 
suggested that murine amelogenesis is unaffected even in the presence of half 
the normal amount of amelotin (Nunez et al., 2015). Altogether, this suggests 
that the AMTN deletion identified in this study may have a dominant-negative 
(toxic gain of function) effect due to the presence of a mutated protein, rather 
than acting through haploinsufficiency. 
 
Whether any toxic gain of function associated with the 8,678bp heterozygous 
genomic deletion reported here is manifest in the extracellular or intracellular  
compartments (or both) is unclear. AMTN has been shown to interact with itself 
and with ODAM, leading to the hypothesis that it forms large extracellular 
aggregates that are integral to the structure and function of the basal lamina-
like layer between the maturation stage ameloblasts and the enamel surface 
(Holcroft and Ganss, 2011, Dos Santos Neves et al., 2012, Bartlett and Simmer, 
2015). Therefore the mutant AMTN protein may fail to form aggregates in 
appropriate extracellular compartments, such as between the ameloblasts and 
the enamel surface but may instead accumulate intracellularly in the ER and 
sequester some of the wild-type protein (as described in Section 4.3.3). The 
AMELX Y64H mouse model is known to have enamel defects as a result of a 
failure to traffic aggregated AMELX out of the ER (Barron et al., 2010, Brookes 
et al., 2014). The phenotype shows that the initial enamel layers form normally, 
but ER stress leads to production of enamel with fewer prisms and a 
disorganised structure that leaves the enamel weak (Brookes et al., 2014). The 
phenotype seen in the teeth from the individual carrying the deletion of AMTN 
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exons 3-6 does not show such defined layers of sound and disorganised 
enamel, but instead shows small regions of disturbed structure distributed 
throughout the enamel layers. Therefore the phenotype seen in the teeth of the 
patients in this study is not similar to that seen in the mouse. This could reflect 
the very different expression profiles of AMELX (secretory stage) and AMTN 
(transition and maturation stage) during amelogenesis. It could also reflect the 
difference in the rate of enamel formation between humans and mice or may 
suggest that ER stress is not the main pathological mechanism in the enamel of 
the patients identified in this study. 
 
Elemental analysis of one of the teeth from a human patient carrying the AMTN 
mutation revealed consistently higher carbon and lower oxygen percentage 
content than control teeth. Also, nitrogen was present in three out of four 
regions analysed for the teeth from the human patient carrying the AMTN 
mutation but was undetected in the control tooth. These data suggest that 
organic material was present within the enamel and are consistent with the 
SEM appearance of the affected teeth, which showed the normal architecture of 
enamel crystals was apparently obscured by a smooth covering. Unusually high 
levels of organic material of developmental origin have been previously 
reported to be present in hypomaturation forms of AI (Wright et al., 1997). 
Organic material of external origin (for example, salivary protein and protein 
from dietary sources) have been detected in carious enamel (Shore et al., 2000) 
suggesting that disruption of the enamel surface may allow organic material to 
enter the enamel layer. In the affected tooth described here, the organic 
material was not confined to the surface layers but was present throughout the 
enamel. However, it is not possible to conclude whether the organic material 
detected entered the tissue post-eruption due to disturbances in the enamel 
structure or whether it is of developmental origin, representing retained matrix 
protein. Treatment of the tooth with sodium hypochlorite solution could allow the 
nature of the material to be determined. If the material was removed upon 
hypochlorite treatment, this would indicate that it was protein. The degree of 
removal could be determined by a combination of SEM and EDX analysis. 
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In summary, in patients with a heterozygous deletion of exons 3-6 of AMTN, the 
whole enamel thickness is hypomineralised, suggesting that the mutant AMTN 
may: 
1. Disrupt the normal function of the basal lamina-like layer, compromising 
mineral ion ingress into the deeper enamel; and/or  
2. Impede the egress of degraded enamel matrix components out of the 
enamel, impacting on the mineralisation of the whole enamel layer (the 
“smooth” appearance of affected enamel (Figure 4.7C-F), as suggested by the 
presence of organic material overlying the crystals and the nitrogen identified in 
EDX elemental analysis (Table 4.3 and Figure 4.9); and/or  
3. Mis-fold, impairing trafficking through the ER, impacting directly on 
ameloblast function or causing cell death through ER stress in a manner similar 
to that described for the Amelx c.249T>C (p.Y64H) mutation (Barron et al., 
2010, Brookes et al., 2014). 
 
4.3.5 Future investigations 
It is important to reiterate that the AMTN deletion identified is simply associated 
with the AI phenotype of affected individuals of the family studied here. No proof 
of causation has been obtained. The discovery of additional AMTN mutations in 
other individuals with AI would provide further evidence that the mutations are 
the cause of disease for this family. It may be more appropriate not to limit 
analysis to families segregating AD AI (as in this study; Section 4.2.7) since it is 
possible that AI caused by AMTN mutations may have more than one 
aetiological mechanism. For example, biallelic null mutations may also lead to 
disease but, counterintuitively, this may in fact be milder like the knockout 
mouse phenotype. This would result in an AR pattern of inheritance. 
 
Neither the Amtn-/- nor the pAmel:Amtn+/+ model are accurate models for the 
effect of the in-frame deletion identified in family AI-154. The development of a 
mouse model with deletion of Amtn exons 3-6, correctly replicating the human 
mutation, could be achieved since a BLASTp search revealed that murine 
AMTN (NP_082069) is highly similar to human AMTN (NP_97722.1) (Identities 
59%, positives 68%, gaps 2%). Importantly, like the human protein, murine 
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AMTN contains an IPLT domain in exon 4 and an SXE domain in exon 7. 
Deletion of exons 3-6 would result in the same amino acid residues as for the 
mutant human protein sequence (LPG), (though the mouse IPT-like motif is 
actually LPK, not LPQ as in humans), because like the human protein, the motif 
spans exons 2-3, and the intron-exon architecture is similar since both species 
have introns that are in phase zero for the deleted exons. This enables the 
potential production of an in-frame protein product. Study of such a mouse 
model would reveal whether heterozygous animals had AI (as would be 
expected for a dominant gain of function model of disease). This would also 
enable the consequences of the deletion on the transcripts produced to be 
defined and would allow examination of how the development of enamel is 
perturbed in both incisors and molar teeth. 
 
4.3.6 AMTN mutations in human variant databases 
The lack of reported mutations in AMTN causing AI is surprising given its long 
standing status as a candidate gene for AI. It is possible that in Sanger 
sequencing and WES-based studies, the type of mutation identified here may 
have been overlooked due to biases inherent in these approaches. 
Furthermore, the large exonic deletion reported here is also unusual in that it 
leaves the protein in frame. It may therefore be the case that the majority of 
heterozygous AMTN mutations in human patients do not result in a toxic gain of 
function, but rather are functional AMTN knockouts, causing either no effect or a 
clinical phenotype so mild that they remain undiagnosed. 
 
In an attempt to investigate the frequency of homozygous loss of function 
mutations, databases of known variation (Section 2.4.3) were searched for 
possible loss of function mutations. Mutations affecting the start codon, stop 
codon, splice acceptor / donor sites and those leading to frameshifts were 
identified and their frequencies, in the populations sampled, were recorded 
(Table 4.4).  
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Whilst this data shows that loss of function mutations are present in the 
databases, it is difficult to estimate an overall frequency. It is also likely that the 
c.466del1 frameshift mutation may represent an erroneous entry since six 
homozygotes are recorded but no heterozygotes have been reported. In 
addition, this variant is only identified in one database (EVS) despite its 
relatively high frequency. EVS specifies that indel calls have not been validated 
and have higher false positive rates in comparison to SNVs, making frequency 
data for indels more unreliable than for SNVs. Therefore, excluding the 
c.466del1 variant, the frequency of loss of function mutations can be estimated 
to be between 1.57 x 10-4 - 2.31 x10-4 (depending upon the database used, 
Table 4.5). If heterozygous AMTN loss of function mutations led to AI, such 
frequencies would equate to around 1 in 4,300 to 1 in 6,400 people having AI 
due to AMTN mutations. Since the estimates of the frequency of AI due to all 
genetic causes range from 1 in 700 in an isolated Swedish population 
(Backman and Holm, 1986) to 1 in 14,000 in the outbred US population (Witkop 
and Sauk, 1976), it seems unlikely that heterozygous loss of function mutations 
in AMTN lead to clinically recognisable disease. Rather it seems more likely that 
it is only very rare gain of function mutations (possibly such as the deletion 
identified here) or homozygous loss of function mutations that cause AI. 
 202 
Variant (Total) Frequency Variant (Total) Frequency Variant (Total) Frequency Reference
4:71384477T>C c.-15-3T>C p.? splice acceptor 3 (121168) 2.5E-05 1 (13006) 7.69E-05 1 (5008) 2.00E-04 rs201193624 0.067
4:71384496T>A c.2T>A p.M1? start loss 2 (121324 1.6E-05 1 (13006) 7.69E-05 2 (121406) 1.65E-05 rs370334023 25.7
4:71384497G>A c.3G>A p.M1? start loss 1 (121320) 8.2E-06 N/A N/A 1 (121406) 8.24E-06 rs755228148  25.5
4:71384544T>G c.50T>G p.L17* stop gain 1 (121260) 8.2E-06 N/A N/A 1 (121406) 8.24E-06 rs769401306 36
4:71384549G>A c.54+1G>A p.? splice donor N/A N/A 1 (13006) 7.69E-05 1 (4542) 2.20E-04 rs141338494 24.6
4:71388470A/C c.55-2A>C p.? splice acceptor 1 (121232) 8.2E-06 N/A N/A 1 (121412) 8.24E-06 rs779389513 9.741
4:71388471G/A c.55-1G>A p.? splice acceptor 1 (121226) 8.2E-06 N/A N/A 1 (121412) 8.24E-06 rs748991501 22.2
4:71388556G/C c.138+1G>C p.? splice donor 2 (121044) 1.7E-05 N/A N/A 2 (121412) 1.65E-05 rs767938897 25.2
4:71389582C/T c.139-3C>T p.? splice acceptor 1 (121154) 8.3E-06 1 (13006) 7.69E-05 1 (121412) 8.24E-06 rs367591948 10.43
4:71389583A/G c.139-2A>G p.? splice acceptor N/A N/A N/A N/A 1 (1318) 7.59E-04 rs201144112 23.5
4:71389585G/T c.139G>T p.V47F splice acceptor 6 (121184)* 5.0E-05 N/A N/A 4 (5008) 7.99E-04 rs192563032 1 (ExAC) 23.3
4:71389585G/A c.139G>A p.V47I splice acceptor 1 (121184) 8.3E-06 N/A N/A 1 (5008) 2.00E-04 rs192563032 25.3
4:71389587C/G c.141C>G p.V47= splice acceptor 13 (121206) 1.1E-04 1 (13006) 7.69E-05 1 (4552) 2.20E-04 rs140471397 12.36
4:71389618C/T c.172C>T p.Q58* stop gain 1 (121270) 8.2E-06 N/A N/A 1 (242822) 4.12E-06 rs752376041 39
4:71390678 T/C c.294T>C p.H98= splice donor 2 (120746) 1.7E-05 N/A N/A 2 (121404) 1.65E-05 rs749175667 0.35
4:71394447-
71394460 
CAATTTTTGTCACA/-
c.302_315del 
CAATTTTTGTCACA p.I102Tfs*39 frameshift N/A N/A N/A N/A 1 (121390) 8.24E-06 rs778954160 35
4:71394461C/T c.316C>T p.Q106* stop gain 1 (114686) 8.7E-06 N/A N/A 1 (121390) 8.24E-06 rs746033781 40
4:71394928G/T c.357+1G>T p.? splice donor 1 (63288) 1.6E-05 1 (12884) 7.76E-05 1 (3546) 2.82E-04 rs142798658 23.8
4:71396754A/T c.358-2A>T p.? splice acceptor 1 (119496) 8.4E-06 N/A N/A 1 (121410) 8.24E-06 rs770675733 21.7
4:71396864G/- c.466del1 p.G156E*5 framehift N/A N/A 12 (12520)* 9.58E-04 N/A N/A N/A 6 (EVS) 27.8
4:71397018G/A c.619+1G>A p.? splice donor 1 (119550) 8.4E-06 N/A N/A 1 (121410) 8.24E-06 rs752143599 23.8
dbSNP144 Homozygotes
(source)
CADD 
v1.3
Alleles
Genomic variant 
(GRCh37) Transcript variant
Predicted 
protein 
variant Type
ExAC EVS
 
Table 4.4: Potential AMTN loss of function mutations identified in publically available databases of variation. 
Mutations in ExACv0.3, EVS and dbSNP144 (Methods section ref) were recorded if they resulted in the loss of a start codon, the gain of a stop codon, a 
frameshift or affected splice acceptors or splice donors (variants positioned within introns up to 8bp away from the splice junction or within the exon, those up 
to 3bp away from the splice junction). Note that dbSNP144 includes some data from the ExAC database. All databases were accessed 16/04/2016.  
The variant highlighted in yellow was excluded from subsequent analysis (Table 4.5) due to number of reported homozygotes relative to heterozygotes.  
The variants highlighted in grey (CADD scores <15) were excluded from subsequent analysis. 
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Database ExAC EVS dbSNP144 
Total number of variant alleles 19 3 20 
Largest number of variant 
alleles sampled at one position 
121,324 13,006 121,412* 
Overall allele frequency 1.57 x 10-4 2.31 x 10-4 1.65 x 10-4 
Alleles per 10,000 1.6 2.3 1.6 
Table 4.5: Allele frequency of potential AMTN loss of function mutations. 
Individual frequencies were calculated separately for information from each database. Mutations 
with CADD scores of <15 were excluded from the analysis.  
* The most frequent number of alleles sampled is used instead of the largest number of alleles 
sampled for dbSNP144 since the largest number is around double that of the number of alleles 
at the majority of the other sites sampled. Information compiled 5th April 2016. 
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5 General Discussion 
5.1 Summary of the key findings 
This thesis describes a study investigating the causes of amelogenesis 
imperfecta (AI), a defect of tooth enamel. One section studied a syndromic form 
of AI and the other researched a cause of isolated non-syndromic AI. 
 
In chapter 3, the aim was to identify the genetic cause of HS, an autosomal 
recessively inherited combination of SNHL, AI and variable retinal dystrophy. 
DNA from fourteen individuals from a total of ten families with SNHL, AI and 
retinal dystrophy was subjected to WES. Biallelic variants in PEX1 and PEX6 
were identified in two and five families respectively. Biallelic variants in PEX1 
and PEX6 were already known to cause ZSSDs. The ZSSDs include ZS, NALD 
and IRD and vary in severity, with ZS being the most severe and more often the 
result of null mutations, and IRD being previously thought to be the least 
severe, more often the result of at least one missense mutation. The 
combinations of PEX1 and PEX6 variants identified in the HS individuals always 
included at least one hypomorphic variant. This results in a phenotype restricted 
to fewer organs, meaning lower disease severity overall by comparison with 
other ZSSDs, and suggests that HS represents the mildest presentation of 
ZSSDs. This study therefore revealed a further extension to the phenotype 
spectrum associated with mutations in these genes, with HS being the mildest 
form of ZSSD. Investigation of the localisation of PEX1, PEX6 and PEX14 
within the murine retina revealed that the proteins are found throughout multiple 
retinal layers, suggesting that they may contribute to the maintenance and 
function of the retina. 
 
Biallelic mutations in USH2A were identified in two other families and therefore, 
these families were assumed to have USH and not HS. No genetic cause for 
the AI phenotype was identified and investigation of the enamel phenotype in 
one family suggested that the enamel defect was not AI. 
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In the remaining family, CNV analysis of WES data predicted a heterozygous 
deletion spanning the start codon of MYO7A. A subsequent search for 
heterozygous SNVs within MYO7A failed to reveal a second potentially 
pathogenic variant. Therefore the genetic cause of disease remains unknown in 
this family. 
 
In chapter 4, the aim was to identify novel AI gene(s). DNA from a family 
segregating autosomal dominant hypomineralised AI underwent WES. Analysis 
of SNVs and small indel variants failed to highlight a strong candidate gene. 
However, CNV analysis using ExomeDepth identified a heterozygous deletion 
spanning exons 3 to 6 of AMTN, a gene implicated in AI through its 
chromosomal location, expression during amelogenesis and the phenotypes of 
the Amtn mouse models. Sanger sequencing revealed that the heterozygous 
CNV segregated with disease in all family members for which DNA was 
available. Screening of an additional thirty-five autosomal dominant AI families 
failed to identify any other mutations in AMTN, or any further occurrence of the 
same deletion. 
 
The enamel phenotype in teeth from an individual with the heterozygous 
deletion of AMTN exons 3 to 6 was investigated using CT, SEM and EDX. 
Analysis of the enamel mineral density by CT found that the enamel of teeth 
from an individual with the heterozygous deletion of AMTN exons 3 to 6 was 
18.8-24.6% less dense than control teeth. SEM revealed that the enamel 
appeared to have regions of very disturbed structure as well as regions with a 
more typical structure, although in all cases, the fine structure of the enamel 
was obscured with an apparently overlying material. Unlike the phenotype seen 
in the Amtn-/- mouse, the regions of disturbed enamel spanned the entire 
enamel layer. EDX analysis identified nitrogen within the enamel of the 
individual affected by AI, suggesting that organic material was present. 
 
These findings, together with the evidence already present in the literature, 
strongly suggest that mutations in AMTN cause AI. However, identification of a 
second family in which an AMTN variant segregates with AI, or the development 
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of a more appropriate mouse model to assess the effects of the CNV identified 
in this study, would further strengthen this conclusion. 
 
5.2 The impact of identification of the genetic cause of 
disease 
Both of the studies undertaken to complete this thesis involved the identification 
of the genetic cause of diseases within families. In the past, disease diagnosis 
in inherited diseases was based solely on symptoms, but diagnosis can now 
often be confirmed by identification and segregation of mutations with disease 
within families. Advances in sequencing methodologies (Bentley et al., 2008), 
combined with the sequencing and detailed annotation of the human genome 
(Lander et al., 2001, McPherson et al., 2001) and its variation (Sherry et al., 
2001, Abecasis et al., 2010), have facilitated this. In some cases, where 
symptoms of different syndromes overlap, such as with USH and HS, this can 
alter the diagnosis from that which was given initially and may prompt the 
implementation of a different lifestyle and/or treatment. 
 
Knowledge of the cause of genetic disease can have both positive and negative 
effects on patients and their families. In cases of positive findings, it has the 
potential to inform life decisions regarding genetic testing, family planning, diet 
or whether to risk certain activities. In cases of negative findings, it can 
eliminate anxiety and the need for health surveillance where a family history 
had previously indicated the possibility of disease. Genetic diagnosis can also 
enable suitable treatments to be prescribed or can be the starting point for their 
development by recruitment to clinical trials of a specific disease cohort. 
However, such knowledge of an individual’s genetic status can also affect life 
aspirations and can change people’s perceptions of themselves and others. 
 
Since the majority of cases of HS with mutations in PEX1 or PEX6 had 
originally been diagnosed as USH, an adjustment was inevitably required for 
families to adapt to the new health information that a correct genetic diagnosis 
brought. USH, whilst potentially progressing to total blindness in the long term, 
does not encompass symptoms other than sensory defects. In contrast, HS as 
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part of the ZSSD spectrum, whilst initially documented solely as a sensory and 
enamel disorder, could involve the development of symptoms in liver, kidney, 
brain or other organs in later life. Such symptoms may even affect life 
expectancy. The majority of currently identified HS patients are in adolescence 
and early adulthood. A few older HS patients exist, but a cohort needs to be 
studied over the longer term in order to determine whether symptoms do 
progress to include defects in other organs. IRD and NALD have already been 
reported to be progressive conditions (Berendse et al., 2016). When first 
described, HS did not encompass an eye phenotype (Heimler et al., 1991), but 
one of the index cases developed visual defects in early adulthood (Lima et al., 
2011). The cases described here all have sight problems and whilst this could 
reflect a recruitment bias, it also might suggest that there is significant 
heterogeneity in the HS phenotype both between individuals and at different 
ages. 
 
Reporting of variants identified in WES and WGS studies to healthcare 
practitioners, and ultimately to patients, is complex. Guidelines have been 
written to direct the classification of the variants identified but include many 
caveats (Richards et al., 2015). Equally, recommendations on the reporting of 
secondary and incidental findings have stressed reporting only variants involved 
in clinically actionable disease or those causing disease likely to have serious 
consequences for future generations (for example, diseases whose onset of 
symptoms is after child-bearing years) (Green et al., 2013). However such 
recommendations were criticised by some for removing individual patient choice 
as to what is reported (Holtzman, 2013, Townsend et al., 2013). Variants 
identified by sequencing may be previously unreported or may be in genes 
about which little is known. Alternatively, variants may reside in genes 
associated with serious disease but may actually be benign. Even variants 
identified in very well studied genes such as breast cancer 1, early onset 
(BRCA1; MIM *113705) and BRCA2 (MIM *600185) known to be associated 
with breast, ovarian and other cancers, are often of unknown significance 
(Cheon et al., 2014). Therefore reporting must consider the certainty of the 
diagnosis and the level of clinical and social benefits that their reporting might 
realise.  
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5.3 Massively parallel sequencing in a clinical setting 
In August 2014, former UK Prime Minister David Cameron announced funding 
for the Genomics England project, which aims to sequence 100,000 genomes, 
in collaboration with Illumina and the Wellcome Trust, by 2017. The project aims 
to sequence the genomes of cancer patients and patients with rare diseases in 
order to identify causative and disease-associated variants. Patients with rare 
diseases will be sequenced in trios, i.e. ideally with their mother and father to 
enable the identification of de novo variants and to allow segregation analysis to 
be performed in silico. At present, AI is not on the 100,000 genomes project’s 
rare disease list, but the list does include PBDs (30th June 2016). 100,000 
genomes and other examples of such large scale sequencing projects around 
the world (Genome of the Netherlands Consortium, 2014, Auton et al., 2015, 
Gudbjartsson et al., 2015) are indicative of the falling cost and greater 
infrastructure to support the use of gene panel / exome / genome sequencing. 
Use of diagnostic massively parallel sequencing seems likely to become routine 
in a healthcare setting in future (Ellingford et al., 2016a, Ellingford et al., 2016b, 
Prasad et al., 2016). Such implementation brings ethical, logistical and 
economic challenges and questions as to best practice. 
 
Currently, genetics services within the UK NHS mainly utilise diagnostic gene 
panels in order to focus NGS on disease genes for particular phenotypes, for 
example, deafness or visual defects. This increases throughput whilst 
decreasing the cost (both for the sequencing and for verification of findings), 
complexity of analysis, data storage requirements and the chance of incidental 
findings. However, it is apparent in many examples of genetic disease that 
Sanger sequencing of exonic regions, WES or sequencing of diagnostic gene 
panels may not identify the causative mutation(s) (Braun et al., 2013, Small et 
al., 2016). Deep intronic, regulatory or splicing variants may be identified by 
WGS or RNA sequencing. However, their recognition as the cause of disease 
amongst thousands of other variants may be difficult, and additional proof of 
causation through experimental assays with patient-derived cell lines or other 
cell biology approaches, such as cell lines engineered with the patient’s 
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mutation, will be required. For example, USH2A mutations have been analysed 
using patient nasal epithelial cells (Vache et al., 2010). However, analysis of 
splicing for genes with tooth specific expression will not be possible or, if 
minigene assays (Gaildrat et al., 2010) are utilised, analysis may be 
confounded by the use of a different promoter or cell type for expression or by 
the small proportion of the gene included in the construct. 
 
5.4 The future of AI genetic diagnostics 
Recently, Leeds Teaching Hospital’s Yorkshire Regional Genetics Service 
designed and carried out a trial of an AI gene diagnostic panel. The panel 
targets a total of twenty-two known non-syndromic, syndromic and candidate AI 
genes. A focused clinical exome reagent is used to capture the sequence of a 
panel of around 6000 genes associated with clinically relevant diseases, 
including the 22 target AI genes. However, analysis is restricted to only DNA 
sequence within AI gene regions. In the trial, ten AI cases were sequenced and, 
of these, mutations in known AI genes were identified in six cases. The 
detection rate is likely to increase with the inclusion of a greater number of 
known and candidate AI genes. Mass screening of UK patients via a diagnostic 
panel will allow estimates of the frequency of AI in the various UK regions to be 
made, to allow for appropriate allocation of treatment and funding. 
Retrospective analysis of the efficacy of AI restorative treatments for groups of 
patients with known AI genotypes may lead to the development of best practice 
guidelines for AI treatments based on the causative mutation identified in each 
case. It will also facilitate the inclusion of AI variants into the Leeds AI LOVD 
and may aid classification of variants as pathogenic or benign through observed 
frequency in patients compared to well phenotyped controls. 
 
Genetic diagnosis of AI will also be important for early implementation of 
appropriate dental treatment and stratification of patients for clinical trials. The 
paradigm that tooth enamel cannot undergo cellular repair has meant that 
current AI treatments have the aim of restoring function by use of artificial 
coverings to maintain crown function (Patel et al., 2013). The recent 
development and clinical safety trial of the use biomimetic self-assembly 
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peptides to treat small pre-carious enamel lesions has shown that such lesions 
are ameliorated by treatment (Brunton et al., 2013). Whilst such treatment is 
promising for minor lesions in otherwise sound enamel, its use in patients with 
very thin or soft enamel, as in AI, would not be effective, even if used from an 
early age. 
However, genetic diagnosis of AI may also bring wider health benefits. AI can 
be part of a more complex phenotype, in which other symptoms only present 
later on in development. For example, CNNM4 mutations cause AI that may be 
obvious from a young age, but cone rod dystrophy may only be identified at an 
early stage by specific ophthalmological investigations in some cases (Jalili, 
2010). Also, whilst children with FAM20A mutations present with AI (O'Sullivan 
et al., 2011), it may not be until adulthood that pathology associated with 
calcification in other organs, such as nephrocalcinosis, is detected (Poulter et 
al., 2015). For genes more recently identified as causal of AI, longer term study 
of molecularly defined patient cohorts will help to determine whether other 
observed phenotypes are typical and indicative of syndromic disease or specific 
to particular patients or families. Early diagnosis of such syndromes may allow 
dietary or pharmaceutical interventions to delay or even to prevent the onset of 
later presenting symptoms. 
 
When panel based NGS, such as that proposed as an NHS diagnostic screen, 
is used in collaboration with research, it allows researchers to focus on 
sequencing only samples without mutations in known AI genes, thus expediting 
new AI gene discovery and maximising the efficient use of research effort and 
funds. Leeds AI genetics research is well placed since it is a recruitment hub for 
cases across much of the UK as well as from other countries including 
Pakistan, Costa Rica and Oman. Such a range of populations show great 
genetic diversity, which facilitates the discovery of new genes for AI. 
Conversely, the identification of multiple patients with a particular mutation or 
mutations in a particular gene will allow for more detailed phenotyping of 
affected enamel, teeth and investigation of the association of other oral 
abnormalities such as anterior open bite with AI. Such information may enable 
more effective, tailored dental treatment for AI patients in future. 
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5.5 New AI genes remain to be identified 
Analysis of AI cohort studies have indicated that there remains a large 
percentage of cases for which exonic mutations in known AI genes are not 
identified. In such AI cohorts, around 51-72% of cases remain genetically 
undiagnosed (Chan et al., 2011, Wright et al., 2011, Prasad et al., 2016). There 
are a number of possible explanations for this observation and it is likely that 
the unexplained cases/families fall into several different categories. 
 
In a proportion of unexplained cases, the variants may affect regulatory regions 
outside of coding exons and therefore the causative variant will not be captured 
or annotated by current sequencing and analysis pipelines. For example, a 
report of biallelic FAM20A variants included an untranscribed allele in one 
family and an allele including a large duplication in another family (Poulter et al., 
2015). In addition, causative mutations within exonic splicing enhancers or 
silencers, may be overlooked even if they are positioned within regions that are 
covered by WES due to the assignment of pathogenicity scores that do not 
reflect their important function. 
 
Large intragenic heterozygous deletions such as the one identified in AMTN in 
this study have not previously been identified in AI patients. There are two 
reports of an identical deletion in SLC24A4 (Seymen et al., 2014, Prasad et al., 
2016), one of a deletion in WDR72 (Hentschel et al., 2016), one of a deletion in 
AMBN (Poulter et al., 2014d) and one deletion in AMELX (Lagerstrom et al., 
1991), identified through arrayCGH, gene panel NGS, WES-based depth of 
coverage analysis and candidate gene PCR respectively. Whilst these kinds of 
mutations were identified in these cases, each was homozygous or 
hemizygous, simplifying detection. The AMTN deletion reported herein is the 
first large heterozygous deletion detected in AI, which is likely to represent the 
technological limits of the available detection methods rather than a deficit of 
this kind of mutation. It is likely that the shift in research methodology from WES 
to WGS will make CNVs, including heterozygous variants, easier to identify. 
However, the nature of the sequence around such variants may mean that it is 
difficult to report them. For example, during the course of this study, a 
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homozygous deletion of C4orf26 exon 2 was identified in one family, but due to 
the repetitive nature of the sequence surrounding the deletion, the breakpoints 
of the deletion could not be identified due to problems in amplifying the region 
using PCR. Such difficulty may be commonly experienced due to the repetitive 
nature of the types of sequences most likely to elicit structural variation (van 
Binsbergen, 2011). 
 
Studies of MIH, that in part phenocopies AI, albeit only in particular teeth, have 
attempted to correlate SNPs in AI genes with MIH risk (Jeremias et al., 2016). 
Similarly, larger AI cohorts in particular populations may reveal that seemingly 
common variants in AI genes and other loci have an additive effect on the 
enamel phenotype and act as polygenic susceptibility loci. However clear 
Mendelian inheritance patterns over a number of generations in the great 
majority of identified families may argue that this is not the case. 
 
In addition to the variants that are not identified due to their non-exonic location 
or type, the large proportion of AI cases without genetic diagnosis after 
candidate gene screening (Chan et al., 2011, Wright et al., 2011, Prasad et al., 
2016) suggests that a number of AI genes remain to be identified. Furthermore, 
it is evident that AI is a genetically heterogeneous disorder and that the lines 
between non-syndromic and syndromic disease are indistinct. The 
heterogeneity of the genetic causes of AI may reflect the complexity of the 
processes involved in amelogenesis and their functional separation from other 
processes necessary to sustain life. The genes identified so far include both 
those with tooth or even ameloblast specific expression and those with more 
general expression, suggesting that mutations may influence the phenotype 
outside of the enamel, much like mutations in PEX1 and PEX6. 
 
5.6 Treatments for mutations leading to protein misfolding 
or causing premature termination codons 
Some of the HS PEX1 and PEX6 variants and the exonic AMTN deletion 
identified in this study lead or may lead to protein misfolding. Protein misfolding 
can induce ER stress, which may lead to apoptosis (Wang and Kaufman, 2016). 
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The persistent state of oxidative stress induced by the reduced function of 
PEX1 or PEX6 in HS may also make cells more susceptible to ER stress 
(Redza-Dutordoir and Averill-Bates, 2016). Chemical chaperones have been 
sought and have undergone clinical trials for ZSSDs (as discussed in Section 
3.3.3). They have also been used to prevent ER stress pathology in the 
AmelxY/Y64H mouse model (Brookes et al., 2014). Systematic study of mutations 
that are predicted to lead to protein misfolding via a cell culture system would 
allow treatments to be targeted to individuals with mutations receptive to such 
treatments. Greater knowledge of which mutations lead to protein misfolding 
could allow a reliable algorithm, specific to each gene to be developed to 
predict the outcome of mutations in silico. in utero administration of treatments 
alleviating protein misfolding may be able to prevent the development of AI and 
other pathology, or to reduce severity, in the case of syndromic disease such as 
HS. 
 
Premature termination codons (PTCs) due to nonsense mutations are common 
in ZS and have been identified in combination with hypomorphic alleles in HS. 
Normal translation termination is not entirely efficient and can result in 
readthrough, although the particular stop codon and downstream sequence 
influences the amount of readthrough (Peltz et al., 2013). In cases of PTCs, 
readthrough can also have the effect of suppressing NMD via removal of the 
exon junctional complex. The natural phenomenon of readthrough has been 
exploited by the design and screening of drugs that target ribosomes to 
enhance readthrough. Therapeutics such as aminoglycoside agents and the 
lower toxicity, non-aminoglycoside agents such as PTC124, also known as 
Ataluren, have been trialled as treatments for Duchenne muscular dystrophy 
and cystic fibrosis, although results are less promising than those obtained in 
animal models (Peltz et al., 2013). These reagents, like natural readthrough, act 
most efficiently on the UGA stop codon and least efficiently on the UAA stop 
codon (Welch et al., 2007). Therefore readthrough therapies would need to be 
prescribed on the basis of prior knowledge of each patient’s genotype. 
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5.7 Correction of genetic defects in AI 
A number of different therapeutic approaches are available for the correction of 
genetic defects, each of which could be applied to the defects identified during 
the course of this project. 
 
At present, carriers of serious genetic diseases are able to choose to attempt to 
circumvent the possibility of passing on an inherited disease to their offspring by 
undergoing in vitro fertilisation and pre-implantation genetic diagnosis of 
embryos. Selection and implantation of only healthy embryos can therefore 
eliminate the inheritance of such diseases by future generations, although such 
selection will not prevent the occurrence of de novo mutations. Whilst ZSSDs 
are included in the Human Fertilisation and Embryology Authority’s list of 
conditions deemed sufficiently serious to allow for such embryo selection, 
unsurprisingly, isolated AI is not. In theory though, not only could embryos be 
selected to avoid genetic disease, but faulty genes could be edited by clustered 
regularly interspaced short palindromic repeats (CRISPR) technologies. 
CRISPR is only currently in use in humans for research, for the purpose of 
studying the genes that control the early development of the embryo (Callaway, 
2016). Current guidelines prohibit the culture of CRISPR-modified human 
embryos beyond seven days post fertilisation. It remains to be seen to what 
extent the advent of CRISPR technologies will result in genetic editing in human 
embryos, or even of adults, in future. Correction of genetic defects in murine 
germ cell progenitor cells and in adult mice has already been demonstrated (Yin 
et al., 2014a, Wu et al., 2015). 
 
Such advances in genetic selection and manipulation must be tempered with 
respect for people’s views on what warrants “genetic correction” and therefore 
also what constitutes disability. For example, deaf individuals have been known 
to identify themselves as belonging to a separate culture with their own identity 
rather than regarding themselves as disabled in any way (Nunes, 2006). 
Similarly, some individuals with primordial dwarfism have been reported to 
favour having a child with the same condition for cultural reasons (Sanghavi, 
2006). Whilst the worldwide moratorium on reproductive human cloning and 
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therapeutic human cloning for medical practice has stood for nearly twenty 
years, it remains to be seen if genome editing will also be subject to such a 
long-standing embargo. Ethical arguments against gene editing are complex 
due to the clear benefit of correcting serious genetic defects with significant 
impact on quality of life for patients. However, even if gene editing was morally 
acceptable, it is not yet refined enough for use in humans due to the high 
chances of off-target effects, low frequency of successful targeting and 
unknown clinical outcome. Moral arguments against gene editing are much the 
same as for any other genetic intervention without defined boundaries: for 
which diseases should it be allowed and should parents be allowed to make 
such decisions for their future child? Such questions have different answers for 
different individuals, but society as a whole will decide what is permissible by 
law. 
 
Viral delivery of genes has been used to treat human disease for over 25 years 
(Samiy, 2014). The use of adenovirus and recombinant adenovirus associated 
vectors (AAV) to deliver gene therapy has been developed in animal models 
and in some cases, has entered clinical trials for treatment of a number of 
diseases, including eye disorders such as LCA (Weleber et al., 2016). Unlike 
some other viral vectors, adenovirus and AAV do not integrate into the host 
genome and therefore insertional mutagenesis is not a safety concern. More 
recently, non-viral vectors such as nanoparticles have been the subject of proof 
of principle studies to show delivery of gene therapy to mouse retina is possible 
(Kachi et al., 2005). 
 
Eye diseases seem suited to such treatments due to the small, enclosed, 
accessible, immune-privileged nature of the eye, the post-mitotic status of the 
cell types targetted and the fact that eye diseases are often only slowly 
progressive therefore providing time for therapies to be given. However, such 
treatment of enamel affected by AI is less practical. Once teeth are formed and 
have erupted to reveal an AI phenotype, such treatment is too late. The 
ameloblasts are lost upon tooth eruption, therefore the developing enamel, 
present in utero for the primary teeth or from around birth for many of the 
secondary teeth, would need to be targetted. Accurate delivery of the therapy 
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would be difficult and the encoded protein would be required to be active over a 
number of years, since the enamel can take years to fully develop. 
 
Development of AI therapies is also hampered by the lack of a robust 
ameloblast cell model in which to screen and study treatments. Primary 
ameloblast cells have been isolated from the developing tooth germ but lack the 
potential for proliferation (Den Besten et al., 1998, DenBesten et al., 2005). 
Ameloblast cell lines have been derived from cells of the developing tooth germ 
in mouse (Chen et al., 1992, Nakata et al., 2003), rat (Kawano et al., 2002) and 
pig (DenBesten et al., 1999) but analysis of some of their expression profiles 
has shown that some cell lines may be more appropriate than others depending 
upon the stage of amelogenesis to be studied (Sarkar et al., 2014). Production 
of ameloblast like cells from induced pluripotent stem cells has been shown to 
be possible in rodents (Arakaki et al., 2012, Yoshida et al., 2015) and could be 
a starting point for regeneration of teeth or autologous transfer of functional 
ameloblasts to tooth buds in some cases. Rodent epithelial skin cells have also 
been shown to have the potential to be induced to become a functional, 
ameloblast-like cell (Liu et al., 2013). However, the question of to what extent 
ameloblasts can function in an environment where cells that participate in 
reciprocal signalling with ameloblasts or that function to support them still 
possess a genetic defect, is unknown. 
 
Organ culture of tooth buds has been achieved and represents an in vitro 
system in which AI and novel therapies could be studied and tested 
respectively. Thin or soft enamel in AI results in both the functional failure of the 
tooth surface and the exposure of underlying dentine and ultimately also the 
innervated pulp tissue to the oral cavity resulting in pain. In theory, such teeth 
could be replaced by tooth buds generated from induced pluripotent stem cell 
(iPSC) populations grown in culture. Although this would require underlying 
tissues to be sufficiently healthy in order to support them. In rodents, tooth 
germs and units consisting of the tooth, periodontal ligament and alveolar bone 
have been successfully transplanted and erupted or engrafted respectively 
(Ikeda et al., 2009, Oshima et al., 2011). 
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Isolation of AI patient ameloblast like cells derived from iPSCs would provide 
opportunities to test gene and drug therapies and could also allow study of the 
effects of the AI causing mutations on ameloblast cell function. However, as 
already stated, ameloblasts function in concert with both the odontoblasts and 
the overlying stratum intermedium, and later, the papillary cell layer. Therefore 
studying ameloblasts in isolation may not accurately reflect their behaviour in 
vivo. One study established a primary AI ameloblast-like cell line from an AI 
patient’s developing third molar tooth and found that it expressed ameloblast 
cell markers and could be transduced by adenovirus, albeit at a low efficiency 
(Borovjagin et al., 2011). However the technical difficulties compared with 
administration of gene therapy or genome editing reagents to the eye mean that 
it is unlikely that gene therapies for AI will be widely adopted in the foreseeable 
future. 
 
In conclusion, research into AI is already translating into genetic diagnosis 
within a clinical setting. Wider application of such diagnosis is likely to increase 
the proportion of patients recruited to research studies without mutations in 
known AI genes. This will lead to expedited detection of new AI genes. 
Increased annotation of non-exonic regions of the genome and the wider 
application of WGS in research studies may also speed discovery of AI causing 
mutations. Identification of new AI genes will prompt studies to identify AI gene 
functions and may include the development of new animal models. This will in 
turn increase the understanding of amelogenesis and of which parts of the 
process are perturbed in AI. Such studies may lead to the identification of 
common pathways to target in the design of treatments. Endoplasmic reticulum 
stress induced activation of the unfolded protein response is already emerging 
as such a common pathway in the pathogenesis of AI. In addition, the 
identification of causative mutations in a large patient cohort will allow 
stratification of patients for clinical trials of restorative treatments and, after 
further research, potentially also genetic or chemical treatments to attenuate the 
AI phenotype or to correct AI gene defects. 
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Appendices 
Appendix 1: Non-syndromic AI genes 
Gene Inheritance 
pattern 
Human enamel 
phenotype 
Proposed function 
in amelogenesis 
Proposed disease mechanism Number of 
mutations 
reported
a
 
References 
Amelogenin, X 
linked (AMELX) 
X linked 
dominant 
Females:  
-stripes of normal 
and AI affected 
enamel  
-hypoplastic (some 
hypomaturation). 
Males:  
-Large deletions 
and N terminal 
mutations cause 
hypomaturation AI 
with variable 
hypoplasia 
-C terminal 
mutations cause 
hypoplastic AI 
-EMP 
-Structural 
component of 
developing enamel 
matrix. 
-Alternative splicing 
and cleavage by 
proteinases leads 
to formation of 
peptide products 
with distinct roles. 
Loss of function:  
Variety of mutations identified 
including large deletions, 
frameshift, stop and missenses. 
? Dominant negative:  
One mutation known to cause a 
change in splicing bias towards 
more frequent inclusion of exon 4 
in transcripts, may result in 
decrease of miRNA originating 
from exon 4 that affects AMTN 
and ODAM expression. 
21 Brookes et al., 1995; 
Hart et al., 2000; 
Veis et al., 2000; 
Lagerstrom et al., 
2001; 
Hart et al., 2002; 
Veis et al., 2003; 
Cho et al., 2014; 
Le et al., 2016. 
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Gene Inheritance 
pattern 
Human enamel 
phenotype 
Proposed function 
in amelogenesis 
Proposed disease mechanism Number of 
mutations 
reporteda 
References 
Ameloblastin 
(AMBN) 
Autosomal 
recessive 
-hypoplastic AI -EMP 
-Influences 
ameloblast 
proliferation and 
differentiation.  
-Undergoes PTM 
and proteinase 
cleavage to form 
products with 
distinct roles, 
including one able 
to bind Ca2+.  
-Possible roles in 
cell adhesion and 
extracellular 
signalling. 
Loss of function:  
Mutations include an in-frame 
deletion of exon 6 and a mutation 
affecting splicing believed to 
either cause retention of intron 6 
or to result in the skipping of exon 
7. 
2 Smith et al., 1998; 
Bartlett and Simmer, 
1999;  
Fukumoto et al., 
2004; 
Beyeler et al., 2010;  
Poulter et al., 2014; 
Prasad et al., 2016; 
Enamelin (ENAM) Autosomal 
dominant 
and 
recessive 
Dominant:  
-severe smooth 
hypoplastic AI or 
milder local 
hypoplastic AI 
Recessive:  
-severe hypoplastic 
AI. 
-EMP 
-Undergoes 
cleavage by 
proteinases to form 
peptides with 
distinct roles, 
including binding 
HA crystals. 
Dominant negative:  
Dominant and recessive severe 
form.  
Loss of function:  
Local milder form caused by 
missense mutations. 
18 Rajpar et al., 2001; 
Mardh et al., 2002; 
Hart et al., 2003; 
Hu and Yamakoshi, 
2003; 
Ozdemir et al., 2005. 
Amelotin (AMTN) Autosomal 
dominant 
-hypomineralised AI -Formation of 
compact aprismatic 
enamel 
? Dominant negative gain of 
function: 
In-frame deletion reported that is 
hypothesised to lead to 
accumulation of protein 
aggregates within the ER. 
1 Abbarin et al., 2015; 
Nakayama et al., 
2015;  
Núñez et al., 2015; 
Smith et al., 2016. 
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Gene Inheritance 
pattern 
Human enamel 
phenotype 
Proposed function 
in amelogenesis 
Proposed disease mechanism Number of 
mutations 
reported
a
 
References 
Matrix 
metalloproteinase 
20 (MMP20) 
Autosomal 
recessive 
-hypomaturation AI -Secretory stage 
cleavage of EMPs. 
-Activation of KLK4 
by cleavage. 
-Mediation of 
ameloblast cell 
movement by 
cleavage of 
extracellular 
domains of 
cadherins. 
-May affects 
ameloblast 
development. 
? Loss of function: 
Includes stop and frameshift and 
missense variants. 
8 Simmer and Hu, 
2002; 
Kim et al., 2005;  
Bartlett et al., 2011; 
Guan and Bartlett, 
2013; 
Yamakoshi et al., 
2013; 
Guan et al., 2016. 
Kallikrein-related 
peptidase 4 
(KLK4) 
Autosomal 
recessive 
-hypomaturation AI -Maturation stage 
enamel matrix 
proteinase. 
-Further degrades 
MMP20 peptide 
cleavage products. 
-Inactivation of 
secretory stage 
proteinase, 
MMP20. 
? Loss of function: 
Frameshift or stop variants 
including one within the final 
exon. 
3 Hu et al., 2000;  
Hu et al., 2002; 
Hart et al., 2004;  
Simmer et al., 2009; 
Yamakoshi et al., 
2013. 
WD repeat-
containing protein 
72 (WDR72) 
Autosomal 
recessive 
-hypomaturation AI -Endocytosis by 
maturation stage 
ameloblasts. 
-Removes EMP 
degradation 
products to allow 
enamel to 
mineralise.  
Loss of function: 
All null or frameshift variants that 
lead to NMD apart from one 
missense found in a compound 
heterozygous individual in trans 
with a null variant. 
9 El-Sayed et al., 
2009; 
Katsura et al. 2014; 
Wang et al., 2015; 
Prasad et al. 2016. 
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Gene Inheritance 
pattern 
Human enamel 
phenotype 
Proposed function 
in amelogenesis 
Proposed disease mechanism Number of 
mutations 
reporteda 
References 
Family with 
sequence 
similarity 83, 
member H 
(FAM83H) 
Autosomal 
dominant 
-hypocalcified AI -Associates with 
perinuclear 
vesicles. 
-Cytoskeletal 
reorganisation, 
desmosome 
formation. 
Dominant negative:  
All variants within final exon.  
All except one are a stop or a 
frameshift. 
26 Foster and Xu, 2003; 
Mendoza et al., 
2007; 
Kim et al., 2008; 
Ding et al., 2009; 
Kuga et al., 2016; 
Wang et al., 2016. 
Solute carrier 
family 24 
(Sodium/potassiu
m/calcium 
exchanger), 
member 4 
(SLC24A4) 
Autosomal 
recessive 
-hypomaturation / 
hypomoineralised 
AI 
-Transport of Ca2+ 
by RE. 
Loss of function: 
Both missense and stop variants 
identified. 
5 Parry et al., 2013; 
Wang et al., 2014; 
Bronckers et al., 
2015. 
Chromosome 4 
open reading 
frame 26 
(C4orf26) 
Autosomal 
recessive 
-hypomineralised AI -Unknown. 
-Promotes 
nucleation and 
crystallisation in 
vitro. 
Loss of function: 
All frameshift or stop variants 
predicted to escape NMD. 
5 Parry et al., 2012. 
G-protein coupled 
receptor 68 
(GPR68) 
Autosomal 
recessive 
-hypomineralised AI -Functions as a pH 
sensor. 
-Expressed 
throughout 
amelogenesis. 
Loss of function: 
Includes a large deletion, 
frameshift and missense variants. 
3 Parry et al., 2016 
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Gene Inheritance 
pattern 
Human enamel 
phenotype 
Proposed function 
in amelogenesis 
Proposed disease mechanism Number of 
mutations 
reported
a
 
References 
Integrin, beta 6 
(ITGB6) 
Autosomal 
recessive 
-hypoplastic / 
hypmineralised AI 
-Cell surface 
adhesion receptor. 
-Mediates cell-cell 
and cell-
extracellular matrix 
interactions.  
-Able to activate 
TGF-1 and other 
signalling 
molecules.  
-Localises to 
maturation stage 
ameloblasts. 
Loss of function: 
Includes a stop and missense 
variants. 
5 Munger et al., 1999; 
Poulter et al., 2014; 
Wang et al., 2014. 
Laminin, alpha 3 
(LAMA3) 
Autosomal 
dominant 
-hypoplastic AI 
-grooved and pitted 
-Control of 
ameloblast 
differentiation and 
adhesion to the 
enamel surface. 
Haploinsufficiency: 
Frameshift variants predicted to 
be subject to NMD.  
1 
(+1 with 
COL17A1 
variant) 
Carter et al., 1991; 
Marchisio et al., 
1993; 
Yoshiba et al., 1998; 
Yuen et al., 2012. 
Laminin, beta 3 
(LAMB3) 
Autosomal 
dominant 
-hypoplastic AI 
-grooved and pitted 
-Control of 
ameloblast 
differentiation and 
adhesion to the 
enamel surface. 
Dominant negative / 
Haploinsufficiency:  
All but one are frameshift and 
stop mutations predicted to 
escape NMD. 
7b Carter et al., 1991; 
Marchisio et al., 
1993; 
McGrath et al., 1995; 
Yoshiba et al., 1998; 
Kim et al., 2013; 
Poulter et al., 2014. 
Collagen, type 
XVII, alpha-1 
(COL17A1) 
Autosomal 
dominant 
-Hypoplastic AI 
-grooved and pitted 
-Ligand of LM-332 
(heterotrimeric 
protein consisting 
of LAMA3, LAMB3 
and LAMC2)  
see LAMA3 / 
LAMB3 
Haploinsufiiciency: 
Frameshift, stop and missense 
variants identified. 
10 
(+1 with 
LAMA3 
variant) 
McGrath et al., 1996; 
Floeth and Bruckner-
Tuderman, 1999; 
Murrell et al., 2007. 
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Gene Inheritance 
pattern 
Human enamel 
phenotype 
Proposed function 
in amelogenesis 
Proposed disease mechanism Number of 
mutations 
reporteda 
References 
Family with 
sequence 
similarity 20, 
member A 
(FAM20A) 
Autosomal 
recessive 
-hypoplastic AIc -Predicted to be a 
pseudokinase that 
might enhance the 
action of FAM20C, 
a Golgi kinase with 
targets associated 
with mineralisation. 
Loss of function: 
Majority are frameshift or stop 
variants predicted to lead to NMD. 
Variants predicted to affect 
splicing also identified. 
38 Jaureguiberry et al., 
2012;  
Wang et al., 2013; 
Cui et al., 2015. 
Non-syndromic AI genes. 
The enamel phenotype, the proposed function of the encoded protein in amelogenesis, the proposed disease mechanism and the number of mutations 
reported, are listed. The list includes amelotin for which mutations are reported in chapter 4 of this work. Note that not all of the references for the 
identification of human mutations are cited. See Leeds NS AI LOVD for further details of the mutations identified. 
a Number of mutations reported is as of 25th May 2016, apart from for GPR68, for which the report identifying the first three mutations is in review and 
FAM20A, for which the LOVD entries are not yet complete (FAM20A is curated by Dr. Poulter (University of Leeds). 
b Due to the severity of the JEB phenotype, the tooth phenotype of carriers is not often reported / reported in sufficient detail. 
c There are also often a variety of associated oral defects present, including delayed tooth eruption, impaction, microdontia and gingival overgrowth, 
suggesting that not only amelogenesis but also tooth morphogenesis is affected. Dental pulp calcification and ectopic gingival and dental follicle calcification 
have also been associated with ERS (de la Dure-Molla et al., 2014). 
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Appendix 2: Mouse models of non-syndromic AI 
Gene Human 
Inheritance 
pattern 
Proposed function in 
amelogenesis 
Mouse enamel phenotype Mouse model references 
Amelogenin, X 
linked (AMELX) 
X linked 
dominant 
-EMP 
-Structural component of 
developing enamel matrix. 
-Alternative splicing and 
cleavage by proteinases leads 
to formation of peptide 
products with distinct roles. 
Amelx
Y/-
  
-less than 10% of WT enamel volume. 
-enamel lacked normal prismatic structure (“Flat, 
plate like”). 
Amelx
Y/Y64H 
-roughened, opaque, chalky white enamel. 
Gibson et al., 2001;  
Barron et al., 2010. 
Ameloblastin 
(AMBN) 
Autosomal 
recessive 
-EMP 
-Influences ameloblast 
proliferation and differentiation.  
-Undergoes PTM and 
proteinase cleavage to form 
products with distinct roles, 
including one able to bind 
Ca2+.  
-Possible roles in cell adhesion 
and extracellular signalling. 
Ambn
-5,6/-5,6
 
-severely hypoplastic enamel. 
-ameloblasts lost contact with the enamel matrix. 
-Tomes’ processes failed to develop. 
p.Krt14:Ambn
+/+
  
-altered rod structure. 
-loss of surface aprismatic enamel. 
-altered craniofacial development. 
Fukumoto et al., 2004;  
Smith et al., 2009; 
Wazen et al., 2009; 
Paine et al., 2003; 
Atsawasuwan et al., 2013. 
Enamelin 
(ENAM) 
Autosomal 
dominant 
and 
recessive 
-EMP 
-Undergoes cleavage by 
proteinases to form peptides 
with distinct roles, including 
binding HA crystals. 
Enam LoF  
-hypomaturation AI in heterozygotes. 
-total lack of enamel in homozygotes. 
Enam
-1-7/-1-7
  
-homozygotes lacked true enamel. 
-heterozygotes had discoloured incisors that wore 
rapidly. 
Masuya et al., 2005; 
Seedorf et al., 2007; 
Hu et al., 2008. 
Amelotin 
(AMTN) 
Autosomal 
dominant 
-Formation of compact 
aprismatic enamel. 
Amtn
-/-  
-chalky maxillary incisors. 
-rough irregular surface enamel that is easily chipped 
away. 
pAmelx:Amtn
+/+
 
brittle, thin enamel. 
defective enamel surface layer. 
Lacruz et al., 2012; 
Nakayama et al., 2015; 
Núñez et al., 2016. 
 288 
Gene Human 
Inheritance 
pattern 
Proposed function in 
amelogenesis 
Mouse enamel phenotype Mouse model references 
Matrix 
metalloproteinas
e 20 (MMP20) 
Autosomal 
recessive 
-Secretory stage cleavage of 
EMPs.  
-Activation of KLK4 by 
cleavage.  
-Mediation of ameloblast cell 
movement by cleavage of 
extracellular domains of 
cadherins.  
-May affect ameloblast 
development. 
Mmp20-/-  
-defective AMELX processing. 
-loss of the typical rod structure.  
-reduced mineral content. 
-enamel softer than WT. 
pAmelx:Mmp20+/+ 
-hypomineralised enamel. 
-large amounts of smaller EMP cleavage products. 
Caterina et al., 2002;  
Shin et al., 2014; 
Hu et al., 2015. 
Kallikrein-
related 
peptidase 4 
(KLK4) 
Autosomal 
recessive 
-Maturation stage enamel 
matrix proteinase. 
-Further degrades MMP20 
peptide cleavage products. 
-Inactivation of secretory stage 
proteinase, MMP20. 
Klk4-/-  
-hypomaturation AI. 
-enamel crystallites did not function as a unit. 
-enamel easily abraded. 
-enamel breaks just above DEJ. 
Simmer et al., 2009; 
Yamakoshi et al., 2013; 
Hu et al., 2015; 
Núñez et al., 2016. 
WD repeat-
containing 
protein 72 
(WDR72) 
Autosomal 
recessive 
-Endocytosis by maturation 
stage ameloblasts. 
-Removes EMP degradation 
products to allow enamel to 
mineralise.  
Wdr72-/- 
-hypomaturation AI. 
-EMP degradation products retained within the 
enamel during maturation. 
-RE may not form. 
-enamel remains unmineralised. 
-disrupted cell matrix attachment to the enamel 
matrix during maturation. 
Katsura et al., 2014; 
Wang et al., 2015. 
Family with 
sequence 
similarity 83, 
member H 
(FAM83H) 
Autosomal 
dominant 
-Associates with perinuclear 
vesicles.  
-Cytoskeletal reorganisation, 
desmosome formation. 
Fam83h-/-  
-majority die within 2 weeks. 
-no defect in enamel or dentine. 
-hair present around base of teeth. 
-scruffy coat. 
-smaller pulp volume. 
pActb:Fam83h+/+ 
-no defects in enamel or dentine. 
Kweon et al., 2013; 
Wang et al., 2015. 
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Gene Human 
Inheritance 
pattern 
Proposed function in 
amelogenesis 
Mouse enamel phenotype Mouse model references 
Solute carrier 
family 24 
(sodium/ 
potassium/ 
calcium 
exchanger), 
member 4 
(SLC24A4) 
Autosomal 
recessive 
-Transport of Ca2+ by RE. Nckx4-/- 
-enamel breaks off incisor after eruption to expose 
underlying dentine.  
Stephan et al., 2012;  
Parry et al., 2013. 
Chromosome 4 
open reading 
frame 26 
(C4orf26) 
Autosomal 
recessive 
-Unknown. 
-Promotes nucleation and 
crystallisation in vitro. 
No model yet characterised. N/A 
G-protein 
coupled 
receptor 68 
(GPR68) 
Autosomal 
recessive 
-Functions as a pH sensor. 
-Expressed throughout 
amelogenesis. 
Ogr1
-/- 
-no major defects. 
-incisor enamel structure mildly affected. 
-delayed yellowing of maxillary incisor teeth. 
Mogi et al., 2009; 
Parry et al., 2016. 
Integrin, beta 6 
(ITGB6) 
Autosomal 
recessive 
-Cell surface adhesion 
receptor. 
-Mediates cell-cell and cell-
extracellular matrix 
interactions.  
-Able to activate TGF-1 and 
other signalling molecules.  
-Localises to maturation stage 
ameloblasts. 
Itgb6
-/-
 
-hypomineralised AI with disorganised enamel prisms 
and pits. 
-retained AMELX within the enamel. 
Mohazab et al., 2013. 
Laminin, alpha 3 
(LAMA3) 
Autosomal 
dominant 
-Control of ameloblast 
differentiation and adhesion to 
the enamel surface. 
Lama3
-/-
 
-smaller ameloblasts. 
-abnormal enamel deposition. 
-disorganised reduced enamel epithelium. 
Ryan et al., 1999. 
Laminin, beta 3 
(LAMB3) 
Autosomal 
dominant 
-Control of ameloblast 
differentiation and adhesion to 
the enamel surface. 
Lamb3
-/-
 
-model dies within 24hr of birth. 
-no assessment of the teeth carried out. 
Kuster et al., 1997. 
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Gene Human 
Inheritance 
pattern 
Proposed function in 
amelogenesis 
Mouse enamel phenotype Mouse model references 
Collagen, type 
XVII, alpha-1 
(COL17A1) 
Autosomal 
dominant 
-Ligand of LM-332 
(heterotrimeric protein 
consisting of LAMA3, LAMB3 
and LAMC2).  
-See LAMA3 / LAMB3. 
Col17a1-/- 
-no tooth phenotype described. 
Hurskainen et al., 2012. 
Family with 
sequence 
similarity 20, 
member A 
(FAM20A) 
Autosomal 
recessive 
-Predicted to be a Golgi kinase 
with targets specific to 
mineralisation, calcium 
transport and proteoglycan 
synthesis or a pseudokinase 
that might enhance the action 
of FAM20C. 
Fam20a-/- 
-ameloblast layer disorganised and detached from 
the DEJ. 
-pitted, thin enamel. 
Vogel et al., 2012. 
Mouse models of non-syndromic AI gene function. 
The proposed roles of the proteins encoded by genes in which mutations are reported to cause non-syndromic AI (note that amelotin is also included) and 
their respective mouse models and phenotypes are described. Mouse models are defined using standard nomenclature where possible. Overexpression 
models where the promoter of another gene is driving expression are denoted: p(gene promoter driving expression):(gene under control). Where specific 
exons have been removed this is reflected in the nomenclature used. For Amelx, which is located on the X chromosome, the nomenclature used refers to 
hemizygous male mutants. Abbreviations used: DEJ dentine enamel junction; EMP enamel matrix protein; HA hydroxy(l)apatite; hr hour; LOF loss of function; 
PTM post translational modification; RE ruffle ended ameloblasts; WT wild-type. 
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Appendix 3: Usher syndrome classification 
USH type 
Representation 
relative to total 
cases 
Phenotype 
Genes 
associated 
MIM 
reference Hearing loss 
Vestibular 
function Ocular 
I Common Profound, 
congenital 
Absent Onset 
before 
puberty 
MYO7A 
USH1C 
CDH23 
PCDH15 
USH1G 
CIB2 
*276903 
*605242 
*605516 
*605514 
*607696 
*605564 
II Most common Prelingual, 
moderate to 
severe, 
especially high 
frequencies 
Normal Onset in 
2nd decade 
USH2A 
ADGRV1 
DFNB31 
*608400 
*602851 
*607928 
III Rare except in certain 
populations, 
e.g. Finnish, 
Ashkenazi. 
Variable onset, 
progressive to 
profound 
Variable Variable 
onset 
CLRN1 
HARS 
*606397 
*142810 
Atypical Rare Variable Variable Variable Various Various 
 
Usher syndrome phenotype classifications and their associated genes. 
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Appendix 4: Whole exome sequencing commands 
 
Alignment 
Align fastq files to GRCh37 reference genome and produce SAM file: 
$ novoalign -c 12 -d human_g1k_v37.nix -f sample_R1_001_fastq.gz 
sample_R2_001_fastq.gz -o SAM 
$’@RG\tID:sample_novo\tSM:sample\tPL:Illumina\tLB:sample_exome’ -k -K 
mismatches_sample_novo.txt 2>novostats_sample_novo.txt > 
sample_novo.sam 
 
Sort alignment and convert SAM to bam using Picard: 
$ java -Xmx2g -jar /picard/picard-tools/SortSam.jar I=input_unsorted.sam 
O=input.bam SO=coordinate CREATE_INDEX=TRUE 
 
Mark duplicates using Picard: 
$ java -Xmx4g -jar /picard/picard-tools/MarkDuplicates.jar I=input.bam 
O=input.rmdups.bam M=input.rmdups.metrics CREATE_INDEX=TRUE 
 
Create indel realigner targets using GATK: 
$ java -Xmx4g -jar GenomeAnalysisTK.jar -T RealignerTargetCreator -R 
human_g1K_v37.fasta -known 1000G_phase1.indels.b37.vcf -known 
Mills_and_1000G_gold_standard.indels.b37.sites.vcf -I input.rmdups.bam -o 
input.rmdups.indelrealign.intervals 
 
Perform Indel realignment using GATK: 
$ java -Xmx4g -jar GenomeAnalysisTK.jar -T IndelRealigner -R 
human_g1k_v37.fasta -known 1000G_phase1.indels.b37.vcf -known 
Mills_and_1000G_gold_standard.indels.b37.sites.vcf -I input.rmdups.bam  
-targetIntervals input.rmdups.indelrealign.intervals -o 
input.rmdups.indelrealign.bam 
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Recalibrate Base Quality Scores using GATK. 
Obtain the recalibration model: 
$ java -Xmx4g -jar GenomeAnalysisTK.jar -T BaseRecalibrator -I 
input.rmdups.indelrealign.bam -R human_g1k_v37.fasta -o 
input.rmdups.indelrealign.recal.grp -knownSites dbSnp142.b37.vcf.gz  
-knownSites 1000G_phase1.indels.b37.vcf -known 
Mills_and_1000G_gold_standard.indels.b37.sites.vcf 
 
Check the recalibration model: 
$ java -Xmx4g -jar GenomeAnalysisTK.jar -T BaseRecalibrator -I 
input.rmdups.indelrealign.bam -R human_g1k_v37.fasta -BQSR 
input.rmdups.indelrealign.recal.grp -o input.rmdups.indelrealign.postrecal.grp  
-knownSites dbSnp142.b37.vcf.gz -knownSites 1000G_phase1.indels.b37.vcf  
-known Mills_and_1000G_gold_standard.indels.b37.sites.vcf 
 
$ java -Xmx4g -jar GenomeAnalysisTK.jar -T AnalyzeCovariates -R 
human_g1k_v37.fasta -before input.rmdups.indelrealign.recal.grp -after 
input.rmdups.indelrealign.postrecal.grp -plots 
input.rmdups.indelrealign.postrecal.plots.pdf 
 
Apply the recalibration: 
$ java -Xmx4g -jar GenomeAnalysisTK.jar -T PrintReads -R 
human_g1k_v37.fasta -o input.rmdups.indelrealign.recal.bam -I 
input.rmdups.indelrealign.bam -BQSR input.rmdups.indelrealign.recal.grp 
 
Variant calling 
Call variants using Haplotype caller: 
$ java -Xmx4g - jar GenomeAnalysisTK.jar -T HaplotypeCaller -R 
human_g1k_v37.fasta -D dbSnp142.b37.vcf.gz -L all_Ref_Seq_genes.b37.bed 
-stand_call_conf 30 -stand_emit_conf 10 -I input.rmdups.indelrealign.recal.bam 
-o var.input.rmdups.indelrealign.recal.raw.vcf 
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Select indels and SNP variants using GATK and split multiallelic variants using 
VCFhacks. 
Select SNPs: 
$ java -Xmx4g - jar GenomeAnalysisTK.jar -T SelectVariants -R 
human_g1k_v37.fasta --variant var.input.rmdups.indelrealign.recal.raw.vcf  
-selectType SNP -o var.input.rmdups.indelrealign.recal.raw.SNPs.vcf 
 
Split SNPs: 
$ perl /home/vcfhacks/splitMultiallelicVariants.pl -i 
var.input.rmdups.indelrealign.recal.raw.SNPs.vcf -o 
var.input.rmdups.indelrealign.recal.raw.SNPs.split.vcf 
 
Select indels: 
$ java -Xmx4g - jar GenomeAnalysisTK.jar -T SelectVariants -R 
human_g1k_v37.fasta --variant var.input.rmdups.indelrealign.recal.raw.vcf  
-selectType INDEL -selectType MNP -o 
var.input.rmdups.indelrealign.recal.raw.indels.vcf 
 
Split indels: 
$ perl /home/vcfhacks/splitMultiallelicVariants.pl -i 
var.input.rmdups.indelrealign.recal.raw.indels.vcf -o 
var.input.rmdups.indelrealign.recal.raw.indels.split.vcf 
 
Perform hard filtering separately on SNPs and indels using GATK. 
SNPs: 
$ java -Xmx4g - jar GenomeAnalysisTK.jar -T VariantFiltration -R 
human_g1k_v37.fasta -V var.input.rmdups.indelrealign.recal.raw.SNPs.split.vcf 
--filterExpression “QD < 2.0 || FS > 60.0 || MQ < 40.0 || HaplotypeScore > 13.0 
|| MappingQualityRankSum < -12.5 || ReadPosRankSum < -8.0” --filterName 
“snp_hard_filter” -o var.input.rmdups.indelrealign.recal.filtered.SNPs.split.vcf 
 
Indels: 
$ java -Xmx4g - jar GenomeAnalysisTK.jar -T VariantFiltration -R 
human_g1k_v37.fasta -V var.input.rmdups.indelrealign.recal.raw.indels.split.vcf 
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--filterExpression “QD < 2.0 || FS > 200.0 || ReadPosRankSum < -20.0”  
--filterName “indel_hard_filter” -o 
var.input.rmdups.indelrealign.recal.filtered.indels.split.vcf 
 
Combine SNPs and indels using GATK: 
$ java -Xmx4g - jar GenomeAnalysisTK.jar -T CombineVariants -R 
human_g1k_v37.fasta --variant 
var.input.rmdups.indelrealign.recal.filtered.SNPs.split.vcf --variant 
var.input.rmdups.indelrealign.recal.filtered.indels.split.vcf -o 
var.input.rmdups.indelrealign.recal.filtered.combined.vcf --genotypemergeoption 
UNSORTED 
 
Variant filtering and annotation 
For recessive disease, variants were filtered if present at ≥1% in publically 
available databases. For dominant disease, variants were filtered if present at 
≥0.1% in publically available databases. The examples below show the filtering 
strategy for recessive disease. 
 
Filter on dbSNP142 at 1%: 
$ perl /home/vcfhacks/annotateSnps.pl -d human_g1k_v37.fasta 
clinvar_20150330.vcf.gz -f 1 -pathogenic -i 
var.input.rmdups.indelrealign.recal.filtered.combined.vcf -o 
var.input.rmdups.indelrealign.recal.filtered.combined.vcf_dbSNP142_1pc 
(Optional: -b 129) 
 
Filter EVS at 1%: 
$ perl /home/vcfhacks/filterOnEvsMaf.pl -d /home/ref/evs/ -f 1 --progress -i 
var.input.rmdups.indelrealign.recal.filtered.combined.vcf_dbSNP142_1pc -o 
var.input.rmdups.indelrealign.recal.filtered.combined.vcf_dbSNP142_EVS_1pc 
 
Filter on ExAC at 1%: 
$ perl /home/vcfhacks/filterVcfOnVcf.pl -f 
ExAC_release/release0.3/ExAC.r0.3/sites.vep.vcf.gz -w -y 0.01 -i 
var.input.rmdups.indelrealign.recal.filtered.combined.vcf_dbSNP142_EVS_1pc 
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-o 
var.input.rmdups.indelrealign.recal.filtered.combined.vcf_dbSNP142_EVS_ExA
C_1pc 
 
Filter on control samples: 
$ perl /home/vcfhacks/filterOnSample.pl -i 
var.input.rmdups.indelrealign.recal.filtered.combined.vcf_dbSNP142_EVS_ExA
C_1pc -r samples_to_filter -o 
var.input.rmdups.indelrealign.recal.filtered.combined.vcf_dbSNP142_EVS_ExA
C_1pc_samplefilter  
 
Annotate variants with VEP: 
$ perl /home/variant_effect_predictor/variants_effect_predictor.pl --offline --vcf --
everything --dir /home/variant_effect_predictor/vep_cache --plugin 
Condel,/home/variant_effect_predictor/vep_cache/Plugins/config/Condel/config/ 
--plugin SpliceConsensus --assembly GRCh37 -input 
var.input.rmdups.indelrealign.recal.filtered.combined.vcf_dbSNP142_EVS_ExA
C_1pc -o 
var.input.rmdups.indelrealign.recal.filtered.combined.vcf_dbSNP142_EVS_ExA
C_1pc_VEP 
 
Get functional variants: 
$ /home/vcfhacks/getFunctionalVariantsVep.pl -i 
var.input.rmdups.indelrealign.recal.filtered.combined.vcf_dbSNP142_EVS_ExA
C_1pc_VEP --consensus_splice_site -o 
var.input.rmdups.indelrealign.recal.filtered.combined.vcf_dbSNP142_EVS_ExA
C_1pc_VEP_func 
 
Find biallelic variants in the same gene in more than one family: 
$ /home/vcfhacks/findBiallelicVep.pl -i 
var.input.rmdups.indelrealign.recal.filtered.combined.vcf_dbSNP142_EVS_ExA
C_1pc_VEP_func -s sample_name -f name.ped -n 2 -o 
var.input.rmdups.indelrealign.recal.filtered.combined.vcf_dbSNP142_EVS_ExA
C_1pc_VEP_func_biall_fam  
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Annotate with Ensembl Gene Annotator: 
$ perl /home/vcfhacks/ensemblGeneAnnotator -d /home/ref/ensAnnotator/ -i 
var.input.rmdups.indelrealign.recal.filtered.combined.vcf_dbSNP142_EVS_ExA
C_1pc_VEP_func_biall_fam -o 
var.input.rmdups.indelrealign.recal.filtered.combined.vcf_dbSNP142_EVS_ExA
C_1pc_VEP_func_biall_fam.geneanno 
 
Convert to Excel file format (.xlsx): 
$ perl /home/vcfhacks/annovcfToSimpleVep.pl -i 
var.input.rmdups.indelrealign.recal.filtered.combined.vcf_dbSNP142_EVS_ExA
C_1pc_VEP_func_biall_fam.geneanno --vep --gene_anno -o 
var.input.rmdups.indelrealign.recal.filtered.combined.vcf_dbSNP142_EVS_ExA
C_1pc_VEP_func_biall_fam.geneanno.simple 
 
Depth of Coverage 
$ java -Xmx10g -jar GATK.jar -T DepthOfCoverage -R human_g1k_v37.fasta -I 
input.rmdups.indelrealign.bam -o output.coveragedepth.txt -L 
SSV4/5_regions_b37.bed -ct 4 -ct 9 -ct 14 -ct 19 -ct 24 -ct 29 
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Appendix 5: Primer sequences for Chapter 3 
Gene Exon Forward Sequence (5′-3′) Reverse Sequence (5′-3′) Product (bp) [Mg2+]/AT/Add. 
USH2A 13 TCATTTTCCCATCCTCACCT ACCCCTAATTTGCAAGGACA 496 1.5/59/- 
USH2A 22 AAGAATCAACAAAACCCCAGC CCTCAGTACCAGGCACCTAC 244 1.5/59/- 
USH2A 60 TGCAAAAGGACAGGTTAAAATAA TCCTCACTGGTAGGTGCTACA 451 1.5/59/- 
USH2A 61 GTGTGCAGCTGTCACTGGTT TTCATATATTTAAGCCCTAAGTGAAGA 507 1.5/60/- 
MYO7A 2 AGCATGACATGGTCTCTCTCC ACAGCAGAGGGAACAGGTTT 264 1.5/58/- 
MYO7A 13 TGATGGGGATAGCTTGCTAA GGGCTCAAAGCAGGGAAG 389 1.5/58/- 
MYO7A 16 CTGTCCCTCAAACCCTGACC CATCCTTCACTCCCACCCTA 344 1.5/58/- 
MYO7A 32 GAATCAGTGAGAAGCCTGGG AGGTTCAGATGAGGCCTGG 397 1.5/58/B 
MYO7A 35 GGCCAGCTCTGACTTAGCCT CATAAATCTCCCAGCCTCCA 490 1.5/59/B 
MYO7A 38 CTCACAACCTGGGGGTTTCT AAGGCAGTGTGCAGACGAA 300 1.5/58/- 
MYO7A 42 AGGGGGCTCAGTATAGGAGG CTCTCTTCCGTCTGCTGTCC 288 1.5/58/- 
ENAM 6 TGGCTGAGTTTTAGAGGCTGA AGTGTGTATATGGGGGTGGC 433 1.5/59/- 
PEX1 10 ACTGGGAAGGCAAAATTCAG TGGTCAAAACCCAAAGAAAGAAAGAT 296 1.5/59/- 
PEX1 13 GCGATACCATACATACTGCACC GAAGCATAAATTTAAAGCCACGA 375 3/59/H D 
PEX1 19 ACCTGGCAGAAGTAAAGCTCA GCTGCTACTAGTCGCCCTGA 166 3/58/H 
PEX6 1(a) CCTTTTCCTCTGGCCTCC GAGCTCAGTCACAGCCAGC 597 3/55/H D 
PEX6 1(b) GTCTTGCGGGTCCTGGAG GGCTGTGAAGTGTTCGATGA 698 3/58/H D 
PEX6 1(c) ACTCGGCTGGCTGTGACT CAAAGTCCGGGATGATATGG 536 3/58/H 
PEX6 4-5 TCCATCTGCATTCCTTTTCC AGGAAGGTCCTCCCAATCC 585 3/58/H 
PEX6 8 CCTAGCACCCACCTCACTTC TCACAAGGCAACAGGACTGA 387 3/58/H 
PEX6 13 CATGTATGTGGGCCAAAGTG TGGACTCTGAAGACTGCTGTG 483 3/58/H 
PEX6 16 CATGCAACATGCAGGATGAG GGTCTCTCTGTGTTGCCCA 371 3/58/H 
Primers sequences used for research presented in Chapter 3. 
Abbreviations are as follows: [Mg2+] Mg2+ concentration present in the PCR reaction (mM); AT Annealing Temperature used in oC; Add. Additives used to 
enhance the PCR; H Hot Shot Mastermix (Section 2.5.3); B 1M betaine; D 10% DMSO. Exons listed as 1(a), 1(b), 1(c) show that one large exon was 
amplified using multiple primers that produced overlapping PCR products to cover the entire exon. 
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Appendix 6: Clinical details of patients in Chapter 3 
 
Clinical detail of the retinal phenotype of individual 2975 (family AI-138). 
Only the right eye is shown. 
A: Fundus image showing peripheral retinal changes without marked pigmentation and a normal 
optic nerve. 
B: Fundus autofluorescence image showing central hypofluorescence and peripheral 
hyperfluorescence. 
C and D: Optical coherence tomography images, the bold green line shown in C indicates the 
plane (through the macula) at which the image in D was obtained. D shows macular oedema 
leading to disruption of the retinal layers. 
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Clinical images of 3000 (family AI-146).  
A and B: Fundus autofluorescence of right (A) and left eye (B). Note the spots of abnormal 
hyperfluorescence. 
C and D: Imagess of right (C) and left (D) feet show toenails with Beau’s lines that are most 
apparent on the halluces. 
E: Image of part of the lower dentition. AI is most apparent in the canine and molar teeth. 
  
 301 
 
 
Clinical Images of 2645 (family AI-71). 
A and B: Images of hands that display dry, split skin. 
C to E: Images of lower limbs; right leg (C), legs (D) and feet (E) that display dry, split skin.  
F to N: Images of dentition: thirteen teeth have been extracted and those that remain display AI. 
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Appendix 7: Segregation of PEX1 and PEX6 variants 
 
Segregation analysis of PEX1 and PEX6 variants in families AI-10, AI-16, AI-71, AI-146, AI-
152, AI-186 and AI-202. 
Affected individuals are denoted by shading. Genotypes for each PEX1 or PEX6 variant 
identified are also presented. 
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Appendix 8: Whole exome sequencing alignment statistics for Heimler syndrome samples 
Family Sample 
Input 
DNA 
/g 
Capture 
reagent 
Mean 
depth of 
coverage 
% 
bases 
covered 
by >4 
reads 
% 
bases 
covered 
by >9 
reads 
% 
bases 
covered 
by >14 
reads 
% 
bases 
covered 
by >19 
reads 
% 
bases 
covered 
by >24 
reads 
% 
bases 
covered 
by >29 
reads 
Total read 
count 
AI-10 1499 2.7 SSV4 89.76 99.4 98.0 95.9 92.9 89.4 85.4 4,594,835,166 
AI-10 1500 1.6 SSV5 37.84 98.0 93.9 86.8 77.9 68.3 58.8 1,905,827,228 
AI-11 1503 3.0 SSV4 84.89 99.3 97.9 95.5 92.3 88.5 84.3 4,345,645,192 
AI-11 1504 3.0 SSV4 80.24 99.2 97.4 94.7 91.1 86.9 82.3 4,107,490,638 
AI-12 1509 2.0 SSV4 91.75 99.5 98.1 95.9 92.9 89.3 85.3 4,696,371,551 
AI-12 1514 2.7 SSV4 103.79 99.5 98.4 96.6 94.2 91.2 87.9 5,313,092,258 
AI-16 2113 3.0 SSV5 65.44 98.8 97.5 95.5 92.3 88.2 83.2 3,295,512,156 
AI-71 2645 3.0 SSV5 67.92 98.5 96.9 94.6 91.3 87.2 82.3 3,420,312,345 
AI-138 2975 3.0 SSV5 76.63 98.9 97.9 96.3 93.9 90.7 86.9 3,859,017,557 
AI-146 3000 1.9 SSV5 58.23 98.9 97.5 94.8 90.5 84.9 78.5 2,932,584,366 
AI-152 3466 3.0 SSV5 64.68 98.6 97.3 95.1 91.9 87.5 82.4 3,257,378,994 
AI-152 4922 3.0 SSV5 76.82 99.0 98.3 97.1 95.3 92.6 89.0 3,868,923,901 
AI-186 4716 3.0 SSV5 83.23 98.9 98.0 96.7 94.8 92.2 89.0 4,191,686,607 
AI-202 4505 3.0 SSV5 61.56 98.4 97.0 94.7 91.1 86.4 80.8 3,099,974,781 
Details of DNA input, capture reagent and alignment statistics for WES of HS DNA samples.  
The standard input for the WES protocol used is 3g. Alignment statistics were generated using the regions targetted by the relevant capture reagent as the 
interval. Abbreviations used: SSV4 SureSelectXT Human All Exon V4; SSV5 SureSelectXT Human All Exon V5. 
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Appendix 9: Family AI-12 SNVs and indels 
Genomic variant 
(GRCh37) 
dbSNP142  
reference 
Amino 
acid 
change 
Gene CADD 
v1.3 
Provean SIFT Polyphen2 
(HumVar) 
Mutation  
Taster 
Ensembl 
transcript 
RefSeq 
protein 
1:215901562delTG N/A p.Q3959* USH2A 35 N/A N/A N/A Disease 
causing 
(1.000) 
ENST 
00000 
307340 
NP_996816 
1:216420437delC rs80338903 p.E767X USH2A 33 N/A N/A N/A Disease 
causing 
(1.000) 
ENST 
00000 
307340 
NP_996816 
1:216270469G>A rs111033333 p.L1572F USH2A 26.8 Neutral  
(-2.39) 
Damaging 
(0.011) 
Probably 
damaging 
(0.885) 
Disease 
causing 
(0.979) 
ENST 
00000 
307340 
NP_996816 
15:22862978G>A rs148108126 p.G667S TUBGCP5a 15.22 Neutral 
(-0.44) 
Tolerated 
(0.187) 
Benign  
(0.276) 
Disease 
causing 
(0.999) 
ENST 
00000 
283645  
NP_443135 
11:1016934G>A N/A p.S1956L MUC6a 15.21 Neutral 
(-1.63) 
Tolerated 
(0.092) 
Benign 
(0.001) 
Polymor 
-phism 
(0.999) 
ENST 
00000 
421673 
NP_005952 
Details of the five genomic variants identified by WES as shared in individuals 1509 and 1514 (family AI-12) after filtering.  
Biallelic variants present in 1509 and 1514 (family AI-12) were selected. These were filtered by removing those with a MAF of 1% or more in dbSNP142, EVS 
or ExAC and by selecting only biallelic variants not present in two unrelated control samples.  
The list is restricted to variants scoring 15 or more when scored with CADD v1.3. All variants listed are heterozygous. 
Provean, SIFT and Mutation Taster annotations were based on Ensembl transcript references, Polyphen-2 annotations were based on RefSeq transcript 
references.  
aThe corresponding biallelic variants for these genes scored <15 and so are not included here. 
All scores were obtained 11th February 2016. 
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Appendix 10: Family AI-138 SNVs and indels 
Genomic 
variant 
(GRCh37) 
Zygo 
-sity 
dbSNP142 
reference 
Amino  
acid  
change 
Gene CADD  
v1.3 
Provean SIFT Polyphen
2
 
(HumVar) 
Ensembl 
transcript 
RefSeq 
transcript / 
protein 
12:42499692 
A>T 
Het. rs77044712 p.Y264* GXYLT1 36 N/A N/A N/A ENST 
00000398675 
NP_775872 
14:64066363 
G>A 
Het. N/A p.R100* WDR89 35 N/A N/A N/A ENST 
00000394942 
NP_542397 
12:42499835 
C>T 
Het. N/A p.D217N GXYLT1 34 Deleterious 
(-4.52) 
Damaging 
 (0) 
Probably 
damaging  
(1) 
ENST 
00000398675 
NP_775872 
1:216420437 
delC 
Het. rs80338903 p.E767X USH2A 33 N/A N/A N/A ENST 
00000307340 
NP_996816 
12:42499802 
C>A 
Het. rs78540738 p.D228Y GXYLT1 29.8 Deleterious 
(-5.55) 
Damaging 
 (0) 
Possibly 
damaging 
(0.885) 
ENST 
00000398675 
NP_775872 
18:5890864 
C>A 
Het. rs577682765 p.S400I TMEM200C 27.2 Neutral  
(0.09) 
Damaging 
 (0.032) 
Neutral  
(0.154) 
ENST 
00000383490 
NP_001073678 
1:216270469 
G>A 
Het. rs111033333 p.L1572F USH2A 26.8 Neutral  
(-2.39) 
Damaging 
(0.011) 
Probably 
damaging 
(0.885) 
ENST 
00000307340 
NP_996816 
14:10399917
1 
C>A 
Het. N/A p.A195D TRMT61Aa 26.8 Deleterious 
(-4.85) 
Damaging 
(0.007) 
Probably 
damaging 
(0.978) 
ENST 
00000389749 
NP_689520 
12:42499825 
A>C 
Het. rs76034661 p.I220S GXYLT1 26.5 Deleterious  
(-3.87) 
Damaging 
(0.002) 
Possibly 
damaging 
(0.579) 
ENST 
00000398675 
NP_775872 
16:2120487 
G>A 
Het. rs1800729 p.A583T TSC2 26.2 
 
Deleterious 
(-3.67) 
Damaging 
(0) 
Probably 
damaging 
(0.997) 
ENST 
00000219476 
NP_000539 
1:215901511 
G>A 
Het. rs142381713 p.T3976M USH2A 25.5 Neutral  
(-2.43) 
Tolerated 
(0.056) 
Probably 
damaging 
(0.982) 
ENST 
00000307340 
NP_996816 
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Genomic 
variant 
(GRCh37) 
Zygo 
-sity 
dbSNP142 
reference 
Amino  
acid  
change 
Gene CADD  
v1.3 
Provean SIFT Polyphen
2 
(HumVar) 
Ensembl 
transcript 
RefSeq 
transcript / 
protein 
12:42499690 
T>C 
Het. rs79044728 p.Y265C GXYLT1 25.5 Deleterious 
(-8.29) 
Damaging 
(0) 
Probably 
damaging 
(0.986) 
ENST 
00000398675 
NP_775872 
12:42499701 
C>A 
Het. rs74583427 p.R261S GXYLT1 25.1 Deleterious  
(-5.1) 
Damaging 
(0.045) 
Probably 
damaging 
(0.823) 
ENST 
00000398675 
NP_775872 
12:42499694 
A>T 
Het. N/A p.Y264N GXYLT1 25.0 Deleterious  
(-7.75) 
Damaging 
(0.079) 
Probably 
damaging 
(0.978) 
ENST 
00000398675 
NP_775872 
14:10678070
6 
C>T 
Het. rs199610585 p.W53* IGHV4-28a 25.0 N/A N/A N/A ENST 
00000390612 
N/A 
16:2124321 
C>A 
Het. rs45517238 p.L826M TSC2 24.4 Neutral  
(-1.15) 
Damaging 
(0.01) 
Probably 
damaging 
(0.996) 
ENST 
00000219476 
NP_000539 
1:215914880 
C>T 
Het. N/A p.splice USH2A 24.1 N/A N/A N/A ENST 
00000307340 
NP_996816 
11:1016892 
G>A 
Het. rs78784632 p.S1970F MUC6 24.1 Neutral  
(-2.11) 
Tolerated 
(0.06) 
Probably 
damaging 
(0.982) 
ENST 
00000421673 
NP_005952 
19:8999468 
C>G 
Het. N/A p.W13569C MUC16 23.8 Deleterious  
(-3.07) 
Damaging 
(0.017) 
Possibly 
damaging  
(0.88) 
ENST 
00000397910 
NP_078966 
19:52888076 
A>ATG 
Het. N/A p.K415Mfs*15 ZNF880 23.3 N/A N/A N/A ENST 
00000422689 
NP_001138906 
18:5890865 
T>G 
Het. rs543455233 p.S400R TMEM200C 23.1 Neutral  
(-1.08) 
Damaging 
(0.0333) 
Benign  
(0.054) 
ENST 
00000383490 
NP_001073678 
19:52888077 
A>AGGTCAG
GAGATCG 
Het. N/A p.A416Vfs*7 ZNF880 23.0 N/A N/A N/A ENST 
00000422689 
NM_001145434 
NP_001138906 
17:38911309 
C>T 
Het. N/A p.R72Q KRT25 22.9 Neutral 
(0.06) 
Tolerated 
(0.167) 
Benign  
(0.002) 
ENST 
00000312150 
NP_853512 
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Genomic 
variant 
(GRCh37) 
Zygo 
-sity 
dbSNP142 
reference 
Amino  
acid  
change 
Gene CADD  
v1.3 
Provean SIFT Polyphen
2
 
(HumVar) 
Ensembl 
transcript 
RefSeq 
transcript / 
protein 
11:1016871 
G>T 
Het. N/A p.P1977H MUC6 22.7 Neutral 
(-1.49) 
Tolerated 
(0.05) 
Benign  
(0.091) 
ENST 
00000421673 
NP_005952 
19:8999488 
C>T 
Het. rs200071553 p.D13563N MUC16 22.3 Neutral  
(-0.69) 
Tolerated 
(0.171) 
Probably 
damaging 
(0.968) 
ENST 
00000397910 
NP_078966 
4:3076609 
G>GCAGCA
GCAGCAGC
AGCAGCAG 
Hom. N/A p.? HTT 18.12 Deleterious  
(-2.95) 
N/A N/A ENST 
00000355072 
NP_002102 
19:8999514 
C>T 
Het. rs548751371 p.R13554H MUC16 17.77 Neutral 
(-1.52) 
Tolerated 
(0.277) 
Possibly 
damaging 
(0.715) 
ENST 
00000397910 
NP_078966 
17:38907503 
T>C 
Het. N/A p.T249A KRT25 17.49 Deleterious 
-3.31 
Damaging 
(0.05) 
Benign  
(0.58) 
ENST 
00000312150 
NP_853512 
14:64066367 
T>A 
Het. N/A p.D98E WDR89 15.72 Unscored Damaging 
(0) 
Possibly 
damaging 
(0.695) 
ENST 
00000349942 
NP_542397 
11:1016934 
G>A 
Het. N/A p.S1956L MUC6 15.21 Deleterious 
(-1.63) 
Tolerated 
(0.092) 
Probably 
damaging 
(0.945) 
ENST 
00000421673 
NP_005952 
Details of the thirty genomic variants identified by WES in individual 2975 (family AI-138) after filtering. 
Biallelic variants present in 2975 were selected and were filtered by removing those with a MAF of 1% or more in dbSNP142, EVS or ExAC and by selecting 
only biallelic variants not present in two unrelated control samples. The list is restricted to variants scoring 15 or more when scored with CADD v1.3. 
Provean and SIFT annotations were based on Ensembl transcript references, Polyphen-2 annotations were based on RefSeq transcript references.  
aThe corresponding biallelic variants for these genes scored <15 and so are not included here. 
Abbreviations: Het. heterozygous; Hom. homozygous.  
All scores were obtained 11th February 2016. 
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Appendix 11: Whole genome sequencing alignment statistics 
Family Sample Depth of 
coverage 
% bases covered 
by >1 reads 
% bases covered  
by >2 reads 
% bases covered  
by >3 reads 
% bases covered  
by >4 reads 
Total read count 
AI-10 1492 0.52 39.5 9.5 1.7 0.3 1481295764 
AI-11 1502 0.72 49.9 16.2 4.0 0.9 2070178231 
AI-16 2113 0.65 46.6 13.7 3.0 0.6 1863736476 
AI-71 2645 0.76 51.5 17.4 4.5 1.0 2174646482 
AI-152 3466 0.42 33.5 6.6 1.0 0.2 1195708362 
AI-186 4716 0.58 43.0 11.3 2.2 0.4 1653366880 
Alignment statistics for low coverage whole genome sequencing of HS DNA samples. 
Alignment statistics were generated using the GRCh37 assembly as the interval. 
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Appendix 12: Family AI-11 SNVs and indels 
Genomic 
variant 
(GRCh37) 
dbSNP142  
reference 
Amino 
acid 
change 
Gene CADD 
v1.3 
Provean SIFT Polyphen
2 
(HumVar) 
Mutation  
Taster 
Ensembl 
transcript 
RefSeq 
protein 
14:64066363 
G>A 
N/A p.R100* WDR89 35 N/A N/A N/A Disease 
causing  
(1) 
ENST 
00000 
394942 
NP_542397 
16:48221232 
G>C 
rs55713504 p.S938* ABCC11 35 N/A N/A N/A Disease 
causing  
(1) 
ENST 
00000 
394747 
NP_149163 
7:20823926 
G>A 
rs368503334 p.R486C SP8a 25.4 Neutral  
(-2.25) 
Damaging 
(0.001) 
Probably 
damaging 
(0.973) 
Disease 
causing 
(0.999) 
ENST 
00000 
361443 
NP_874359 
1:12907518 
T>A 
rs201750607 p.S209C HNRNPCL1 23 Neutral  
(-1.27) 
Damaging 
(0.037) 
Probably 
damaging 
(0.994) 
Disease 
causing 
(0.969) 
ENST 
00000 
317869 
NP_001139653 
8:110503307 
T>C 
N/A p.I3364T PKHD1L1 22.9 Deleterious  
(-3.24) 
Damaging 
(0.006) 
Benign 
(0.15) 
Polymor 
-phism  
(0.836) 
ENST 
00000 
378402 
NP_803875 
16:48226474 
G>A 
rs200992288 p.T888M ABCC11 22.7 Deleterious  
(-4.44) 
Damaging 
(0.029) 
Benign 
(0.148) 
Polymor 
-phism  
(0.999) 
ENST 
00000 
394747 
NP_115972 
1:12907519 
C>A 
rs6702447 p.Q208H HNRNPCL1 22.1 Neutral  
(0) 
Tolerated 
(0.096) 
Probably 
damaging 
(0.989) 
Disease 
causing 
(0.830) 
ENST 
00000 
317869 
NP_001139653 
1:12907446 
C>T 
rs116578678 
 
p.E233K HNRNPCL1 20.4 Neutral  
(-1.02) 
Tolerated 
(0.117) 
Benign 
(0.031) 
Polymor 
-phism  
(0.561) 
ENST 
00000 
317869 
NP_001139653 
8:110498978 
G>A 
rs200880307 p.G3270S PKHD1L1 19.90 Neutral  
(-0.68) 
Tolerated 
(0.646) 
Benign 
(0.017) 
Polymor 
-phism  
(0.973) 
ENST 
00000 
378402 
NP_803875 
11:1016881 
C>T 
N/A p.G1974R MUC6a 19.33 Neutral  
(-1.05) 
Damaging 
(0.019) 
Benign 
(0.114) 
Polymor 
-phism  
(0.999) 
ENST 
00000 
421673 
NP_005952 
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Genomic 
variant 
(GRCh37) 
dbSNP142  
reference 
Amino 
acid 
change 
Gene CADD 
v1.3 
Provean SIFT Polyphen
2 
(HumVar) 
Mutation  
Taster 
Ensembl 
transcript 
RefSeq 
protein 
14:64066367 
A>T 
N/A p.D98E WDR89 15.72 Deleterious 
(-3.53) 
Damaging 
(0) 
Possibly 
damaging 
(0.695) 
Disease 
causing 
(0.999) 
ENST 
00000 
394942 
NP_542397 
Details of the eleven genomic variants identified by WES as shared in individuals 1503 and 1504 (family AI-11) after filtering. 
Biallelic variants present in 1503 and 1504 (family AI-11) were selected. These were filtered by removing those with a MAF of 1% or more in dbSNP142, EVS 
or ExAC and by selecting only biallelic variants not present in two unrelated control samples. The list is restricted to variants scoring 15 or more when scored 
with CADD v1.3. All variants listed are heterozygous. 
Provean, SIFT and Mutation Taster annotations were based on Ensembl transcript references, Polyphen-2 annotations were based on RefSeq transcript 
references. 
aThe corresponding biallelic variants for these genes scored <15 and so are not included here. 
All scoring accessed 12th February 2016. 
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Appendix 13: Family AI-11 ENAM variant details 
Genomic 
variant 
(GRCh37) 
Transcript  
variant 
Amino 
acid  
change 
Exon dbSNP142 
reference 
CADD  
v1.3 
Provean SIFT Polyphen2 
(HumVar) 
Mutation 
Taster 
4:71500146A>C c.332A>C p.K111T 6 rs532584416 16.01 Neutral 
(-0.29) 
Tolerated 
(0.087) 
Benign 
(0.368) 
Polymorphism 
(0.999) 
Details of the heterozygous genomic ENAM variant identified by WES in family AI-11. 
The list is restricted to variants scoring 15 or more when scored with CADD v1.3. 
Provean, SIFT and Mutation Taster annotations were based on Ensembl transcript ENST00000396073, Polyphen-2 annotations were based on RefSeq 
protein NP_114095. 
All scores were obtained 12th February 2016. 
 
Genomic variant 
(GRCh37) 
dbSNP142 reference; 
number of variant alleles (total 
alleles at this position);  
allele frequency (all reported 
individuals heterozygous) 
ClinVar 
(release 
07/01/2016) 
ExAC (v0.3)  
number of variant alleles (total 
alleles at this position);  
allele frequency (all reported 
individuals heterozygous) 
EVS  
number of variant alleles 
(total alleles at this position); 
allele frequency (all reported 
individuals heterozygous) 
4:71500146A>C rs532584416; 1 (5008); 2 x 10-4 N/A 31 (121310); 2.56 x10-4 N/P 
Details of the known variation in public databases for the ENAM variant identified in family AI-11.   
Abbreviation is as follows: N/P Not present. 
All databases accessed 12th February 2016. 
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Appenndix 14: Family AI-202 SNVs and indels 
Genomic 
variant 
(GRCh37) 
Zygo-
sity 
dbSNP142  
reference 
Predicted 
amino 
acid 
change 
Gene CADD 
v1.3 
Provean SIFT Polyphen2 
(HumVar) 
Mutation  
Taster 
Ensembl 
transcript 
RefSeq 
transcript  
/ protein 
11:1017041 
G>T 
Het. rs75482640 p.Y1920* MUC6a 42 N/A N/A N/A Disease 
causing  
(1) 
ENST 
00000 
421673 
NP_ 
005952 
7:92132483 
T>TA 
Het. N/A p.I700Yfs*
42 
PEX1 27.6 N/A N/A N/A Disease 
causing  
(1) 
ENST 
00000 
248633 
NP_ 
000457 
2:70524515 
T>A 
Het. rs201866753 p.D108V FAM136Aa 25.9 Deleterious 
(-6.13) 
Damaging 
(0.001) 
Possibly 
damaging 
(0.643) 
Disease 
causing 
(0.999) 
ENST 
00000 
037869 
NP_ 
116211 
6:117128308 
C>T 
Het. rs145460545 p.R187Q GPRC6A 25.3 Deleterious 
(-3.9) 
Damaging 
(0) 
Probably 
damaging  
(1) 
Disease 
causing 
(0.996) 
ENST 
00000 
310357 
NP_ 
683766 
20:50803572 
C>T 
Het. N/A p.D29N ZFP64 23.4 Neutral 
(-0.95) 
Damaging 
(0.035) 
Probably 
damaging 
(0.990) 
Disease 
causing 
(0.999) 
ENST 
00000 
361387 
NP_ 
060667 
18:21483967 
C>T 
Het. rs199684626 p.S2130F LAMA3a 22.6 Deleterious 
(-5.11) 
Damaging 
(0.001) 
Probably 
damaging 
(0.999) 
Disease 
causing 
(0.999) 
ENST 
00000 
313654 
NP_ 
937762 
2:141116420 
C>T 
Het. rs150879175 p.G3743S LRP1B 22.1 Deleterious 
(-3.74) 
Tolerated 
(0.1) 
Probably 
damaging 
(0.998) 
Disease 
causing 
(0.999) 
ENST 
00000 
389484 
NP_ 
061027 
7:92136369 
C>G 
Het. N/A p.R581P PEX1 21.8 Deleterious 
(-3.16) 
Damaging 
(0.006) 
Probably 
damaging 
(0.923) 
Disease 
causing 
(0.926) 
ENST 
00000 
248633 
NP_ 
000457 
16:70164435 
C>A 
Het. N/A p.N239K PDPR 21.1 Deleterious 
(-5.17) 
Damaging 
(0.004) 
Probably 
damaging 
(0.958) 
Disease 
causing 
(0.999) 
ENST 
00000 
288050 
NP_ 
060460 
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Genomic 
variant 
(GRCh37) 
Zygo-
sity 
dbSNP142  
reference 
Predicted 
amino 
acid 
change 
Gene CADD 
v1.3 
Provean SIFT Polyphen2 
(HumVar) 
Mutation  
Taster 
Ensembl 
transcript 
RefSeq 
transcript  
/ protein 
6:117113765 
T>TTTCC 
Het. N/A p.FS GPRC6A 21.0 N/A N/A N/A Disease 
causing  
(1) 
ENST 
00000 
310357 
NP_ 
683766 
2:97851077 
C>A 
Het. N/A p.S655* ANKRD36a 20.8 N/A N/A N/A Disease 
causing  
(1) 
ENST 
00000 
420699 
NP_ 
001157787 
2:141032021 
T>A 
Het. rs149644677 p.N4372Y LRP1B 20.2 Neutral 
(-1.44) 
Damaging 
(0.008) 
Benign  
(0.123) 
Disease 
causing 
(0.896) 
ENST 
00000 
389484 
NP_ 
061027 
16:70162749 
C>A 
Het. rs199978223 p.R142C PDPR 18.82 Deleterious 
(-5.01) 
Damaging 
(0.001) 
Probably 
damaging  
(1) 
Disease 
causing 
(0.999) 
ENST 
00000 
288050 
NP_ 
060460 
20:50781298 
T>TAA 
Hom. rs72411807 p.splice ZFP64 18.75 N/A N/A N/A Disease 
causing  
(1) 
ENST 
00000 
361387 
NP_ 
060667 
3:126722305 
G>A 
Het. rs138997671 p.E504K PLXNA1a 17.72 Deleterious 
(-2.8) 
Tolerated 
(0.084) 
Benign  
(0.132) 
Disease 
causing 
(0.999) 
ENST 
00000 
393409 
NP_ 
115618 
1:228509579 
C>T 
Het. rs199935165 p.R5970W OBSCN 17.50 Deleterious 
(-5.54) 
Damaging 
(0) 
Probably 
damaging 
(0.997) 
Disease 
causing 
(0.994) 
ENST 
00000 
570156 
NP_ 
001092093 
11:48387284
G>A 
Het. N/A p.S245L OR4C5a 16.37 Deleterious 
(-5.45) 
Damaging 
(0) 
Not scored Polymorphi
sm (0.999) 
ENST 
00000 
319813 
N/A 
6:32489745 
CGGCGCGC
CTGTCT>C 
Het. N/A p.D99Rfs*
26 
HLA-DRB5a 15.81 N/A N/A N/A Disease 
causing  
(1) 
ENST 
00000 
374975 
NP_ 
002116 
13:25671163 
T>A 
Het. N/A p.L276H PABPC3a 15.65 Deleterious 
(-6.67) 
Damaging 
(0) 
Probably 
damaging 
(0.999) 
Disease 
causing 
(0.999) 
ENST 
00000 
281589 
NP_ 
112241 
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Genomic 
variant 
(GRCh37) 
Zygo-
sity 
dbSNP142  
reference 
Predicted 
amino 
acid 
change 
Gene CADD 
v1.3 
Provean SIFT Polyphen2 
(HumVar) 
Mutation  
Taster 
Ensembl 
transcript 
RefSeq 
transcript  
/ protein 
1:228467095 
T>C 
Het. rs200720682 p.V2878A OBSCN 15.50 Deleterious 
(-2.52) 
Damaging 
 (0.041) 
Possibly 
damaging 
(0.622) 
Disease 
causing  
(1) 
ENST 
00000 
570156 
NP_ 
001092093 
Details of the twenty genomic variants identified by WES in individual 4505 (family AI-202) after filtering. 
Biallelic variants present in 4505 (family AI-202) were selected. These were filtered by removing those with a MAF of 1% or more in dbSNP142, EVS or ExAC 
and by selecting only biallelic variants not present in two unrelated control samples. The list is restricted to variants scoring 15 or more when scored with 
CADD v1.3. 
Provean, SIFT and Mutation Taster annotations were based on Ensembl transcript references, Polyphen-2 annotations were based on RefSeq transcript 
references. 
aThe corresponding biallelic variants for these genes scored <15 and so are not included here. 
Abbreviations: Het. heterozygous; Hom. homozygous.  
All scoring accessed 15th February 2016. 
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Appendix 15: Family AI-202 LAMA3 variant segregation 
 
Segregation of heterozygous LAMA3 c.6389C>T variant in family AI-202. 
Refseq transcript: NM_198129; Refseq protein: NP_937762. 
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Appendix 16: Markers and SNPs used to analyse the haplotype surrounding the PEX6 c.1802G>A variant 
Marker Physical 
location 
(hg19 / 
GRCh37) 
Genetic location Forward primer (5-3) Reverse primer (5-3) Size 
(bp) G
e
n
e
th
o
n
 
M
a
rs
h
fie
ld
 
D
e
c
o
d
e
 
D6S1552 
AFM157XE11 
41955110-
41955373 
63.50 63.28 N/A AGCCTGAACGACAGAACAAG CTGCTTAACTTNAGATCTTTGGTAT 156-184 
D6S400 
UT2081 
42156381-
42156758 
N/A 63.28 N/A AGCCTGGGTAACTTAGTGAG TCTTTGCTCAAGTCTTTCTCC 182 
D6S1582 
AFMA272ZB5 
43098617-
43098961 
65.20 65.14 N/A CTAGGTAGTCAGGTGGTCATAGTC AGTAGGGCTGGAACCTTCT 133-151 
D6S282 
AFM184XA11 
43234575-
43234945 
66.40 66.37 66.10 ATGGCCCAGACAGTGGGTAT ATGGTTTGTGCAGGTTCAGA 108-126 
D6S271 
AFM136YF8 
43500818-
43501193 
66.40 66.37 66.44 AACAATTGGGAAATGGCTTA TAGGTTGTGGTGGGTGTTAC 166-208 
D6S1604 
AFMB007XA9 
43679700-
43680083 
66.40 66.37 N/A CTGGGACTACAGGCATGAGC CTAGGACTGGGCAGGATTTG 189-205 
D6S1650 
AFMB334YG9 
44130031-
44130426 
68.70 68.65 N/A GGGCTCCACTGTTTAACC CCCTCGGGCTATGATTAC 113-126 
Summary of chromosome 6 Sequence Tagged Site (STS) markers genotyped to analyse the haplotype surrounding the shared PEX6 c.1802G>A 
variant identified in families AI-10, AI-146 and AI-186. 
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dbSNP 
build 142 
Physical 
location  
(hg19 / 
GRCh37) 
Reference 
(allele 
frequency) 
Alternative 
(allele 
frequency) 
Forward Primer (5-3) Reverse Primer (5-3) 
rs7770760 42915403 C (52.935%) T (47.064%) TCCTGGGTTCACGCCATT TGCTAGCAGATCCACCCAC 
rs9471978 42929533 C (50.319%) T (49.681%) GATGAAGTCGTGCTCTGTCG CCATTTGAGAGACAGACAAGCT 
rs34324426 42935188 C (99.900%) T (0.100%) CCTAGCACCCACCTCACTTC TCACAAGGCAACAGGACTGA 
Summary of the Single Nucleotide Polymorphisms (SNPs) on chromosome 6 sequenced to analyse the haplotype surrounding the shared PEX6 
c.1802G>A variant (rs34324426) identified in families AI-10, AI-146 and AI-186. 
Allele frequencies relate to dbSNP build 142. 
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Appendix 17: Coomassie blue stained SDS PAGE gel 
 
Coomassie stained SDS PAGE gel. 
50μg total protein samples from both kidney (K) and brain (B) from two mice were 
electrophoresed by SDS PAGE under reducing conditions. 
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Appendix 18: X-ray photographs of decalcified mouse jaws 
 
 
 
X-ray images of demineralised mouse jaws. 
A and B: Radiographs of a demineralised mouse jaw. An overexposed image is represented in 
B to show that demineralisation is complete. Note the absence of any distinct region of incisor 
or molar tooth that is more radio-dense than the remainder of the jaw. 
 
A 
B 
 320 
Appendix 19: Previously reported ENAM variants 
Genomic variant 
(GRCh37) 
Transcript  
variant 
Predicted amino 
acid  
change 
Reference(s) 
including dbSNP142 
(frequency) 
CADD 
v1.3 
Provean SIFT Polyphen-2 Mutation 
Taster 
4:71497439delA c.107delA p.(N36Ifs*22) Simmer et al., 2013 29.2 N/A N/A N/A Disease 
causing (1) 
4:71497456G>A c.123+1G>A p.? Prasad et al., 2016 26.9 N/A N/A N/A Disease 
causing (1) 
4:71497581delA c.139delA p.(M47Cfs*11) Wang et al., 2015 35 N/A N/A N/A Disease 
causing (1) 
4:71497599A>T c.157A>T p.(K53*) Mårdh et al., 2002 
Kim et al., 2006 
rs121908109  
(no frequency data) 
43 N/A N/A N/A Disease 
causing (1) 
4:71500023A>C c.211-2A>C p.(M71_Q157del) Kim et al., 2005 23.9 N/A N/A N/A Disease 
causing (1) 
4:71500146A>C c.332A>C p.(K111T) This study: 
rs532584416  
(2 x 10-4) 
16.02 Neutral  
(-0.29) 
Tolerated 
(0.087) 
Benign 
(0.368) 
Polymorphism 
(1) 
4:71500172C>T c.358C>T p.(Q120*) Seymen et al., 2014 37 N/A N/A N/A Disease 
causing (1) 
4:71500221_ 
71500221insTCA
AAAAAGCCGAC
CACAA 
c.407_408ins
TCAAAAAA
GCCGACCA
CAA 
p.(K136Nfs*16) Wang et al., 2015 25.8 N/A N/A N/A Disease 
causing (1) 
4:71500268G>T c.454G>T p.(Q152*) Seymen et al., 2014 39 N/A N/A N/A Disease 
causing (1) 
4:71501612G>A c.534+1G>A 
 
p.(A158_Q178del) Rajpar et al., 2001 
Song et al., 2012 
26.7 N/A N/A N/A Disease 
causing (1) 
4:71503505A>G c.535-2A>G 
 
p.(R179-N196del) Wright et al., 2011 
 
23.3 N/A N/A N/A Disease 
causing (1) 
4:71503508G>T c.536G>T 
 
p.R179M Guitierrez et al., 2007 
 
21.5 Neutral 
(-0.87) 
Tolerated 
(0.084) 
Probably 
damaging 
(0.911) 
Polymorphism 
(0.996) 
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Genomic variant 
(GRCh37) 
Transcript  
variant 
Predicted amino 
acid  
change 
Reference(s) 
including dbSNP142 
(frequency) 
CADD 
v1.3 
Provean SIFT Polyphen-2 Mutation 
Taster 
4:71503561delG c.588+1delG 
 
p.(N197Ifs*81) 
p.(?) 
 
 
Kida et al., 2002 
Hart PS et al., 2003 
Kim et al., 2005 
Pavlic et al., 2007 
Wright et al., 2011 
24.3 N/A N/A N/A Disease 
causing (1) 
4:71507790C>T c.647G>T p.(S216L) Chan et al., 2010 26.4 Deleterious 
(-5.93) 
Damaging 
(0.002) 
Probably 
damaging  
(1) 
Disease 
causing 
(0.996) 
4:71507880C>A c.737C>A p.(S246*) Ozdemir et al., 2005 36 N/A N/A N/A Disease 
causing (1) 
4:71508164_ 
71508165insGTC
AGTACCAGTAC
TGTGTCA 
c.1021_1022 
insGTCAGT
ACCAGTAC
TGTGTC 
p.(V340_M341 
insSQYQYCV) 
 
Ozdemir et al., 2005 0.001 Deleterious 
(-13.38) 
N/A N/A Polymorphism 
(1) 
4:71508402_7150
8403insAG 
c.1259_1260 
insAG 
 
p.(V422Pfs*27) 
 
Hart, TC et al., 2003 
Ozdemir et al., 2005 
Pavlic et al., 2007 
Kang et al., 2009 
Chan et al., 2010 
Lindemeyer et al., 2010 
23.3 N/A N/A N/A Disease 
causing (1) 
4:71510134delT c.2991delT p.(L998Wfs*65) Kang et al., 2009 26.1 N/A N/A N/A Disease 
causing (1) 
ENAM variants reported in individuals with AI and in AI-11. 
The variant identified in AI-11 is shaded grey. 
Provean, SIFT and Mutation Taster annotations were based on the Ensembl transcript ENST00000396073, Polyphen-2 annotations were based on the 
RefSeq protein NP_114095. 
All scores were obtained 2nd March 2016. 
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Appendix 20: USH2A c.2299delG haplotypes analysis for 
families AI-12 and AI-138 
Variant dbSNP142 
Family 
AI-12 
Aller et al. (2010) 
haplotype Family 
AI-138 
Aller et al. 
(2010) 
haplotype 
M6 M7 M3 
c.373G>A 
p.A125T 
rs10779261 A/A A A A/A A 
c.504A>G 
p.T168= 
rs4253963 G/G G G G/G G 
c.1419C>T 
p.T473= 
rs1805050 C/C C C C/C C 
c.2299delG 
p.E767Sfs*21 
rs80338903 G/- - - G/- - 
c.3157+35G>A 
p.? 
rs1324330 A/A A A A/A A 
c.4457G>A 
p.R1486K 
rs1805049 A/A A A A/A A 
c.4714C>T 
p.L1572F 
rs111033333 C/T T T C/T T 
c.6506T>C 
p.I2169T 
rs10864219 T/C T C T/C T 
c.6857G>A 
p.R2292H 
rs41277210 G/G G G G/G G 
c.10232A>C 
p.E3411A 
rs10864198 C/C C C A/A A 
c.11602A>G 
p.M3868V 
rs35309576 A/A A A A/A A 
c.11677C>A 
p.P3893T 
rs41303285 C/C C C C/C C 
c.12612A>G 
p.T4204= 
rs2797235 A/G G G A/A A 
c.12666A>G 
p.T4222= 
rs2797234 A/A A A A/A A 
c.13191G>A 
p.E4397= 
rs2009923 G/A G G A/A A 
Comparison of the sequences identified at specific SNPs within the USH2A gene for 
families AI-12 and AI-138 with the genotypes previously identified in European patients. 
Aller et al., (2010) described ten haplotypes associated with the USH2A c.2299delG mutation 
(labelled M1 to M10).  The genotypes of the SNPs used to identify the ten haplotypes are listed 
for AI-12 and AI-138 from available WES data. For simplicity, the transcript variant (Ensembl 
ENST00000307340) not the genomic variant is presented. The predicted protein change is 
based on RefSeq protein NP_996816. Underlining indicates the allele of each heterozygous call 
that the c.2299delG mutation is present on (confirmed by Sanger sequencing). For the 
genotypes highlighted grey, it is uncertain which allele carries the c.2299delG mutation. A 
selection of the haplotypes identified by Aller et al., (2010) are presented for comparison (M6, 
M7 and M3) and represent the closest matches to the SNP calls obtained for AI-12 and AI-138 
WES data. 
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Appendix 21: Primer sequences for Chapter 4 
Amplicon Forward primer (5-3) Reverse primer (5-3) Size (bp) [MgCl2]/AT/Add 
exon 2 TTGACCATGTTTCAAGTAGAACTTTT AGGGCAGGAGAGAGGTAGGT 246 3/59/H 
exon 3 AACCTGGATATAAATGGACACAAA AACGTGTTTTCTTTACCGGTTT 239 3/59/H 
exon 4 GAGGATATCCACCACTGACAGA CACCCATATACATGCTCCCC 228 3/59/H 
exon 5 TGTATTTACATAGCAACTCCTTCCTTT GGGCAAAATTTTCAAGAAGC 311 3/59/H 
exon 6-7 CAGTGAGCCAAGACCATGC TTAGGATTTATGGTCAAAAGAGACTAT 713 3/59/H 
exon 8 CTACCCAAACTTGCTCCCCT CAAGGCAAGACAAAGAACTCCT 428 3/59/H 
exon 9 GGATGCTCCTAATCCTGCAA CCAATGTGTCTCAATCTATTCCA 211 3/59/H 
exon 2F-exon 6-7R TTGACCATGTTTCAAGTAGAACTTTT TTAGGATTTATGGTCAAAAGAGACTAT 10,638  
(Wild-Type) 
Approx 2,000 
(Mutant) 
3/56/H 
intron 2-intron 6 TGTCCTCCTTGAAAGAAGTTGTC CAGCATATGATGTGAGACTGCT 9,073  
(Wild-Type)  
399  
(Mutant) 
3/59/H 
exon 3-exon 6 
(deletion 5 breakpoint) 
CAAATGGTTCTTTCACTTCGTCA CCTGCCCCACTAGCTCTCTA 225 
(Wild-Type) 
3/59/H 
Primers sequences used for research presented in Chapter 4. 
All amplicons refer to AMTN. Abbreviations are as follows: [Mg2+] represents the Mg2+ concentration present in the PCR reaction (mM); AT represents the 
annealing temperature used in oC. Add. details the use of additives to enhance the PCR. H Hot Shot Mastermix (Section 2.5.3). 
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Appendix 22: Clinical details of AI-154 unaffected individual 
 
Deciduous dentition of family AI-154 unaffected individual IV:2. 
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Appendix 23: Whole exome sequencing alignment statistics for family AI-154 samples 
Sample Input DNA 
/g 
Capture 
reagent 
Depth of 
coverage 
% bases 
covered by 
>4 reads 
% bases 
covered by 
>9 reads 
% bases 
covered by 
>14 reads 
% bases 
covered by 
>19 reads 
% bases 
covered by 
>24 reads 
% bases 
covered by 
>29 reads 
II:2 3.0 SSV5 60.06 98.9 97.6 95.4 91.9 87.1 81.3 
II:3 0.2 SSV5 89.77 99.6 99.0 98.1 96.6 94.5 91.8 
III:3 3.0 SSV5 66.44 98.7 97.3 94.9 91.6 87.3 82.2 
IV:1 0.2 SSV5 110.54 99.8 99.4 98.8 97.8 96.5 94.8 
Details of DNA input, capture reagent and alignment statistics for WES of AI-154 DNA samples. 
The standard input for the WES protocols used is either 3g or 200ng. Alignment statistics were generated using the regions targetted by the capture reagent 
as the interval. Abbreviation used: SSV5 SureSelectXT Human All Exon V5. 
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Appendix 24: Family AI-154 SNVs and indels 
Genomic variant 
(GRCh37) 
dbSNP 
reference 
Amino acid 
change 
Gene CADD 
v1.3 
SIFT Polyphen RefSeq 
transcript 
1:45471767G>C N/A p.R583G HECTD3 32 Deleterious (0) Probably damaging (0.982) NM_024602 
1:155028673C>T N/A p..R288C ADAM15 32 Deleterious (0) Probably damaging (1) NM_207197 
20:2796081T>G rs117426258 p.L84R C20orf141 28.5 Deleterious (0) Possibly damaging (0.883) NM_080739 
10:129681992G>A rs141771225 p.P126L CLRN3 27.1 Deleterious (0) Probably damaging (1) NM_152311 
3:49845339T>C  rs561051731 p.I849V UBA7 26.4 Deleterious (0) Probably damaging (0.999) NM_003335 
19:12429806C>A N/A p.G345C ZNF563 26.0 Deleterious (0) Probably damaging (0.999) NM_145276 
7:55266431T>C N/A p.M908T EGFR 25.5 Deleterious 
(0.02) 
Probably damaging (1) NM_005228 
1:159899551C>T N/A p.V735M IGSF9 25.1 Deleterious (0) Possibly damaging (0.632) NM_001135050 
18:59221687T>C rs147507320 p.V722A CDH20 24.9 Deleterious 
(0.03) 
Probably damaging (0.996) NM_031891 
7:73038619C>G N/A p.Q68H MLXIPL 23.9 Tolerated (0.37) Possibly damaging (0.620) NM_032951 
1:167343355C>T rs375705900 p.T138M POU2F1 23.8 Tolerated (0.14) Unknown (0) NM_002697 
1:35650194G>A N/A p.R663C SFPQ 23.4 Tolerated (0.15) Benign (0.217) NM_005066 
18:33785103CCT>C N/A p.? MOCOS 23.2 N/A N/A NM_017947 
20:3145149T>G N/A p.K612T LZTS3 23.3 Tolerated (0.14) Possibly damaging (0.859) NM_001282533 
20:3145150T>C N/A p.K612E LZTS3 23.1 Tolerated (0.18) Possibly damaging (0.801) NM_001282533 
1:190234086G>A rs200575097 p.T176M BRINP3 22.9 Deleterious 0.03 Benign (0.235) NM_199051 
6:37605158C>T rs201115181 p.A952T MDGA1 22.9 Tolerated low 
confidence 
(0.19) 
Benign (0.040) NM_153487 
2:171641303C>T rs551957588 p.P59L ERICH2 22.8 Deleterious low 
confidence 
(0.01) 
Benign (0.269) NM_001289947 
3:75788040G>A rs111880168 p.A195V ZNF717 22.6 Tolerated (0.06) Possibly damaging (0.739) NM_001289020
9 
17:48195540 
ATCCGAGCCTTCA
CCATCC>A  
N/A p.E59_S64d
el 
SAMD14 22.1 N/A N/A NM_174920 
17:48687281G>A N/A p.A1582T CACNA1G 22.0 Tolerated (0.41) Benign (0.027) NM_018896 
11:85435159C>T N/A p.E1305K SYTL2 21.6 N/A Benign (0.005) NM_001162953 
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Genomic variant 
(GRCh37) 
dbSNP 
reference 
Amino acid 
change 
Gene CADD 
v1.3 
SIFT Polyphen RefSeq 
transcript 
20:23472425T>C N/A p.S41P CST8 21.5 Deleterious (0) Probably damaging (0.991) NM_005492 
1:115226899C>A rs139582106 p.Q189H AMPD1 18.62 Tolerated (0.29) Probably damaging (0.928) NM_000036 
6:80341219T>A N/A p.V14E SH3BGRL2 17.56 Tolerated (0.38) Benign (0.112) NM_031469 
11:70172724A>C rs534856862 p.S224R PPFIA1 15.91 Tolerated (0.34) Benign (0.035) NM_003626 
Details of the twenty-six genomic variants identified by WES after filtering. 
Variants shared by II:2, III:3 and IV:1, but not present in II:3 were selected and these remaining variants were filtered by removing those with a MAF of 0.1% 
or more in dbSNP142, EVS or ExAC, that are homozygous and those located on the X chromosome. The list is restricted to variants scoring 15 or more when 
scored with CADD v1.3. 
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Appendix 25: AI-154 copy number variants 
Gene CNV 
type 
Span 
(GRCh37) 
No. of affected; 
total; protein 
coding exonsa 
Bayes Factor Reads ratio 
III:3 IV:1  III:3 IV:1 
AMTNb Deletion 4: 71388473-
71394475 
4; 9; 8 13.6 24.4 0.538 0.519 
NAT8c Deletion 2: 73868073-
73868755 
1; 2; 1 4.97 0.59 16 0.538 
Details of the CNVs identified by ExomeDepth from AI-154 WES data that remained after 
filtering. 
CNVs were retained only if present in III:3 and IV:1 and not present in II:3. Any CNV with a 
boundary that overlapped in III:3 and IV:1 was retained. For a CNV to be excluded, the 
boundary specified in II:3 had to include the entire region present in both III:3 and IV:1. CNV 
data from individual II:2 was not included since the number of control samples available for 
ExomeDepth analysis was insufficient. 
a Column details the number of exons deleted by each CNV followed by the total number of 
exons in the transcript specified and the number of protein coding exons. 
b AMTN Refseq transcript NM_212557. 
c NAT8 Refseq transcript NM_003960. 
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Appendix 26: Additional families screened for AMTN variants 
 
Details of the families screened for AMTN mutations. 
Abbreviations used: AD autosomal dominant; AR autosomal recessive; hemi. hemizygous; het. 
heterozygous; hom. homozygous; N/K not known; WES whole exome sequencing. 
 
 
  
Family
Country 
recruited Inheritance Phenotype
Ethnic 
origin Subsequent findings
AI-26 UK AD Pitted with hypoplasia Caucasian
AI-29 UK AD Hypomaturation with some hypoplasia Caucasian
AI-32 UK AD Hypomaturation with some hypoplasia Caucasian
AI-34 UK AD Crowned (hypomaturation?) Caucasian FAM83H het. c.1354C>T, p.(Q452*)
AI-57 UK Probable AD Hypomineralised Pakistani
AI-73 UK AD Pitted with hypoplasia Caucasian
AI-75 Pakistan AD Hypomaturation / hypomineralisation Pakistani
AI-83 Pakistan N/K Hypomaturation Pakistani
AI-115 UK AD N/K Caucasian
AI-153 UK AD Hypomaturation Caucasian WES - no clear candidate - ongoing
AI-157 UK AD Hypomaturation Caucasian WES - no clear candidate - ongoing
AI-165 UK AD Hypomineralised (hypocalcified) Caucasian FAM83H het. c.2028C>T, p.(Q677*)
AI-168 UK AD   N/K N/K
AI-192 UK Probable AD Hypocalcified Pakistani
AI-197 UK AD N/K Caucasian
AI-210 UK Probable AD Hypomineralised Caucasian
AI-211 UK AD Hypomineralised with some hypoplasia N/K
AI-212 UK AD Hypoplastic and hypomineralised N/K ENAM het. c.92T>G, p.(L31R)
AI-213 UK AD Hypoplastic Caucasian
AI-214 UK AD Hypoplastic Caucasian ENAM het. c.92T>G, p.(L31R)
AI-215 UK Probable AD Hypoplastic, pitted Caucasian
Actually AR consanguineous: FAM20C 
hom. c.1376G>A, p.R459H
AI-236 UK AD Hypoplastic and hypomineralised Caucasian
AI-241 UK AD Hypoplastic and hypomineralised Caucasian
AI-244 UK AD Hypoplastic Caucasian
AI-246 Costa Rica AD N/K N/K FAM83H het. c.1363C>T, p.(Q455*)
AI-251 UK AD N/K N/K FAM83H het. c.1282C>T, p.(Q428*)
AI-253 UK AD N/K Asian
AI-254 UK AD N/K N/K
AI-255 UK AD N/K N/K
AI-271 Slovenia AD Hypomaturation Caucasian WES - no clear candidate - ongoing
AI-272 UK AD N/K N/K
Dentinogenesis imperfecta - excluded 
from study
AI-273 UK AD Hypoplastic Caucasian
AI-274 UK AD Hypoplastic Caucasian AMELX het./hemi. c.100G>A, p.(E34K)
AI-275 UK AD Hypoplastic Caucasian ENAM het. c.92T>G, p.(L31R)
AI-276 UK AD Hypomaturation Caucasian
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Appendix 27: Photographs of tooth D from individual IV:1 
 
Photographs of exfoliated deciduous lateral incisor tooth D from individual IV:1 (family 
AI-154). 
A Cervical view. 
B Coronal view. 
C Labial view. 
D Lingual view. 
E and F Mesial and distal views (exact tooth position within the mouth unknown).  
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Appendix 28: Relative positions of the signal peptide and the IPV-like motif in selected secreted proteins 
Protein Group Amino acid sequence Reference 
sequence 
Location 
AMELX Enamel MGTWILFACLLGAAFAMP<>LPPHP NP_001133 / 
NM_001142.2 
Xp22.2 
AMBN Enamel MSASKIPLFKMKDLILILCLLEMSFAVP<>FFPQQ 
 
NP_057603 / 
NM_016515.5 
4q13.3 
AMTN Enamel MRSTILLFCLLGSTRSLP<>QLKPA NP_997722 / 
NM_212557.3 
4q13.3 
ENAM Enamel MLVLRCRLGTSFPKLDNLVPKGKMKILLVFLGLLGNSVAMP<>MHMPR NP_114095 / 
NM_031889.2 
4q13.3 
ODAM Enamel MKIIILLGFLGATLSAP<>LIPQR NP_060325 / 
NM_017855.3 
4q13.3 
DMP1 Dentine / Bone MKISILLMFLWGLSCALP<>VTRYQ NP_004398 / 
NM_004407.3 
4q13.3 
DSPP Dentine / Bone MKIITYFCIWAVAWAIP<>VPQSK NP_055023 / 
NM_014208.3 
4q22.1 
SPP1 Dentine / Bone MRIAVICFCLLGITCAIP<>VKQAD NP_000573 / 
NM_000582.2 
4q22.1 
MEPE Dentine / Bone MRVFCVGLLLFSVTWAAP<>TFQPQ NP_064588 / 
NM_020203.3 
4q22.1 
BGN Dentine / Bone MWPLWRLVSLLALSQALPFEQRG NP_001702 / 
NM_001711.5 
Xq28 
DCN Dentine / Bone MKATIILLLLAQVSWAGPFQQRG NP_001911 / 
NM_001920.4 
12q21.33 
SPARCL1 Other* MKTGLFFLCLLGTAAAIP<>TNARL NP_004675 / 
NM_004684.5 
4q22.1 
SPARC Dentine / Bone* MRAWIFFLLCLAGRALAAP<>QQEAL NP_003109 / 
NM_003118.3 
5q33.1 
C3 Blood protein MGPTSGPSLLLLLLTHLPLALGSP<>MYSII NP_000055 / 
NM_000064.3 
19p13.3 
AHSG Blood protein MKSLVLLLCLAQLWGCHSAPHGPGL NP_001613 / 
NM_001622.2 
3q27.3 
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Protein Group Amino acid sequence Reference 
sequence 
Location 
SERPINC1 Blood protein MYSNVIGTVTSGKRKVYLLSLLLIGFWDCVTCHGSPVDICT NP_000479 / 
NM_000488.3 
1q25.1 
PRL Pro-hormone MNIKGSPWK<>GSLLLLLVSNLLLCQSVAPLPICPGG NP_000939 / 
NM_000948.5 
6p22.3 
LEP Pro-hormone MHWGTLCGFLWLWPYLFYVQAVPIQKVQ NP_000221 / 
NM_000230.2 
7q32.1 
GH1 Pro-hormone MATGSRTSLLLAFGLLCLPWLQEGSAFPTIPLS NP_000506 / 
NM_000515.4 
17q23.3 
CHGA Neuroendocrine 
secretion-
associated protein 
MRSAAVLALLLCAGQ<>VTALPVNSPM NP_001266 / 
NM_001275.3 
14q32.12 
CHGB Neuroendocrine 
secretion-
associated protein 
MQPTLLLSLLGAVGLA<>AVNSMPVDNRN NP_001810 / 
NM_001819.2 
20p12.3 
FGF23 Neuroendocrine 
secretion-
associated protein 
MLGARLRLWVCALCSVCSMSVLRAYPNASPL NP_065689 / 
NM_020638.2 
12p13.32 
Positions of the signal peptide relative to the IPV-like motif for selected proteins of the enamel matrix, dentine matrix and other secreted proteins. 
The sequence shown is limited to that spanning from the N-terminus to 4 amino acids beyond the IPV-like motif. 
The signal peptide is highlighted yellow, the IPV-like motif is underlined and the positions of exon boundaries are denoted by chevrons. 
The signal peptide was identified using SignalP 4.1 (http://www.cbs.dtu.dk/services/SignalP/) and IPV-like motifs were identified from previous reports by von 
Marschall et al., 2012, Nam et al., 2014 and Liang et al., 2015. 
Note that for ENAM, a signal peptide was not detected, but a peak, indicating a predicted cleavage site, was present at 39-40, although this peak did not reach 
significance. The inferred position of the signal peptide agreed with the considerable literature on the murine and porcine ENAM proteins. 
The reference sequences listed include both the amino acid sequence used to identify the signal peptide and the transcript used to identify the positions of exon 
boundaries relative to the amino acid sequence. 
SPARCL1 and SPARC are included here since both the enamel and dentine / bone matrix genes arose from these genes (Kawasaki & Weiss, 2003).   
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Appendix 29: Clustal Omega multiple sequence alignment of homologous protein sequences for AMTN 
 
CLUSTAL O(1.2.1) multiple sequence alignment    
Guinea pig     1    MKTVILLLGLLGWAQSLPKQLNSALEVSPTKPAPDQVTPLSQQQPTQVFPSLSLISLTQL 60  
Mouse       1    MKTMILLLCLLGSAQSLPKQLNPASGVPATKPTPGQVTPLPQQQPNQVFPSISLIPLTQL 60  
Rat    1    MKTVVLLLCLLGSAQSLPRQLSPALGAPATKPTPGQVTPLTQQQPNQVFPSISLIPLTQL 60  
Elephant  1  MKTTILLFCLLGSTQSLP-QLNPALGLSAAKLVPDQATLLNQQQPNQVFPSLSLIPLTQL 59  
Rhesus macaque       1 MKTMILLFCLLGSTQSLP--LKPALGLPPTKLAPDQGTLPNQQQSNQVFPSLSLIPLTQM 58  
Gorilla        1 MRSTILLFCLLGSTRSLP-QLKPALGLPPTKLAPDQGTLPNQQQSNQVFPSLSLIPLTQM 59  
Human           1 MRSTILLFCLLGSTRSLP-QLKPALGLPPTKLAPDQGTLPNQQQSNQVFPSLSLIPLTQM 59  
Chimpanzee       1 MRSTILLFCLLGSTRSLP-QLKPALGLPPTKPAPDQETLPNQQQSNQVFPSLSLIPLTQM 59  
Horse        1 MKTVILLFCLLGSTLSLPMQF-PALGLPPTKPVPDQATQLNQQQPNQVFPSLNLIPLTQM 59  
Cat        1 MKTMILLLYLLGSTQSLPTQLNPALGLP-TKLALDQATLLNQQQLNQVFPSLSLIPLTQM 59  
Dog            1 MKTMILLLYLLGSTQSLPAQLNPALGLPPTKLTPHQATLLNQQQPNQVFPSLSLIPLTQM 60  
Wild boar       1 MKTTILLFCLLGSTLSLPMQFNPVLGLPPTKLVPDQATLRNQQQPNQVFPSLSLIPLTQM 60  
Sheep   1       MKAAILLFCLLGSTLSLPMQLNPALVLPPTKLVPDQATLLNPQQPSQVFSSLSLIPLTHM 60  
Cow       1 MKAAILLFCLLGSTLSLPMQLNPALVLPPTKLVPDQATLLNPQQPNQVFSSLSLIPLTHM 60  
    *:: :**: *** : ***  :  .     :* .  * *    ** .*** *:.** **::   
 
Guinea pig    61      LTLASDLQLLTPASGTKPGAQTLQLSLGALQGQNQLQPQLLPIFVAQLGAPAAILSSEEL 120  
Mouse    61   LTLGSDLPLFNPAAG-PHGAHTLPFTLGPLNGQQQLQPQMLPIIVAQLGAQGALLSSEEL 119  
Rat      61    LTLGSDLPLFNPATM-PHGTQTLPFTLGPLNGQQQLQPQMLPIIVAQLGAQGALLSSEEL 119  
Elephant        60 LTLGSDLQQLNPATGMAPGTQTFPLNLGRLTIKQQLQSQLLPIIVAQLGAQGAILSSEEL 119  
Rhesus macaque       59 LTLGPDLHLLNPAAGMTPGTQAHPLTLGVLNLPQQLQPHMLPIFVTQLGAQGTILSSEEL 118  
Gorilla        60 LTLGPDLHLLNPAAGMTPGTQTHPLTLGGLNVQQQLHPHMLPIFVTQLGAQGTILSSEEL 119  
Human           60 LTLGPDLHLLNPAAGMTPGTQTHPLTLGGLNVQQQLHPHVLPIFVTQLGAQGTILSSEEL 119  
Chimpanzee       60 LTLGPDLHLLNPAAGMTPGTQTHPLTLGGLNVQQQLHPHVLPIFVTQLGAQGTILSSEEL 119  
Horse       60 LKLGSDLQLLNPAAGVAPGAQTLPLTLGGLKAQQQLQSQMLPIFVAQFGAQGTILSSEEL 119  
Cat        60 ITLGADLQLLNPPAGLAPGTQTLPLTLGGLNTQQPLQAQMLPVIVAHLGAQGTILSSEEL 119  
Dog     61   FTLASDLQLLNPAAGMASGTQTLPLSLGVLNTQQQLQPQMLPVIVAHLGAHGAILSSEEL 120  
Wild boar       61  LTLGSDLQLLNPAIGMVPSSQTLPLTLGALNVQQQLQPQMIPVIVAHLGAQGAILSSEEL 120  
Sheep        61 LTLGSDLQLLNPAAGMPSGTQTLPLALGGLKVQQQLQPQMLPVIVAHFGAQGTILSSEEL 120  
Cow        61 LTLGSNLQLLNPAAGMPSGTQTLPLALGGLKVQQQLQPQMLPVIVAHFGAQGTILSSEEL 120 
    :.*. :*  :.*      .:::  : ** *   : *: :::*::*:::** .::******   
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Guinea pig     121  PLAPQIFTGLLLNPLFPEGTLPTSQAGASPNIQEEAIPAGQTGVNTNMQVTTEGQLSTPG 180  
Mouse          120  PLASQIFTGLLIHPLFPGAIPPSGQAGTKPDVQNGVLPTRQAGAKAVNQGTTPGHVTTPG 179  
Rat        120 PLASQIFTGLLIHPLFPGAIQPSGQTGAKPDVQNGALPTRQAGASPANQATTPGHT-TPA 178  
Elephant       120 PMAPQIFAGLLIQPLFPGAILPTSLAGATPEVQEGILPAGQAGLNPAIQRTPEKHPSTSS 179  
Rhesus macaque       119 P---QIFTSLIIHSLFPGGILPTSQAGANPDVQDGSLPAGQAGVNPAIQGTPAGRLPTPS 175  
Gorilla        120 P---QIFTSLIIHSLFPGGILPTSQAGANPDVQDGSLPAGGAGVNPAIQGTPAGRLPTPS 176  
Human           120 P---QIFTSLIIHSLFPGGILPTSQAGANPDVQDGSLPAGGAGVNPATQGTPAGRLPTPS 176  
Chimpanzee       120 P---QIFTSLIIHSLFPGGILPTSQAGANPDVQDGSLPAGGAGVNPATQGTPAGRLPTPS 176  
Horse        120 PAAPQIFAGLIFQPLFPGGILPTSQ--ATPDVQNGILPAGQGGVKPAIQGTSESPLPTTS 177  
Cat        120 PMAPQIFTGLIFQPLFPGSTLPNSQ--ANPDAQNGILPAGQAGMNPAIQGTSEGFSPTPS 177  
Dog            121 PGSPQIFTGLIFQPLFPGAILPTSP--ANPDAQNGILPAGQAGGNPAIQGTPESFSTTPS 178  
Wild boar       121  PATRQILTGLIFHTLFPGAILPPSP--AKPDAQNGIHPAGQAGANPAVQGTPRGPFPTSS 178  
Sheep       121  QGTSQILTGLIFHPLFPGAILPTSQ--ANPDAQNGILPAGQAGANPATQGTPEDPFSTPS 178  
Cow        121 QGTSQILTGLIFHPLFPGAILPTSQ--ANPDAQNGILPAGQAGANPAAQGTPEDPFSTPS 178 
                               **::.*::. *** .  * .   :.*: *:   *:   * .   * *      * .   
 
Guinea pig     181   VT-DDDFEVTTTLGIQKVTHTPEKTTTGSPNCEFL------------------------- 214  
Mouse    180   VTDDDDYEMSTPAGLRRATHTTEGTTIDPPNRTQ-------------------------- 213  
Rat       179   VTDDDDYEMSTPAGLQRATHTTEGTTMDPPNRTK-------------------------- 212  
Elephant       180  DT-DSVFGVTTPAGLQRGMRTTGETTTESPNDEPQNLLYVVLQPDTSNR----LELAQ-- 232  
Rhesus macaque       176  GT-DDDFAVTTPAGIQRSTHATEETTTE-------------------------------- 202  
Gorilla        177 GT-DDDSAVTTPAGIQRSTRAIEETTIESANGIQ-------------------------- 209  
Human           177 GT-DDDFAVTTPAGIQRSTHAIEEATTESANGIQ-------------------------- 209  
Chimpanzee       177 GT-DDDFAVTTPADIQRSTRAIEEATTESANGIQ-------------------------- 209  
Horse        178 DT-DDDFGGTTPAGIQRGMRTTEETITKSPNEFSTDQLLALNFRDLFSRPLPRTSATKHS 236  
Cat        178 DT-DDDFEVTAPTGIRRGMHTTQETTTGPPNGNQ-------------------------- 210  
Dog            179  DT-DDDFGVTAPAGIQRGTHTTQETTSGPPNGKFSEPGKCC-------RSHRRVGTG--- 227  
Wild boar       179 GT-DDDFDVTTPAGLQRGTHATEETTTGSPNGMQ-------------------------- 211  
Sheep        179 GT-DDDFAATTPAGIQRGRQTTEEAPTGSPKGRFSKPGRHP-------RAMRVICGVREK 230  
Cow    179    GT-DDDFASTTPAGIQRGRPTTEETPTGSPKGIQ-------------------------- 211 
                               * *.    ::   :::   :   :                                      
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Guinea pig      214 ----------------------------------- 214  
Mouse           213 ----------------------------------- 213  
Rat        212 ----------------------------------- 212  
Elephant        232 ----------------------------------- 232  
Rhesus macaque       202 ----------------------------------- 202  
Gorilla        209 ----------------------------------- 209  
Human           209 ----------------------------------- 209  
Chimpanzee       209 ----------------------------------- 209  
Horse        237 GLVHIAMPPLTFHFGVPTLDALRQCRGRSIPESHF 271  
Cat        210 ----------------------------------- 210  
Dog            228 -F-LV-------------LP--------------- 232  
Wild boar       211 ----------------------------------- 211  
Sheep        231 GSLSC-------------LDKYRS----------- 241  
Cow        211 ----------------------------------- 211 
 
Clustal Omega multiple sequence alignment of homologous protein sequences for AMTN. 
The red boxed region indicates the position of the signal peptide. Yellow shaded residues indicate those that span the IPV-like motif. The green boxed region 
indicates the region of the human protein deleted (if translated) by deletion exons 3-6. Green shaded residues indicate the IPLT motif that is predicted to be an 
O-glycosylation site. Magenta shaded residues indicate the SXE motif. An asterisk (*) indicates positions which have a single, fully conserved residue. A colon (:) 
indicates conservation between groups of strongly similar properties. A full stop (.) indicates conservation between groups of weakly similar properties. 
AMTN sequences used: Guinea pig, Cavia porcellus XP_003467586.2; Mouse, Mus musculus NP_082069.1; Rat, Rattus norvegicus NP_001037761.1; 
Elephant, Loxodonta africana XP_010592490.1; Rhesus macaque, Macaca mulatta XP_014994036.1; Gorilla, Gorilla gorilla XP_004038827.1; Human, Homo 
sapiens NP_997722.1; Chimpanzee, Pan troglodytes XP_001160426.1; Horse, Equus caballus XP_014594023.1; Cat, Felis Catus XP_00395385.2; Dog, Canis 
lupus familiaris XP_854599.1; Wild boar, Sus scrofa XP_01384473.1; Sheep, Ovis aries XP_012035497.1; Cow, Bos taurus NP_001289882.1. 
